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Abstract 
The aims of this study tested the hypothesis that expression of heparin-binding growth factors 
(HBGFs) in normal placental development was altered in a specific pregnancy disorder pre-
eclampsia. HBGFs bind to heparin, a glycosaminoglycan (GAG) affecting activity. I 
investigated the role of heparin and HBGFs in pathophysiology of pre-eclampsia. Placental 
tissue from a cohort study of 87 women was performed following uncomplicated pregnancy 
at term, but not in labour (TNL, n=26), preterm labour (PTL, n=17), following labour onset 
(TL, n=21), first trimester (FNL, n=4) and pre-eclampsia (PE, n=19). The HBGFs studied 
were vascular endothelial growth factor (VEGF), placental growth factor (PLGF), fibroblast 
growth factor 2 (FGF2), hepatocyte growth factor (HGF), platelet-derived growth factor 
(PDGF), heparin-binding epidermal growth factor (HB-EGF), midkine (MK), pleiotrophin 
(PTN), and cluster differentiation (CD105). The localisation of HBGFs and receptors 
VEGFR-1, /(sflt-1), PLGFR-1, VEGFR-2 and FGF2R-1 in placenta were detected. The 
expression of VEGF, PLGF, FGF2, HGF, PDGF, CD105 was confined to villous trophoblast, 
endothelial cells except for MK, HB-EGF and PTN was specifically to villous trophoblast. 
The total RNA production in human placentae samples (n=7) from PE and controls were 
analysed using qRTPCR. Placental expression of mRNA was extracted for primer assays of 
PLGF, FGF2, MK, PTN, and endogenous housekeeping gene as Succinate dehydrogenase 
complex subunit A (SDHA). FGF2 and SDHA mRNA expression was significantly different 
using Mann-Whitney U test. An in vitro villous trophoblast invasion model was performed 
with human fibrosarcoma HT1080 invasive cells (positive control), mouse embryonic 
fibroblast NIH/3T3 non-invasive cells (negative control) and immortalised human primary 
villous trophoblastic cell lines TCL-1.The greatest stimulation was by FGF2, PDGF-BB, 
HGF, MK and co-incubation with heparin enhanced these responses, except for PTN using 
the Mann-Whitney U test. Heparin’s role is indicated in mediating the effects of HBGFs.  It’s 
suggests heparin therapeutic use in the treatment of pre-eclampsia. 
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List of Figures           
1.Figure 1. represents a schematic drawing of a normal section through a full-term 
placenta. The physiology of maternal-placental circulations is shown. The embryonic 
circulation consists of umbilical arteries in blue and umbilical vein is red. The arrow 
in black present maternal blood that circulates in spaces between the villi. Modified 
from Williams, (2010). 
2.Figure 2. the blastocyst development and differentiation between placental 
trophectoderm and foetal inner cell mass. From Carlson, (2011). 
3. Figure 3A. represents blastocyst implantation and differentiation. Figure 3B 
represents the blastocyst and cytotrophoblast proliferation during invasion. Figure 3B 
represents the invasive multinucleated syncytiotrophoblast. Adapted from Kay et al, 
(2011).  
4.Figure 4. represents the differentiation of trophoblast  lineage  and  subtypes 
(Modified from Benirschke et al, 2006; Kay et al, 2010; Wang et al, 2010; and 
Williams, 2010). 
5.Figure 5a. represents a human placental villous tree (Modified from Benirschke et 
al, 2006). Figure 5b. represents cross section of different types of villi and vessel 
branches of a cotyledon (Modified from Benirschke et al, 2006).                                                    
6.Figure 6. Represents villi within a cotyledon of placental circulation. Modified from 
(Kay et al, 2010).  
7.Figure 7. placental villous detailed structure as in the cross section above.1. 
Intervillous space, 2. Syncytiotrophoblast, 3. Foetal capillaries, 4. Extraembryonic 
mesenchyme, 5. Cytotrophoblast, 6. Hofbauer macrophages. Modified from Human 
Embryology, (Law, 1999). 
8.Figure 8. represents the relationship between foetus and maternal decidua from 8 
weeks of pregnancy. Modified from (Carlson, 2009). 
9.Figure 9. represents the interactions between the foetus, placenta, and mother during 
human pregnancy. Modified from (Murphy et al, 2006). 
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10.Figure 10. represents the trophoblast invasion and placental implantation in normal 
pregnancy and pre-eclampsia. Modified from (Williams, 2010). 
11.Figure 11.	 represents the normal human placental development where EVT 
cytotrophoblasts proliferate in anchoring columns and invade the decidua (Kingdom 
et al, 2011).    
12.Figure 12. representation of major factors affecting development and function, and 
ways in which these may affect the developmental programming of the foetus 
modified from (Burton et al, 2011). 
13.Figure 13. during pregnancy the spiral artery remodels. Adapted from (Williams 
Obstetrics; Wang & Zhao (2010). 
 14.Figure 14. the vascular endothelial growth factors (VEGF) and their receptors 
interactions and signalling. Abbrevations: Vascular endothelial growth factors 
(VEGF), vascular endothelial growth factors receptors (VEGFR1, VEGFR2 and 
VEGFR3) and neuropilin (NRP-1 and -2). Modified from (Wang and Zhao, 2010). 
15.Figure 15. the fibroblast growth factor 2 and its receptor (FGF2/FGF2R) signalling 
is presented and modified from Wang and Zhao, (2010). 
16.Figure 16. pre-eclampsia is presented as two stages of evolution. Modified from 
(Redman and Sargent, 2000; Lyall and Belfort, 2007). Other disorders associated with 
placental insufficiency include pre-term labour, foetal growth restriction. 
17.Figure 17. represents uteroplacental vascular insufficiency (Adapted from 
Kingdom et al, 2011). 
18.In Figure.18a. and 18b. presents functions of VEGF, sfIt1, and PLGF in normal 
pregnancy and pre-eclampsia (Luttun & Carmeliet, 2003). 
19. Figure 19. Heparin structure modified from Mulloy et al, (1993). 
20.Figure 20. Three-dimensional chemical structure of heparin polysaccharide 
Modified from Ferro et al, (1990). 
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21.Figure 21. The structure of GAG linkage to protein in proteoglycans is presented. 
Modified from King, (2013).  
22.Figure 22. Modified from Glycobiology (King, 2001).  
23.Figure 23. The principle of immunohistochemistry.  
24.Figure 24.  Illustration of a Cell Invasion assay. 
25.Figure 25.  RNAeasy mini procedure using placental cells. Modified from (Qiagen, 
2013).    
26.Figure 27. The localisation of fibroblast growth factor 2 (FGF2) representative 
negative staining in absence of citrate buffer magnification (x100). PE-Pre-eclampsia, 
PTL-Pre-term Labour, TNL-Term-non-Labour, and TL-term labour, (n=56). The 
arrows indicate the trophoblast and (*) the  endothelial cells. 
27.Figure 28a. Immunohistochemical moderate to strong positive staining in villous 
trophoblast (both syncytiotrophoblast and cytotrophoblast), weaker staining in the 
mesenchyme, and in the core foetal vessels for fibroblast growth factor 2 (FGF2) 
expression distributed in placental tissues for Pre-eclampsia (PE), (n=19). 
Magnification of original (x400). The arrows indicates the trophoblast and (*) the  
endothelial cells. 
28.Figure 28b. Immunohistochemical moderate to strong positive staining in villous 
trophoblast (both syncytiotrophoblast and cytotrophoblast), weaker staining in the 
mesenchyme, and in the core foetal vessels for placental growth factor (PLGF) 
expression distributed in placental tissues for Pre-eclampsia (PE), (n=19). 
Magnification of original (x400). The arrows indicates the trophoblast and (*) the 
endothelial cells.  
29.Figure 28c. Immunohistochemical moderate to strong positive staining in villous 
trophoblast (both syncytiotrophoblast and cytotrophoblast), weaker staining in the 
mesenchyme, and in the core foetal vessels for vascular growth factor (VEGF) 
expression distributed in placental tissues for Pre-eclampsia (PE), (n=19). 
Magnification of original (x400). The arrows indicates the trophoblast and (*) the 
endothelial cells.   
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30.Figure 28d. Immunohistochemical moderate to strong positive staining in villous 
trophoblast (both syncytiotrophoblast and cytotrophoblast), weaker staining in the 
mesenchyme, and in the core foetal vessels for platelet-derived growth factor (PDGF-
BB) expression distributed in placental tissues for Pre-eclampsia (PE), (n=19). 
Magnification of original (x400). The arrows indicates the trophoblast and (*) the 
endothelial cells. 
31.Figure 28e. Immunohistochemical moderate to strong positive staining in villous 
trophoblast (both syncytiotrophoblast and cytotrophoblast), weaker staining in the 
mesenchyme, and in the core foetal vessels for hepatocyte growth factor (HGF) 
expression distributed in placental tissues for Pre-eclampsia (PE), (n=19). 
Magnification of original (x400). The arrows indicates the trophoblast and (*) the 
endothelial cells.   
32.Figure 28f. Immunohistochemical moderate to strong positive staining in villous 
trophoblast (both syncytiotrophoblast and cytotrophoblast), weaker staining in the 
mesenchyme, and in the core foetal vessels for cluster differentiation (CD105) 
expression distributed in placental tissues for Pre-eclampsia (PE), (n=19). 
Magnification of original (x400). The arrows indicates the trophoblast and (*) the 
endothelial cells. 
33.Figure 28g. Immunohistochemical moderate to strong positive staining in villous 
trophoblast (both syncytiotrophoblast and cytotrophoblast), weaker staining in the 
mesenchyme, and in the core foetal vessels (*) for heparin binding growth factor 
(HB-EGF) expression distributed in placental tissues for Pre-eclampsia (PE), (n=21). 
Magnification of original (x400). The arrows indicates the trophoblast.  
34.Figure 28h. Immunohistochemical moderate to strong positive staining in villous 
trophoblast (both syncytiotrophoblast and cytotrophoblast), weaker staining in the 
mesenchyme, and in (*) the core foetal vessels for midkine (MK) expression 
distributed in placental tissues for Pre-eclampsia (PE), (n=19). Magnification of 
original (x400). The arrows indicates the trophoblast.  
35.Figure 28i. Immunohistochemical moderate to strong positive staining in villous 
trophoblast (both syncytiotrophoblast and cytotrophoblast), weaker staining in the 
mesenchyme, and in (*) the core foetal vessels for pleiotrophin (PTN) expression 
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distributed in placental tissues for Pre-eclampsia (PE), (n=19). Magnification of 
original (x400). The arrows indicates the trophoblast.  
36.Figure 28j. Immunohistochemical representative negative control, 0 = none, 
without the antibody distributed in placental tissues in Figure 28j. for Pre-eclampsia 
(PE), (n=19) in the absence of citrate buffer. Magnification of original (x401). The 
arrows indicate the trophoblast and the endothelial cells. The arrow indicates the 
trophoblast and (*) the endothelial cells. 
37. Figure 29. The expression of the vascular endothelial growth factor (VEGF), 
placental growth factor (PLGF), 2 = moderate, fibroblast growth factor 2 (FGF2), 4 = 
strong, and cluster differentiation (CD105), 3 = moderate to strong, hepatocyte 
growth factor (HGF) was distributed with 2 = moderate positive staining in villous 
trophoblast (both syncytiotrophoblast and cytotrophoblast), for PTL-Pre-term Labour, 
TL-term labour, and TNL-Term-non-Labour, (n=68) at a magnification of original 
(x401). In the absence of (HBGFs) the placental tissue expressed negative staining 
with a magnification of original (x401). This control was confirmed without the 
antibody. The arrows indicate the trophoblast and (*) the endothelial cells.  
 
38. Figure 30. The expression of the platelet-derived growth factor (PDGF-BB), 
4=strong, heparin binding-epidermal growth factor (HB-EGF), 1=weak, pleiotrophin 
(PTN), (n=30), and Midkine (MK), (n=35), 2=moderate were distributed with 
moderate to strong positive staining in villous trophoblast (both syncytiotrophoblast 
and cytotrophoblast), and the endothelial cells, weaker staining in the mesenchyme, 
and in the core foetal vessels PTL-Pre-term Labour, TL-term labour, and TNL-Term-
non-Labour, (n=68), with a magnification of original (x401). The control showed 
negative staining, i.e.in the absence of the antibody of magnification of original 
(x401). The preincubation with non-specific binding of Human IgG confirmed 
negative staining and does not affect the staining intensity or pattern with a 
magnification of original (x101). The arrows indicate the trophoblast and (*) the 
endothelial cells. 
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39. Figure 31A. The vascular endothelial growth factor (VEGF) expression staining 
score (intensity x coverage) in the four placenta groups studied. Values for each group 
as pre-eclampsia PE versus pre-term PTL, term labour TL, and term non-labour TNL 
(*p <0.05 is considered statistically significant difference in staining in Term non-
labour) using Mann-Whitney U test. The horizontal red line indicates the median 
values.  
40. Figure 31B. represents the placental growth factor (PLGF) expression staining 
score (intensity x coverage) in the four placenta groups studied. Values for each group 
as pre-eclampsia PE versus pre-term PTL, term labour TL, and term non-labour TNL 
(*p <0.05 is considered statistically significant difference in staining in pre-
eclampsia) using Mann-Whitney U test. Figure 31C. represents the cluster 
differentiation (CD105) expression staining score .The horizontal red line indicates 
the median values.  
41. Figure 31D. represents the fibroblast growth factor 2 (FGF2) expression of 
staining score (intensity x coverage) in the four placenta groups studied. Values for 
each group as pre-eclampsia PE versus pre-term PTL, term labour TL, and term non-
labour TNL (*p <0.05 is considered statistically significant difference in staining in 
Term Labour) using Mann-Whitney U test.  Figure 31E. represents the platelet-
derived growth factor (PDGF) expression staining score in the four placenta groups 
studied. The horizontal red line indicates the median values. 
42. Figure 31F. The heparin-binding epidermal growth factor (HB-EGF) expression 
staining score (intensity x coverage) in four placenta groups studied. Values for each 
group as pre-eclampsia PE versus pre-term PTL, term labour TL, and term non-labour 
TNL (*p <0.05 is considered statistically significant difference in staining in Term 
non-labour) using the Mann-Whitney U test. The horizontal red line indicates the 
median values.  
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43. Figure 31G.  represents the midkine (MK) expression staining score (intensity x 
coverage) in the four placenta groups studied. Values for each group as pre-eclampsia 
PE versus pre-term PTL, term labour TL, and term non-labour TNL (*p <0.05 is 
considered statistically significant difference in staining in pre-eclampsia) using the 
Mann-Whitney U test. Figure 31H.  represents the pleiotrophin (PTN) expression 
staining score  values in the four placenta groups studied (*p <0.05 is considered 
statistically significant difference in staining in pre-eclampsia using the Mann-
Whitney U test). The horizontal red line indicates the median values. 
44. Figure 31I. represents the hepatocyte growth factor (HGF) expression staining 
score (intensity x coverage) in the four placenta groups studied. Values for each group 
as pre-eclampsia PE versus pre-term PTL, term labour TL, and term non-labour TNL 
(*p <0.05 is considered statistically significant difference in staining in Pre-term 
Labour and Term Labour using the Mann-Whitney U test). The horizontal red line 
indicates the median values.  
45. Figure 31J. represents the placental growth factor (PLGF) expression staining 
score (intensity x coverage) in Labour and non-Labour placenta groups studied (*p 
<0.05 is considered statistically significant difference in staining in Labour using the 
Mann-Whitney U test). The horizontal red line indicates the median values. 
46. Figure 31K. represents the hepatocyte growth factor (HGF) expression staining 
score (intensity x coverage) in pre-term and term placenta groups studied (* p <0.05 is 
considered statistically significant difference in staining in Pre-term) using the Mann-
Whitney U test. The horizontal red line indicates the median values. 
47. Figure 32. Immunohistochemical moderate to strong positive staining in villous 
trophoblast (both syncytiotrophoblast and cytotrophoblast), weaker staining in the 
mesenchyme, and in the core foetal vessels for fibroblast growth factor 2 (FGF2) 
receptor expression distributed in placental tissues for the four groups PE-Pre-
eclampsia, (n=12), and PTL-Pre-term Labour, (n=6), TL-term labour, (n=22), and 
TNL-Term-non- Labour, (n=21), 3=moderate to strong with a magnification of x401. 
The arrow indicates the trophoblast and (*) the endothelial cells. 
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48. Figure 33.Immunohistochemical moderate to strong positive staining in villous 
trophoblast (both syncytiotrophoblast and cytotrophoblast), weaker staining in the 
mesenchyme, and in the core foetal vessels for vascular endothelial growth factor 
(VEGF) receptor I expression distributed in placental tissues for the four groups PE-
Pre-eclampsia, (n=12), 4=strong, of magnification of original x 101, and TL-term 
labour, (n=22), 2=moderate, PTL-Pre-term Labour, (n=6), and TNL-Term-non-
Labour, (n=21), 3=moderate to strong with a magnification of original x401. The 
arrow indicates the trophoblast and (*) the endothelial cells. 
49. Figure 34. Immunohistochemical moderate to strong positive staining prominent 
in villous trophoblast (both syncytiotrophoblast and cytotrophoblast), weaker staining 
in the mesenchyme, and in the core foetal vessels for vascular endothelial growth 
factor (VEGF) receptor II expression in placental tissues for the four groups PE-Pre-
eclampsia, (n=12), 4=strong, magnification of original x 101, TL-term labour (n=22), 
and TNL-Term-non-Labour (n=21), and PTL-Pre-term Labour, (n=6), 3=moderate to 
strong with a Magnification of x 401 The arrow indicates the trophoblast and (*) the 
endothelial cells. 
50.Figure 35A. Represents the % of assumed invasion for the following cell line 
human trophoblast TCL-1 with the relative fluorescent unit (RFU) at 1000 gain. 
51.Figure 35B. Represents the % of assumed invasion for the following cell line 
human trophoblast TCL-1 with the relative fluorescent unit (RFU) at 2000 gain.   
52. Figure 36. Represents the percentage of invasion presented as mean ± SEM for 
the following cell lines HT 1080 (+ve control) of (n=3, 83.2% ± 1.28%, p<0.05), 
3T3/NIH (-ve control) (n=3, 27.8% ± 2.64%, p<0.05), and human trophoblast TCL-1 
cell line at (n=3, 61.6% ± 1.25%, p<0.05) 0nmol/l. (*p <0.05 vs. HT1080 and 
3T3/NIH, Mann-Whitney U test). 
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53. Figure 37. Represents the percentage of invasion presented as mean ± SEM for 
the following cell lines HT 1080 (+ve control) of (n=3,	57.6% ± 10.8%, p<0.05) 1000 
gain, (n=3,	59.7% ± 11.1%, p<0.05) 1500 gain, (n=3,	65.5% ± 12.3%, p<0.05) 2000 
gain 3T3/NIH (-ve control) (n=3,	21.9% ± 5.1%, p<0.05) 1000 gain, (n=3,	22.5% 
±5.2%, p<0.05) 1500 gain, (n=3,	 25.2% ± 5.8%, p<0.05) 2000 gain and human 
trophoblast TCL-1 cell line in DMEM at (n=3, 21.5% ± 5.0%, p<0.05) 1000 gain, 
(n=3, 22.0% ± 5.1% , p<0.05) 1500 gain, (n=3, 24.6% ± 5.7% , p<0.05) 2000 gain. 
The TCL-1 cell line  in RPMI at  (n=3, 22.9% ± 5.2%, p<0.05) 1000 gain, (n=3, 
23.2% ± 5.3%, p<0.05) 1500 gain,  (n=3, 25.9% ± 5.9%, p<0.05) 2000 gain. (*p 
<0.05 vs. HT1080 and 3T3/NIH, Mann-Whitney U test) at 1000,1500 and 2000 gains. 
54. Figure 38. Represents the percentage of invasion presented as mean ± SEM for 
the following cell lines HT 1080 (+ve control) of (n=3, 100% ± 20.1%, p<0.05), 
3T3/NIH (-ve control) (n=3, 36.5% ± 7.5%, p<0.05), and human trophoblast TCL-1 
cell line with the presence of heparin binding-epidermal growth factor (HB-EGF) 
expression at (n=3, 28.5% ± 2.3%, p<0.05) 0nmol/l, (n=3, 28.7% ± 1.5%, p<0.05) 
1nmol/l, (n=3, 30.2% ± 3.0%, p<0.05) 10nmol/l and (n=3, 29.9% ± 2.4%, p<0.05) 
100nmol/l. (*p <0.05 vs. HT1080 and 3T3, Mann-Whitney U test). 
55. Figure 39A. Represents the percentage of invasion presented as mean ± SEM for 
the following cell lines HT 1080 of (n=3,	60.95% ± 15.70%; and 76.9% ± 6.26%, 
p<0.05), and TCL-1 with the presence of heparin-binding-epidermal growth factor 
(HB-EGF) expression at (n=3, 46.43% ± 4.40%, p<0.05) 0nmol/l, (n=3, 51.794.39%, 
p<0.05) 1nmol/l, (n=3, 53.06% ± 2.58% p<0.05) 10nmol/l and (n=3, 54.28% ± 
2.26%, p<0.05) 100nmol/l. In the presence of heparin at (n=3, 55.72% ± 6.38%, 
p<0.05) 0ng/ml, (n=3, 68.06% ± 4.45%, p<0.05) 1ng/ml, (n=3, 76.51% ± 6.80%, 
p<0.05) 10ng/ml, and (n=3, 79.30% ± 6.84%, p<0.05) 100ng/ml. (* p <0.05 vs. 0 
growth factor, Mann-Whitney U test; † p <0.05 vs. 0 heparin). 
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56. Figure 40B. Represents the percentage of invasion presented as mean ± SEM for 
the following cell lines HT 1080 of (n=3,	10.46% ± 18.68,	and 11.48% ± 19.56%, 
p<0.05), and TCL-1 with the presence of vascular endothelial growth factor (VEGF) 
expression at (n=3, 9.69% ± 1.54%, p<0.05) 0nmol/l, (n=3, 12.28% ± 1.65%, p<0.05) 
1nmol/l, (n=3, 12.41% ± 0.58%, p<0.05) 10nmol/l and (n=3, 13.47% ± 0.98%, 
p<0.05) 100nmol/l. In the presence of heparin at (n=3, 15.87 % ± 1.05%, p<0.05) 
0ng/ml, (n=3, 15.88% ± 0.91%, p<0.05) 1ng/ml, (n=3,18.22% ± 2.15%, p<0.05) 
10ng/ml, and (n=3, 20.24% ± 3.63%, p<0.05) 100ng/ml. (*p <0.05 vs. 0 growth 
factor, Mann-Whitney U test; †p <0.05 vs. 0 heparin). 
57. Figure 41C. Represents the percentage of invasion presented as mean ± SEM for 
the following cell lines HT 1080 of (n=3, 24.7% ± 2.08%;	and 29.17% ± 1.56%, 
p<0.05), and TCL-1 with the presence of fibroblast growth factor 2 (FGF2) 
expression at (n=3, 9.69% ± 1.54%, p<0.05) 0nmol/l, (n=3, 12.28% ± 1.65%, p<0.05) 
1nmol/l, (n=3, 12.41% ± 0.58%, p<0.05) 10nmol/l and (n=3, 13.47% ± 0.98%, 
p<0.05) 100nmol/l. In the presence of heparin at (n=3, 15.87% ± 1.05%, p<0.05) 
0ng/ml, (n=3, 15.88% ± 0.91%, p<0.05) 1ng/ml, (n=3, 18.22% ± 2.15%, p<0.05) 
10ng/ml, and (n=3, 20.24% ± 3.63%, p<0.05) 100ng/ml. (*p <0.05 vs. 0 growth 
factor, Mann-Whitney U test; † p <0.05 vs. 0 heparin). 
58.Figure 42D. Represents the percentage of invasion presented as mean ± SEM for 
the following cell lines HT 1080 of (n=3, 17. 84% ± 2.88%;	and 20.16% ±9.87%, 
p<0.05), and TCL-1 with the presence of placental growth factor (PLGF) expression 
at (n=3, 15.02% ± 2.70%, p<0.05) 0nmol/l, (n=3, 20.18% ± 2.88%, p<0.05) 1nmol/l, 
(n=3, 23.88% ± 7.19%, p<0.05) 10nmol/l and (n=3, 26.72% ± 10.18%, p<0.05) 
100nmol/l. In the presence of heparin at (n=3, 22.33% ± 4.03%, p<0.05) 0ng/ml, 
(n=3, 23.89% ± 6.51%, p<0.05) 1ng/ml, (n=3, 26.64% ± 7.80%, p<0.05) 10ng/ml, 
and  (n=3, 28.30% ± 8.82%, p<0.05) 100ng/ml. (*p <0.05 vs. 0 growth factor, Mann-
Whitney U test; † p <0.05 vs. 0 heparin). 
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59. Figure 43E.Represents the percentage of invasion presented as mean ± SEM for 
the following cell lines HT 1080 of (n=3, 54.99% ± 3.65%;	and 72.68% ± 5.22%, 
p<0.05), and TCL-1 with the presence of platelet-derived growth factor (PDGF) 
expression at (n=3, 27.31% ± 4.50%, p<0.05) 0nmol/l, (n=3, 28.18% ± 6.91%, 
p<0.05) 1nmol/l, (n=3, 40.22% ± 18.74%, p<0.05) 10nmol/l and (n=3, 83.51% ± 
3.80%, p<0.05) 100nmol/l. In the presence of heparin at (n=3, 42.03% ± 6.79%, 
p<0.05) 0ng/ml, (n=3, 43.87% ± 6.91%, p<0.05) 1ng/ml, (n=3, 71.50% ± 18.74%, 
p<0.05) 10ng/ml, and (n=3, 92.1% ± 8.85%, p<0.05) 100ng/ml. (*p <0.05 vs. 0 
growth factor, Mann-Whitney U test; † p <0.05 vs. 0 heparin). 
60. Figure 44F. Represents the percentage of invasion presented as mean ± SEM for 
the following cell lines HT 1080 of (n=3,	11.92% ± 0.58%;	12.01% ± 0.133% and, 
p<0.05), and TCL-1 with the presence of hepatocyte growth factor (HGF) expression 
at (n=3, 11.94% ± 0.61%, p<0.05) 0nmol/l, (n=3, 11.94% ± 0.055%, p<0.05) 1nmol/l, 
(n=3, 12.37% ± 0.10%, p<0.05) 10nmol/l and (n=3, 12.43% ± 0.20%, p<0.05) 
100nmol/l. In the presence of heparin at (n=3, 12.28%±0.15%, p<0.05) 0ng/ml, (n=3, 
12.37% ± 0.18%, p<0.05) 1ng/ml, (n=3,12.46 % ± 0.02%, p<0.05) 10ng/ml, and 
(n=3, 12.52% ± 0.14%, p<0.05) 100ng/ml. (*p <0.05 vs. 0 growth factor, Mann-
Whitney U test; † p <0.05 vs. 0 heparin). 
61. Figure 45G. Represents the percentage of invasion presented as mean ± SEM for 
the following cell lines HT 1080 of (n=3, 42.38% ±1.54%; and	46.27% ± 4.97%, 
p<0.05), and TCL-1 with the presence of Midkine (MK) expression at (n=3, 44.16% 
± 5.80%, p<0.05) 0nmol/l, (n=3, 45.11% ± 4.09%, p<0.05) 1nmol/l, (n=3, 46.23% ± 
4.95%, p<0.05) 10nmol/l and (n=3, 46.30% ± 5.57%, p<0.05) 100nmol/l. In the 
presence of heparin at (n=3, 50.69% ± 1.84%, p<0.05) 0ng/ml, (n=3, 51.63% ± 
2.58%, p<0.05) 1ng/ml, (n=3, 66.58% ± 5.72%, p<0.05) 10ng/ml, and (n=3, 68.82% 
± 5.11%, p<0.05) 100ng/ml. (*p <0.05 vs. 0 growth factor, Mann-Whitney U test; † p 
<0.05 vs. 0 heparin). 
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62. Figure 46H. Represents the percentage of invasion presented as mean ± SEM for 
the following cell lines HT 1080 of (n=3, 45.67%	± 2.88%; and	45.96%	± 9.87%, 
p<0.05), and TCL-1 with the presence of Pleoitrophin (PTN) expression at (n=3, 
75.65%	± 12.83%, p<0.05) 0nmol/l, (n=3, 78.09% ± 3.03%, p<0.05) 1nmol/l, (n=3, 
85.94% ±8.02%, p<0.05) 10nmol/l and (n=3, 99.84%	± 6.35%, p<0.05) 100nmol/l. In 
the  presence of heparin at (n=3, 81.38% ± 13.39%, p<0.05) 0ng/ml, (n=3, 83.25%	± 
6.73%, p<0.05) 1ng/ml, (n=3, 87.94%	± 9.76%, p<0.05) 10ng/ml, and (n=3, 101.09%	
± 20.78%, p<0.05) 100ng/ml.  (*p <0.05 vs. 0 growth factor, Mann-Whitney U test; 
†p <0.05 vs. 0 heparin).                       
63. Figure 47. An agarose gel electrophoresis for 7 different placental tissue mRNA 
samples with a concentration of 100ng/ul for Fibroblast growth factor 2 (FGF2) 
primer assay a, b, c, d and e. This analysis required the DNA ladder and 2 internal 
standard markers (LM and UM). 
 
64. Figure 48. RT-PCR analysis for 7 different placental tissue mRNA samples from 
control and pre-eclampsia (100bp respectively) with their concentration (100ng/ul)  
for Fibroblast growth factor 2 (FGF2) primer assay. This analysis required the DNA 
ladder 100bp ladder (2072-100bp), lanes A1-7 by agarose gel electrophoresis, MW 
Lane: Molecular weight and 2 internal standard markers (LM and UM). 
 
 
65.Figure 49. A gel electrophoresis representation analysis on Multina of 7 different 
placental tissue RNA samples with their concentration (100 ng/ul) for lanes (A1-7) 
Placental growth factor (PLGF), lanes (B1-7) Pleiotrophin (PTN), and lanes  (C1-7) 
Fibroblast growth factor 2 (FGF2) primer assays using the DNA sizing ladder on 
lanes (X1-2) and 2 internal standard markers (LM and UM). 
 
66.Figure 50. An electropherogram analysis on Multina of 7 placental tissue mRNA 
samples at a concentration of 100ng/ul for lanes (A1-7) Midkine (MK) primer assay 
using the DNA sizing ladder on lanes (X1-2) and 2 internal standard markers (LM 
and UM).  
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67.Figure 51. A gel electrophoresis representation analysis on Multina of 7 placental 
tissue mRNA samples at a concentration of 100ng/ul for Succinate dehydrogenase 
complex subunit A (SDHA) primer assay (A1-7) analysis using the DNA sizing 
ladder on lanes (X1) and 2 internal standard markers (LM and UM). 
68.Figure 52. A gel electrophoresis representation analysis on Multina of 7 placental 
tissue mRNA samples with their sensitivity detection for dilutions at a concentration 
of 100ng/ul for Fibroblast growth factor 2 (FGF2) primer assay: analysis using the X1 
and X2  DNA ladder and 2 internal standard markers (LM and UM).   
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(FGF2), platelet-derived growth factor (PDGF), hepatocyte growth factor (HGF), 
vascular endothelial growth factor (VEGF), placental growth factor (PLGF) and 
cluster differentiation (CD105), midkine (MK), pleiotrophin (PTN), heparin-binding 
epidermal growth factor (HB-EGF) using the Spearman’s rank correlation test. The 
Rho represents Spearman’s rank correlation coefficient.  The p-value of < 0.05* and 
p-value of < 0.01** is considered statistically significant. 
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9.Table 9. Correlation between expression of staining intensity for Heparin binding 
growth factors present in placental tissues. Abbreviations: Fibroblast growth factor 2 
(FGF2), platelet-derived growth factor (PDGF), hepatocyte growth factor (HGF), 
vascular endothelial growth factor (VEGF), placental growth factor (PLGF) and 
cluster differentiation (CD105), midkine (MK), pleiotrophin (PTN), heparin-binding 
epidermal growth factor (HB-EGF) using the Spearman’s rank correlation test. The 
Rho represents Spearman’s rank correlation coefficient.  The p-value of < 0.05* and 
p-value of < 0.01** is considered statistically significant.  
 
10.Table 10 a and b. Represents the comparison expression of staining score for 
Heparin binding growth factors present in placental tissues using the Mann-Whitney 
U test. Abbreviations: Fibroblast growth factor 2 (FGF2), platelet-derived growth 
factor (PDGF), hepatocyte growth factor (HGF), vascular endothelial growth factor 
(VEGF), placental growth factor (PLGF) and cluster differentiation (CD105), midkine 
(MK), pleiotrophin (PTN), heparin-binding epidermal growth factor (HB-EGF). PE-
Pre-eclampsia, PTL- Pre-term Labour, TNL-Term-non-Labour, and TL-term labour. 
Comparisons between each group versus all other groups combined. The median is 
given above and p- values are shown. The p-value of < 0.05* and p-value of < 0.01** 
is considered statistically significant. 
 
11.Table 11.Represents the  comparison  expression of staining intensity for Heparin 
binding growth factors present in placental tissues using the Mann-Whitney U test. 
Abbreviations: Fibroblast growth factor 2 (FGF2), platelet-derived growth factor 
(PDGF), hepatocyte growth factor (HGF), vascular endothelial growth factor 
(VEGF), placental growth factor (PLGF) and cluster differentiation (CD105), midkine 
(MK), pleiotrophin (PTN), heparin-binding epidermal growth factor (HB-EGF). PE- 
Pre-eclampsia, PTL- Pre-term Labour, TNL-Term-non-Labour, and TL-term labour. 
Comparisons between each group versus all other groups combined. The median is 
given above and p-values are shown. The p-value of < 0.05* and p-value of < 0.01** 
is considered statistically significant.  
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12.Table 12. Represents the comparison  expression of staining score for Heparin-
binding growth factors present in placental tissues using the Mann-Whitney U test. 
Abbreviations: Fibroblast growth factor 2 (FGF2), platelet-derived growth factor 
(PDGF), hepatocyte growth factor (HGF), vascular endothelial growth factor 
(VEGF), placental growth factor (PLGF) and cluster differentiation (CD105), midkine 
(MK), pleiotrophin (PTN), heparin-binding epidermal growth factor (HB-EGF). PE-
Pre-eclampsia, PTL- Pre-term Labour, TNL-Term-non-Labour, and TL-term labour. 
Comparisons are labour (TL + PTL) versus non-labour (PE + TNL) and Term (TL + 
TNL) versus Pre-term (PE + PTL). The medians and p-values are shown. The p-value 
of < 0.05* and p-value of < 0.01** is considered statistically significant. 
13.Table 13. Repesents the comparison expression of   staining intensity for Heparin-
binding growth factors present in placental tissues using the Mann-Whitney U test. 
Abbreviations: Fibroblast growth factor 2 (FGF2), platelet-derived growth factor 
(PDGF), hepatocyte growth factor (HGF), vascular endothelial growth factor 
(VEGF), placental growth factor (PLGF) and cluster differentiation (CD105), midkine 
(MK), pleiotrophin (PTN), heparin-binding epidermal growth factor (HB-EGF). PE- 
Pre-eclampsia, PTL-Pre-term Labour, TNL-Term-non-Labour, and TL-term labour. 
Comparisons are labour (TL + PTL) versus non-labour (PE + TNL) and Term (TL + 
TNL) versus Pre-term (PE + PTL). The median is given above and p-values are 
shown. The p-value of < 0.05* and p-value of < 0.01** is considered statistically 
significant.   
14.Table 14. Represents the comparison expression of staining scoring results for 
each Heparin- binding growth factors present in placental tissues. Abbreviations: 
Fibroblast growth factor 2 (FGF2), platelet-derived growth factor (PDGF), hepatocyte 
growth factor (HGF), vascular endothelial growth factor (VEGF), placental growth 
factor (PLGF) and cluster differentiation (CD105), midkine (MK), pleiotrophin 
(PTN), heparin- binding epidermal growth factor (HB-EGF). Comparison here is 
between the four groups overall using the Kruskal Wallis analysis of variance. PE-
Pre-eclampsia, PTL-Pre-term Labour, TNL-Term-non-Labour, and TL-term labour. 
The t values and p values are shown. The p-value of < 0.05* and p-value of < 0.01** 
is considered statistically significant. 
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15.Table 15. Comparison expression of staining intensity results for each Heparin- 
binding growth factors present in placental tissues. Abbreviations: Fibroblast growth 
factor 2 (FGF2), platelet-derived growth factor (PDGF), hepatocyte growth factor 
(HGF), vascular endothelial growth factor (VEGF), placental growth factor (PLGF) 
and cluster differentiation (CD105), midkine (MK), pleiotrophin (PTN), heparin- 
binding epidermal growth factor (HB-EGF). Comparison here is between the four 
groups overall using the Kruskal Wallis analysis of variance. PE-Pre-eclampsia, PTL-
Pre-term Labour, TNL-Term-non-Labour, and TL-term labour. The t values and p 
values are shown. The p-value of < 0.05* and p-value of < 0.01** is considered 
statistically significant.       
16.Table 16. Comparison for expression of staining score for fibroblast growth factor 
2 receptor (FGF2R-1), vascular endothelial growth factor (VEGFR-1, and VEGFR 2) 
receptors in placental tissues using the Mann-Whitney U test. PE-Pre-eclampsia, 
PTL-Pre-term Labour, TNL-Term-non-Labour, and TL-term labour. Comparisons 
between each group versus all other groups combined. The medians and p values are 
shown.  
17.Table 17. Comparison for expression of staining intensity for fibroblast growth 
factor receptor 2 (FGF2R-2), vascular endothelial growth factor (VEGFR-1, and 
VEGFR 2)  receptors  in placental tissues using the Mann-Whitney U test. PE-Pre-
eclampsia, PTL-Pre-term Labour, TNL-Term-non-Labour, and TL-term labour. 
Comparisons between each group versus all other groups combined. The medians and 
p values are shown.  
18.Table 18. Comparison for expression of staining score for fibroblast growth factor 
2 receptor (FGF2R-1), vascular endothelial growth factor (VEGFR-1, and VEGFR 2) 
receptors present in placental tissues using the Mann-Whitney U test. PE-Pre-
eclampsia, PTL-Pre-term Labour, TNL-Term-non-Labour, and TL-term labour. 
Comparisons are labour (TL + PTL) versus non-labour (PE + TNL) and Term (TL + 
TNL) versus Pre-term (PE + PTL). The medians and p-values are shown.  
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19.Table 19. Comparison for expression of staining intensity for fibroblast growth 
factor 2 receptor (FGF2R-1), vascular endothelial growth factor (VEGFR-1, and 
VEGFR 2)   receptors present in placental tissues using the Mann-Whitney U test. PE-
Pre-eclampsia, PTL-Pre-term Labour, TNL-Term-non--Labour, and TL-term labour. 
Comparisons are labour (TL + PTL) versus non-labour (PE + TNL) and Term (TL + 
TNL) versus Pre-term (PE + PTL). The medians and p- values are shown.  
20.Table 20. Comparison for expression of staining scoring results for fibroblast 
growth factor 2 receptor (FGF2R-1), vascular endothelial growth factor (VEGFR-1, 
and VEGFR 2) receptors present in placental tissues. Comparison here is between the 
four groups overall using the Kruskal Wallis analysis of variance. PE-Pre-eclampsia, 
PTL-Pre-term Labour, TNL-Term-non-Labour, and TL-term labour. The t values and 
p values are shown.  
21.Table 21. Comparison for expression of staining intensity results for fibroblast 
growth factor 2 receptor (FGF2R-1), vascular endothelial growth factor (VEGFR-1, 
and VEGFR 2) receptors present in placental tissues. Comparison here is between the 
four groups overall using the Kruskal Wallis analysis of variance. PE-Pre-eclampsia, 
PTL-Pre-term Labour, TNL-Term-non--Labour, and TL-term labour. The t values and 
p values are shown.  
22.Table 22. Correlation between expression of staining score for fibroblast growth 
factor 2 receptor (FGF2R-1), vascular endothelial growth factor (VEGFR-1 and 
VEGFR-2) receptors in placental tissues. Using the Spearman’s rank correlation test. 
The Rho represents Spearman’s rank correlation coefficient.   
23.Table 23. Correlation between expressions of staining intensity for fibroblast 
growth factor 2 (FGF2), vascular endothelial growth factor (VEGFR-1 and VEGFR-
2) receptors present in placental tissues. Using the Spearman’s rank correlation test. 
The Rho represents Spearman’s rank correlation coefficient.   
24.Table 28. The 7 different placental tissue mRNA samples with their sensitivity 
dilutions at a concentration of 100ng/ul for Placental growth factor (PLGF), 
Fibroblast growth factor 2 (FGF2), Pleiotrophin (PTN), and Midkine (MK) primer 
assays.  
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25.Table 29. Comparison of 7 placental tissue mRNA expression with their sensitivity 
at concentration  (100ng/ul) for the following Heparin-binding growth factors primer 
assays using the Mann Whitney U test. Abbreviations: fibroblast growth factor 2 
(FGF2), placental growth factor (PLGF), midkine (MK), and pleiotrophin (PTN). The 
control (Term (TL + TNL) not in labour) was compared versus pre-eclampsia (PE). 
The median is given above and p-values are shown. The p-values are indicated p < 
0.05* and p< 0.01. ** 
26.Table 25. The clinical characteristics of pregnancies in this large study cohort of 
87 women. The values are expressed as mean ± (interquartilerange-IQR). PE-Pre-
eclampsia, PTL-Pre-term Labour, TNL-Term-non-Labour  (Caesarean section), and 
TL-term labour.  
27.Table 26. The 7 different Placental tissue mRNA samples (control and pre-
eclampsia (PE) at a concentration of 100ng/ul for Placental growth factor (PLGF), 
Fibroblast growth factor 2 (FGF2), Pleiotrophin (PTN), Midkine (MK), and Succinate 
dehydrogenase complex subunit A (SDHA) primer assays. 
28.Table 27. Comparison of 7 different placental tissue mRNA expression at a 
concentration of 100ng/ul for the following heparin binding growth factor primer 
assays using the Mann-Whitney U test. Abbreviations: fibroblast growth factor 2 
(FGF2), placental growth factor (PLGF), midkine (MK), pleiotrophin (PTN) and 
Succinate dehydrogenase complex subunit A (SDHA). Control (Term (TL + TNL) 
not in labour) and pre-eclampsia (PE) were compared. The median is given above and 
p-values are shown. The p-values are indicated p < 0.05* and p< 0.01**. 
29.Table 28.The 7 different placental tissue mRNA samples with their sensitivity 
dilutions at a concentration of 100ng/ul for Placental growth factor (PLGF), 
Fibroblast growth factor 2 (FGF2), Pleiotrophin (PTN), and Midkine (MK) primer 
assays.  
30.Table 29. Comparison of 7 placental tissue mRNA expression with their sensitivity 
at concentration (100ng/ul) for the following Heparin-binding growth factors primer 
assays using the Mann Whitney U test. Abbreviations: fibroblast growth factor 2 
(FGF2), placental growth factor (PLGF), midkine (MK), and pleiotrophin (PTN). The 
control (Term (TL + TNL) not in labour) was compared versus pre-eclampsia (PE). 
The median is given above and p-values are shown. The p-values are indicated p < 
0.05* and p< 0.01. ** 
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Acronym and abbreviations 
ACTH        Adrenocorticotropic hormone 
ABC          Avidin biotin complex 
ADAM12  Disintergrin & Metalloproteinase domain-containing protein 12 
AFP           Alpha-Fetoprotein        
A1M          Alpha-1-Microglobulin 
APS           Antiphospholipid syndrome 
CC             Cytotrophoblast column 
CD105      Cluster differentiation 105 (endoglin) 
CRH          Corticotrophin releasing hormone 
CT             Cytotrophoblasts 
DAB          3,3’-Diaminobenzidene 
ECM         Extracellular matrix 
EGF           Epidermal growth factor 
EVT           Extravillous trophoblast 
EnEVT       Endovascular Extravillous trophoblast 
InEVT        Interstitial Extravillous trophoblast 
FTN           First trimester non-Labour 
GnRH         Gonadotropin releasing hormone 
GHRH        Somatostain, and growth hormone-releasing hormone  
hACTH       Human chorionic adrenocorticotropin 
HbF            Free foetal haemoglobulin 
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HBGF         Heparin-binding growth factor 
HB-EGF     Heparin-binding epidermal growth factor 
hCT            Human chorionic thyrotropin. 
hCG            Human chorionic gonadotropin 
hCS             Human chorionic somatomammotropin 
HGF            Hepatocte growth factor 
HELLP        Hemolysis, elevated liver enzymes, low platelet count 
HIER           Heat induced epitope retrieval 
hpl               Human placental lactogen 
Hrp              Horseradish peroxidise 
HGH-V        Growth hormone variant 
Inhibin A     Hormone Inhibin A  
IL-11           Interleukin II 
kDa              Kilodalton 
LIF               Leukaemia inhibitory factor  
FGF2            Fibroblast growth factor 2   
FGF2R-1      Fibroblast growth factor 2 receptor-2  
FGR              Foetal growth restriction 
FSH               Follicle stimulating hormone 
IgG                Immunoglobulin 
IGFs              Insulin-like growth factors 
IGF-1            Insulin-like Growth factors I 
IGF-11          Insulin-like Growth factors II 
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IUGR            Intrauterine growth retardation 
LH                Luteinizing hormone 
MK               Midkine 
MMPs           Matrix metalloproteinases 
MW               Molecular weight 
mRNA          messenger Ribonucleic Acid 
PBS               Phosphate buffered saline 
PE                  Pre-eclampsia 
PIH                Pregnancy-induced hypertension 
PP13              Placental Protein13 
PLGF             Placenta growth factor 
PLGFR-1       Placenta growth factor receptor-1 
PDGF            Platelet-derived growth factor  
PDGF!          Platelet-derived growth factor-alpha 
PDGF!          Platelet-derived growth factor-beta 
PAPP-A         Pregnancy- associated Protein A 
PTL                Preterm labour 
PTN               Pleiotrophin  
SA                  Spiral artery 
SGA               Small for gestational age 
ST           Syncytiotrophoblast 
STBM            Syncytiotrophoblast membrane fragments 
TGF               Transforming growth factor 
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TGFβ              Transforming growth factorβ 
TL                   Term Labour 
TNFα              Tumor necrosis factor 
TNL                Term non-Labour 
TRH                Thyrotropin releasing hormone 
VEGF  Vascular Endothelial Growth Factor 
sVEGFR-1/ sflt-1  soluble vascular endothelial growth factor receptor-1/ flt-1 
VEGFR-2        Vascular endothelial growth factor receptor-2 
uE3                  Unconjugated Oestriol 
uNK cells        Uterine Natural Killer cells  
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1.1.  Pre-eclampsia.  
Pre-eclampsia (PE) is a complex multifactorial pregnancy-specific disorder 
originating in the placenta. Pre-eclampsia is the leading cause of maternal and foetal 
morbidity, and mortality	(Lyall and Belfort, 2007; Meis et al, 1998; Duley et al, 2006; 
Steegers, et al, 2010; Tuffnell et al, 2010; Uzan et al, 2011; and Munir et al, 2013).	
Even without progression to eclampsia, the syndrome presents substantial risk to 
mother and baby. Each year, worldwide ≥ 4 million women will develop pre-
eclampsia and approximately 100 000 women will have eclamptic convulsions, with 
over 90% occurring in developing countries (RCOG, 2010). Estimates of incidence in 
developed countries vary. Pre-eclampsia complicates 2–3% of all pregnancies and 2% 
of women with pre-eclampsia will develop eclampsia, a potentially fatal condition 
(RCOG, 2010). Eclampsia affects 700,000 pregnancies each year, leading to 43,000 
maternal deaths worldwide. Many factors, including genetic predisposition, 
immunological interactions, maternal endothelial function and environmental factors 
interact and culminate in the disease manifestation	(RCOG, 2010). 
The main clinical characterization is recognised by onset of hypertension (blood 
pressure ≥ 140/90mm Hg) developing after the 20th week of pregnancy and 
proteinuria (urine protein level ≥ 300 mg/L) (Lyall and Belfort, 2007; and Williams, 
2010). Symptoms include high blood pressure, headaches, blurred vision, abdominal 
pain, nausea, vomiting, confusion, shortness of breath and excessive swelling 
(oedema) of the hands and feet (Lyall and Belfort, 2007). Pre-eclampsia can progress 
to seizures such as eclampsia, renal impairment, thrombocytopenia, liver dysfunction 
or foetal compromise and coagulopathy (Akercan et al, 2008; and Lyall and Belfort, 
2007). Occasionally, PE may progress to another illness; such as the HELLP 
syndromes were haemolysis, elevated liver function tests and platelets. This condition 
is characterised by nausea, malaise, abdominal pain, affecting women of severe PE 
and those who have progressed to eclampsia (Lyall and Belfort, 2007; and Williams, 
2010). Pre-eclampsia can quickly develop into a life-threatening condition for both 
mother and foetus (Kingdom et al, 2000; and Lyall and Belfort, 2007). 
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1.1.1. Normal development and the Human placenta. 
The placenta is a vital specialized organ connecting the mother and the foetus and has 
an essential role for the maintenance of a healthy normal pregnancy (Johnson, & 
Everitt, 2007;	 Wang & Zhao, 2010; Williams, 2010; and Kay et al, 2011). The 
placenta forms an interface between the maternal and foetal circulations (Johnson, & 
Everitt, 2007;	Wang & Zhao, 2010; Williams, 2010; and Kay et al, 2011). The mother 
is the supplier of oxygen and essential nutrients to the foetus via the placenta 
(Johnson, & Everitt, 2007;	Wang & Zhao, 2010; Williams, 2010; and Kay et al, 
2011). This is the site for physiological exchange of, metabolites, carbon dioxide and 
waste products (Johnson, & Everitt, 2007;	Wang & Zhao, 2010; Williams, 2010; and 
Kay et al, 2011).The placenta performs a remarkable range of functions at various 
stages of foetal development until the foetal organs become functional (Johnson, & 
Everitt, 2007;	Wang & Zhao, 2010; Williams, 2010; and Kay et al, 2011). During 
early pregnancy, the placenta synthesizes glycogen, cholesterol and fatty acids, which 
serve as sources of nutrients and energy for the embryo and foetus (Johnson, & 
Everitt, 2007;	Wang & Zhao, 2010; Williams, 2010; and Kay et al, 2011). In addition 
to its crucial transporting role, the placenta is also an important endocrine organ that 
secretes a wide variety of hormones (Johnson, & Everitt, 2007;	Wang & Zhao, 2010; 
Williams, 2010; and Kay et al, 2011). It produces numerous growth factors, secretes 
peptides, synthesizes steroids, protein hormones, transfers nutrients and prevents 
immune rejection of the foetal allograft (Johnson, & Everitt, 2007;	Wang & Zhao, 
2010; Williams, 2010; and Kay et al, 2011). Foetal survival, foetal growth and 
successful development are dependent on a normal functional placenta (Johnson, & 
Everitt, 2007;	Wang & Zhao, 2010; Williams, 2010; and Kay et al, 2011). There are 
many growth factors that are required in foetal growth and development of the normal 
functional placenta that act via different mechanism of action (Ruoslahti and 
Yamaguchi, 1991; Wang & Zhao, 2010 Williams, 2010; and Kay et al, 2011). 
Adequate trophoblast invasion, increased uteroplacental blood flow and proper 
physiological remodelling of uterine spiral arteries ensure growth of the uterus, 
placenta, and foetus (Johnson, & Everitt, 2007;	Wang & Zhao, 2010; Williams, 2010; 
and Kay et al, 2011). 
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1.1.2. The mature placenta. 
The human placenta is termed haemochorial villous organ because it provides direct 
contact between maternal blood and the chorionic (foetal) villi in the intervillous 
space (Williams, 2010). The structure of the placenta provides a very large surface 
area by 28 weeks and progressively increases throughout pregnancy (Williams, 2010). 
At term, it has a diameter of 22 cm, a central thickness of 2.5 cm, and weighs 
approximately 500g, with a surface area of almost 11 square metres (Williams, 2010). 
Five to ten percent of this surface area is thin, measuring a few microns (Williams, 
2010). Foetal membranes are attached to the uterus in the placenta (Williams, 2010). 
A discoidal placenta is shown in Figure 1. As can be seen, the placental villi are 
surrounded by blood from the maternal circulation (Williams, 2010).  
                                                                                                     Foetal side   
  
                                           
 
 
      Placental villi                                                                                           Maternal side 
Figure 1. represents a schematic drawing of a normal section through a full-term placenta. The 
physiology of maternal-placental circulations is shown. The embryonic circulation consists of 
umbilical arteries in blue and umbilical vein is red. The arrow in black presents maternal blood that 
circulates in spaces between the villi. Modified from Williams, (2010). 
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1.1.3. Placental function. 
1.1.3.1. Haemochorial placental blood flow. 
There is no intermingling of maternal and foetal blood in the placenta. The placenta is 
a unique vascular organ. It receives blood supplies from both the maternal and the 
foetal circulatory systems, which are separated by several tissues called the placental 
membrane or placental barrier. Some villi anchor the villous tree to the basal plate 
whereas the bulk of the placenta comprises trees of gas-exchanging terminal villi 
floating in the maternal blood.  
The placental circulation consists of two distinctly different systems (Wang & Zhao 
2010). The uteroplacental blood circulation is essential for sufficient exchange of 
gases as oxygen, water, nutrients and waste products. It’s the terminal villi that are 
grape-like structures that are important as these are characterized by capillarization 
and dilated sinusoids. The terminal villi are linked to stem villi that connect to 
chorionic plate and are characterized by condensed fibrous stroma containing both 
large vessels with microvessels. As maternal blood flows around terminal villi and 
into the intervillous space this process occurs via decidual arteries. The in-flowing 
maternal arterial blood pushes the deoxygenated blood into the endometrial veins. 
However, it is the uterine veins that drain the deoxygenated blood. The maternal rate 
of placental blood flow at term is approximately 600–700 ml/minute (80% of the 
uterine perfusion). The foetoplacental blood circulation involves two umbilical 
arteries that carry deoxygenated and nutrient-depleted foetal blood into the villous 
core foetal vessels to the placenta. It is the umbilical vein, which supplies fresh 
oxygenated and nutrient-rich blood from the placenta to the foetus. Wang & Zhao, 
(2010), estimated that the surface area of syncytiotrophoblasts is approximately 12m2 
and the length of foetal capillaries is approximately 320 kilometres. The terminal villi 
are essential components of the functional unit of maternal-foetal exchange of oxygen 
and nutrients (Wang & Zhao, 2010). 
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1.1.3.2. Transfer between mother and foetus. 
The mechanisms by which transfer of substances across the placenta between the 
mother and foetus occurs include passive diffusion, facilitated diffusion, active 
transport, endocytosis and exocytosis. The placental transfer or transport involves 
bidirectional movement of gases, nutrients, waste materials, drugs and other 
substances across the placenta between maternal and foetal circulations. The process 
of transfer of substances across the placenta requires blood flow from the foetus via 
the umbilical vein into the foetal capillary epithelium across the placental membrane, 
entering the intervillous space and then into the endometrial spiral arteries. Blood 
flows from the mother via the endometrial spiral arteries, and enters the intervillous 
space across the placental membrane into the foetal capillary via the umbilical vein. A 
counter current mechanism exists whereby blood from the maternal circulation as 
shown in red in Figure 1. (modified from Williams, 2010) is separated from foetal 
blood containing foetal waste products, as shown in blue, returning back to the 
maternal circulation via the umbilical vein that carries oxygenated blood to the foetus. 
Transport across the placenta increases during the course of gestation due to changes 
in placental structure (decreasing the distance between maternal and foetal blood), 
increased foetal and maternal blood flow, and greater foetal demands. Placental 
transfer increases as the foetal growth rate increases (Wang & Zhao 2010; and Kay et 
al, 2011).  
Syncytiotrophoblasts are an important site of transport with substances moving from 
the apical membrane close to the maternal blood in intervillous space, and across the 
cell wall to the basal membrane of foetal capillary epithelium. Several mechanisms 
are summarised by which specific substances across are transferred the placenta. 
Protein carriers and other transporters mediate facilitated diffusion and active 
transport. For pregnancy the placental syncytiotrophoblast represents the barrier 
between the maternal and foetal circulations, (Wang & Zhao 2010; Williams, 2010; 
and Kay et al, 2011). 
1.1.3.3a. Simple (passive) diffusion. Diffusion is movement of a substance from 
higher to lower concentration down electrochemical gradients and is a passive 
process. Diffusion is the major mechanism of placental transfer. For example water, 
electrolytes, oxygen, carbon dioxide, urea, simple amines, creatinine, fatty acids, 
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steroids, fat-soluble vitamins, narcotics, antibodies, barbiturates, and anesthetics. 
Simple diffusion allows most substances with a molecular mass ≤ 5000 Da to pass 
through the placental tissue (Johnson, & Everitt, 2007;	Wang and Zhao, 2010; and 
Kay et al, 2011). 
1.1.3.3b. Facilitated diffusion. This involves transport via protein carriers and other 
transporters to move substances like glucose and oxygen across the placental 
membrane. Transporters are located on both the maternal-facing border 
sycytiotrophoblast and the foetal-facing basal membrane (Johnson, & Everitt, 2007;	
Wang and Zhao, 2010; and Kay et al, 2011).  
1.1.3.3c. Active Transport. This utilizes energy-dependent carrier systems and other 
transporters to move substances against concentration or electrochemical gradients. 
For example: amino acids, water-soluble vitamins, calcium, iron, and iodine (Johnson 
& Everitt, 2007;	Wang and Zhao, 2010; and Kay et al, 2011). 
1.1.3.3d. Pinocytosis. This is nonspecific in the substances that it transports and is 
used primarily for the absorption of extracellular fluids (ECF) (Johnson, & Everitt, 
2007;	Wang and Zhao, 2010; and Kay et al, 2011). 
1.1.3.3e. Endocytosis and exocytosis. These include the globulins, phospholipids, 
lipoproteins, antibodies and viruses (Johnson, & Everitt, 2007;	Wang and Zhao, 2010; 
and Kay et al, 2011). 
1.1.3.3f. Bulk flow and ‘solvent drag,’ for example, are water and electrolytes. 
Capillary breaks, for example, are the intact blood cells. However, the maternal 
leukocytes - organisms such as Treponema pallidum - are known for independent 
movement (Johnson, & Everitt, 2007;	Wang and Zhao, 2010; and Kay et al, 2011). 
The foetus communicates with the mother via the placenta. Several factors, including 
maternal health, smoking, hypoxia, and nutritional status, may influence the maternal 
pregnancy (Johnson, & Everitt, 2007;	Wang and Zhao, 2010; and Kay et al, 2011). 
Hormones produced by the placenta alter maternal metabolism and behavior, nutrient 
intake, and uterine artery blood flow. These changes are necessary to promote 
placental development and growth (Johnson, & Everitt, 2007;	Wang and Zhao, 2010; 
and Kay et al, 2011). 
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1.2. Synthesis and secretion of placental hormones and growth factors.  
A wide variety of hormones are produced that shift control of many regulatory 
functions away from the mother to the foetus. This is essential for optimal control of 
the gestation (Kay et al, (2011).     
1.2.1. Placental hormones. 
Most placental hormones are synthesised and secreted from the cytotrophoblast, 
syncytiotrophoblast, or both during pregnancy. The villous stromal cells and 
macrophages i.e. Hofbauer cells, are another source of hormones and growth factors	
(Kay et al, (2011).	 By 10 days post-conception cytotrophoblast and 
syncytiotrophoblast are present. Cytotrophoblast stains positive for expression of 
hypothalamic-like protein hormones: gonadotropin releasing hormone (GnRH), 
corticotrophin releasing hormone (CRH), and thyrotropin releasing hormone (TRH). 
Syncytiotrophoblast stain for the corresponding pituitary-like peptide hormones for 
example (hCG) analogous to pituitary (LH), (ACTH) and (hCT). 
The villous syncytiotrophoblast is a major source of placental hormones such as 
Human chorionic gonadotropin (hCG), Oestrogens and progesterone, Human 
placental lactogen (hPL), Human placental growth hormone,	 Insulin	growth	factors	and	endothelial	growth	 factor.	Autocrine, paracrine and endocrine hormones from 
the cytotrophoblasts and syncytiotrophoblast regulate placental development and 
function. These hormones also modulate maternal physiological changes that occur in 
pregnancy and promote foetal growth. The EVTs synthesize human placental lactogen 
(hPL) and markers of migrating cells	 within the endometrium and myometrium 
(Knobil et al, 1994; Wang & Zhao, 2010; and Kay et al, 2011).	The lytic activity of 
the syncytiotrophoblast cells causes the rupture of both maternal arterial and venous 
blood vessels with a resultant flow of maternal blood from the arteries into the lacunar 
spaces and back into the maternal system via the veins (Wang & Zhao, 2010; and Kay 
et al, 2011).	 
The syncytiotrophoblast is the main endocrine component of the placenta and forms 
the epithelial covering of the villous tree (Wang & Zhao, 2010; Williams, 2010; and 
Kay et	al,	2011).		
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The major placental hormones for successful pregnancy outcome are listed below	(Knobil et al, 1994; Johnson & Everitt, 2007; Wang and Zhao, 2010; and Kay et al, 
2011).  
1.2.1.1. Human chorionic gonadotropin (hCG). Structurally, this glycoprotein 
resembles luteinizing hormone (LH) and is synthesized by syncytiotrophoblast before 
implantation. It is responsible for maintaining the maternal corpus luteum that 
secretes progesterone and oestrogens essential for pregnancy maintenance. Thus, 
(hCG) stimulates (LH) receptor in the foetus (Kay et al, 2011) and is the basis for 
early pregnancy tests.  Production peaks at eight weeks and then gradually declines. 
By the end of the first trimester, the placenta produces enough of these steroids to 
maintain the pregnancy and the corpus luteum is no longer needed (Kay et al, 2011).		
1.2.1.2.	 	 Oestrogens and progesterone.	 The placenta can produce progesterone 
independently from cholesterol precursors and oestrogen together with the foetal 
adrenal gland, as it does not contain all the necessary enzymes itself. Oestrogen 
stimulates uterine blood flow and contributes to maternal weight gain. However, 
progesterone’s primary function is endometrial decidualsation, myometrial 
quiescence, and decreases insulin sensitivity	(Kay	et al,	2011).		
1.2.1.3. Human placental lactogen (hPL).	 Human placental lactogen (hPL) is also 
called human chorionic somatomammotropin (hCS):  it is similar in structure to 
growth hormone and influences growth, maternal mammary duct proliferation and 
lipid and carbohydrate metabolism. This hormone is also called human chorionic 
somatomammotropin (hCS):  It is similar in structure to growth hormone and 
influences growth, maternal mammary duct proliferation, and lipid and carbohydrate 
metabolism	(Kay	et al,	2011).			 
1.2.1.4. Human placental growth hormone.	 This differs from pituitary growth 
hormone by 13 amino acids and replaces maternal pituitary growth hormone from 15 
weeks until the end of pregnancy. Its function is the regulation of maternal blood 
glucose levels for the foetus with adequate nutrient supply. Its secretion is stimulated 
by insulin production, i.e. low maternal blood glucose levels. It promotes weight gain 
(Kay	et al,	2011).		It stimulates gluconeogenesis in the maternal liver.		
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1.2.1.5. Other hormones.	 Human placental growth hormones function is the 
regulation of maternal blood glucose levels for the foetus with adequate nutrient 
supply. It is the Insulin-like growth factors (IGFs) produced in large quantities by 
cytotrophoblasts that regulate foetal and placental growth. IGFs stimulate 
proliferation, and differentiation (Kay	et al,	2011). Matrix metalloproteinases (MMPs) 
are proteolytic enzymes that break down the extracellular matrix within the deciduas. 
IGFs and MMPs are both believed to be important for placental development	(Hills	et 
al,	2004).	It is from the 4 to 5-week-old placenta that the endothelial growth factor is 
produced and stimulates proliferation of the trophoblast.  
In the placenta, both Human chorionic thyrotropin (hCT) and Human chorionic 
adrenocorticotropin (hACTH) are produced in small amounts. Their functions are 
similar to pituitary thyrotropin and pituitary adrenocorticotropic hormone (ACTH). It 
is the decidua cells that produce relaxin that softens the cervix and pelvic ligaments in 
preparation for childbirth. Also, produced are the growth hormone variant (HGH-V), 
parathyroid hormone-related protein (PTH-rP), calcitonin, relaxin, leptin, 
neuropeptideY, inhibins, activins, and atrial natriuretic peptide. In addition there are 
hypothalamic –like releasing and inhibiting hormones namely thyrotrophin-releasing 
hormone (TRH), gonadotrophin-releasing hormone (GnRH), corticotrophin-releasing 
hormone (CRH), somatostain and growth hormone-releasing hormone (GHRH)	
(Wang & Zhao, 2010; Williams, 2010; Kay	et al,	2011). 
1.2.1.6. Embryonic and placental development. 
The process of fertilization is fusion of spermatozoon and an ovum in the ampulla of 
the fallopian tube (Johnson, & Everitt, 2007: Wang & Zhao, 2010: Williams, 2010: 
Kay et al, 2011). This is followed by differentiation during embryonic development. 
The formation of the placenta begins with the outer cell layer trophectoderm, which 
consists of a simple layer of specialized epithelial cells termed trophoblast. 
Trophoblastic cells are formed during the process embryogenesis and have a critical 
role at the foetal-maternal interface until term. The trophoblast exhibits the most 
variable structure, function and developmental pattern of all placental components. 
The inner layer embryoblast consists of undifferentiated pluripotent embryonic stem 
cells that develop into the embryo. These differentiate at the morula stage and form 
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the embryonic part of the placenta. Several days of slow cleavage division occurs for 
the first 3 to 4 days, as the blastomeres divides continually without growth to produce 
the morula. This enters the uterine cavity about 3 to 4 days after fertilization. It is the 
gradual accumulation of fluid between the cells of the morula	(Johnson, & Everitt, 
2007; Wang & Zhao, 2010; Williams, 2010; and Kay et al, 2011).  
 
1.2.1.7.  Implantation and the Blastocyst. 
Implantation of the embryo into the uterine wall takes place 6 or 7 days after 
fertilization. This process involves three phases: the initial adhesion of the blastocyst 
to the uterine wall is known as apposition and adhesion brings an increased physical 
contact between the blastocyst and the uterine epithelium. The final phase is 
trophoblast invasion, an essential process for embryo implantation and placental 
formation (Kay et al, 2011). The main structural and functional units of the placenta 
are chorionic villi. Key cells inside chorionic villi are cytotrophoblast. They 
proliferate, invade, migrate and differentiate to syncytiotrophoblast (Kay et al, 2011; 
and Williams, 2010). It’s the extravillous trophoblast (EVT) invasion that migrates 
into the maternal decidualized endometrium, invades the myometrium, penetrates the 
maternal uterine vasculature and remodels the uterine spiral arteries supplying oxygen 
and nutrients during early placentation (Kay et al, 2011; Williams, 2010). The 
trophoblast cells derived from the outer cell layer of the blastocyst (trophectoderm) 
mediate implantation. This is the process by which the early embryo establishes a 
physical connection with the mother. This is called placentation. The placenta begins 
to develop after implantation approximately eight days after fertilisation. However, 
the precursor cells to the placenta are present at the first differentiation stage of the 
blastocyst as shown in Figure 2. In the first stage of implantation day 6 there is a 
change in structure of the trophoblast cells with a reduction in number of apical 
microvilli allowing a closer association of the trophoblast cells and the uterus 
(Williams, 2010). The embryonic stem cells that develop into the embryo during 
implantation actively secrete hCG, which is detected in maternal serum on the 8th day 
after ovulation (Wang & Zhao, 2010; and Williams, 2010). 
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Figure 2. The blastocyst development and differentiation between placental 
trophectoderm and foetal inner cell mass (from Carlson, 2011). 
Implantation is accomplished through the invasive activities of syncytiotrophoblast 
that are derived from the cytotrophoblast	(Johnson, & Everitt, 2007; Wang & Zhao, 
2010; Williams, 2010; and Kay et al, 2011). This is then followed by interdigitation 
of the uterine microvilli and the trophoblast cell membrane. At this stage the 
trophoblast differentiates into two layers, the cytotrophoblast and the 
syncytiotrophoblast, which is made from fused cytotrophoblast formed into 
multinucleated cells. The inner cytotrophoblast layer is composed of individual and 
rapidly dividing cells. 
	
A)                                                  B)                                                 C) 
Figure 3A represents blastocyst implantation and differentiation. Figure 3B represents 
the blastocyst and cytotrophoblast proliferation during invasion. Figure 3C represents 
the invasive multinucleated syncytiotrophoblast. Adapted from Kay et al, (2011).  
 
Trophectoderm 
(will become placenta) 
Inner cell mass 
(will become foetus) 
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The first step in implantation of the blastocyst is known as apposition, as shown in 
Figure 3A. The outer layer is trophectoderm that is comprised of trophoblast cells 
(yellow). The trophectoderm cells form the multiple cytotrophoblasts. The adhesion 
process occurs within the inner cell mass near the decidua in the blastocyst. An 
invasive multinucleated syncytiotrophoblast (ST) is formed. The bilaminar disk of 
embryoblast and amnioblast arise because of inner cell mass differentiation, as shown 
in Figure 3B. The synctiotrophoblast vacuoles coalesce to form the lacunae following 
the process of invasion in Figure 3C. The maternal blood at a high volume and low 
pressure with erosion of maternal capillaries fills in the intervillous space of lacunae. 
The syncytiotrophoblast (ST) cells have highly invasive properties during 
implantation and penetrate the uterine epithelium into the underlying stromal. As the 
syncytiotrophoblast continue to proliferate and delineate extracytoplasmic cavities. 
This process results in formation of lacunae lined with syncytiotrophoblast cells, as 
shown in Figure 3C above. Primary villi formed by the trophoblast cells are invaded 
by mesenchyme cells and transformed into secondary villi. Syncytiotrophoblast lines 
the foetal side of the intervillous space opposite the decidualized endometrium of the 
maternal side (Kay et al, 2011).  
Syncytiotrophoblast cells are exposed to the maternal bloodstream and separated from 
the foetal circulation, as shown in Figure 6.  
Therefore, most placental hormones are protein hormones for example PAPPA, hCG, 
ADAM12, PP-13 are for the first trimester, and hCG, Inhibin A, uE3, AFP for second 
trimester prenatal diagnosis (Kay et al, 2011). These are mainly secreted into the 
maternal circulation in concentrations much higher than in the foetus. 
Syncytiotrophoblasts interact with the maternal blood supply to secrete placental 
hormones directly into the circulation. Decidua lines the maternal surface of the 
intervillous space and secretes protein hormones (Williams, 2010). Decidual 
hormones include epidermal growth factor (EGF) and vascular endothelial growth 
factor (VEGF) and leukaemia inhibitory factor (LIF) (Lyall and Belfort, 2007; and 
Kay et al, 2011). 
At this stage, the embryo develops inside the uterus and there is very little maternal 
blood supply to the embryo.  
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1.2.1.8. Placental oxygenation.  
Normal early placental villous development occurs in a low oxygen environment (PO2 
˜
 3%), which increases to 8% oxygen during 10-12 weeks of pregnancy (Rodesch et 
al, 1992). The higher level then persists for the remainder of a successful pregnancy. 
This change in placental oxygen supply for the first 10 and 12 weeks of gestation is a 
critical time for establishing the maternal-placenta circulation. The cytotrophoblast 
plugs in maternal spiral arteries limit the access of maternal arterial blood flow to the 
placenta intervillous space. During weeks 10-12 of pregnancy the cytotrophoblast 
plugs are lost from the maternal spiral arteries, which leads directly to increased 
maternal blood supply and oxygen to the placenta (Wang & Zhao 2010). Crucially, 
this change is linked to increased expression of enzymes in the placenta that protect 
against oxidative stress (Jauniaux et al, 2000). It is suggested that cytotrophoblast 
plugs give rise to intermittent placental blood flow, hypoxia/reperfusion and oxidative 
stress (Wang & Zhao 2010; Burton et al, 2003; and Hubel, 1999). This results in 
extensive cellular damage, which is believed to be a key factor in the pathogenesis of 
pre-eclampsia (Burton and Jauniaux 2004). However, the maternal blood supply is 
transformed from around eight weeks gestation following a secondary wave of 
invasion.  
 
1.2.1.9. Trophoblast differentiation and different subtypes.  
The trophoblast has a critical role at the foetal-maternal interface until term. The 
trophoblast exhibits the most variable structure, function and developmental pattern of 
all placental components. The trophoblast lineage develops first at the blastocyst 
stage. After blastocyst implantation is complete, further differentiation occurs, as 
generations of the syncytiotrophoblast subsequently form two main trophoblast types 
of placental villi known as villous cytotrophoblast and villous syncytiotrophoblast 
(Benirschke et al, 2006; Kay et al, 2010; and Williams, 2010). Those trophoblast cells 
that start to invade the maternal uterine tissues are termed extravillous trophoblast 
with the respective subtypes (Modified from Benirschke et al, 2006; Kay et al, 2010; 
Wang & Zhou, 2010; and Williams, 2010) as shown in Figure 4. Eventually, these 
extravillous trophoblast cells migrate as interstitial trophoblast first enter the decidua, 
then subsequently the endometrial stroma. The interstitial trophoblasts penetrates 
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further into the wall of spiral arteries known as intermural trophoblast, that reach the 
vessels are called endovascular trophoblast. There are some interstitial trophoblast 
that both fuse and cause generation of multinucleated trophoblast giant cells between 
the endometrium and myometrium.  
 
 
 
               
   
Figure 4. represents the differentiation of trophoblast lineage and subtypes (modified 
from Benirschke et al, 2006; Kay et al, 2010; Wang & Zhou, 2010; and Williams, 
2010).            
1.2.2.  Placentl villous tree.  
An outer layer of multinucleated syncytiotrophoblast and a subjacent layer of 
mononucleated cytotrophoblasts form a placental villous trees structure in Figure 5a. 
(Modified from Benirschke et al, 2006), in Figure 5b. represents cross section of 
different types of villi and vessel branches of a cotyledon (Modified from Benirschke 
et al, 2006), with the villi projections are shown in Figure 6 (Kay et al, 2010; and 
Williams, 2010). 
 
 
 
 
																																																												Trophoblast	of	blastocyst	
																																																				í																																																						î	
																																							Cytotrophoblast																																												Syn2otrophoblast	
																																				í																										î              ê	
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																								ê	
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																								ê																																																																																																																																																																						
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  Farha Nazir Ahmad M00201045                                                            49 
a. 
	
	 	
b.                                                                                                                                 
Figure 5a. represents a human placental villous tree. Figure 5b represents cross section of different 
types of villi and vessel branches of a cotyledon (Modified from Benirschke et al, 2006). 
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Figure 6. represents villi with in a cotyledon of placental circulation (modified from 
Kay et al, 2010). 
 
1.2.2.1. Types of placental villi. 
Placental villous detailed structure as in the cross section in Figure 7. Modified from 
Human Embryology (Law, 1999). It’s development starts with the mesenchymal villi	
from 5 weeks’ p.c. (post conception), differentiate into four villus types: Immature 
intermediate villi, stem villi, terminal villi and mature intermediate villi that are the 
tertiary villi prominent beyond 20 weeks of gestation	(Benirschke et al, 2006; Kay et 
al, 2010; and Williams, 2010). These different types of placental villi are shown in 
Figure 5b (Modified from Benirschke et al, 2006). The primary chorionic villi are 
formed by the syncytiotrophoblast by about 20 days of p.c., and intermediate 
trophoblast between the lacunae that are invaded by columns of cytotrophoblastic 
cells	 (Kay et al, 2010; and Williams, 2010).	These form the cytotrophoblast shell 
from the growth to the periphery and the interface between the trophoblast and 
endometrium. Secondary chorionic villi develop from the mesenchymal core as 
extraembryonic mesoderm invades the primary villi. As the foetal vessels are 
vascularised, the mesenchymal villus becomes the tertiary villus with both 
syncytiotrophoblasts and cytotrophoblasts that are the outer layer of the trophoblasts 
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(Kay et al, 2010; Williams, 2010). At the end of 4 months essentially, placenta is 
established as it grows in diameter, thus villous tree expansion occurs, complementing 
growth in size of the uterus throughout pregnancy (Kay et al, 2010; and Williams, 
2010).  
 
1.2.2.2. Placental villous.  
 
Figure 7. Placental villous detailed structure as in the cross section above. 1. 
Intervillous  space, 2. Syncytiotrophoblast, 3. Foetal capillaries, 4. Extraembryonic 
mesenchyme, 5. Cytotrophoblast, 6. Hofbauer macrophages. Modified from Human 
Embryology (Law, 1999). 
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1.2.2.3.  Placental development in pregnancy.    
In early pregnancy, the villi are distributed over the entire periphery of the chorionic 
membrane. The progression of human blastocyst implantation requires 
cytotrophoblast cells fusion and formation of non-proliferative multinucleated 
syncytiotrophoblast (Benirschke et al, 2006; Kay et al, 2010; and Williams, 2010).  
Syncytiotrophoblast’s vital role in foetal maternal exchanges and endocrine activity to 
release hormones that are involved in homeostasis of pregnancy for example 
polypeptide hormones as chorionic gonadotrophin (CG) and placental lactogen (PL) 
and steroid hormones as progesterone and oestrogens (Benirschke et al, 2006; Kay et 
al, 2010; and Williams, 2010). Soon after implantation, around day 14 
cytotrophoblast cells and the syncytiotrophoblast layer give rise to extravillous 
trophoblast (EVT) cells (Benirschke et al, 2006; Kay et al, 2010; and Williams, 
2010). Thus, EVTs invade the maternal endometrium and migrate into the decidua. 
Then, one pole extends outward toward the endometrial cavity and the opposite pole 
forms the placenta from villous trophoblast and anchoring cytotrophoblasts. The 
chorion grows fairly uniformly around the whole periphery of the vesicle during 2 
months of embryological development (Benirschke et al, 2006; Kay et al, 2010; and 
Williams, 2010).  
	
Figure 8. Represents the relationship between foetus and maternal decidua from 8 
weeks of pregnancy (modified from Carlson, 2009). 
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However, 3 months later the chorion in contact with the decidua basalis develops 
extensive frond-like villous outgrowths into the decidua as the chorion frondosum, as 
shown in Figure 8.  
Chorionic villi proliferate to form the chorion frondosum, the foetal component of the 
placenta. Then, the remainder of the chorion becomes smooth chorion laeve. The 
chorion frondosum and decidua capsularis develop into the flattened placenta and the 
vessels connecting the chorion to the embryonic circulation becomes the umbilical 
cord (Benirschke et al, 2006; Kay et al, 2010; Williams, 2010). With continued 
growth of the embryo to foetus, the decidua capsularis merges with the parietalis. 
Eventually, the EVTs invade the myometrium and penetrate into the uterine 
vasculature (Benirschke et al, 2006; Kay et al, 2010; and Williams, 2010).  
1.2.2.4. Placental functions for foetal growth and development depends on trophoblast 
invasion, as shown in Figure 9. 
 
 
 
Figure 9. represents the interactions between the foetus, placenta and mother during 
human pregnancy (modified from Murphy et al, 2006). 
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During the first trimester an increase in blood flow in the placenta is necessary for 
placental growth which in turn increases hormone production in order for the placenta 
to carry out functions discussed earlier and transporters to transfer nutrients and waste 
exchange between the mother and foetus. Adequate placental function promotes foetal 
growth, which is influenced by the foetal genome and maternal constraint this refers 
to the limited capacity of the uterus to support foetal growth and is important to limit 
foetal overgrowth to ensure the mother’s capacity for future successful pregnancies. A 
defect in any of these processes can lead to alterations in foetal growth, which has 
adverse consequences both in the short term and long term (Murphy et al, 2006; and 
Kay et al, 2011). 
                                                                      Foetal side 
 
 
                                                  Normal pregnancy                        Pre-eclampsia 
                                                                                 Maternal side 
Figure 10. represents the trophoblast invasion and placental implantation in normal 
pregnancy and pre-eclampsia (modified from Williams, 2010). 
In Figure 10. trophoblast invasion and placental implantation shows proliferation of 
extravillous trophoblast cells (EVTs) from the anchoring villous. The trophoblastic 
lineage gives rise to the three main cell types in the human placenta: 
syncytiotrophoblast, villous cytotrophoblast and extravillous trophoblast cells. 
Trophoblastic invasion in the myometrium and the decidua precedes endovascular 
invasion. The extravillous trophoblast cells (EVTs) proliferate to form the cell 
columns. The EVT invades the decidua and eventually penetrates the myometrium to 
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form trophoblast giant cells. This trophoblastic also surrounds the spiral arteries 
(Lyall and Belfort, 2007; Kay et al, 2010; and Williams, 2010; Kingdom et al, 2011). 
The EVT are interstitial trophoblast and endovascular trophoblast as in Figure 11 that 
invade and transform uterine spiral arteries during extensive remodelling for 
pregnancy to create low-resistance blood flow that is characteristic of the human 
placenta.  
 
Figure 11. represents the normal human placental development where EVT 
cytotrophoblasts proliferate in anchoring columns and invade the decidua. 1) 
Transformation of uterine spiral arteries. 2) Changes arbitrate high volume at low 
pressure into the intervillous space. 3) Placental villi covered by villous trophoblast 
compartment. 4) Cytotrophoblasts proliferate to generate the outer synctiotrophoblast 
directly with the maternal blood (modified from Kingdom et al, 2011).  
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1.2.2.5.  Invasion and spiral artery remodelling. 
Vascular remodelling is a characteristic of pregnancy comprising a complex sequence 
of key events that begins after implantation. There are many growth factors that have 
been described to be important in the process of invasion and involved in 
angiogenesis, for example: VEGF, FGF2, PLGF, HB-EGF, PDGF, HGF, PTN, MK, 
CD105 and Eng a cell surface co-receptor of TGF)- β1 and (TGF)-β3 (Pijnenborg et 
al, 2010). Trophoblast has an important role in the complete physiological change of 
the spiral arteries. It is during the first 10-12 weeks of gestation, extravillous 
trophoblasts ‘plugging’ the spiral arteries are blocked, thus preventing the maternal 
blood flow from entering the villous space (Kay et al, 2010: Wang & Zhao 2010; 
Williams, 2010). An environment of physiological hypoxia is created for early 
placental villous and foetal development (James et al, 2006). This study of (James et 
al, 2006) implied that the maternal-placenta circulation is partially established at the 
end of the first trimester between 10 and 12 weeks of gestation. Blood flow into the 
extravillous space is established by the 11th week. Spiral artery remodelling is 
detected after 18 weeks (Wood, 2014). The trophoblastic invasion process begins 
early in pregnancy and continues until 20th week of gestation. As trophoblastic 
differentiates into villous trophoblast and extravillous trophoblast. These two types of 
extravillous trophoblast are found outside the villous, endovascular and interstitial 
trophoblast (Kay et al, 2010: Wang & Zhao 2010; and Williams, 2010). It is the 
villous trophoblasts that give rise to the chorionic villi, which primarily transport 
oxygen and nutrients between foetus and mother (Kay et al, 2010: Wang & Zhao 
2010; Williams, 2010). The villous cytotrophoblast cells proliferate throughout 
pregnancy and fuse to generate the syncytiotrophoblast (Kay et al, 2010: Wang & 
Zhao 2010; Williams, 2010).  
Remodelling creates a dilated high-flow, low-resistance vessel and endovascular 
extravillous trophoblast (EnEVT) arises as groups of trophoblastic cells that detach 
from the trophoblastic shell. The endovascular trophoblast cells express the adhesion 
molecule CD56, which is thought to function in the formation of the endovascular 
trophoblast plugs (Kay et al, 2010; Williams, 2010). These trophoblast plugs 
disappear as the extensive remodelling of the spiral arteries within the decidual and 
myometrium takes place (Kay et al, 2010; and Williams, 2010). Then, EVTs enlarge 
the vessel diameter by replacing the maternal vascular endothelial and muscular lining 
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(Kay et al, 2010; and Williams, 2010). Fibrinoid necrosis of the vessel media and a 
loss of endothelium occurs, converting muscular vessels into flaccid sinusoidal sacs. 
This vascular transformation is necessary to accommodate the huge increase in blood 
flow (3.5-fold) to the intervillous space required to support the developing foetus 
(Kay et al, 2010; and Williams, 2010). Thus, EVTs are non-proliferative and separate, 
and invade the maternal endometrium, migrate into the decidua, myometrium and 
penetrate into the uterine vasculature, as shown in the Figure 11.  
During early placentation, human extravillous cytotrophoblasts invade the maternal 
uterine spiral arteries of the decidua and myometrium in the haemochorial 
arrangement (Lyall and Belfort, 2007; Kay et al, 2010; Pijnenborg et al, 2010;	Wang 
& Zhao 2010; and Williams, 2010; and Kingdom et al, 2011). Maternal uterine spiral 
arteries remodelling is an important event that takes place in the tunica media. This is 
unique to human pregnancy. Tunica media provides the mechanical strength of the 
blood vessel because of its circular layer of the smooth muscle (Lyall and Belfort, 
2007; Kay et al, 2010; Pijnenborg et al, 2010;	Wang & Zhao 2010; and Williams, 
2010; and Kingdom et al, 2011). This contains elastin, collagen and is innervated by 
sympathetic nerve fibers. EVT provides steady perfusion of the placental sinusoids. 
These placental sinusoids are a type of vessel with large capacity low resistance, but 
lack contractibility with maternal blood. They are unimpeded by the influence of 
vasoactive substances (Lyall and Belfort, 2007; Kay et al, 2010; Pijnenborg et al, 
2010;	 Wang & Zhao 2010; and Williams, 2010; and Kingdom et al, 2011). The 
conversion of these spiral arteries is associated with the loss of their vascular smooth 
muscle cells (VSMCs) and most of their endothelial cells by apopotosis or migration 
out of the vessel wall (Lyall and Belfort, 2007; Kay et al, 2010; Pijnenborg et al, 
2010;	 Wang & Zhao 2010; and Williams, 2010; and Kingdom et al, 2011). This 
vascular transformation causes the muscular, tightly coiled decidua spiral arteries into 
dilated sinusoids, allowing an increase in uterine blood flow to perfuse the placenta 
(Lyall and Belfort, 2007; Kay et al, 2010; Pijnenborg et al, 2010;	Wang & Zhao 2010; 
and Williams, 2010; and Kingdom et al, 2011).  
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1.2.2.6. There are many factors that influence the growth and development of the 
placenta as shown in the Figure 12.    
 
 
Figure 12. Representation of the major factors affecting placental development and 
function, and the ways in which these may affect the developmental programming of 
the foetus modified from (Burton et al, 2011). 
 
 
Maternal and periconceptional factors body composition, birthweight, macro and 
micronutrients, hormones, oxygen availability, stress and pregnancy adaptations. 
 
       Decidualization                                          Genetics 
      Endometrial secretions                                                         Trophoblast  
                                                                                                          stem cells  
                                                                                                          and differentiation 
                                             Immune interactions 
  
 
                                        Implantation Spiral artery remodelling 
                                            
                                 Uteroplacental blood flow (effects of changes) 
 
                               Placental growth, differentiation, and adaptation 
Oxidative stress                Epigenetics               Metabolism                    Imprinted 
Umbilical blood flow      Transporters              Cytoarchitecture                genes 
 
 
Vascular resistance                  Placental supply of nutrients                  Foetal genetic 
                                                           To foetus                                     drive for growth 
 
                                                 Foetal phenotype 
                                    Organ, metabolism and homeostatic endpoints 
 
                                    Developmental  programming. Adult phenotype 
 
 
 
 
 
Figure 12. Representation of the major factors affecting placental development and 
function, and the ways in which these may affect the developmental programming of 
the foetus modified from (Burton et al, 2011). 
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1.2.2.7. In normal pregnancies, the transformation of spiral arteries into utero–
placental arteries is around mid-gestation.  
After reaching and remodelling the spiral arteries, the EVT then gradually extends 
laterally, reaching the periphery of the placenta around mid-gestation (Pijnenborg et 
al, 1980), as shown in Figure 13.  
 
Figure 13.  During pregnancy the spiral artery remodels (adapted from Williams 
Obstetrics; Wang & Zhao 2010).  
Depth-wise changes normally extend as far as the inner third of the uterine 
myometrium within the central region of the placental bed, but the extent of invasion 
gets progressively shallower towards the periphery (Pijnenborg et al, 1980), as shown 
in Figure 13. 
The main aim of these vascular changes is to optimize the distribution of maternal 
blood into a low-resistance uterine vascular network and ultimately inside the 
placental intervillous chamber. At term, the utero–placental circulation carries 
approximately 600 ml of maternal blood per minute (Ramsey and Donner, 1980; and 
Lyall and Belfort, 2007). During this process trophoblastic cells aggregate within the 
vessels lumen and plug the distal segments of the spiral arteries. Thus, before 10 
weeks of gestation, the intervillous space contains mostly glandular secretion products 
together with the plasma filtrate that is free of maternal blood cells (Williams, 2010: 
Wang & Zhao, 2010; and Kay et al, 2011). The remodelling of the maternal uterine 
spiral arteries involves a series of steps (Lyall and Belfort, 2007), which are critical 
for the normal growth and development of the foetus. The term ‘physiological 
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change’ in spiral arteries was originally used to describe the disappearance of the 
normal muscular and elastic structures of arteries and their replacement by fibrinoid 
material in which trophoblastic cells are embedded. Thus, a healthy utero-placental 
homeostasis depends on highly regulated extravillous trophoblastic cell functions, 
such as proliferation, migration and invasion. This process is impaired in pre-
eclampsia, foetal growth restriction, and invasion (Kay et al, 2010: Wang & Zhao 
2010; and Williams, 2010).   
Angiogenesis and vascular remodelling mechanisms in the foetomaternal unit 
function are poorly understood, but are crucial for normal foetal development. There 
are a series of growth factors and angiogenic growth factors that are important in the 
process of invasion. 
1.2.2.8.  Angiogenesis. 
Angiogenesis is a physiological process involving the formation of new blood vessels 
from pre-existing vessels. This is a critical process for normal tissue growth and 
development, as well as the formation of arteries, veins and capillaries in an embryo. 
Angiogenesis is important and necessary for repair of wounds or regeneration of 
tissue during wound healing and is promoted by growth factors. It is essential for the 
formation of the placenta during pregnancy (Kingdom et al, 2000; and Kay et al, 
2011). Angiogenic factors that are produced locally have been identified in the human 
placenta. These promote vasculogenesis and angiogenesis in the placenta and the 
most potent include the VEGF, FGF2 and PLGF family. There are many other growth 
factors for example heparin-binding growth factor (HB-EGF), platelet-derived growth 
factor (PDGF), hepatocyte growth factor (HGF), pleiotrophin (PTN), midkine (MK), 
cluster differentiation (CD105) and Endoglin (Eng) a cell surface co-receptor of 
transforming growth factor (TGF)-β1 and (TGF)-β3 (Pijnenborg et al, 2010). 
Placental vascular growth begins at 21st day p.c. and continues throughout gestation 
(Wang et al, 2010). During vasculogenesis and angiogenesis, many angiogenic factors 
produced by the placenta cells play important roles in regulating the development of 
placental vasculature, for example trophoblast, Hofbauer cells, pericytes and 
endothelial cells.  
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Angiogenesis is an important process in the normal development of the placenta, as 
it’s responsible for many growth factors. Vascular endothelial growth factor (VEGF) 
is a potent angiogenic growth factor that initiates vasculogenesis and stimulates 
angiogenesis whilst modulating trophoblastic survival and function (Kay et al, 2011; 
and Pijnenborg et al, 2010). Extensive angiogenesis and invasion of the maternal 
decidua by trophoblast are essential for the development and function of the placenta. 
Knockout studies in mice demonstrate the crucial role of vascular endothelial growth 
factor (VEGF) in embryonic development (Ferrara et al, 1996; and Cameliet et al, 
1996). Vascular endothelial growth factors (VEGF), placenta growth factor (PLGF) 
and their receptors VEGFR-1/Flt-1, VEGFR-2/KDR and VEGFR-3 have important 
roles in vasculogenesis and angiogenesis (Kay et al, 2011; and Pijnenborg et al, 
2010). 
 
1.2.2.9.  Key factors involved in trophoblast invasion. 
In addition to placental hormones, development of placenta is believed to involve a 
series of growth factors. There are many growth factors that have been described to be 
important in the process of invasion. Key factors are thought to include a series of 
autocrine growth factors, such as angiogenic factors that are produced locally and 
have been identified in the human placenta, the most potent of which include the 
vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF2) and 
placental growth factor (PLGF) family. There are many other growth factors, for 
example heparin-binding growth factor (HB-EGF), platelet-derived growth factor 
(PDGF), hepatocyte growth factor (HGF), pleiotrophin (PTN), midkine (MK), cluster 
differentiation (CD105) and Endoglin (Eng), a cell surface co-receptor of 
transforming growth factor (TGF)-β1 and (TGF)-β3 (Pijnenborg et al, 2010).    
 
1.2.3. The vascular endothelial growth factor (VEGF) family. 
Vascular endothelial growth factor (VEGF) is synthesised by cells that stimulate new 
blood vessel formation. In addition, it is a mitogen for vascular endothelial cells. The 
VEGF family has at least 7 members, VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
VEGF-E, PLGF and snake venom-derived (SV) VEGFs. All these members, except 
VEGF-E and vs. VEGF are encoded in the mammalian genome. VEGF is a 
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polypeptide structurally related to platelet-derived growth factor (PDGF). VEGF 
regulates the growth and differentiation of multiple components of the vascular 
system, especially blood and lymph vessels. VEGF and their receptors interactions 
and signalling are shown in Figure 14.  
 
Figure 14. The Vascular endothelial growth factors (VEGF) and their receptors’ 
interactions and signalling. Abbrevations: Vascular endothelial growth factors 
(VEGF), vascular endothelial growth factors receptors (VEGFR1, VEGFR2, and 
VEGFR3) and neuropilin (NRP-1 and -2) (modified from Wang and Zhao, 2010). 
1.2.3.1.  The vascular endothelial growth factor (VEGF) receptors. 
VEGF receptors are present in the human placenta and bind VEGF to initiate 
important interactions. The vascular endothelial growth factor receptor family 
consists of three members, VEGF receptor-1 (VEGFR-1, FLt-1), VEGF receptor-2 
(VEGFR-2, Flk-1/KDR) and VEGF receptor-3  (VEGFR-3), and they are structurally 
distantly related to the PDGFR family, as shown in Figure 1. These participate in 
vasculogenesis and angiogenesis during placental development. VEGFR-1 has a very 
high affinity for VEGF-A, but under physiological conditions, VEGFR-1 only weakly 
stimulates endothelial proliferation. It is expressed not only on vascular endothelial 
cells, but also in monocyte/macrophage-lineage cells, and stimulates their migration 
(Shibuya, 2008). The VEGFR-1 gene expresses two types of mRNA, one for the full-
length VEGFR-1 receptor, and another for the ligand-binding region alone as a 
secreted soluble protein (sFlt-1), an important mediator in pre-eclampsia. The level of 
sFlt-1 protein was reported to be abnormally high in the serum of preeclampsia 
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patients, and recent studies indicated that abnormal trapping of natural VEGF-A with 
a large amount of sFlt-1 results in hypertension and proteinuria, the major symptoms 
on the maternal side of pre-eclampsia. Thus, sFlt-1 is an important target in the 
treatment of pre-eclampsia. 
The ability of VEGFR-2 to bind with VEGF-A is about one order of magnitude 
weaker than that of VEGFR-1. VEGFR-2 generates a variety of angiogenic signals 
not only for endothelial proliferation, but also for cell migration/morphogenesis 
including tubular formation. The 951-tyrosine was shown to regulate cell migration 
by binding with an adaptor, TSAd (Shibuya, 2008). 
1.2.3.2.  Actions of vascular endothelial growth factor (VEGF). 
The VEGF family is important in many cellular functions including proliferation, 
apoptosis, mitogenesis and permeability. The angiogenic activity of PLGF and 
VEGF-B is usually about 10-fold weaker than that of VEGF-A. VEGF-A, and VEGF-
E induce angiogenesis with very low side effects, such as oedema, cytokine 
production and inflammatory reactions, commonly observed both with VEGF-A 
treatment and in VEGF-A transgenic mice. These unique characteristics of VEGF-E 
indicate humanized VEGF-Es to be good candidates for proangiogenic agents 
(Shibuya, 2008). 
1.2.3.3.  Placental Growth Factor (PLGF) and their receptors. 
Persico discovered in (1991) that PLGF is an angiogenic factor of the VEGF family. 
There are four isoforms of mature PLGF proteins in humans, PLGF-1, PLGF-2, 
PLGF-3 and PLGF-4. Hauser and Weich (1993) showed that PLGF-1 and PLGF-2 are 
the dominant forms and differ by an insertion of a highly basic 21 amino acid at the 
carboxyl terminal sequence. This is an important region that contains a heparin-
binding motif allowing the PLGF-2 to bind to heparin (Hauser and Weich, 1993). 
Although both PLGF-1, and PLGF-2 bind to the VEGFR-1, Ribatti, (2008) showed 
that PLGF-2 binds to the (neuropilin-1 and neuropilin-2) and to the heparin sulphate 
proteoglycans (HSPG). PLGF functions are important for angiogenesis and 
inflammation. Vuorela et al, (1997) demonstrated that immunostaining of PLGF is 
localized on the trophoblast and the villous core of the endothelial cells. Ribatti et al, 
(2008) proposed these mechanisms for angiogenic function of PLGF. First, in the 
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endothelial cells PLGF binds to VEGFR-1 and facilitates VEGF binding that activates 
VEGFR-2 (Ribatti et al, (2008). Secondly, it promotes the vessel growth and the 
recruitment of monocytes and macrophages (Ribatti et al, (2008). Thirdly, it 
mobilises the hematopoietic progenitor cells from the bone marrow (Ribatti et al, 
(2008). PLGF is a multitasking cytokine affecting various cellular activities. The 
pleiotrophic actions of PLGF, includes effects on survival, migration, proliferation, 
metabolism and activation effects on vascular endothelial cells, pericytes and smooth 
muscle cells. Nonvascular cells are macrophages, fibroblasts and epithelial cells 
(Ribatti et al, (2008). 
Carmeliet et al, (2001) showed a PLGF/VEGF heterodimer that is highly potent 
endothelial mitogen. As shown in Figure 12b, (Luttun and Carmeliet, 2003) in pre-
eclampsia the hypoxia promotes VEGF and VEGFR-1 (sFlt-1) expression, but down-
regulates PLGF production. Altered, Flt-1 affects the villous development and 
releases excess amount of soluble sFlt-1 into the maternal circulation. This excess 
sFlt-1 in the bloodstream is associated with a lower free VEGF and PLGF in the 
systemic vasculature. An increased production of sFlt-1 by trophoblast is a critical 
pathogenic factor in pre-eclampsia (Wang and Zhao, 2010). PLGF expression is a 
promising PE marker to be used during the first trimester of pregnancy. 
Carmeliat et al, (2001) suggested that VEGF and PLGF contribute to both 
physiological angiogenic processes. There are several mechanisms that are involved 
in angiogenic functions of PLGF, it binds to VEGFR-1 in the endothelial cells 
facilitating VEGF binding and activation of VEGFR-2 (Ribatti et al, 2008) and 
interacts with VEGFR-2 that differentiates this growth factor from VEGF- mediated 
angiogenesis (Kay et al, 2011). Although numerous factors have been implicated in 
angiogenesis, recent observations, including gene knockout studies in mice, have led 
to the identification of the major factors regulating the angiogenic process, including 
those that occur during placental vascularisation.  
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1.2.3.4. Fibroblast growth factor 2 (FGF2) and their receptors. 
The FGFs major functions are potent angiogenic factors that promote endothelial cell 
proliferation and vascularisation (Kay et al, 2011). Gospodarowicz et al, (1985) study 
showed that the placenta is a good source of FGFs. FGFs are multifunctional proteins 
and stimulate a variety of biological effects including pluripotency and angiogenesis. 
The localization of PLGF is expressed strongly by the villous trophoblast cells. These   
regulate the vascularization process in both decidua and in the placenta (Pijnenborg et 
al, 2010). The fibroblast growth factor (FGF) family consists of 18 members: FGFs 
1–10 and FGFs 16–23 that are structurally related multifunctional polypeptide growth 
factors (Beenken & Mohammadi, 2009). FGFs are important in many cellular 
processes including proliferation, differentiation, migration and cell survival 
throughout prenatal and postnatal life. FGFs are major growth factors of the placenta 
with FGF2 as the dominant form (Arany and Hill, 1998; Borowicz et al, 2007). The 
study of Yamaguchi & Rossant (1995) suggests that FGFs are important regulators of 
multiple developmental processes. FGF1 is known as the “acidic” and FGF2 is the 
“basic” form. They function as potent angiogenic factors and promote endothelial cell 
proliferation and vasculogenesis. Some FGFs exert their effects by interacting with 
four different receptors (FGFR1–4) identified in humans as activating signal 
transduction pathways, such as the MAPK cascade, and stimulate mitogenesis, 
differentiation and cell migration. FGFR receptors FGFR1 and FGFR3 are expressed 
only within the villous stroma, whereas FGFR2 and FGFR4 are expressed both within 
the villous stroma and in the trophoblast (Anteby et al, 2005), suggesting that these 
receptors may mediate the responsiveness of trophoblast to the growth-promoting 
effects of FGFs. Their expression is controlled at the levels of transcription, mRNA 
stability and translation (Szebenyl & Fallon, 1999). FGF signalling is important as the 
regulator of embryonic development, homeostasis and regenerative processes. FGFs 
biological actions are through the binding, dimerizing and activating cell surface FGF 
receptors (FGFRs). In Figure 15. FGF/FGFR (FGF receptor) signalling for heparan 
sulphate proteoglycans (HSPG)-binding proteins, as both the growth factor and 
receptor bind to heparan sulphate (HS), and HS or heparin (Harmer, 2006; Wang and 
Zhao, 2010). Brown et al, (2014), study confirmed the crystal structure of fibroblast 
growth factor 18 (FGF18) being a glycoprotein. Zhong et al’s, (2006) study suggests 
that, FGF18 were present in the trophoblast stem (TS) cells and in pre-implantation 
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embryos. FGF18 was expressed in both the human and mouse placenta is important 
for implantation and early placental function (Zhong et al, 2006). In vitro and in vivo 
studies of mice by (Hague et al, 2007) suggested that FGF18 has a prominent role in  
chondrongenesis, osteogensis, for skeletal development and growth, embryogenesis 
and post-natal development. 
 
Figure 15. Fibroblast growth factor 2 and its receptor (FGF2/FGF2R) signalling is 
presented and modified from Wang and Zhao, (2010). 
1.2.3.5. Hepatocyte growth factor (HGF). 
Hepatocyte growth factor (HGF) is a potent mitogen. It has been shown to stimulate 
dissociation and mobility of epithelial cells. HGF is a secreted heparin-binding 
glycoprotein originally identified in rat platelets because of its ability to stimulate 
mitogenesis in hepatocytes (Strain et al, 1982). Uehara et al, (1995) demonstrated 
HGF importance in mammalian pregnancy using the HGF knock out mice. Somerset 
et al’s (1998), immunocytochemical study localised HGF protein throughout 
placental villi across gestation. The c-met (HGF receptor) protein was localized only 
in the perivillous trophoblast and vascular endothelium. They suggested that HGF, 
derived from the perivascular tissue of the stem villous arteries, might be important in 
controlling normal villous development. They showed reduced expression of HGF 
within IUGR placenta does not provide a causative link with abnormal villous 
development. The study of Somerset et al’s, (2000) suggested that a circulating serine 
protease known as HGF-activator (HGF-A) is responsible for activation of HGF. This 
study throughout gestation demonstrated the anti-HGF-A/zymogen antibody 
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immunostaining in placental villi and membranes (Somerset et al, 2000). The active 
HGF is an important regulator of trophoblast growth (Somerset et al, 2000). In 
placenta, HGF promotes trophoblast migration and invasion, but does not affect 
cellular proliferation (Somerset et al, 2000).   
 1.2.3.6. Platelet-derived Growth factor (PDGF). 
The platelet-derived growth factor (PDGF) family induces a variety of cell processes 
including proliferation, survival, movement, deposition of extracellular matrix (ECM) 
and tissue remodelling. The PDGF family is composed of two classical growth 
factors, PDGF-A and PDGF-B. These factors interact with two receptors, PDGFR 
alpha (PDGFRα) and PDGFR beta (PDGFRβ), with cell and specific affinities and 
specificities. The PDGFs A–C and their receptors PDGFRα and PDGFRβ have been 
shown to promote cellular responses such as proliferation, survival and migration 
(Hoch & Soriano 2003). In the human placenta, PDGFRα/β is expressed within the 
syncytiotrophoblast and the villous cytotrophoblast (Gurski et al, 1990) this 
localization together with reduced expression in FGR placentas suggests that 
signalling via PDGFRα may regulate trophoblast proliferation in the human placenta.  
The classical PDGFs can bind directly to their surface receptors. PDGF-A and 
PDGFRα are associated with embryogenesis, CNS and organ development whereas; 
PDGF-B and PDGFRβ are involved with the development of vasculature, especially 
with vascular smooth muscle cells. PDGF-BB/PDGFR-BB is important in 
angiogenesis at the level of cell development, vascular smooth muscle cells (VSMC) 
and pericytes. The active PDGFs are homodimers, PDGF-AA, PDGF-BB, PDGF-CC, 
PDGF-DD and the heterodimer PDGF-AB. PDGF induces mitogenic and migratory 
responses in a wide variety of cells by activating specific receptor tyrosine kinases in 
both PDGF α- and ß receptors. The different isoforms of PDGF bind to 
glycosaminoglycans. The study by Rolny et al, (2002) showed that exogenous heparin 
amplifies a homodimer PDFG-BB that is induced by the PDGF α-receptor 
phosphorylation and signalling, for cellular responsiveness. 
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1.2.3.7. Midkine (MK). 
This is a heparin-binding growth factor with a molecular weight of 13kDa (Iwaski et 
al, 1997: Muramatsu, 1993: Muramatsu, 2010). MK and pleiotrophin (PTN) share 10 
conserved cysteine residues and show 50% identity in the amino acid sequence. MK 
has many functions including cell proliferation, migration, survival, differentiation 
and angiogenesis. MK is highly expressed during mid-to-late gestation and studies 
suggest its role in embryonic and foetal development (Iwaski et al, 1997; and  
Muramatsu, 1993: Muramatsu, 2010). Qi-Wen Fan et al, (2000) showed that among 
the placental tissues, MK was detected in the chorion, the fetal component of the 
placenta, whereas PTN was found in the decidua basalis and the placenta (Qi-Wen 
Fan et al, 2000). Thus, MK and PTN distinctive expression suggests their differential 
role in early development of a mouse. MK has been most extensively studied in 
neural tissue (Qi-Wen Fan et al, 2000).  
1.2.3.8. Pleiotrophin (PTN). 
This is a 136 amino acid secreted heparin-binding growth factor with a lower  
molecular weight  than MK (Schulte et al, 1996; Ball et al, 2009). PTN has many 
functions and is involved in cell growth, migration and differentiation mediated 
through multiple receptors (Schulte et al, 1996; and  Ball et al, 2009). PTN, its 
receptor syndecan-1 (SDC-1) and receptor protein tyrosine phosphatase beta (RPTPβ) 
are expressed in the placenta (Schulte et al, 1996; Ball et al, 2009). They are 
important for invasion of trophoblast cells and vascular endothelial injury (Schulte et 
al, 1996; and Ball et al, 2009). PTN/RPTPβ can regulate the metabolism of 
catecholamines and participates in the oxidative stress response (Schulte et al, 1996; 
Ball et al, 2009). Syndecan-1 and syndecan-3 (SDC1 and SDC3) are important for the 
developmental processes in first-trimester human placentation. Expression of PTN 
and its receptors in the trophoblast is found exclusively in humans (Schulte et al, 
1996; and Ball et al, 2009). PTN blocks apoptosis in heptoma cell lines and inhibits 
apoptosis of lung cancer cells (Schamberger et al, 2004).  
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1.2.3.9. Endoglin (CD105). 
CD105 is a cell-surface glycoprotein most recently identified as an optimal indicator 
of proliferation of human endothelial cells. The finding that CD105 is over-expressed 
on vascular endothelium in angiogenesis tissues has prompted several pre-clinical 
studies designed to gain a deeper understanding of the role of CD105 in angiogenesis, 
and to evaluate the most appropriate clinical settings to utilize CD105 as a therapeutic 
target. 
CD105 is a component of the receptor complex of transforming growth factor (TGF)-
β - a pleiotropic cytokine involved in cellular proliferation, differentiation and 
migration. The binding of TGF-β1 to CD105 reduces the levels of CD105 
phosphorylation and the levels of CD105 expression modulate the effects of TGF-β1 
(Duff et al, 2003). In this respect, it is of interest that the inhibition of CD105 
expression enhanced the ability of TGF-β1 to suppress growth, migration and 
capacity to form capillary tubes of cultured endothelial cells. In the absence of TGF-
β1, CD105 shows an anti-apoptotic effect in endothelial cells under hypoxic stress, 
suggesting a protective role of CD105 against pro-apoptotic factors. In addition, the 
discovery that levels of CD105 regulate the expression of different components of the 
extracellular matrix including fibronectin, collagen, PAI-1 and lumican, is also 
suggestive of a crucial role of CD105 in cellular transmigration. The complex 
experimental findings indicate that CD105 is a powerful marker of angiogenesis, and 
that it might play a critical role in the pathogenesis of vascular disease and tumour 
progression (Fonsatti et al, 2001). 
In summary, important maternal growth factors and the signalling cascades in the 
placenta are transforming growth factor (TGF)-β1, insulin-like growth factors (IGF1) 
and (IGF2), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), 
fibroblast growth factors (FGF)-2 and FGF4, that bind to a variety of receptors. All of 
these are increased within the maternal circulation, and their elevated levels are 
sustained throughout gestation. They all have important roles in promoting the growth 
of the developing foetus. However, all of these growth factors exert their effects via 
intracellular cascades that utilize signalling molecules, many of which are 
dysregulated in foetal growth disorders. These growth factors induce receptor 
autophosphorylation and bind various scaffolding proteins that activate the PI3K and 
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MAPK (ERK) pathways via a sequence of phosphorylation resulting in transcription 
of target genes. These are involved in regulating cellular events such as proliferation 
and survival (Forbes and Westwood, 2010). 
1.2.4. The heparin-binding epidermal growth factors (HB-EGF). 
Studies by Lash et al, (2003) and Hills et al, (2006) showed that the effects of 
HBEGF, VEGF and PLGF and interferon gamma IFN γ are modified in placenta by 
heparin. Their studies found levels of HB-EGF mRNA were low in pregnant 
endometrium and high in placental tissues at an early stage of development. Recently 
there has been much interest in the effects of heparin-binding epidermal growth factor 
(HB-EGF) as a possible cytoprotective factor in human placenta. HB-EGF may be 
induced by low oxygen tension and is expressed in both villous and extravillous 
trophoblast at high levels in the first trimester and throughout gestation (Yoo et al, 
1997). HB-EGF has a strong cytoprotective activity and is an important signalling 
protein that regulates trophoblast invasion during early placentation. Within the 
human placenta HB-EGF expression is down-regulated following hypoxia/reperfusion 
(Leach et al, 2008). In other tissue systems, both HB-EGF and amphiregulin are 
increased following oxidative stress (Hurbin et al, 2005). Since these factors are also 
expressed in placental tissue, it seems likely that they are also important survival 
factors for trophoblast. 
Imudia et al, (2008) and Leach et al, (2004) suggested that within the human placenta 
HB-EGF stimulates trophoblast invasion and acts as a survival factor and blocks 
apoptosis induced by hypoxia. Imudia et al’s, (2008) study suggests that HB-EGF 
induces trophoblast extravillous differentiation and prevents apoptosis. Deficient HB-
EGF signalling during placental development could impair trophoblast survival, 
differentiation and invasion, leading to poor placental perfusion and hypertension as 
in pre-eclampsia because HB-EGF is down-regulated in placentas delivered by 
women with pre-eclampsia. It is suggested that the effects of heparin are mediated 
through binding to HB-EGF and enhancement of HB-EGF activity (Bose et al, 2005; 
and Hills et al, 2006).  
 
 
 
  Farha Nazir Ahmad M00201045                                                            71 
1.2.4.1. Human placental abnormalilties related to pre-eclampsia. 
Pre-eclampsia is an obstetrical disorder of placental function. Trophoblast 
proliferation, angiogenesis and invasion are important and are decreased in pre-
eclampsia (Benirschke et al, 2006; Crocker, 2007; Lyall and Belfort, 2007; Kay et al, 
2010; Kingdom et al, 2011; Wang & Zhau, 2010; and Williams, 2010). Humans are 
predisposed to pre-eclampsia because of individual or combination of these features, 
for example: the depth of extravillous trophoblast invasion, maternal uterine artery 
remodelling, complex structure of the chorionic villous tree, and surface area of 
transport and diffusion in the villous trophoblast (Benirschke et al, 2006; Crocker, 
2007; Lyall and Belfort, 2007; Kay et al, 2010; Kingdom et al, 2011; Wang & Zhou, 
2010; and Williams, 2010). 
The novel hypothesis for pre-eclampsia is that it evolves in two stages as shown in 
Figure 15. (Redman and Sargent, 2000; and Lyall and Belfort, 2007). The prevailing 
theory is that pre-eclampsia is an obstetrical syndrome that starts in the placenta and 
ends in the maternal endothelium (Lyall and Belfort, 2007; Kay et al, 2010; Kingdom 
et al, 2011; Wang & Zhou, 2010; and Williams, 2010).  
Defective placentation is initiated in the first stage, resulting in inadequate formation 
of extravillous trophoblastic invasion, incomplete remodelling of the spiral arteries in 
the decidua, maintenance of vascular activity and resistance in the myometrium 
(Brosens et al, 1972; Lyall and Belfort, 2007; Kay et al, 2010; Kingdom et al, 2011; 
Wang & Zhau, 2010; and Williams, 2010). As a consequence, placental ischaemia, 
reperfusion, hypoxia, and oxidative stress and formation of reactive oxygen species 
(ROS) follow. The second stage of the disease is characterized by the clinical 
obstetrical symptoms, for example hypertension, proteinuria, and oedema, caused by 
release of placental derived factors maternal vascular endothelial cell dysfunction, 
maternal systemic inflammation and organ failure (Lyall and Belfort, 2007; Kay et al, 
2010; Kingdom et al, 2011; Wang & Zhau, 2010; and Williams, 2010). It was 
suggested that the vascular endothelial damage is caused by placental-derived 
material or anti-angiogeneic growth factors (Lyall and Belfort, 2007; Kay et al, 2010; 
Kingdom et al, 2011; Wang & Zhau, 2010; and Williams, 2010). 
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        1.2.4.2. Pre-eclampsia is presented as a two-stage model. 
 
Figure 16. Pre-eclampsia presented as two stages of evolution. Modified from 
(Redman and Sargent, 2000; and Lyall and Belfort, 2007). Other disorders associated 
with placental insufficiency include pre-term labour and foetal growth restriction. 
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As in Figure 10. the decidua vessels become lined with EVTs because of the shallow 
invasion (Benirschke, 2006; Lyall and Belfort, 2007; Kay et al, 2010; Kingdom et al, 
2011; Wang & Zhau, 2010; and Williams, 2010).  
 
 
 
Figure 17. represents Uteroplacental vascular insufficiency. 1) EVT cytotrophoblast 
are less and may be removed by the maternal immune system. 2) Distal spiral arteries 
are narrower. 3) Diseased followed by atherosis or local fibrin deposition. 4) Reduced 
Endovascular invasion. 5) Hypoxia or hypoxia-re-oxygenation injury in the placenta. 
6) Direct effects on villous trophoblast compartments. 7) May trigger the formation of 
syncytial knots. 8) Accumulation, with fragmentation and shedding may occur into 
the maternal blood. 9) Areas that are deficient in syncytial fusion may exhibit focal 
necrosis. (Adapted from Kingdom et al, 2011). 
 
Brosens et al, (1972), in situ study confirmed inadequate shallow cytotrophoblast 
invasion in placentas from pregnancies that are complicated by pre-eclampsia. In PE, 
trophoblastic invasion of the spiral arteries appears to be incomplete, as shown in 
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Figure 10. and 17, and the vessels remain responsive to vasoconstrictors. Vasospasm, 
increased peripheral vascular resistance, and thus reduced organ perfusion 
characterize the disease. The syndrome is polymorphic in that virtually every organ 
system can be affected (Lyall and Belfort, 2007; and Williams, 2010). In pre-
eclamptic women defective physiological changes were restricted to the decidual 
segments of the uterine spiral arteries (Brosens et al, 1972). Some studies have also 
shown evidence of endothelial dysfunction in women with PE. There is a reduction in 
secretion of endothelial vasodilator substances, but increase in concentration of potent 
vasoconstrictor endothelium (Lyall and Belfort, 2007; and Williams, 2010). The 
effect of all these changes is the reduction in placental blood flow (Lyall and Belfort, 
2007; and Williams, 2010). PE adversely affects the mother, by vascular dysfunction, 
and is frequently associated with intrauterine growth restriction (IUGR) of the foetus, 
presumably as a result of the reduction in nutrient supply (Lyall and Belfort, 2007; 
and Williams, 2010; and Kingdom et al, 2011).  
 
Studies of women with abnormal placental syndromes have shown that they are at 
risk of developing cardiovascular diseases and metabolic disorders such as 
hypertension, ischaemic heart disease, stroke, obesity, and diabetes mellitus after 
pregnancy. Abnormal placental function impacts on the foetus because of the 
increased vascular resistance and improper nutrient transport. The mother and foetus 
interact via endocrine signals from the placenta, which control the complex process of 
foetal growth together with environmental factors. Over the last decade significant 
research progress has been made in the field of placental vascular biology because of 
advanced cellular and molecular technologies (Knobil & Neil, 2006; Pijenborg et al, 
2010; Wang & Zhao 2010; Williams, 2010;and Kay et al, 2011).  
 
1.2.4.3. Angiogenic growth factors in pre-eclampsia.  
There were several varying hypotheses and theories for the placenta in the aetiology 
of pre-eclampsia. Proangiogenic and anti-angiogenic growth factors are released 
during a normal healthy pregnancy (Kingdom et al, 2011; and Lyall and Belfort, 
2007). An appropriate placental expression of angiogenic factors may therefore be an 
important cause of infertility and foetal growth retardation (Williams, 2010). Recent 
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clinical work on regulation of placental angiogenesis could become a novel and 
powerful method for ensuring positive outcomes for most pregnancies. Several studies 
on expression of anti-angiogenic growth factors, soluble fms-like tyrosine kinase 1 
(sFIt-1), transforming growth factor β (TGF-β) and endoglin are upregulated in 
pregnancies affected with PE. However, pro-angiogenic growth factors such as 
VEGF, and PLGF are downregulated in these pregnancies inadequate cytotrophoblast 
invasion, endothelial dysfunction and impaired placental angiogenesis in PE women 
(Ahmad and Ahmed, 2004; Ahmed and Ramma, 2014; Maryland et al, 2003; and 
Young et al, 2010).  
There is evidence that the VEGF family of growth factors and receptors are important 
during placental development. Geva et al’s, (2002) study suggested that high levels of 
VEGF, VEGFR-1, and sVEGFR-1 are seen in pre-eclampsia, which is related to the 
hypoxic status of the placenta. Current knowledge has advanced beyond early 
hypothesis that were suggested 12 years ago and at that time data was relevant for 
example a possible mechanism was outlined in Figure 18a,b (Luttun & Carmeliet, 
2003). During normal pregnancies (18a) the blood flow and supply of nutrients with 
oxygen to the foetus increases by vascular remodelling. The VEGFR Flt-1 acts as a 
potent VEGF antagonist by binding VEGF, reducing free circulating concentrations 
of VEGF and may contribute to the pathogenesis of pre-eclampsia opposing 
vasodilation and contributing to the development of hypertension (18b).  
Another hypothesis was suggested 16 years ago by (Lash et al, 1999), that 
extravillous trophoblast invasion and motility is mediated by VEGF. VEGF may limit 
the degree to which trophoblast cells invade. Once again, at that time data was 
relevant. Akercan et al, (2008) suggested that the placental villi show branching 
angiogenesis, as is the case with anaemic pregnancy, pregnancy at high altitude, and 
in pre-eclampsia. VEGF is up-regulated in response to placental hypoxia. Tsatsaris et 
al’s (2003) study suggests VEGFs are involved in placental vascular development. 
Increased levels of VEGF-A and VEGF-1 mRNAs in compromised pregnancies may 
reflect the hypoxic status of the placenta. Kingdom & Kaufmann, (1999), and Khaliq 
et al, (1999) suggest VEGF-A is one of the most important growth factors for 
endothelium and is involved in regulating vasculogenesis, as it induces endothelial 
cell proliferation as well as angiogenesis. VEGF-A transcription is activated by 
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oncogenes in response to hypoxia. The results are conflicting in several studies 
aiming to analyze the expression of VEGF-A in pathological conditions during 
pregnancy. Lyall et al, (1997) measured free VEGF using maternal serum samples. 
The free VEGF decreased in pre-eclampsia, compared with normal pregnancies. Some 
authors report reduced levels of VEGF-A in maternal circulation and others show 
increased levels of VEGF-A in maternal circulation compared with normal 
pregnancies.  
.  
In Figure 18a and 18b presents functions of VEGF, sfIt1, and PLGF in normal 
pregnancy and pre-eclampsia (Luttun & Carmeliet, 2003). 
Recent evidence also confirms a role for VEGF in foetal and placental angiogenesis, 
as during early pregnancy expression of VEGF mRNA is greater in foetal placenta 
compared with maternal placental (endometrial) tissues. Gene knockout studies have 
provided convincing evidence for a central role of VEGF in foetal and placental 
angiogenesis. In mice, homozygous knockouts of the genes for VEGFRs (VEGFR-1 
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[also known as flt-1] or VEGFR-2 [KDR or flk-1] led to defects in foetal and 
placental vasculogenesis (the initial formation of the vasculature) and angiogenesis 
resulting in embryonic death by about Day 8. of pregnancy (length of pregnancy  20 
days) (Fong et al, 1995; and Shalabi et al, 1995). Similarly, homozygous gene 
knockouts for VEGF itself were lethal by about Day 11. of pregnancy, and these 
embryos exhibited dramatic cardiovascular defects, such as delayed or abnormal 
development of the heart, aorta, major vessels and extraembryonic vasculature, 
including the yolk sac and placenta (Carmeliet et al, 1996). Foetal and placental 
angiogenesis are absolutely dependent on VEGF, but threshold levels of VEGF must 
be achieved for normal vascular development to occur.  
1.2.4.4.  Pathogenesis of pre-eclampsia. 
PE has been the subject of extensive research, but the pathophysiology of the disease 
and precise causes are unknown. Failure of placental oxidative stress and placental 
development as a result of deficient spiral artery remodelling are believed to be 
important in the development of pre-eclampsia (Lyall and Belfort, 2007). It stems 
from a defect of placentation in early trophoblast invasion of the spiral arteries as 
depicted in Figure 1. Many investigators have confirmed observations of restricted 
physiological conversion of spiral arteries in pre-eclampsia over several years (Frusca 
et al, 1989; Gerretsen et al, 1981; Hanssens et al, 1998; Hustin et al, 1983; Khong et 
al, 1986; Lyall et al, 2001b; Meekins et al, 1994a; Moodley and Ramsaroop, 1989; 
Pijnenborg et al, 1991; and Sheppard and Bonnar, 1981). 
Presently, there is no accepted treatment for these conditions. Although, the causes of 
pre-eclampsia are unclear, it is accepted that a failure of placental development is an 
important predisposing factor and that the resulting alterations in placental oxygen 
levels may be crucial in the development of this disorder (Hung et al, 2002, and 
Rajmakers et al, 2004). Abnormal first-trimester trophoblast differentiation is 
associated with pregnancies complicated by pre-eclampsia and/or intrauterine growth 
restriction (IUGR). A key histopathologic correlation is shallow invasion and aberrant 
remodelling of maternal spiral arteries, which leads to decreased uteroplacental 
perfusion and the resulting alterations in placental oxygen levels may be crucial in the 
development of this disorder (Hung et al, 2002; and Rajmakers et al, 2004).  
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Experimental hypoxia is correlated with pre-eclampsia features, inducing trophoblast 
cell death, release of proinflammatory cytokines and oxidative stress (Hung et al, 
2002; Hung et al, 2004; Benyo et al, 1997; and Benyo et al, 2001). The putative 
effect of reduced oxygenation on global gene expression changes in placental tissues 
from pre-eclamptic patients remains unclear. Failure of the oxygen-associated 
developmental events contributes to placental disease (Hung et al, 2004; Genbacev et 
al, 1996; and Caniggia et al, 2000). Flow patterns can also be obtained from 
individual spiral arteries. Matijevic et al, (1995) evaluated blood flow through central 
and lateral spiral arteries at 17–20 weeks, revealing lower resistance and pulsatility 
indices in the central arteries known to undergo physiological change at that period of 
gestation (Pijnenborg et al., 1983). In the third trimester, women with pre-eclampsia 
show significantly higher impedance to flow in the spiral arteries than normotensive 
controls (Matijevic and Johnston, 1999). These findings, therefore, provide a strong 
support for the original hypothesis that defects in the uterine vasculature underlie 
impaired maternal placental blood flow. 
It is suggested that intermittent placental blood flow, hypoxia/reperfusion, oxidative 
stress (Hubel et al, 1999; and Burton et al, 2003) and the appearance of free radicals 
occur. This results in extensive cellular damage, lipid peroxidation and apoptosis 
within the placenta. The resulting tissue damage is believed to be a key factor in the 
pathogenesis of pre-eclampsia (Burton and Jauniaux, 2004). Louwen et al, (2013) 
demonstrated increased expression of a key oncogene in B lymphoma genesis known 
as B-cell Lymphoma 6 in pre-eclamptic placentas. It was localised in the nucleus of 
villous cytotrophoblasts. Alterations in B-cell Lymphoma 6 may be involving 
pathogenesis in pre-eclampsia. 
 
1.2.4.5. Treatment and prevention of pre-eclampsia. 
In severe pre-eclampsia, there is greater risk of serious complications to both mother 
and baby. The only complete cure for pre-eclampsia women is the delivery of the 
baby. Prevention or treatments of PE options available are limited. The studies by 
Kingdom et al, (2011), and Lyall and Belfort, (2007) investigated the effects of 
heparin on placental function by a pilot randomized trial using unfractionated heparin 
(UFH) in preventing recurrent PE. Proteoglycans (PG) are abundantly expressed in 
the placenta and a reduction in Glycosaminoglycans (GAGs) may contribute a 
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possible mechanism. Recently, pharmacological use of GAGs during pregnancy is 
popular with randomised controlled trials suggesting that patients that were treated 
throughout pregnancy with heparin had decreased risk of developing PE. Hills et al, 
(2006) study suggests that unfractionated heparin inhibits apoptosis, which was 
induced by different signals in the human 1st trimester cytotrophoblast cells. Clinical 
administration of heparin during pregnancy could be influenced via the actions of 
HB-EGF because of heparin sulphate is a co-factor of HB-EGF. The use of heparins 
to prevent PE appears promising. Therefore, dysregulation of heparin-binding growth 
factors could have a crucial role in the aetiology of PE. The mechanisms by which 
heparin act within the placenta requires further research to maximise the efficacy of 
pharmacologic GAGs and minimise their side effects. 
1.2.4.6. Animal models of pre-eclampsia. 
Animal models have failed to provide definitive insights into the pathogenesis of pre-
eclampsia because of their limited applicability to the human form of the disease. 
Despite these limitations, several theoretical mechanisms have been proposed that 
reconcile foeto-placental abnormalities and clinical features of the maternal 
syndrome. These include apoptosis, oxidative stress and hypoxia.  
 
 
1.2.4.7.  Mechanisms of placental insufficiency. 
The conditions described above are believed to have a common aetiology in pre-
eclampsia that involves several common pathological pathways such as apoptosis, 
hypoxia and oxidative stress. 
 
1.2.4.8.  Apoptosis. 
Apoptosis is programmed cell death (Kingdom et al, 2000) and has been observed in 
pregnancies complicated by pre-eclampsia or intrauterine growth retardation (IUGR) 
(Allaire et al, 2000). It is important for normal placental development, but it may also 
be involved in the pathophysiology of pregnancy-related diseases. It differs from 
necrosis in that the former is an active form of cell death dependent on the internal 
machinery of the cell and the latter is an accidental death caused by factors outside the 
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cell. Trophoblast apoptosis increases in normal placentas as gestation proceeds. 
Depending on the stimuli, apoptosis may be initiated intrinsically by the mitochondrial 
pathway or extrinsically by either the death receptor-mediated pathway or in response 
to exogenous stimuli such as cytokines. These factors, such as superoxide anion 
radical, O2-, and peroxynitite anion induce a variety of forms of cellular damage 
including endothelial dysfunction, abnormal platelet activation and apoptosis (Lyall et 
al, 2007). It is unknown whether the regulators of apoptosis are differentially 
expressed placentas of pre-eclamptic women (Sakuragi et al, 1994; and Kim et al, 
1995).  
1.2.4.9. Hypoxia and oxidative stress. 
Hypoxia and oxidative stress promote the excess release of placental tumour necrosis 
factor (TNFα) (Kingdom et al, 2000) into the maternal circulation by the hypoxic 
placenta that might promote endothelial dysfunction in pre-eclampsia (Benyo et al, 
1997). Amplification of injurious effects of placental TNFα by increased maternal 
free fatty acids is then possible. Free fatty acids are highly inflammatory (Toboreket et 
al, 1996). Placental Lipid peroxidation produced in pregnancy may mediate 
disturbance of the maternal vascular endothelium. It is not clear whether this 
mechanism results in impaired placental development or if the impaired development 
results in hypoxia (Hills et al, 2006).  
Hypoxia as in Figure 17. is a potent stimulus for endothelial dysfunction during 
pregnancy. Placento-foetal hypoxia may provide a link for pre-eclampsia. Another 
mechanism via which placento-foetal hypoxia may affect several circulations is 
through the activation of oxidative stress (Lyall and Belfort, 2007; and  Kay et al, 
2011). 
1.2.5. Oxidative stress. 
Oxidative stress arises in the presence of ROS and excess oxygen. Both high and low 
levels of oxygen can cause tissue damage including the low non-physiological oxygen 
levels (hypoxia) (Kay et al, 2011; Pijenborg et al, 2010; Wang & Zhao 2010; and 
Williams, 2010; and Hansson et al, 2015). Oxidative stress may be the point at which 
multiple factors converge resulting in endothelial cell dysfunction and the consequent 
clinical manifestations of pre-eclampsia. ROS production seems increased in pre-
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eclamptic placentae, as evidenced by increased peroxynitrite formation. Additionally, 
the concentration of ascorbic acid is decreased in the maternal circulation in pre-
eclamptic women, which could be indicative of reduced anti-oxidant potential. 
Increased ROS and potentially decreased anti-oxidant capacity will propagate lipid 
peroxidation leading to leukocyte activation, platelet adhesion and vasoconstriction. 
Increased placental oxidative stress in pre-eclampsia promotes formation of lipid 
peroxides, which alter cell membranes by increasing incorporation of cholesterol, 
oxidised free fatty acids and low density lipoprotein. There is evidence that an 
imbalanced angiogenic factors such as VEGF/sflt-1, PLGF are early markers to the 
pathogenesis of pre-eclampsia and oxidative stress is induced in placenta as a result. 
There is evidence of oxidative stress in pre-eclampsia, in both the maternal circulation 
and in the placenta (Kay et al, 2011; Pijenborg et al, 2010; Wang & Zhao 2010; and 
Williams, 2010; and Hansson et al, 2015). 
There appears to be an increase in ROS generation in the placenta of pre-eclamptic 
women (Kay et al, 2011; Pijenborg et al, 2010; Wang & Zhao 2010; and Williams, 
2010). There is evidence for increased nitrotyrosine formation in the preeclampsia 
placenta suggestive of ONOO- production, perhaps arising from local nitric oxide 
(NO) production coupled with increased xanthine oxidase generation of O2·- and either 
regionally decreased or inadequate SOD. Whether this could lead to oxidative stress 
and/or endothelial dysfunction in the systemic circulation is uncertain. 
Beneficial/compensatory effects of ONOO- are also plausible. For example, ONOO- 
can lessen leukocyte rolling and adhesion to endothelial cells and inhibit platelet 
aggregation (Lyall and Belfort, 2007). 
The genesis of pre-eclampsia is clearly related to deficient trophoblast invasion and 
failure of uterine artery remodelling (Kay et al, 2011; Pijenborg et al, 2010; Wang & 
Zhao 2010; Williams, 2010). In normal pregnancy the spiral arteries feeding the 
intervillous space of the placenta increase greatly in diameter and become refractory 
to vasomotor agents. This involves replacement of endothelium by invading 
trophoblast (the trophoblast cells assuming an endothelial cell adhesion molecule 
phenotype) and replacement of the internal elastic lamina and smooth muscle by 
trophoblast and fibrinoid matrix (Lyall and Belfort, 2007; Wang & Zhao 2010). This 
transformation is complete by 20 weeks of gestation. Along with venous distension, 
this accounts for the increased blood supply to the intervillous space necessary to 
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meet the demands of the rapidly growing feto-placental unit during the later stages of 
gestation (Lyall and Belfort, 2007; and Wang & Zhao 2010). 
1.2.5.1. Placental Lipid peroxidation. 
 
Lipid peroxidation products are candidate factors that may mediate disturbance of the 
maternal vascular endothelium. In vitro production of lipid hydroperoxides and 
thromboxane are reportedly increased in both trophoblast cell and villous tissues from 
women with pre-eclampsia (Kay et al, 2011; Lyall and Belfort, 2007; Wang & Zhao 
2010; and Williams, 2010). Glutathione peroxidase, an enzyme that removes 
hydrogen peroxide and converts lipid hydroperoxides to less reactive alcohols, may be 
deficient in placental tissue from pre-eclamptic women. This is observed in 
conjunction with increased in vitro placental production. The altered prostaglandin 
ratio might provoke vasospasm with exacerbation of placental ischemia, increased cell 
damage and increased lipid peroxidation (amplification of oxidative stress). There are 
scores of reports that lipid peroxidation products, primarily measured as thiobarbituric 
acid-reactive substances (which include malondialdehyde), are increased in 
plasma/sera of women with pre-eclampsia (Lyall and Belfort, 2007; and Wang & 
Zhao 2010). 
1.2.5.2. Placental Nitrotyrosine, Xanthine Oxidase, and superoxide dismutase SOD. 
 
Peroxynitrite anion (ONOO-) is capable of nitrating proteins and inducing lipid 
peroxidation. The nitration of tyrosine can occur by other free radical processes 
(Wang & Zhao 2010). Superoxide-independent pathways have been reported, such as 
interaction of nitrogen dioxide (NO2·) with tyrosyl radicals generated by 
myeloperoxidase during oxidative stress. Changes in xanthine oxidase in the pre-
eclampsia placenta further suggest ischemic or inflammatory injury. However, a 
recent reappraisal of xanthine oxidase in human tissues has suggested that both D and 
O isoforms can generate reactive oxygen species during posthypoxic reperfusion. 
There appears to be an increase in ROS generation in the placenta of pre-eclamptic 
women. There is evidence for increased nitrotyrosine formation in the preeclampsia 
placenta suggestive of ONOO- production, perhaps arising from local NO· production 
coupled with increased xanthine oxidase generation of O2·- and either regionally 
  Farha Nazir Ahmad M00201045                                                            83 
decreased or inadequate SOD. Whether this could lead to oxidative stress and/or 
endothelial dysfunction in the systemic circulation is uncertain. 
Beneficial/compensatory effects of ONOO- are also plausible. For example, ONOO- 
can lessen leukocyte rolling and adhesion to endothelial cells and inhibit platelet 
aggregation (Lyall and Belfort, 2007; and Wang & Zhao 2010). 
1.2.5.3. Ascorbate Oxidative Consumption.  
During its antioxidant action, ascorbate undergoes two consecutive one-electron 
oxidations to dehydroascorbic acid with intermediate formation of the ascorbate 
radical (Lyall and Belfort, 2007; and Wang & Zhao 2010). Ascorbate radical is 
detectable by electron paramagnetic resonance (EPR) spectroscopy whereas ascorbate 
and dehydroascorbate are EPR-silent. The initial signal amplitude of ascorbate radical 
is directly proportional to the overall rate of ascorbate oxidation, whereas the signal 
duration is inversely proportional. Ascorbate radical thus serves as a gauge of ongoing 
oxidative stress in plasma (Lyall and Belfort, 2007; and Wang & Zhao 2010). If stable 
peroxidation metabolites are produced during placental oxidative stress and enter the 
maternal circulation, these could contribute to widespread endothelial dysfunction 
(Lyall and Belfort, 2007; and Wang & Zhao 2010). 
1.2.5.4. Placental syncytiotrophoblast microvesicles (STBM) and pre-eclampsia. 
Placental cytokines and anti-angiogenic factors produce excessive maternal 
inflammatory response in pre-eclampsia (Kay et al, 2010; and Reddy et al, 2008). 
Placental debris comprises from trophoblasts cells, cellular fragments as shown in 
Figure 16. and multinucleated syncytial knots (Kay et al, 2010; Kingdom et al, 2011; 
and Reddy et al, 2008).  Human placental microparticles are membrane-bound 
structures that derive from synctiotrphoblast are known as placental 
syncytiotrophoblast microvesicles (STBM) (Kay et al, 2010; and Reddy et al, 2008). 
These are generated from trophoblast cell activation, apoptosis or necrosis. The 
STBM’s are shed into the maternal circulation in normal pregnancy and are 
significantly increased in early-onset pre-eclampsitic women. In vitro studies suggest 
that microparticles modulate maternal vascular endothelial dysfunction. The plasma 
from pre-eclamptic women contains placental microparticles as soluble fms-like-
tyrosine kinase (sFlt-1) and influences angiogenesis (Kay et al, 2010; and Reddy et al, 
2008).  
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Some recent studies have hypothesized the possible role of STBM in the new 
aetiology of pre-eclampsia. Reddy et al, (2008) hypothesized that labour and placental 
separation leads to an increase in shedding of placental debris (STBM, cell-free foetal 
and maternal DNA and cell-free placental mRNA) into maternal circulation. Another, 
hypothesis that placental STBM proteins are differentially expressed in pre-eclampsia 
when compared to normal pregnancies was reported by (Baig et al, 2014). They 
suggested that differential placental protein expression of STBM pathophysiological 
importance in pre-eclampsia.  
Dusse et al, (2012) study suggested endothelium activation is important because there 
was a higher number of endothelial cell-derived Microparticles (MPs) in women with 
severe pre-eclampsia, as erythrocyte-derived MPs levels were increased in women of 
pre-eclampsia. Cronqvist et al, (2014) study showed that haemoglobin Hb perfusion 
alters of two placenta specific micro-RNAs; mir-517a and mir-517b content of release 
placental syncytiotrophoblast vesicles (STBMs). STBMs may function as carriers of 
Hb into the maternal circulation. 
1.2.5.5. Disorders associated with placental insufficiency. 
Pregnancy complications such as preterm labour (PTL), pre-eclampsia (PE), and 
intrauterine growth retardation (IUGR) affect a considerable number of pregnancies 
and account for significant perinatal morbidity and mortality. These diseases consists 
of an abnormal development and function of the placenta, that is, placental 
insufficiency (Lyall and Belfort, 2007; Williams, 2010). The most common adverse 
pregnancy outcomes in women are pre-eclampsia, pre-term labour, and intrauterine 
growth restriction (Williams, 2010; Pijenborg et al, 2010; and Kay et al, 2011).  
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1.2.5.6.  Preterm labour. 
The WHO defines preterm or premature as delivery of an infant before 37 completed 
weeks of gestation (Williams, 2010). Clinically, deliveries below 34 weeks' gestation 
may be a more relevant definition. There is no set lower limit to this definition, but 
23–24 weeks' gestation is widely accepted, which approximates to an average foetal 
weight of 500g. Preterm birth occurs in about 5–10% of all births in resource-rich 
countries, but in recent years the incidence seems to have increased in some countries, 
particularly the USA, where the rate reached 12.7% in 2005. Williams, (2000) found 
little reliable evidence for incidence in resource-poor countries.  
Preterm birth is the leading cause of neonatal death and infant mortality, often as a 
result of respiratory distress syndrome due to immature lung development.  Children 
who survive are also at high risk of neurological disability. Observational studies have 
found that one preterm birth significantly raises the risk of another in a subsequent 
pregnancy (Williams, 2010).   
 
1.2.5.7.  Foetal growth restriction. 
The clinical term “small for gestational age” (SGA) is used for foetuses whose birth 
weight falls below the 10th percentile of weight for their gestational age. Foetal 
growth restriction (FGR) is a condition where infants have failed to achieve their 
growth potential and are small, because baby’s growth slows and have experienced 
foetal growth restriction (Williams, 2010). Imprinting in the placenta is an important 
means of regulating placenta and foetal growth and disturbances result in disorders. 
Genomic imprinting is an example of regulating foetal growth. IUGR is a 
characteristic of the imprinting disorder. Mouse knockout studies have also 
demonstrated that altered expression of imprinted genes can cause changes in the 
ability of the placenta to exchange nutrients by altering the thickness and surface area 
of exchange in placental tissues (Murphy et al, 2006).  
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1.2.5.8. Heparin-binding growth factors and their receptors in the human 
placenta. 
There is an increasing list of growth factors whose activity is modified following 
binding to heparin. Furthermore, cells within the human placenta as shown in table 1. 
express a large number of these heparin-binding growth factors. In the following 
sections these factors are described in detail. 
Factor 
Placental 
expression 
Reference 
Regulates 
placental 
function 
Reference 
Modified 
by heparin 
Reference 
VEGF Y Tseng et al, 2006 Y Anteby et al, 2004 Y Lash et al 2003 
PLGF Y Clark et al, 1998 Y Dessai et al, 1995 Y Lash et al 2003 
HB-EGF Y Leach et al, 2002 Y Hills et al, 2006 Y Hills 2006 
IFN γ Y Bulmer et al, 1990 Y Karmakar et al, 2004 Y Hills et al 2006 
bFGF Y Zhong et al, 2006 Y Anteby et al, 2004 - - 
PDGF Y Gurski et al, 1990 Y Lash et al, 2003 - - 
HGF Y Kilby et al, 1996 Y Dash et al, 2005 - - 
TGFβ Y Selik et al, 1994 Y Cannagia et al, 1999 - - 
IL-8 Y Abrahams et al,  2005 Y Abrahams et al, 2005 - - 
AR Y Lyssiak et al, 1995 Y Lyssiak et al ,1995 - - 
PTN Y Shulte et al, 1996 - - - - 
MK Y Milner et al,  1992 - - - - 
AT Y Corfman et al, 1987 - - - - 
 Table 1. Heparin-binding growth factors present in placental tissues. 
Abbreviations: vascular endothelial growth factor (VEGF), placental growth factor (PLGF), 
heparin-binding epidermal growth factor (HB-EGF), interferon gamma (IFNγ), fibroblast 
growth factor 2(FGF2), platelet-derived growth factor (PDGF), hepatocyte growth factor 
(HGF), transforming growth factor beta (TGFβ), interleukin-8 (IL-8), amphiregulin (AR), 
pleiotrophin (PTN), midkine (MK), Amphoterin (AT) and – not tested. 
These include the vascular endothelial growth factor (VEGFs), placental Growth 
Factor (PLGF), transforming growth factor (TGF) and hepatocyte growth factor 
(HGF) (Selick et al, 1994; Kilby et al, 1996; Clark et al, 1998; Leach et al, 2002; and 
Tseng et al, 2006). As can be seen in the Table 2. many of these factors have been 
shown to modify placental function in vitro. These include, but may not be limited to 
promotion of invasion, motility, proliferation and cytoprotection. In addition to these 
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anti-inflammatory and immunomodulatory effects, heparin also enhances the ability 
of several growth factors, including hepatocyte growth factor, epidermal growth factor 
(EGF), heparin-binding EGF (HB-EGF) and fibroblast growth factors (FGFs), to 
activate their cognate cell surface receptors (Folkman and Shing, 1992; and Li et al, 
1999). Whereas the angiogenic effects of VEGF are known, there is increasing 
evidence that these factors are important in blocking the effects of oxidative stress. 
For example, MK blocks apoptosis induced by hypoxia reperfusion in cardiomyocytes 
(Horiba et al, 2006). PTN blocks apoptosis in heptoma cell lines and inhibits 
apoptosis of lung cancer cells (Park et al, 2008). Basic FGF blocks apoptosis of rat 
embryonic cells (Schamberger et al, 2004). 
 
The nine growth factors studied in this study are summarised in Table 2. In summary, 
various growth factors are involved in placental development. Many of these bind to 
glycosaminoglycans (GAGs) affecting activity.  
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Table 2.  Some of the heparin-binding growth factors present in placental tissues. Abbreviations: vascular 
endothelial growth factor (VEGF), placental growth factor (PLGF), heparin binding epidermal growth factor (HB-
EGF), fibroblast growth factor 2 (FGF2), platelet-derived growth factor (PDGF), hepatocyte growth factor (HGF), 
pleiotrophin (PTN), midkine (MK) and cluster differentiation (CD105). 
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As mentioned earlier, there is evidence that the activities of many of these growth 
factors are regulated by a series of sugar polymers consisting of chains of 
monosaccharide’s or disaccharide units known as glycosaminoglycans, for example 
heparin. 
 
1.2.5.9. Heparin. 
A number of growth factors described bind to a series of carbohydrate polymers 
called glycosaminoglycans. Heparin is a well-known soluble glycosaminoglycan 
(GAG) with a molecular weight ranging from 6,000 to 40,000 Daltons (Da). Low 
molecular weight heparin (LMWH) is made by partial hydrolysis or enzymatic 
degradation of unfractionated heparin (UFH; Shriver et al, 2000). Heparin is a 
polymeric chain composed of repeating disaccharide units of D-glucosamine and 
uronic acid linked by 1¯¯> 4 interglycosidic bond. The uronic acid residue can be 
either D-glucuronic acid or L-iduronic acid (Mulloy et al, 1993; Said et al, 2013). The 
linear structure of Heparin is shown in Figure 19. A single disaccharide unit of 
heparin is composed of a 2-O-sulphated α-L-iduronic acid and 6-O-sulphated, N-
sulphated glucosamine. 
 
Figure 19. Heparin structure modified from Mulloy et al, (1993). 
The three-dimensional structure of heparin is complicated and the conformational 
equilibrium is influenced by sulphation state of adjacent glucosamine sugars. These 
are essential for determining the critical functional groups involved in the recognition 
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and activation of different proteins. Heparan sulphate (HS) carboxyl groups, give it a 
very strong negative charge. HS are produced in living cells by a complex multi-step 
enzymatic biosynthetic process.  
A heparin dodecasaccharide is composed of  6-O-sulphated, N-sulphated glucosamine 
and 2-O-sulphated α-L-iduronic acid (GlcNS(6S)-IdoA(2S) repeat units. The two 
models in Figure 20. show: one in which all IdoA two sulphur (2S) = (2-O-sulpho-α-
L-iduronic acid) are in the 2S0 conformation (A), and one in which they are in the 
carbon ( 1C4) conformation (B ).  
 
                   
 
              A                                                       B 
• A = 1HPN (all IdoA (2S) residues in 2S0 conformation)  
• B = 1HPN (all IdoA (2S) residues in 1C4 conformation)  
Figure 20. Three-dimensional chemical structure of heparin polysaccharide. Modified 
from Ferro et al, (1990). 
Heparin has a helical conformation, the rotation of which places clusters of sulphate 
groups on either side of the helical axis. The clour key as carbon is white, oxygen is 
red, nitrogen is blue and sulphate is yellow. 
Heparin is also effective in lowering the recurrence of pre-eclampsia (Mello et al, 
2005; Rai et al’s, 1997) and other disorders associated with placental development 
and oxidative stress. Heparin acts as an anticoagulant, preventing the formation of 
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clots and extension of existing clots within the blood. In normal pregnancy there is an 
increase in procoagulants and impaired fibrinolysis. The beneficial effects of heparin 
on pregnancy outcome in women with prothrombotic disorders are mediated by its 
anticoagulant properties, but intravascular or intervillous blood clots are rarely found. 
There is evidence that the underlying mechanism is not through its anticoagulant 
effects. To determine the rationale for this treatment a series of studies have been 
carried out. Bose et al, (2005); Hills et al, (2006), and Mello et al, (2004) showed that 
heparin has direct effects on placental and trophoblast cells, in addition to its vascular 
effects. The in vitro studies of Hills et al, (2006) demonstrated that heparin itself 
inhibits trophoblast apoptosis from a variety of stimuli. Results suggest that heparin 
may be useful in the management of at-risk patients, even in the absence of an 
identifiable thrombophilic disorder. Said et al, (2013) suggested that heparin therapy 
might reduce the development of pre-eclampsia, as observed in recent clinical studies. 
The mechanism that mediates these effects may be brought about through the 
interactions with heparin-binding growth factors (HBGFs). Signal transduction by the 
epidermal growth factor (EGF) receptor tyrosine kinase, as evidenced by receptor 
autophosphorylation, is induced by HB-EGF only in the presence of heparin, in 
contrast to EGF-induced receptor autophosphorylation, which is independent of 
heparin. In summary, it has been demonstrated to us Hills et al, (2006) that heparin 
activates multiple anti-apoptotic pathways in human trophoblast.  
Proteins involved in signalling and adhesion at the cell surface recognize and bind HS 
chains (Said et al, 2013). There is evidence that some actions are mediated via a series 
of growth factors (Hills et al, 2006). These are called heparin-binding growth factors 
(HBGFs) (Hills et al, 2006; and Said et al, 2013).  
1.2.6. Other glycosaminoglycans.  
Glycosaminoglycans (GAGs) are large linear polysaccharides constructed of 
repeating disaccharide units either of two modified sugars N-acetylgalactosamine 
(GalNAc) or N-acetylglucosamine (GlcNAc) with the primary configurations 
containing an amino sugar (either GlcNAc or GalNAc) and an uronic acid (either 
glucuronic acid and/or iduronic acid).  
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1.2.6.1. Actions of proteoglycans. 
The majority of GAGs are linked to core proteins involving a specific trisaccharide 
composed of two galactose residues and a xylose residue, forming proteoglycans as 
shown in Figure 21. The protein cores of proteoglycans allow multiple GAG 
attachments. 
 
Figure 21. The structure of GAG linkage to protein in proteoglycans is presented. 
Modified from King, (2013).  
The specific GAGs of physiological significance are five identified glycosaminoglycan 
chains: Hyaluronan (also called hyaluronic acid), dermatan sulphate, chondroitin 
sulphate, heparin, heparan sulphate, and keratan sulphate (King, 2013). Hyaluronate are 
large polymers and are synthesized in the plasma membrane. Chondroitin sulphates are 
the most abundant GAG and are associated with protein to form proteoglycans. They are 
the major component of the extracellular matrix (ECM). Heparan sulphate is associated 
with protein forming heparan sulphate proteoglycans (HSPG) and are major HSPG forms 
are the syndecans and glypicans (Said et al, 2013). Sydecans are membrane-bound 
protein glycosaminoglycans. Glypicans are heparan sulphate protein glycosaminoglycans 
linked to the plasma membrane. They are comprised of polysaccharide chain of heparan-
sulphate covalently linked to proteins (proteoglycans). These differ according to the 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Protein!core!!!Glycosaminoglycan!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Trisaccharide!link!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
                                                                                                            O=C  
                                                                                                                                                                                                                                      
                                                                                          -O-CH2-C-H                                                                              serine 
                    n        galactose               xylose                 N-H 
 
             Uronic acid 
 
N-acetyledsugar 
 
  Farha Nazir Ahmad M00201045                                                            93 
extent of sulphation of the saccharides. For example a syndecan HS proteoglycan 
involves a single transmembrane α-helix and a glypican HS proteoglycan attaches to the 
outer surface of the plasma membrane via covalent linkage to a phosphatidylinositol lipid. 
Perlicans are expressed in the basement membrane and extracellular matrix and are 
components of the extracellular space in tissues. Dermatan sulphate may function in 
wound repair and infection. Keratan sulphates are associated with protein forming 
proteoglycans. 
1.2.6.2. Heparin-binding growth factors (HBGFs) and glycosaminoglycans 
(GAGs) interactions. 
The biological activity of HBGFs is brought about through different mechanisms. The 
HSPGs stabilizes the growth factor and protects it from proteolytic degradation. 
Heparan-sulphate proteoglycans (HSPGs) may activate an intracellular transduction 
signal by interacting directly with growth receptors through three different 
mechanisms, as indicated in Figure 22.  
 
Figure 22. Modified from (Ruoslahti and Yamaguchi, 1991).  
HSPGs increase the local concentration of the growth factor (GF) to the tyrosine-
kinase (TK) receptor. HSPGs induce a conformational change of the growth factor for 
its interaction with TK receptor. HSPGs induce growth factor oligomerization with 
TK receptor dimerization and activation. HBGFs all have a heparin-binding motif.  
Hills et al, (2006) demonstrated that heparin abrogates apoptosis of primary first 
trimester villous trophoblast in response to treatment with the pro-inflammatory 
cytokines interferon (IFN)-  and tumour necrosis factor (TNF)-α. Heparin suppresses 
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natural killer cell cytotoxicity (Yamamoto et al, 1985; and Johann et al, 1995), 
prevents leukocyte adhesion/influx (Christopherson et al, 2002; Manduteanu et al, 
2002; and Wan et al, 2002), antagonizes interferon (IFN)-  signalling (Fritchley et al, 
2000) and inhibits complement activation (Girardi et al, 2004). The ability of heparin 
to antagonize cell death induced by such diverse apoptotic signals suggested that it 
acts as a survival factor for human trophoblast. It has been demonstrated in the study 
of Hills et al, (2006) that heparin, like epidermal growth factor (EGF) and heparin-
binding EGF (HB-EGF), elicit phosphorylation of the EGF receptor and activation of 
the phosphatidyl inositol 3-kinase (PI3K)-, the extracellular signal-related kinase 1/2 
(ERK1/2)- and the c-Jun NH2 terminal kinase (JNK)-signal transduction pathways in 
primary villous trophoblast. 
1.2.7. Aim of the Project. 
In summary, various growth factors are involved in placental development and 
many of these bind glycosaminoglycans (GAGs) and this binding affects activity. 
Several aims in this study were therefore to test the main hypothesis that pre-
eclampsia is associated with dysregulation of heparin-binding growth factors.  
These aims were: 
1. To determine whether heparin and heparin-binding growth factors have a role in 
regulating normal placental development and disorder as pre-eclampsia. 
2. To determine whether midkine and pleiotrophin’s expression may have a role in 
placental development.  
3. To identify if heparin-binding growth factors and their receptors could be detected 
in placental tissue.  
4. To determine heparin-binding growth factors’ role for the villous trophoblast 
invasion and migration in vitro with in presence and absence of heparin.  
5. To determine the amount of total quantitative mRNA production of placental 
expression in normal placenta and in pre-eclampsia with primer assays of heparin-
binding growth factors using quantitative real-time reverse transcription- 
polymerase chain reaction (qRTPCR).  
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I investigated the expression of heparin-binding growth factors VEGF, PLGF, 
FGF2, HGF, PDGF- BB, HB-EGF, MK, PTN and CD105 in normal pregnancy 
and pre-eclampsia. This study used immunohistochemical  staining procedures in 
human placenta samples of patients with normal pregnancy and pre-eclampsia. I 
examined the role of these heparin-binding growth factors on trophoblast invasion 
using in vitro studies in cultures of human fibrosarcoma HT1080 invasive cells 
(positive control); NIH 3T3 mouse embryonic fibroblast non-invasive cells 
(negative control) and immortalized human primary villous trophoblastic cell-line 
TCL-1. Since immunohistochemistry can only give semiquantitative information, 
this study was extended to quantify mRNA expression with HBGFs using real 
time PCR and the identification of HBGF receptors. 
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Chapter 2 
Materials and Reagents 
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2.1 Equipment 
2.1.2.General equipment 
Pipettes                                                Fisher Laboratories (Loughborough, UK) 
Pipette controller                                 Fisher Laboratories (Loughborough, UK) 
Pipettors                                              Fisher Laboratories (Loughborough, UK) 
Sterile graduated pipettes                    Fisher Laboratories (Loughborough, UK) 
Manual pipettes and sterile filter tips Fisher Laboratories (Loughborough, UK) 
5ml Bijou tubes   Fisher Laboratories (Loughborough, UK) 
Eppendorf tube   Fisher Laboratories (Loughborough, UK) 
Ceti inverted microscope  Jencons (Milton Keynes, UK) 
Vortex mixer    Fisher Laboratories (Loughborough, UK) 
Vortex mixer    Vortex-2-genie          Scientific industries Inc (USA) 
Lens cleaning tissue                           Whatman International Ltd (Maidstone, UK) 
Balancer Acculab                                Jencons (CO, UK) 
ALC multispeed refrigerated centrifuge   PK131R (DJBLab care Co, UK) 
Tissue Tek embedding centre             Leica EG1150H( Milton Keynes UK) 
2.1.3.Disposables 
Sterile disposable serological graduated pipettes  
                                                            Fisher Laboratories (Loughborough, UK) 
15/50mlSterile,polypropylene disposable centrifuge tubes  
                                                            Fisher Laboratories  (Loughborough, UK)  
1-20µl, 20-200 µl, and 200-1000 µl pipette tips   
                                                    Fisher Scientific Laboratories  (Loughborough, UK)  
Powder free nitrile Gloves                 Fisher Laboratories (Loughborough, UK)  
2.1.4.Immunohistochemistry (IHC)  
Pipettes    Fisher Laboratories (Loughborough, UK) 
Glass cover slips   Fisher Laboratories (Loughborough, UK) 
Superfrost poly-L lysine glass slides Fisher Laboratories (Loughborough, UK) 
Ceti microscope                        Nikon, and Ceti (Kingston, UK) 
 Camera                                     Nikon, and Ceti (Kingston, UK) 
Diaphot microscope and                     Nikon, and Ceti (Kingston, UK) 
Digital camera DXM1200F             Digital camera DXM1200F Labmade  
                                                             (Leighton Buzzard, UK)           
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Lucia Digital camera software Lucia imaging (Drahou, Czech Republic 
Fluormeter 96 well plate reader         Leica (Milton Keynes, UK)  
Tissue Tek embedding centre  Leica (Milton Keynes, UK) 
Microtome RM2235   Leica (Milton Keynes UK) 
Tissue Floatation Bath  Medite (Milton Keynes, UK) 
Microwave                                          Jencons (CO, UK) 
 
2.1.5.Cell Culture plus invasion and migration studies 
Corning cell culture flask                (Corning Incorporated, USA) 
canted neck, sterile, pyrogenic and polystyrene. 
1/2ml pastette                                   Fisher Laboratories (Loughborough, UK) 
100ml Sterile flask or plate               Fisher Laboratories (Loughborough, UK) 
BD Falcon FluoroBlok 96-Multiwell insert system Fisher Laboratories 
(Loughborough, UK) 
Fluorimeter 96 well plate reader          
                                                            BMG Labtech, Aylesbury, UK         
Haemocytometer                                Thermo Fisher Scientific (Loughborough, UK) 
Super frost plus coverslip                   Fisher Laboratories (Loughborough, UK) 
Manzel- Glaser cover glasses             Fisher Laboratories (Loughborough, UK)  
Cell counter                                        Fisher Laboratories (Loughborough, UK) 
Sterile Cryogenic vials Nalgene             Thermo Fisher Scientific Laboratories  
                                                                 (Loughborough, UK, Rochester, USA)  
Sterile Eppendorf tubes   Nalgene      Thermo Fisher Scientific Laboratories  
                                                            (Loughborough, UK, fAG-Germany)  
Incubator water bath                           (JB Aqua26 Grant, UK)     
37°C CO2 incubator                            Lab mode, Milton Keynes  (UK) 
Timer                                                   Fisher Laboratories (Loughborough, UK)    
Light microscope                                 GXD202 Model XD 202  
                                                             Fisher Laboratories (Loughborough, UK)    
BD Bio coat Invasion System-20°C BD Biosciences (Discovery Lab ware Bedford, 
USA)                      
BD Bio coat Migration System BD Biosciences (Discovery Lab ware Bedford, USA)                      
Microchip Electrophoresis System for DNA/RNA Analysis  
                            MCE®-202 MultiNA Shimadzu Laboratories  (Loughborough, UK) 
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PCR Tech TC- 512                Jencons-PLS Fisher Laboratories   (Loughborough, UK) 
PCR Tech TC-3000G           Jencons-PLS  Fisher Laboratories   (Loughborough, UK) 
Autochemi system UVP         Jencons-PLS Fisher Laboratories  (Loughborough, UK) 
UV –visible Spectrophotometer 1650 PC    Fisher Laboratories  (Loughborough, UK)  
UV –Trans illuminator PC with camera      Fisher Laboratories  (Loughborough, UK)     
UV – Trans illuminator portable                  Fisher Laboratories  (Loughborough, UK)      
Microwave Proline Fast set 600                   Fisher Laboratories  (Loughborough, UK) 
 
2.1.6.  Materials and Reagents 
Immunohistochemistry (IHC)  
Antibodies to the following: 
 VEGF vascular endothelial growth factor                        Dako cytomation  (Ely, UK) 
CD105 cluster differentiation                                            Dako cytomation  (Ely, UK) 
PLGF placental growth factor                         Abcam, (Cambridge, UK) 
FGF 2 basic fibroblast growth factor                                                 (RDsystems ,UK) 
PDGF- BB platelet-derived growth factor                            Abcam, (Cambridge, UK) 
HGF hepatocyte growth factor                                                     (Sigma-Aldrich, UK)  
HB-EGF heparin-binding epidermal growth factor                           (RDsystems ,UK)   
MK midkine                                                                                       (RDsystems, UK) 
PTN pleiotrophin                                                                          (Sigma-Aldrich, UK) 
Vascular endothelial growth factor receptor-1  FLT-1                (Sigma-Aldrich, UK)                                                                                                                                                                                             
 VEGFR-2                                                                                    (Sigma-Aldrich, UK)                                                                                                                               
Fibroblast growth factor receptor-1 FGFR-1                               (Sigma-Aldrich, UK)                                                                                                                               
Phosphate buffered sterile saline – PBS            Vector Labs (Peterborough, UK) 
Secondary antibodies and conjugate             Vector Labs (Peterborough, UK) 
Protein blocking reagent              Vector Labs (Peterborough, UK) 
Normal Goat/Rabbit/Horse Serum             Vector Labs (Peterborough, UK) 
Triton                             VWR  (Lutterworth, UK) 
Vector ABC Universal kit                                         Vector Labs (Peterborough, UK) 
Vector EliteABC kit (PK-6100)             Vector Labs (Peterborough, UK) 
Hydrogen peroxide                       Fisher Laboratories (Loughborough, UK) 
Citric acid                        VWR Ltd (Lutterworth UK) 
Ethanol                      VWR Ltd (Lutterworth UK) 
Xylene                       VWR Ltd (Lutterworth UK) 
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DAB (3,3’-Diaminobenzidene) substrate (SK-4100)  
                                                                                  Novacostra (Milton Keynes, UK) 
PBS (Phosphate buffered saline, (20 mM sodium phosphate, 150 mM NaCl, pH 8.0) 
Mayer’s Haematoxylin                            Fisher Laboratories (Loughborough, UK) 
 
2.1.8.Cell Culture 
Cells lines  
 HT-1080 cells, NIH/3T3(ATCC), JEG-3                                      ATCC 
 TCL-1.                                                                                        Imperial College 
Heparin                                                                                         (Sigma-Aldrich, UK) 
Presept (hypochlorite) Tablets Johnson and Johnson      (Medical Company Ltd, UK) 
Foetal bovine serum -20°C                                                                      (Bios era, UK) 
Antibiotic (penicillin, 50X) solution                       (Gibco invitrogenTM Paisely, UK)                           
L-glutamine 2-4mM -20°C                                           (Sigma-Aldrich company, UK)  
Tryple express                                                         (Gibco invitrogenTM Paisely, UK)                                                           
 Tissue culture growth media 
Serum free medium with antibiotic (penicillin/ streptomycin) solution                             
RMPI media 1640/ DMEM                                      (Gibco invitrogenTM Paisely, UK)                                          
Serum free medium with antibiotic, L-glutamine and foetal bovine serum (10%) 
RMPI media 1640/ DMEM                                     (Gibco invitrogenTM Paisely, UK)                                                               
RMPI1640                                                               (Gibco invitrogenTM Paisely, UK)   
DMEM Dulbecco’s Modified Eagle Medium    
                                                                   (Gibco Life Technologies Corporation, UK)   
Complete medium Fisher Laboratories                                         (Loughborough, UK) 
Sterile PBS                                                                Fisher Laboratories 
(Loughborough, UK)  
Distilled or deionized water                                 (Middlesex University, Hendon, UK) 
Cell wash buffer                                                             (Sigma-Aldrich company, UK)    
Calcein AM                                                                    (Sigma-Aldrich company, UK) 
 
Chemoattractant:  
5% foetal bovine serum in DMEM. 
                                                    (Bios era, Gibco Life Technologies Corporation, UK)  
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2.1.9.Polymerase chain reaction (PCR)                           
 
Mortor and pestle                                        Fisher Laboratories (Loughborough, UK)                                        
Liquid nitrogen                                           Fisher Laboratories (Loughborough, UK)                                        
Stabilization Reagent                                   Qiagen Ltd (Manchester, UK) 
QIA Shredder                                               Qiagen Ltd (Manchester, UK) 
RNA Later RNA Stabilization Reagent      Qiagen Ltd (Manchester, UK) 
Reverse transcription reaction                     Qiagen Ltd (Manchester, UK) 
Cyber Green kit                                           Qiagen Ltd (Manchester, UK) 
FGF2 Primer assay                                      Qiagen Ltd (Manchester, UK) 
PGF   Primer assay                                      Qiagen Ltd (Manchester, UK) 
Succinate dehydrogenase complex subunit A (SDHA) Primer assay  
                                                                     Qiagen Ltd  (Manchester, UK)                               
MK Primer assay                                          Qiagen Ltd (Manchester, UK) 
PTN     Primer assay                                    Qiagen Ltd (Manchester, UK) 
RNase-free water                                         Qiagen Ltd (Manchester, UK) 
Ambion TBE Buffer                          Invitrogen Life Technologies Ltd (Paisley, UK) 
Blue juice gel loading buffer              Invitrogen Life Technologies Ltd (Paisley, UK) 
Ultra Pure Agarose gel                       Invitrogen Life Technologies Ltd (Paisley, UK) 
RNAse  Away                                               Qiagen Ltd  (Manchester, UK) 
DNA ladder                                         Invitrogen Life Technologies Ltd (Paisley, UK) 
SYBER safe DNA gel stain                Invitrogen Life Technologies Ltd (Paisley, UK) 
ß-mercaptoethanol (ß-ME) Fisher Laboratories (Loughborough, UK)    
Gel electrophoresis camera                           Fisher Laboratories  (Loughborough, UK) 
Gel electrophoresis plate tray                       Fisher Laboratories  (Loughborough, UK) 
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2.2. Tissue Samples: 
Tissues used in this study comprised of placenta samples collected from 87 women 
(n=87) attending Queen Charlotte, Chelsea Hospitals and Chase Farm. The group 
comprised first trimester prior to labour (n=4), term placenta (after 36 weeks 
gestation) not in labour (n=26), preterm labour (before 36 weeks gestation, n=17), 
term following labour onset (n=21), and (after 20 weeks of gestation) pre-eclampsia 
(n=19).  
The VEGFR-1, (sflt), VEGFR2 and FGF2 receptor study group comprised term 
placenta (after 36 weeks gestation) not in labour (n=22), preterm labour (before 36 
weeks gestation, n=6), term following labour onset (n=21), and pre-eclampsia (n=12).  
Protocol A was performed for fibroblast growth factor 2 (FGF2) on placental 
specimen (n=109) in different dilutions (1 in 100, n=15), (1 in 200,n=56), and (1 in 
400,n=10), control (n=17), and a negative control IgG (n=11) were optimised in the 
absence of citrate buffer. These slides (n=56) in dilution 1 in 200 were incubated 
overnight at 2-8°C. However, in protocol B the procedure was performed on placental 
specimen in the presence of citrate buffer for the following heparin-binding growth 
factors VEGF (n=87), PLGF (n=87), FGF2 (n=87), HGF (n=87), PDGF-BB (n=87), 
and CD105 (n=87) except for HB-EGF (n=42), MK (n=35), and PTN (n=30), control 
using placental specimens in different dilutions, control (n=51), and a negative control  
IgG (n=10). 
2.3. Ethical considerations 
There are ethical considerations involving the Human Tissue Act (HTA) 2004 
(Herrings, 2006). The Hammersmith, Queen Charlotte and Chelsea Hospitals, NHS 
Trust Research Ethics Committee, and Barnet, Haringey and Enfield local Research 
Ethics Committee approved study. Informed written consent was obtained from each 
patient before obtaining the placenta samples. The Department of Natural Sciences 
Research Ethics subcommittee (Montgomery, 2003) of Middlesex University 
approved this study. 
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Following collection, tissues were numerically coded and anonymised so that no 
information could be traced back to an individual. All tissues are stored within a 
controlled laboratory area with restricted access. 
2.4. Methods    
2.4.1. Principle of immunohistochemistry. 
Immunohistochemistry (IHC) was first described in the 1930s, but it was not until 
1942 that the first immunohistochemistry study was reported. The term 
immunohistochemistry is often used interchangeably with immunocytochemistry and 
immunostaining (Crowther, 1995; Law, 1996). However, immunohistochemistry 
specifically refers to a technique applied to intact tissue, whereas 
immunocytochemistry refers to a technique applied to isolated cells. 
Immunohistochemical staining is used for detecting specific antigens in placenta 
tissues. It combines anatomical, immunological and biochemical techniques for the 
identification of specific tissue components by means of a specific antigen/antibody 
reaction tagged with a visible label. This makes it possible to visualize the distribution 
and localization of specific cellular components within a cell or tissue. Improvements 
have been made in protein conjugation, tissue fixation methods, detection labels and 
microscopes, making immunohistochemistry a routine and essential tool in many 
laboratories. A primary antibody is used that is designed to specifically bind to a 
molecule of interest on the tissue. An enzyme-conjugated secondary antibody was 
then applied. These are designed to specifically bind to the primary antibody, which is 
itself bound to the molecule of interest. The secondary antibody labelled with biotin 
was visualized after adding the enzyme-specific substrate. A complex of avidin, 
labelled with horseradish peroxidase, and biotin (ABC) is applied to identify levels of   
molecule of interest protein within the placenta tissue. Avidin, a large glycoprotein, 
has a very high affinity for biotin. Biotin, a low molecular weight vitamin, can be 
conjugated to a variety of biological molecules including antibodies. The presence of 
the peroxidase labelled avidin biotin complex is visualised by the addition of 3, 3’-
Diaminobenzidene (DAB) and hydrogen peroxide. The DAB reaction deposits a 
brown chromagen substrate where there are peroxide enzymes present as shown in 
Figure 23. 
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In the current study, this technique has been applied to identify the expression of a 
series of heparin binding growth factors; namely VEGF, PLGF, FGF2, HGF, PDGF- 
BB, HB-EGF, MK, CD105, and PTN in placental tissue.  
 
Figure 23. The principle of immunohistochemistry.  
Key   *  Molecule of interest,  YPrimary antibody,  Ysecondary antibody. 
 
 
Epitope retrieval- Unmasking of Antigen and blocking of peroxidase activity 
In the current study, including an epitope retrieval step for antigens requiring 
“unmasking” according to the primary antibody specifications refined the 
immunohistochemistry technique.  
Several endogenous substances may interfere with IHC results, such as endogenous 
peroxidase, endogenous fluorescence, endogenous antibody binding capability (Fc 
Tissue containing molecule of interest
Add primary antibody. This only binds 
molecule of interest
Add secondary antibody.
•Different species to first antibody
•Specific for first antibody
•Labelled with biotin 
Add ABC followed by substrate
•Colour reaction only where the antibody is present
** *
** *
Biotin
** *
Biotin Biotin
Biotin
** *
Biotin Biotin
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receptors), endogenous biotin. Therefore, blocking the background staining is crucial 
in IHC to avoid acquiring false positive staining. The blocking of endogenous 
enzymes, such as alkaline phosphatase, acidic phosphatase and esterase’s can be 
achieved with destroying their activity by boiling, even for a short time at 100ºC. This 
boiling prevents blocking of peroxidase and this may be achieved by preincubating 
the slides in 3% H2O2 in 1% sodium azide PBS for 30 minutes followed by several 
washes. The heat retrieval method used here involved the use of a citric acid solution 
maintained at pH of 6.0 and the container being placed with the slide in a microwave 
oven. The temperature was set to 100ºC and left for 20 minutes. The tissue sections 
were incubated and then rinsed with PBS. The primary antibody was applied to the 
slide covering the placental specimen with different dilutions to allow optimisation 
(Abcam, 2010). 
 
2.4.2. Photomicrographs of Immunohistochemical staining. 
Photomicrographs were taken in Cell Culture Laboratory using the diaphot 
microscope, digital Nikon (Kingston, UK) camera DXM1200F, and LUCIA digital 
camera software, Lucia imaging (Drahou, Czech Republic) from (2010 to 2011), Ceti 
microscope Nikon, and Ceti (Kingston, UK) from (2012 to 2014). 
 
2.4.3.     Immunocytochemistry protocol. 
2.4.5.   Tissue fixing and processing. 
The placenta tissue samples were fixed as a standard procedure using neutral buffered 
formalin fixative solution incubated overnight to preserve the chemical structure of 
the tissue. Tissues were then stored in 70% ethanol prior to processing. For tissue 
processing the water in the tissues was gradually replaced by using a graded solvent 
series of dehydration agents namely ethanol and finally xylene. The tissue was 
immersed in 50% ethanol for three minutes. The secondary solvent fixation was with 
70% ethanol for 3 minutes, 95% for 3 minutes, and 100% for 3 minutes. Following 
this, using xylene cleared the placental tissue samples.  
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2.4.6 Tissue embedding. 
The Tissue embedding process was carried out using our automated Tissue Tek. 
Metal moulds and labelled plastic cassettes were used to form embedding tissue 
specimens in molten paraffin wax as ‘block’, from which sections may be cut. The 
tissue specimen was picked with warm forceps and placed in the centre of the metal 
mould on the hotplate. The metal mould was placed under the heated lamp to allow 
the molten paraffin to be poured over the tissue specimen. The labelled plastic 
cassette was placed over the metal mould with the tissue specimen in the centre and 
more paraffin wax was added to cover the cassette. The tissue specimen metal was 
placed on a cold plate for rapid cooling of the paraffin wax. When the paraffin wax 
had solidified and was stable, the metal mould and excess wax from the plastic 
cassette were removed. The tissue specimen was then mounted in the clamp of a 
microtome for thin microscopic sectioning. 
2.4.7. Slide preparation. 
A microtome was used to cut 5µm sections of each tissue. Sections were placed onto 
a tissue flotation bath at 37°C. This allowed the tissue to stretch and soften so that it 
would easily be mounted onto the poly L-lysine coated super frost glass slides. 
 
2.4.8. Protocol A and B for VEGF, PLGF, FGF2, HGF, PDGF- BB, HB-EGF, 
MK, CD105 and PTN  Immunohistochemistry. 
Protocol A was performed for fibroblast growth factor 2 (FGF2) the primary antibody 
was applied to the slide covering the placental specimen in different dilutions (1 in 
100), (1 in 200), and (1 in 400) control, and a negative control IgG were optimised in 
the absence of citrate buffer. These slides in dilution 1 in 200 were incubated 
overnight at 2-8°C. However, in protocol B the procedure was performed in the 
presence of citrate buffer for the following heparin-binding growth factors VEGF, 
PLGF, FGF2, HGF, PDGF-BB, and CD105 except for HB-EGF, MK, and PTN, 
using placental specimens in different dilutions, control, and a negative control IgG  
were optimised. 
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The primary antibody was applied to the slide covering the placental specimen (n=87) 
in the presence of citrate buffer with different dilutions and optimised for VEGF 
primary antibody (goat, 1 in 50 dilution), HGF primary antibody (goat, 1 in 100 
dilution) and PDGF-BB primary antibody (rabbit, 1 in 100 dilution) and control. After 
preparation of slides, the sections were deparaffinised by 2 changes of xylene, of 5 
minutes each, then re-hydrated in 2 changes of absolute alcohol, for 3 minutes each. 
The re-hydrating procedure was continued by incubation with 90% alcohol for 3 
minutes and then 70% alcohol for 3 minutes. The slide was blocked with (50% in 
PBS) diluted normal serum (horse serum) in PBS for 5 minutes and incubated with 
VEGF primary antibody (goat, 1 in 50 dilution); HGF primary antibody (goat, 1 in 
100 dilution) and PDGF-BB primary antibody (rabbit, 1 in 100 dilution) for 30 
minutes at room temperature. The sections were incubated in preheated citrate buffer 
with 1M Tris to at pH 8.0 with HCL, and 0.5M EDTA for 10 minutes in a microwave 
and boiled in a microwave for 4 minutes. The slides were left to cool in heated buffer 
for 20 minutes. Rinses and washes in PBS were carried out in between the following 
steps. The next steps of this protocol are described below. 
The procedure was identical to that used for VEGF, HGF and PDGF-BB except after 
the sections were deparaffinised the slides for FGF2, PLGF, CD105, HB-EGF, IgG, 
MK and PTN were quenched by the endogenous peroxidase activity, and incubated 
with a blocking reagent 3% H2O2 in PBS for 1 minute. The slides were then washed 
in running tap water for 1 minute. The sections were incubated in preheated citrate 
buffer with 1M Tris to at pH 8.0 with HCL, and 0.5M EDTA, for 10 minutes in a 
microwave and boiled in a microwave for 4 minutes. The slides were left to cool in 
heated buffer for 20 minutes. Rinses and washes in PBS were carried out in between 
the following steps. Normal horse serum (50% in PBS) was used to non-specific 
binding of secondary antibody and blocked for 5 minutes. The FGF2 primary 
antibody was raised in a final dilution of (goat, 1 in 200 and 1 in 2000), control and 
IgG (a negative control) was applied to the slide covering the placental specimen with 
different dilutions and optimistised. The slide was incubated with primary antibody 
(rabbit, 1 in 1000) dilution for PLGF, and CD105, primary antibody (goat, 1 in 50 
dilution) for HB-EGF, primary antibody (rabbit, 1 in 200 dilution) for MK and 
primary antibody (goat, 1 in 100 dilution) for PTN and control incubated overnight at 
2-8°C. The next steps of this protocol are described below. 
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2.5.3. The VEGFR-1 (sflt-1)/ PLGF, VEGFR2 and FGFR-1 receptors. 
The primary antibody was applied to the slide covering the placental specimen in the 
presence of citrate buffer with different dilutions and optimised. These slides were all 
prepared the same day for VEGFR-1 (sflt-1)/ PLGF receptor primary antibody (goat, 
1 in 200 dilution), VEGFR-2 primary antibody (goat, 1 in 400 dilution) and FGFR-1 
primary antibody (goat, 1 in 200 dilution) and control. After preparation of slides the 
sections were deparaffinised with 2 changes of xylene of 5 minutes each. In 100% 
alcohol for 3 minutes, 90% alcohol for 3 minutes, and 70% alcohol for 3 minutes. 
Then, the slide was blocked with 50% in PBS normal serum for 5 minutes. The slide 
was incubated with primary antibody rabbit for VEGFR-1 (sflt-1)/ PLGF (1 in 200 
dilution), primary antibody VEGFR2 (1 in 400 dilution) and primary antibody goat 
FGF2 (1 in 200 dilution) and control for 2 hours. Then, secondary antibody was 
applied for 30 minutes for VEGFR-1 (sflt-1)/ PLGF and VEGFR-2 at room 
temperature.  For FGFR-1 the secondary antibody was applied for 45 minutes at room 
temperature. The sections were incubated in preheated citrate buffer with 1M Tris to 
at pH 8.0 with HCL, and 0.5M EDTA for 10 minutes in  a microwave and boiled in a 
microwave for 4 minutes. The slides were left to cool in heated buffer for 20 minutes. 
Rinses and washes in PBS were carried out in between the following steps. The next 
steps of this protocol are described below. 
The diluted secondary biotinylated antibody (anti-rabbit Ig G (H+L) or anti-goat Ig G 
(H+L), 1 in 100 dilution) was applied for 30 minutes at room temperature. The 
section was incubated with a complex of avidin, labelled with horseradish peroxidase, 
and biotin (ABC) was applied for 20 minutes at room temperature. The slide was 
developed with 3, 3’-Diaminobenzidene (DAB) and hydrogen peroxide for 5 minutes 
followed by a counter staining in Mayer’s Haematoxylin solution for 10 minutes. 
Next the slide was differentiated in 1% acid alcohol for a few seconds. The slides 
were washed in running tap water for 5 minutes and followed the dehydration 
procedure. The slides were incubated in 70% alcohol for 2 minutes, 90% alcohol for 2 
minutes, and 100% alcohol for 2 minutes, and in 2 changes of absolute alcohol for 3 
minutes each. Finally, the slide was cleared in 2 changes of xylene, 3 minutes each. 
The slide was mounted in xylene -based mounting medium. The slide was then ready 
for examination under the Ceti microscope. 
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 2.5.4. Scoring and staining.  
Staining was scored according to intensity (0 none, 1= weak, 2= moderate, 3= 
moderate to strong and 4= strong) and coverage (0 = negative, 1-20%= 1, 21- 40= 2, 
41-60=3, 61-80=4, 81-100=5). The overall score was given as the product of intensity 
and coverage.  
 
2.5.5. Statistical Analysis.  
Since the tissue scoring represented did not show a normal distribution, all analysis 
was carried out using non-parametric statistical tests on computer software Stats 
Direct. All the values were expressed as medians. Comparison between staining for 
each set of placental tissues versus all other groups combined, comparisons between 
the four individual groups and comparison of labour versus non-labour was carried 
out using the Kruskal-Wallis ANOVA test, and the Mann-Whitney U test. 
Correlations between variables non-grouped were performed using the Spearman rank 
correlation test. Differences were considered significant when the probability of 
events occurring by chance alone was < 1 in 20 (p-value of < 0.05) was considered 
statistically significant. The Rho represents Spearman’s rank correlation coefficient. 
The p-value of < 0.05 and p-value of < 0.01 is considered statistically significant.  
 
 
2.5.6. Photomicrographs of IHC. 
Photomicrographs were taken for the immunohistochemistry in the Biomedical Cell 
Culture Laboratory using the camera Nikon and Ceti (Kingston, UK). 
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2.5.6. Cell Tissue Culture. 
The cell lines analysed were TCL-1, a human villous trophoblast cell line, NIH/3T3 
as negative control, a non-invasive mouse fibroblast cell line, and HT-1080 cells, a 
highly invasive human fibrosarcoma cell line as a positive control. All were grown in 
cell culture prior to being used for invasion assay. The protocol used for the following 
invasion assay applied thawing cells, trypsinsing cells and counting cells in the 
absence of BD FluoroBlok 96-Multiwell insert plate uniformly coated with Matrigel 
Matrix. 
A one hundred millitre bottle of complete medium (with antibiotic-100IU/ml 
penicillin and 100µg/ml streptomycin), 2mM L-glutamine and (10%) foetal bovine 
serum was warmed in a water bath at 37°C. A vial of cells was removed from the 
liquid nitrogen carefully using cryogloves. Warm medium was added to thaw cells. 
The thawed contents were transferred to a sterile fifteen ml centrifuge tube containing 
10ml complete medium. The tube was centrifuged at 1500rpm for five minutes at 
room temperature. The cell pellet was checked and was visible at the bottom of the 
tube. Carefully, the medium was poured off into waste container leaving cell pellet 
behind. An appropriate volume of fresh complete medium (3ml for a 25cm2 flask and 
15ml for a 75 cm2 flask) was added. The cells were resuspended in the medium by 
vortex mixing. The cell suspension was transferred to a sterile flask, then to incubator.  
The cells were examined using a phase contrast microscope. The medium was 
removed from the cells and replaced with ten ml serum-free medium. Then, the 
serum-free medium was removed, and replaced with 10ml fresh serum-free medium. 
1-2 ml trypsin solution was added to cells. The flask of cells was placed in standard 
CO2 incubator until the cells began to detach from the flask surface. The time for this 
to happen varied with each cell type, but usually took about five minutes. A phase 
contrast microscope was used to check the cells had detached. 10ml fresh complete 
medium was added to flask to neutralise trypsin activity. The cell suspension was 
transferred to a 15ml centrifuge tube, and then centrifuged at 1500rpm for three 
minutes at room temperature. The cell pellet was then checked and was visible at the 
bottom of the tube. The medium was carefully poured off into waste container leaving 
cell pellet behind. An appropriate volume of fresh complete medium (3ml for a 25cm2 
flask and 15 ml for a 75 cm2 flask) was added. The cells were resuspended in medium 
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by vortex mixing of the centrifuge tube. The cell suspension was transferred to a 
sterile flask. 
Follow the trypsinsing protocol, the cells were thoroughly resuspended in the 
appropriate volume of complete medium. This volume was dependent on how many 
cells were present in the cell pellet. The haemocytometer (and cover slip) was aligned 
on the phase contrast microscope under two hundred magnification. Twenty 
microliters (µl) of the cell suspension were taken and placed on the haemocytometer 
close to (but not on) the cover slip. The cells were counted in the large square that 
takes up almost the whole field of view. The cells were counted in two more grids of 
the same size. The average value was calculated and the mean multiplied by ten 
thousand. This was number of cells in one millitre.  
2.5.7. Principles of invasion and migration for cellular analysis: Cell Invasion Assay. 
 
Cell invasion is the intrusion on and destruction of adjacent tissues, particularly with 
respect to cancer cells. Cell migration is the movement of cells from one area to 
another, generally in response to chemical signal, and is important in diverse 
physiological and pathological processes including embryonic development, cell 
differentiation, wound healing, immune response, inflammation, angiogenesis and 
metastasis. Cell invasion is related to, and encompasses, cell migration. 
2.5.8. Cell Invasion assay.  
 
The invasion chamber consists of two chambers separated by a filter coated with 
ECM. The upper surface of the insert membrane is coated with a uniform layer BD 
Matrigel Matrix which serves as a reconstituted dried basement membrane in vitro 
providing a true barrier to non-invasive cells while presenting an appropriate protein 
structure to study invasion. Invasive cells are able to degrade the matrix proteins in 
the layer. Invasive cells move through the extracellular matrix (ECM), which is a 
complex structure that surrounds and supports the cells within living systems. These 
then pass through the pores of the polycarbonate membrane. Finally, the cells are 
removed from the top of the membrane and the invaded cells are stained and 
quantified. The detection of cell invasion is quantified using Calcein AM. Calcein Am 
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is a non-fluorescent, hydrophobic compound that easily permeates intact, live cells. 
Cells internalize it, and intracellular esterases cleave the acetomethylester (AM) 
moiety to generate free calcium. This cleavage makes Calcein AM fluorescent. It may 
be used to quantitate the number of cells that have migrated or invaded. Thus, the 
invasive capacity of a given cell sample is determined by measuring Calcein AM 
measured by fluorescence at ex 490nm, em 520nm. The cell invasion assay was 
performed using a BD Falcon FluoroBlok 96-Multiwell insert plate with an 8-micron 
pore size polyethylene terephthalate (PET) membrane that has been uniformly coated 
with Matrigel Matrix. The coating process occludes the pores of the membrane, 
blocking non-invasive cells from migrating through the membrane. The invasive cells 
are able to detach themselves from and migrate through the coated membrane 
(Partridge & Flaherty, 2009). The BD Bio Coat invasion assay system provides cells 
with conditions that allow assessment of their invasive property in vitro. 
Quantitation of cell invasion was achieved by post-cell invasion labelling with 
Calcein AM and measuring the fluorescence of invading cells. Since the BD Falcon 
FluoroBlok membrane effectively blocks the passage of light from 490-700nm at ˃ 
99% efficiency, a bottom-reading fluorescence plate reader does not detect 
fluorescently labelled cells that have not invaded. However, cells that have invaded to 
the underside of the membrane are no longer shielded from the light source and are 
detected with the respective plate reader (Partridge & Flaherty, 2009). 
The cell suspension was placed in serum-free medium at the top (apical) chamber on 
an artificial extra cellular matrix (ECM) within insert. Then the cells are incubated 
overnight at 37°C, standard culture conditions in the presence of test media 
containing specific chemoattractant (5% foetal calf serum FCS) in the bottom (basal) 
chamber. Heparin binding growth factor (HBGF) was added to cells in apical 
chamber. Cells migrate from the top chamber through the coated to the bottom of the 
filter. Cells were pre-incubated with calcein AM and 4µM was added. Cell 
dissociation/Calcein AM solution is placed in the bottom chamber to dissociate the 
invading cells from the filter. Calcein fluorescence in live cells was observed as 
shown in Figure 24. 
  Farha Nazir Ahmad M00201045                                                            113 
 
Figure 24. Illustration of a Cell Invasion assay. 
2.5.9.  An  in vitro cell invasion assay in the absence of BD Falcon fluoroblok. 
 
A total of 40,000 cells are required per insert and 200,000 cells for standard curve 
(about 500,000 cells in total). 
Preparing inserts: The extracellular matrix (ECM) gel aliquot at 4°C was thawed out 
for about 30 minutes along with small tips and about 15ml serum free medium (sfm). 
These items were placed in flow hood on ice along with a 24-well plate with 8µm 
pore size inserts in 6 of the wells. The ECM 1 in 10 with SFM (100µl + 900µl) was 
diluted and mixed by flushing with the cold pipette tip. 
A one hundred microliter (µl) diluted ECM was transferred into each of the inserts. It 
was incubated for 4-24 hours at 37°C. 
 
Seeding cells: as this protocol uses different cell types as the human fibrosarcoma 
HT1080 invasive cells (positive control), and human villous trophoblast cell-line 
TCL-1. The cells were trypsinised and washed with warmed medium. Then, cells 
were counted and diluted to a concentration of 20,000 cells/100µl. Then, 500µl of 
warmed medium with 10% FCS was added to each well under the insert. Then, 200µl 
cell suspension was added to each insert (40,000 cells in total). Then, factors to test to 
the cell suspension (pre-incubate) were added. Then, these were incubated overnight 
at 37°C under standard conditions. 
!
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Staining: a two micromolar (µM) calcein solution (stock 400µM, 1 in 200, 25µl in 
5ml PBS) was prepared. Then, ten percent (%) acetic acid (1ml glacial acetic acid 
plus 9ml PBS) was prepared. Then, 200µl of 2µM calcein was transferred to 6 fresh 
wells of 96-well plates. The medium was removed from the inserts and place inserts 
in wells with Calcein. Then, incubated for 1 hour at 37°C in incubator. Then, 200µl of 
the 10% acetic acid was transferred to 6 other fresh wells of 96-well plates. The 
inserts were placed into wells with 10% acetic acid and gently agitated for 5-7 
minutes. The inserts were removed and transferred acetic acid to 96-well plates. The 
fluorescence of each well was read in plate reader 492nm excitation, 520nm emission. 
 
Standard curve 
 
The cells were trypsinised and washed with warmed medium. Then, cells were 
counted and diluted to a concentration of 20,000 cells/100µl in medium containing 
10% foetal calf serum (FCS). The cell suspension and medium (containing 10% FCS) 
was added to a 96-well plate as shown in Table 3. 
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Well Volume cell 
suspension (µl) 
Volume medium 
(µl) 
Cell number 
1 200 0 40,000 
2 200 0 40,000 
3 100 100 20,000 
4 100 100 20,000 
5 50 150 10,000 
6 50 150 10,000 
7 25 175 5000 
8 25 175 5000 
9 10 190 2000 
10 10 190 2000 
11 5 195 1000 
12 5 195 1000 
13 0 200 0 
14 0 200 0 
 
Table 3. The different cell types, cell suspension and medium (containing 10% FCS) 
added to a 96-well plate. 
Then incubated at 37°C under standard culture conditions until cells adhered to the 
plate (2-24h). 2µM calcein (stock 400µM, 1 in 200, 25µl in 5ml PBS) and 10% acetic 
acid (1ml glacial acetic acid plus 9ml PBS) was prepared. The medium from each 
well was removed and replaced with 200 µl calcein (2µM) and incubated for 1 hour at 
37°C, but calcein was removed. 200µl acetic acid was added to the cells and 
incubated for 5-7 minutes with gentle agitation. The fluorescence of each well was 
read in plate reader 492nm excitation, 520nm emission. A standard curve was plotted 
and the derived equation used to convert fluorescence to cell number. 
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2.5.9.1. An in vitro cell invasion assay in presence of BD Falcon fluoroblok.  
This protocol analysed different types of cell lines. These were TCL-1, a human 
villous trophoblast cell line, NIH/3T3 as negative control, a non-invasive mouse 
fibroblast cell line, and HT-1080 cells, a highly invasive human fibrosarcoma cell line 
as a positive control. The cell invasion assay upper surface of the insert membrane is 
coated with a uniform layer of dried basement membrane matrix solution. The 
basement membrane layer serves as a barrier for invasive cells from non-invasive 
cells. Invasive cells are able to degrade the matrix protein in the layer and to pass 
through pores of the polycarbonate membrane. However, the migration assay 
principle is different because it has the uncoated membrane that serves as a barrier for 
migratory cells from non-migratory cells. Migratory cells are able to extend 
protrusions towards chemoattractants and pass through pores of the polycarbonate 
membrane. Finally, cells are removed from the top of the membrane and the invaded 
and migratory cells are stained and quantified. Detection of cell invasion is quantified 
using Calcein AM. 
The plate to be used was removed from -20°C storage and allowed to come to room 
temperature. 75µl of warm (37°C) media was added to the apical chamber interior of 
the insert wells of the invasion plate. The plate was allowed to rehydrate for 2 hours at 
37°C, 5% CO2. After rehydration, 50µl of medium was removed carefully from each 
apical chamber without disturbing the layer of BD Matrigel Matrix on the membrane. 
The system was then ready to use. For the migration plate, 25µl of medium in the 
apical chamber was added prior to cell addition. The cell suspension was prepared by 
trypsinizing cell monolayers and resuspending the cells in serum-free media at 5x 105 
cells/ml, determined by the haemocytometer. As this protocol uses different cell types 
HT-1080 cells, NIH/3T3 and TCL-1 cell lines, an optimal seeding density was first 
determined. Then 25µl of cell suspension (1.25x 104 cells) was added to the apical 
chambers, and 25µl of serum-free medium added to each apical chamber in the 
uncoated system. The cells were grown to a~80% confluence in DMEM/ in 10% 
foetal calf serum (FCS) and antibiotic. Then, 200 µl of chemo attractant (5% FBS) 
was added to each of the basal chambers. Then, the BD Bio Coat Invasion system and 
the uncoated migration BD Falcon FluoroBlokTM 96-Multiwell insert plate was 
incubated overnight (depending on the cell type) at 37°C, 5% CO2 atmosphere. 
Heparin (0,100ng/ml) and heparin-binding growth factors (0,1,10, 100nmol/L) were 
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added to the apical chamber. Following incubation, the medium was removed 
carefully from the apical chambers. This can be accomplished by flicking the contents 
into a waste container. The insert systems were transferred into a second 96-well plate 
containing (200µl of 4µg/ml Calcein AM in PBS. Then was incubated for 1 hour at 
37°C, 5% CO2. The Calcein AM solution was not removed from the lower chamber 
before reading fluorescence, because it is a non -fluorescent vital dye that is converted 
into green fluorescent calcein by cytosolic esterases. Readings were taken. The 
fluorescence of invaded cells was read at wavelengths of 497/517nm or 549/595 nm 
(EX/EM) on the bottom plate reader. 
 
Data reduction: 
Data is expressed as in the following equation 
 
% Invasion = Mean RFU of cells invaded through BD Matrigel Matrix coated 
membrane towards chemoattractant x 100 
                      Mean RFU of cells migrated through uncoated BD FluoroBlok 
membranes towards chemoattractant. 
 
The background was subtracted prior to the calculation of percent cell invasion. 
RFU = relative fluorescent units.  
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2.5.9.2. Statistical Analysis.  
For the invasion assay results these values were expressed as mean ± SEM using the 
Mann-Whitney U test on computer software Stats Direct. A value of p < 0.05 was 
considered statistically significant. 
 
2.6.  Principle procedure of Polymerase Chain Reaction (PCR). 
 
Polymerase Chain Reaction (PCR) is a technique for amplifying. Firstly, simply to 
create multiple copies of a rare piece of DNA and secondly to compare two different 
samples of DNA to see which is the more abundant. Because mRNA, is microscopic 
it is not possible to see which sample contains the most mRNA. However, if both 
samples are amplified at the same rate, it can be calculated which sample was the 
biggest to begin with by establishing which is the biggest after amplification. It is a 
polymerase enzyme that drives PCR. A polymerase will synthesize a complementary 
sequence of bases to any single strand of DNA providing it has a double stranded 
starting point. This is very useful because one can choose the gene the polymerase 
should amplify in a mixed DNA sample by adding small pieces of DNA 
complimentary to the gene of interest. These small pieces of DNA are known as 
primers because they prime the DNA sample ready for the polymerase to bind and to 
begin copying the gene of interest. 
During PCR, changes in temperature are used to control the activity of the polymerase 
and the binding of primers. To begin the reaction the temperature is raised to 95°C. At 
this temperature all double-stranded DNA is “melted” in to single strands. 
 
Real-Time (PCR) 
Real-Time (PCR) is identical to simple PCR except that the progress of the reaction is 
monitored in “real-time”. There are a number of techniques that are used to allow the 
progress of a PCR reaction to be monitored. Real-time quantitative PCR is a powerful 
technique for advancing functional genomics (Qiagen, (a), 2013). 
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Reverse-transcriptase is a multifunctional enzyme with three distinct enzymatic 
activities an RNA-dependent DNA polymerase, a hybrid-dependent exoribonuclease 
(RNase H), and a DNA-dependent DNA polymeras (Qiagen, (a), 2013). 
Stabilization using RNA Later 
Immediate stabilization of RNA is necessary because changes in the gene expression 
pattern occur due to specific and nonspecific RNA degradation and transcriptional 
induction. It is important for a reliable q-gene expression analysis (Qiagen, (c), 2013). 
 
2.6.1. Protocol 1: Stabilization of RNA. 
 
The weight of the sample was stabilized in RNA later, and RNA Stabilization 
Reagent was estimated before the tissue was excised. For preserving the tissue, it is 
important to determine an appropriate volume of RNA later RNA Stabilization 
Reagent. Approximately 10µl reagent per 1mg of tissue was used, that is at least 10 
volumes of the reagent. The correct amount of reagent was pipetted into collection 
tube. The excised tissue sample was cut into slices less than 0.5 cm thick for effective 
RNA stabilization, a procedure performed as quickly as possible. This tissue sample 
was completely submerged in the collection tube containing the RNAlater, and   RNA 
stabilization reagent to protect the RNA. Purification was the next step using the 
Qiagen kit (Qiagen, (d), 2013). 
 
2.6.2. RNA purification.  
 
RNA purification depends on the selective binding properties of a silica-based 
membrane with the speed of microspin technology. A specialised high-salt buffer 
system allows up to 100µg of RNA longer than 200 bases to bind to the RNAeasy 
silica membrane. Biological samples were first lysed and homogenised in the 
presence of a highly denaturing guanidine-thiocynate-containing buffer, which 
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immediately inactivates RNAse to ensure purification of intact RNA. Ethanol was 
added to provide appropriate binding conditions, and the sample was then applied to 
an RNAeasy Mini spin column, where the total RNA binds to the membrane and 
contaminants are efficiently washed away. High-quality RNA was then eluted in 30-
100µl of water (Qiagen, (d), 2013). 
2.6.3.Disruption using a mortar and pestle. 
The sample was frozen immediately and ground to a fine powder under liquid 
nitrogen. The suspension consisting of tissue powder and liquid nitrogen was 
transferred into a liquid-nitrogen cooled 2ml collection tube and the liquid nitrogen  
was allowed to evaporate without allowing the sample to thaw. Then, lysis buffer was 
added and continued as quickly as possible grinding the sample using the mortar and 
pestle to disrupted the sample. Complete disruption of cell walls and the plasma 
membranes of cells and organelles are absolutely required to release all the RNA 
contained in the sample. Different samples require different methods to achieve 
complete disruption. Incomplete disruption results in significant reduced RNA yields 
(Qiagen, (d), 2013). 
 
2.6.4. Homogenization. 
Homogenization is necessary to reduce the viscosity of the lysates produced by 
disruption. It shears high molecular weight genomic DNA and other high-molecular-
weight cellular components to create a homogeneous lysate. Incomplete 
homogenization results in inefficient binding of RNA to the RNAeasy spin column 
membrane and therefore significantly reduced RNA yields. Using QIA shredder 
homogenizers provides a fast and efficient way to homogenize cell and tissue lysates 
without contamination of samples (Qiagen,(d), 2013). 
An aliquot of 700µl of lysate was loaded onto a QIAshredder spin column placed in a 
2ml collection tube, and spun for 2 minutes at maximum speed in a microcentrifuge. 
The lysate was homogenized as it passed through the spin column (Qiagen, (d), 
2013).  
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2.6.5. Protocol 2: extraction and purification of the total RNA from tissues using the  
RNAeasy mini kit and spin technology as shown in Figure 25. 
 
The tissue sample was removed from storage -80°C. The amount of tissue was not 
more than 30mg. 
 
The RNAeasy protect mini procedure using placental cells. 
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Figure 25. RNAeasy mini procedure was used for placental cells. Modified from 
(Qiagen, (d), 2013). 
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2.6.5.2. Extraction. 
Thirthy milligram of  tissue were disrupted and the lysate in buffer RLT Plus was 
homogenized. Disruption using a mortar and pestle followed by homogenization 
using a QIAshredder homogenizer: the frozen, or RNAlater stabilized tissue is placed 
in liquid nitrogen, and ground thoroughly with a mortar and pestle. Then, decant 
tissue powder and liquid nitrogen into an RNAase-free, liquid-nitrogen-cooled, 2ml 
microcentrifuge tube. It is important that the tissue does not thaw, allowing the liquid 
nitrogen to evaporate. A 600µl volume of Buffer RTL is added. Then, pipetted the 
lysate directly in to a QIAshredder spin column placed in a 2ml collection tube, and 
centrifuge for 2 minutes at full speed (Qiagen, (c, d), 2013). 
 
2.6.5.3. Purification. 
The lysate was centrifuged for 3 minutes at 13,000rpm. The supernatant was carefully 
removed by pipette, and then transferred to a new 1.5ml microcentrifuge tube. It is 
important to use only this supernatant (lysate) in subsequent steps. One volume of 
70% ethanol was added to the cleared lysate and mixed immediately by pipetting. An 
aliquot of 700 µl of the sample, including the precipitate that had formed was 
transferred to an RNeasy spin column placed in a 2ml collection tube. The tube was 
centrifuged for 15 seconds at (13,000 rpm). The flow through was discarded. Then 
700 µl of the Buffer RW1 was added to the RNAeasy spin column and centrifuged for 
15 seconds at 13,000 rpm to wash the spin column membrane. The flow through was 
again discarded. The collection tube was reused for the following steps: 7, 8. Then, 
500µl of the Buffer RPE was added to the RNAeasy spin column and the flow 
through was discarded. This step was repeated. The RNAeasy spin column was 
placed in a new 2ml collection tube and centrifuged at full speed for 1 minute. The 
RNAeasy spin column was placed in a new 1.5ml collection tube and 50µl RNase-
free water was added directly to the spin column membrane and centrifuged for 1 
minute at 13,000 rpm to elute the RNA (Qiagen, (d), 2013). 
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2.6.5.4. Quantification of RNA. 
The concentration of RNA was determined by measuring the ratio between 
absorbance at 260 nm (A260) and 280 nm (A260/A280) in a spectrophotometer. This 
RNA purity was an estimate with respect to contaminants that absorbed the UV, such 
as protein. An absorbance of 1 unit at 260 nm corresponds to 44 µg of RNA per ml 
(A260=1 → 44 µg/ml) is based on an extinction coefficient calculated for RNA at 
neutral Ph, because the A260/A280 ratio is influenced considerably by pH. When 
measuring RNA samples, the cuvettes must be RNAase-free (Qiagen, (d), 2013).  
 
 
2.6.5.5. Purity of RNA. 
For accurate values, measured the absorbance in 10 mM Tris·Cl, pH 7.5. Pure RNA 
has an A260/A280 ratio of 1.9–2.1 in 10mM Tris·Cl, pH 7.5 and calibrating the 
spectrophotometer with this solution (Qiagen, (d), 2013). 
 
2.6.5.6. Integrity of RNA. 
Denaturing agarose checked the integrity and size distribution of total RNA gel 
electrophoresis and by using Agilent 2100 bioanalyzer. The Agilent 2100 bioanalyzer 
provides an RNA Integrity Number (RIN) (Qiagen, (d), 2013). 
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2.6.5.7. Protocol 3: Reverse-transcription with elimination of genomic DNA for 
quantitative, Real-Time PCR. 
The template RNA was thawed on ice. The following were thawed at room 
temperature (15°-25°C): gDNA wipeout buffer, quantscript reverse transcriptase, 
quantiscript RT Buffer, RT primer mix, and RNase-free water. The genomic DNA 
eliminator reaction on ice was prepared as in the table 4 (Qiagen, (b), 2013). This 
protocol was performed for 7 different placental tissue mRNA samples at dilutions (1 
in 10, 1 in 50, and 1 in 100) were optimised. Using 10pg to 1µg RNA.   
            Component Volume/reaction 
gDNA wipeout buffer,      
7x 
2µl 
   Template RNA (10-11µg RNA) 
  RNase-free water Variable 
     Total volume 14 µl 
 
Table 4. The genomic DNA eliminator reaction components (Qiagen, (b), 2013). 
 
This was incubated for 2 minutes at 42° C. Then, the contents were immediately 
placed on ice. The reverse-transcriptase master mix was prepared on ice as in table 5. 
               Component          Volume/reaction 
Reverse-transcriptase 
master mix 
                  
Quantscript reverse 
transcriptase 
                 1µl 
Quantiscript RT Buffer                   4µl 
RT primer mix                   1µl 
 Entire genomic DNA 
eliminator reaction 
                 14µl 
Total volume                  20µl 
 
Table 5. Reverse-transcriptase reaction components. (Qiagen, (b), 2013). 
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The template RNA was added (14µl) to each tube containing the reverse-transcriptase 
master mix. This was mixed and stored on ice. Then, it was incubated for 15 minutes 
at 42° C. Then, the contents were immediately placed on ice. Then, the template RNA 
was incubated for 3 minutes at 95°C to inactivate quantscript reverse transcriptase. 
Then, an aliquot of each finished reverse transcriptase reaction was immediately 
added to real-time PCR mix. This was stored at-80°C. 
 
2.6.5.8.   Protocol 4.  Real Time PCR and two-step  RT-PCR using cycler. 
 
The 2x QuantiTect SYBR Green PCR Master Mix was thawed including template 
RNA, primers, and RNAase-free water. The individual solutions were mixed. As 
shown in Table 6, a reaction mix was prepared. 
 
 
                     Component 
 
      Volume / Reaction 
2x QuantiTect SYBR Green PCR 
Master Mix 
                  25µl 
Primer                    2.5µl 
Template RNA                     12µl 
RNase-free water                  10.5µl 
Total reaction time                   50µl 
 
Table 6. A reaction mix. (Qiagen,  (e), 2013). 
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The reaction mix was prepared thoroughly, and appropriate volumes were dispensed 
into PCR tubes. The template RNA was added to the individual tubes containing the 
reaction mix. The real-time cycler was programmed according to the Table 7. 
 
               
                Step 
     
       Time  
 
Temperature 
PCR initial activation step 15 minutes 
 
50oC 
 
3-step cycling   
Denaturation 15s 95oC 
 
Annealing 30s 55oC 
 
Extension 30s 72oC 
 
Number of cycles 40s  
  
Table 7. The real-time cycler programme. (Qiagen,(e), 2013). 
 
 The PCR tubes were placed in the real-time cycler, and the cycling programme was 
started. A melting curve was analysed for the PCR product. The specificity of PCR 
products  was  observed by agarose gel electrophoresis. 
2.8. Principles of DNA Gel Electrophoresis. 
Gel electrophoresis separates DNA fragments by size in a solid support medium (an 
agarose gel). DNA samples were pipetted into the sample wells, seen as dark slots at 
the top of the picture. Application of an electric current at the top (anodal, negative) 
end causes the negatively charged DNA to migrate (electrophorese) towards the 
bottom (cathodal, positive) end.  
The gel contains small pores through which the DNA molecule pass  and the rate of 
migration occurs at a speed inversely related to their length. Smaller fragments move 
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more quickly, and finish at the gel. Although each of the fragments of a single class of 
molecule is present in equimolar proportions, the smaller fragments include less mass 
of DNA.  
 
2.8.1. Protocol 4. Agarose gel electrophoresis for mini casting tray. 
 
A 1.5% of agarose gel was prepared to 35ml TBE Buffer and 315ml of deionized 
water. The solution was heated in a microwave for 1 to 3 minutes. The agarose 
mixture was carefully swirled once or twice during the microwaving. It was important 
that all agarose particles were dissolved. A 3µl of SYBER Safe DNA gel was added 
to the mixture in mini casting tray and allowed it to cool down. The RT-PCR product 
and DNA ladder of 100base pairs were thawed on ice. The gel was poured into 
casting tray with the well combs for 20-30 minutes at room temperature. The mini-
casting tray was covered with 200ml of TBE Buffer completely. Then, a 10µl   
loading sample was transferred into epindorf tube and 2µl of Blue Juice gel loading 
Buffer on ice. A DNA ladder of 100base pairs was loaded into the sample well. A 
sample of 12µl was placed into the sample wells. The gel was run at 80V to 120V for 
30-40 minutes. 
2.8.1.2. The protocol specificity of PCR products by RNA agarose gel electrophoresis 
for mini casting tray was performed on (n=7) different placental tissue mRNA 
samples at a concentration of 100ng/µl for FGF2, and MK primer assay. The analysis 
required the DNA ladder and 2 internal standard markers (LM and UM). However, a 
gel electrophoresis representation analysis was performed on (n=7) different placental 
tissue mRNA samples at a concentration of 100ng/µl for FGF2, PLGF, MK, PTN and 
Succinate dehydrogenase complex subunit A (SDHA) primer assay using DNA ladder 
and 2 internal standard markers (LM and UM).  
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2.8.2. Statistical Analysis.  
For the real-time PCR results of (n=7) different placental tissue mRNA samples at a 
concentration of 100ng/µl for FGF2, PLGF, MK, PTN and Succinate dehydrogenase 
complex subunit A (SDHA) primer assay values were expressed as medians. The 4 
groups studied PE, PTL, TNL and TL values were expressed as mean ± interquartile 
range (IQR). The comparisons using non-parametric statistical tests, the Mann-
Whitney U test on computer software Stats Direct. The control (Term (TL+TNL) not 
in labour) and Pre-eclampsia (PE) of placental tissue mRNA expression with their 
sensitivity were compared. A value of p < 0.05 were considered statistically 
significant. 
 
2.8.3. Photomicrographs of PCR. 
Photomicrographs were taken for the agarose gel electrophoresis in the Lee Smith 
Foundation Laboratory using the camera Nikon (Kingston, UK). 
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Results 
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3.1.Immunohistochemistry (IHC):  
Expression of heparin-binding growth factor (HBGF) and their receptors. 
This first technique I performed was immunohistochemical staining procedures for 
expression of fibroblast growth factor 2 (FGF2) that was localised showing negative 
staining for the trophoblast and the endothelial cells. These slides (n=56) in dilution 1 
in 200 were incubated overnight at 2-8°C in the absence of citrate buffer in placental 
tissue of the four groups PE- Pre-eclampsia, TL-term labour, TNL-Term-non- Labour, 
and PTL-Pre-term Labour PE, PTL, TNL, and TL in the placenta as in Figure 26.  
 
Figure 26. The expression of fibroblast growth factor 2 (FGF2) was distributed 
representative negative staining in the absence of citrate buffer in placental tissue with 
magnification of original x101. PE-Pre-eclampsia, PTL-Pre-term Labour, TNL- 
Term-non-Labour, and TL-term labour, (n = 56). The arrow indicate the trophoblast 
and (*) the endothelial cells. 
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In Figure 27. I confirmed staining, scored according to intensity, as grading was 
performed as 0 = none, 1 = weak, 2 = moderate, 3 = moderate to strong, and 4 = 
strong staining on human placenta samples of (n = 87) patients in dilution 1 in 200. 
These slides were incubated overnight at 2-8°C in the presence of citrate buffer for 
the expression of (FGF2), in PE-Pre-eclampsia, and PTL-Pre-term Labour 
distribution.  There were numerous and prominent villous trophoblasts, but the villi 
were poorly vascularised with large number of syncytial knots. However, weaker 
staining in the mesenchyme, endothelial cells and in the core foetal vessels was 
observed in the placenta.  
 
I performed immunohistochemical staining procedures to a series of heparin binding 
growth factors (HBGFs): vascular endothelial growth factor VEGF, placental growth 
factor PLGF, fibroblast growth factor 2 FGF2, hepatocyte growth factor HGF, 
platelet-derived growth factor PDGF-BB, and cluster differentiation CD105 (n = 87) 
except for heparin binding epidermal growth factor HB-EGF (n = 42), midkine MK (n 
= 35), and pleiotrophin PTN (n = 30), control using placental specimens in different 
dilutions, control (n = 51), and a negative control  IgG (n = 10) specifically on human 
placenta samples of patients with normal pregnancy and pre-eclampsia all yielded 
positive staining results. The staining level was scored according to intensity and 
coverage (0 = negative, 1-20%= 1, 21- 40= 2, 41-60=3, 61-80=4, 81-100=5). The 
overall score was given as the product of intensity and coverage. I confirmed in the 
four groups PE- Pre-eclampsia, TL-term labour, TNL-Term-non- Labour, and PTL- 
Pre-term Labour distribution with numerous and prominent villous trophoblast, but 
the villi were poorly vascularised with large number of syncytial knots. There was 
irregular thickening of the trophoblastic basement membrane. However, the 
syncytiotrophoblast showed no degenerative changes. Figure 28a,b,c,d,e,f,g,h,i, and j. 
shows the characteristic feature of the villous trophoblast (both syncytiotrophoblast 
and cytotrophoblast), weaker staining in the mesenchyme, and in the core foetal 
vessels in the placenta for VEGF, PLGF, FGF2, HGF, PDGF- BB, and CD105 from 
women with pre-eclampsia. The villous trophoblast and the endothelial cells were 
analyzed. 
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Syncytial knots 
	
Figure 28a.                                                                              
                                                            Syncytial knots  
	
Figure 28b.  
Immunohistochemical positive staining in villous trophoblast (both syncytiotrophoblast and 
cytotrophoblast), in Figure 28a. for fibroblast growth factor 2 (FGF2) expression, 3 = moderate to 
strong, Magnification of original (x101) and in Figure 28b. for placental growth factor (PLGF) 
expression, 2 = moderate distributed in placental tissues for Pre-eclampsia (PE), (n = 19). 
Magnification of original (x401). The arrows indicate the trophoblast and (*) the endothelial cells.  
	
	
	
																								
																																		*	
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                                                                                     Syncytial knots	
	
Figure 28c.  
                                                               Syncytial knots	
	
Figure 28d.  
Immunohistochemical positive staining in villous trophoblast (both syncytiotrophoblast and 
cytotrophoblast), in Figure 28c for vascular endothelial growth factor, placental growth factor (VEGF) 
expression, 3 = moderate to strong, Magnification of original (x401), and in Figure 28d platelet-derived 
growth factor (PDGF-BB) expression, 4 = strong distributed in placental tissues for Pre-eclampsia 
(PE), (n = 19). Magnification of original (x101). The arrows indicate the trophoblast and (*) the 
endothelial cells. 
	
	
	
	
	
	
	
	
											*		
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                                                                       Syncytial knots	
			 																																																																																																																																																																																																		
Figure 28e. 
                                                                        Syncytial knots	
	
Figure 28f. 
 Immunohistochemical positive staining in villous trophoblast (both syncytiotrophoblast and 
cytotrophoblast), in Figure 28e for hepatocyte growth factor (HGF) expression, and in Figure 
28f for cluster differentiation (CD105) expression, 2 = moderate, distributed in placental 
tissues for Pre-eclampsia (PE), (n = 19). Magnification of original (x401 and x402). The 
arrows indicate the trophoblast and (*) the endothelial cells. 
 
	
						*		
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                                                                                     Syncytial knots	
 
 
Figure 28g.  
Immunohistochemical moderate to strong positive staining in villous trophoblast (both 
syncytiotrophoblast and cytotrophoblast), for heparin binding epidermal growth factor (HB-
EGF) expression, 4 = strong, distributed in placental tissues for Pre-eclampsia (PE), (n = 21). 
Magnification of original  (x401). The arrow indicate the trophoblast and (*) the endothelial 
cells. 
 
 
 
 
 
 
 
 
										*	
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                              Syncytial knots	
	
Figure 28h.  
                                     Syncytial knots	
	
Figure 28i. 
Immunohistochemical positive staining in villous trophoblast (both syncytiotrophoblast and 
cytotrophoblast), as in Figure 28h for midkine (MK) expression, (n = 19) and in Figure 28i for 
pleiotrophin (PTN) expression,  (n = 19). 4 = strong, distributed in placental tissues for Pre-eclampsia 
(PE). Magnification of original  (x401). The arrows indicate the trophoblast and (*) the endothelial 
cells. 
	
*		
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                                                                                                            Syncytial knots	
	
	
Figure 28J. Immunohistochemical representative negative control, 0 = none, without 
the antibody  distributed in placental tissues for Pre-eclampsia (PE), (n = 19) in the 
absence of citrate buffer. Magnification of  original (x401). The arrows indicate the 
trophoblast and the endothelial cells. The arrow indicate the trophoblast and (*) the 
endothelial cells. 
 
 
		
	
 
	
	
	
							*	
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 VEGF         PTL                                              PLGF         PE     
			 			
FGF2        PE                                                          CD105      TNL 
	 																	
    HGF       PTL                                                   PE           Negative control 
Figure 29. The expression of the vascular endothelial growth factor (VEGF), placental 
growth factor (PLGF), 2 = moderate, fibroblast growth factor 2 (FGF2), 4 = strong, 
and cluster differentiation (CD105), 3 = moderate to strong, hepatocyte growth factor 
(HGF) was distributed with 2 = moderate positive staining in villous trophoblast (both 
syncytiotrophoblast and cytotrophoblast), for PTL-Pre-term Labour, TL-term labour, 
and TNL-Term-non-Labour, (n = 68) at a magnification of original (x401). In the 
absence of (HBGFs) the placental tissue expressed negative staining with a 
magnification of original (x401). This control was confirmed without the antibody. 
The arrows indicate the trophoblast and (*) the endothelial cells.  
						*		
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PDGF-BB    PTL                                                      HBEGF        PTL   
								 										
PTN     PTL                                                            MK            TNL 
	 	
PE           Negative control                                   Human IgG   TNL 
Figure 30. The expression of the platelet-derived growth factor (PDGF-BB), 
4=strong, heparin binding-epidermal growth factor (HB-EGF), 1=weak, pleiotrophin 
(PTN), and Midkine (MK), 2=moderate were distributed with moderate to strong 
positive staining in villous trophoblast (both syncytiotrophoblast and cytotrophoblast), 
and the endothelial cells, weaker staining in the mesenchyme,  and in the core foetal 
vessels PTL-Pre-term Labour, TL-term labour, and TNL-Term-non-Labour, (n = 68)  
with a magnification of original (x401). The control showed negative staining, i.e.in 
the absence of the antibody of magnification of original (x401). The preincubation 
with non-specific binding of Human IgG confirmed negative staining and does not 
affect the staining intensity or pattern with a magnification of original (x101). The 
arrows indicate the trophoblast and (*) the endothelial cells. 
	
																			
																			*		
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The four groups of placenta tested in this study were as follows: preterm pre-
eclampsia (PE after 20 weeks of gestation, n = 19), preterm labour (PTL before 36 
weeks gestation, n = 17), term following labour onset (TL, n = 21) and term placenta 
(after 36 weeks gestation) not in labour (TNL, n = 26). The expression of HBGFs was 
confined to villous trophoblast and endothelial cells for VEGF, FGF2, PDGF-BB, 
CD105, HGF and PLGF. For HB-EGF, MK and PTN, expression was confined 
specifically to villous trophoblast. The colour intensity and clarity of staining was 
observed in the photomicrographs as shown in Figure 30A,B,C,D,E,F,G,H, and I. 
Values for each group as pre-eclampsia PE, versus pre-term PTL, term labour TL, and 
term non-labour TNL, are indicated using Mann-Whitney U test.  As, each symbol 
corresponds to a different individual in the four placenta study groups. The horizontal 
red line indicates the median values. The expression of percentage scoring was used 
to establish differences between the four groups for VEGF, PLGF, HB-EGF, FGF2, 
CD105, PDGF-BB, HGF, MK, and PTN that provided additional information about 
the trophoblast and endothelial cells. The expression of VEGF in the large blood 
vessels was greater than in the trophoblast. For expression of PLGF and FGF2 the 
trophoblast exhibited greater staining intensity in the large blood vessels. 
Comparisons between four groups: 
The groups were compared by analysing differences between normal pregnancy and 
pre-eclampsia in various ways. The differences in expression associated with pre-
eclampsia PE versus pre-term PTL, term labour TL, and term non-labour TNL. Then, 
differences between term (TL and TNL combined, n = 47) and preterm (PTL and PE 
combined, n = 36) and finally differences in expression according to the presence or 
absence of labour (TL and PTL combined, n = 38 versus PE and TNL combined, n = 
45) were examined. In this way it is possible to determine whether differences in 
expression in pre-eclampsia are actually due to the fact these women tend to deliver 
preterm in the absence of labour.  
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Differences between groups with pre-eclampsia 
The staining score for MK and PTN expression was significantly lower in pre-
eclamptic versus other placenta groups in this study p = 0.03 and p = 0.04 Mann-
Whitney U and Kruskal Wallis analysis of variance test respectively as shown in 
Figure 27G and H. The median for pre-eclampsia was lower than the other placenta 
groups. In contrast, the expression of PLGF as shown in Figure 28B was significantly 
higher in pre-eclampsia compared to other placenta groups studied p = 0.02 using the 
Mann-Whitney U test and Kruskal Wallis analysis of variance test. The VEGF, FGF2, 
HGF, PDGF-BB, PLGF, HB-EGF and CD105  investigated did not show a significant 
difference in staining expression in pre-eclampsia.  
 
Comparison Term versus pre-term 
As shown in Figure 28B the levels of PLGF were significantly higher in preterm 
compared to term placentas using the Mann-Whitney U test, p =0.05 respectively. In 
Figure 28C the levels of CD105 were significantly higher in preterm compared to 
term placentas using the Mann-Whitney U test, p = 0.01. In Figure 28I, and K, the 
placental expression of HGF was significantly higher in pre-term compared to term 
placentas, as judged by obtaining a p = 0.005 by the Mann-Whitney U test. The 
expression of HGF staining intensity was significantly higher in pre-term compared to 
term placentas, p = 0.003 by the Mann-Whitney U test. The comparison of staining 
intensity revealed a significant difference in HGF expression which was higher for 
pre-term compared to term with p = 0.02 using the Mann-Whitney U test. The 
HBEGF expression was significantly higher in pre-term compared to term with p = 
0.02 as in Figure 28F. The expression staining score was not significantly different in 
term compared to preterm according to gestational age in any of the following tested 
VEGF, FGF2, PDGF-BB, MK and PTN. 
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Comparison Labour versus non-labour 
As shown in Figure 28D the levels of FGF2 were significantly lower in term labour 
compared to other groups using the Mann-Whitney U test, p = 0.04 respectively. The 
PLGF score was significantly lower after labour onset using the Mann-Whitney U test 
p = 0.03, as in Figure 28B and J. The expression of PLGF intensity score was 
significantly lower after labour onset using the Mann-Whitney U test p = 0.02 
respectively. The HGF expression was significantly higher in pre-term labour 
compared to term with p = 0.02 using the Mann-Whitney U test as in Figure 28I and 
K. The HGF median was higher for pre-term labour than the term. The CD105 
expression was higher in pre-term labour compared to term in Figure 28C. HBEGF 
expression was significantly higher in pre-term labour compared to term with p = 
0.03. The PTN expression was significantly higher in pre-term labour compared to 
term with p = 0.04 using the Mann-Whitney U test as in Figure 28H. The VEGF, 
FGF2, PDGF-BB, and MK tested showed no significant difference in expression 
according to the presence or absence of labour. 
Comparisons between each group versus all other. 
 The FGF2 expression was significantly different for staining and intensity score as (p 
= 0.004, and 0.02) for term Labour using the Mann-Whitney U test respectively. The 
VEGF expression was significantly different for staining score as p=0.03 for term 
Labour. The PTN expression was significantly different for staining and intensity 
score as (p = 0.01, and p = 0.04) for term non-Labour. The HBEGF expression was 
significantly different for staining and intensity score for term non-Labour and Pre-
term Labour as (p = 0.01, and p = 0.04). There was a significant difference observed 
for HGF expression of staining and intensity score in pre-term Labour (p = 0.01 and p 
= 0.001) compared to term Labour (p = 0.002 and p = 0.01).  
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Figure 31A. The vascular endothelial growth factor (VEGF) expression staining score 
(intensity x coverage) in the four placenta groups studied. Values for each group as 
pre-eclampsia PE versus pre-term PTL, term labour TL, and term non-labour TNL 
(*p <0.05 is considered statistically significant difference in staining in Term non-
labour) using Mann-Whitney U test. The horizontal red line indicates the median 
values.  
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      Figure 31B. 
 
Figure 31C. 
Figure 31B. represents the placental growth factor (PLGF) expression staining score (intensity x coverage) in the 
four placenta groups studied. Values for each group as pre-eclampsia PE versus pre-term PTL, term labour TL, 
and term non-labour TNL (*p <0.05 is considered statistically significant difference in staining in pre-eclampsia) 
using Mann-Whitney U test. Figure 31C. represents the cluster differentiation (CD105) expression staining score. 
The horizontal red line indicates the median values.  
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Figure 31D.  
 
Figure 31E.  
Figure 31D. represents the fibroblast growth factor 2 (FGF2) expression of staining 
score (intensity x coverage) in the four placenta groups studied. Values for each group 
as pre-eclampsia PE versus pre-term PTL, term labour TL, and term non-labour TNL 
(*p <0.05 is considered statistically significant difference in staining in Term Labour) 
using Mann-Whitney U test.  Figure 31E. represents the platelet-derived growth factor 
(PDGF) expression staining score in the four placenta groups studied. The horizontal 
red line indicates the median values. 
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Figure 31F. The heparin-binding epidermal growth factor (HB-EGF) expression 
staining score (intensity x coverage) in four placenta groups studied. Values for each 
group as pre-eclampsia PE versus pre-term PTL, term labour TL, and term non-labour 
TNL (*p <0.05 is considered statistically significant difference in staining in Term 
non-labour) using the Mann-Whitney U test. The horizontal red line indicates the 
median values.  
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Figure 31G. 	
 
Figure 31H.  
Figure 31G.  represents the midkine (MK) expression staining score (intensity x coverage) in the four 
placenta groups studied. Values for each group as pre-eclampsia PE versus pre-term PTL, term labour 
TL, and term non-labour TNL (*p <0.05 is considered statistically significant difference in staining in 
pre-eclampsia) using the Mann-Whitney U test. Figure 31H.  represents the pleiotrophin (PTN) 
expression staining score  values in the four placenta groups studied (*p <0.05 is considered 
statistically significant difference in staining in pre-eclampsia using the Mann-Whitney U test). The 
horizontal red line indicates the median values.	
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Figure 31I. represents the hepatocyte growth factor (HGF) expression staining score 
(intensity x coverage) in the four placenta groups studied. Values for each group as 
pre-eclampsia PE versus pre-term PTL, term labour TL, and term non-labour TNL 
(*p <0.05 is considered statistically significant difference in staining in Pre-term 
Labour and Term Labour using the Mann-Whitney U test). The horizontal red line 
indicates the median values.  
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Figure 31J. represents the placental growth factor (PLGF) expression staining score 
(intensity x coverage) in Labour and non-Labour placenta groups studied (*p <0.05 is 
considered statistically significant difference in staining in Labour using the Mann-
Whitney U test). The horizontal red line indicates the median values. 
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Figure 31K. represents the hepatocyte growth factor (HGF) expression staining score 
(intensity x coverage) in pre-term and term placenta groups studied (* p <0.05 is 
considered statistically significant difference in staining in Pre-term) using the Mann-
Whitney U test. The horizontal red line indicates the median values. 
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Correlation between growth factors  
The Spearman rank correlation test was performed to investigate correlation 
relationships between the expression of variables that were non-grouped for the 
different growth factors VEGF, PLGF, FGF2, HGF, PDGF-BB, and CD105 (n = 87) 
and HB-EGF (n = 42), MK (n = 35) and PTN (n = 30) because data was not normally 
distributed as in the staining score table 8 and staining intensity table 9. The Rho 
represents Spearman’s rank correlation coefficient. The p-value of < 0.05 and p-value 
of < 0.01 was considered statistically significant.  
 There was a significant positive correlation was shown between FGF2 and HGF 
expression (Rho = 0.35, p = 0. 01**), HGF and PDGF expression (Rho = 0.43, p = 
0.001) and for PLGF and CD105 expression (Rho = 0.31, p = 0.01**) shown in the 
staining score in table 8. 
Whereas, all the other HBGFs expression showed a weak positive correlation between 
FGF2 and PDGF expression (Rho = 0. 24, p = 0. 08), HGF and VEGF expression 
(Rho =0.06, p = 0.67), HGF and CD105 expression (Rho =0. 35, p =0.79), HGF and 
PTN expression (Rho = 0. 27, p = 0.86), VEGF and PLGF expression (Rho = 0.08, p 
= 0.48), VEGF and CD105 expression (Rho = 0.19, p = 0.10), VEGF and PTN 
expression (Rho = 0.39, p = 0.95), PLGF and VEGF expression (Rho = 0.08, p = 
0.48), PLGF and MK expression (Rho = 0.06, p = 0.62), PLGF and PTN expression 
(Rho = 0.05, p = 0.58), PDGF and PTN expression (Rho = 0.22, p = 0.83), CD105 
and MK expression (Rho = 0.41, p = 0.98), CD105and PTN expression (Rho = 0.21, 
p = 0.19), MK and HBEGF expression (Rho = 0.18, p = 0.76) and PTN and HBEGF 
expression (Rho = 0.40, p = 0.92) respectively. 
However, a negative correlation was observed for the reminder of HBGFs between 
staining score FGF2 and VEGF expression (Rho = -0.14, p =0. 27), FGF2 and PLGF 
expression (Rho = -0.04, p =0.73), FGF2 and CD105 expression (Rho =-0.11, p =0. 
41), FGF2 and MK expression (Rho = -0.25, p =0. 11), FGF2 and PTN expression 
(Rho = -0.01, p = 0.49), FGF2 and HBEGF expression (Rho = -0.32, p =0. 11), HGF 
and PLGF expression (Rho = -0.13, p =0.35), HGF and MK expression (Rho = -0.08, 
p = 0. 33), HGF and HBEGF expression (Rho = -0.36, p = 0.06), VEGF and PDGF 
expression (Rho = -0.01, p = 0.93), VEGF and MK expression (Rho = -0.19, p = 
0.14),VEGF and HBEGF expression (Rho = -0.19, p = 0.19), PLGF and PDGF 
expression (Rho = -0.13, p = 0.36), PLGF and HBEGF expression (Rho = -0.07, p = 
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0.62), PDGF and CD105 expression (Rho = -0.22, p = 0.12), PDGF and MK 
expression (Rho = -0.05, p = 0.22), PDGF and HBEGF expression (Rho = -0.005, p = 
0.50), CD105 and HBEGF expression (Rho = -0.12, p = 0.29) and MK and PTN 
expression (Rho = -0.06, p = 0.59) respectively  as in table 8. 
 
 
 
Table 8. Represents the correlation between expressions of staining score for Heparin- 
binding growth factors present in placental tissues. Abbreviations: Fibroblast growth 
factor 2 (FGF2), platelet-derived growth factor (PDGF), hepatocyte growth factor 
(HGF), vascular endothelial growth factor (VEGF), placental growth factor (PLGF), 
cluster differentiation (CD105) were of (n = 87), except for midkine (MK), (n = 35), 
pleiotrophin (PTN), (n = 30), and heparin binding epidermal growth factor (HB-
EGF), (n = 42), using the Spearman’s rank correlation test. The Rho represents 
Spearman’s rank correlation coefficient. The p-value of < 0.01** and p-value of < 
0.001** is considered statistically significant.  
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CD105 
 
P=0.41 
 
P= 0.79 
 
P=0.12 
 
P=0.10 
 
P=0.01** 
  
Rho=0.41 
 
 
Rho=0.21 
 
Rho=-0.12 
 
MK 
 
P=0.11 
 
P=0.33 
 
P=0.22 
 
P=0.14 
 
 
P=0.62 
 
P=0.98 
 
  
Rho=-0.06 
 
Rho=0.18 
 
  PTN 
 
P= 0.49 
 
P= 0.86 
 
P=0.83 
 
P=0.95 
 
P=0.58 
 
P=0.19 
 
P=0.59 
  
Rho=0.40 
 
HBEGF 
 
P= 0.11 
 
P=0.06 
 
P=0.50 
 
P=0.19 
 
P=0.62 
 
P=0.29 
 
P=0.76 
 
P=0.92 
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Table 9. Correlation between expression of staining intensity for Heparin-binding 
growth factors present in placental tissues. Abbreviations: Fibroblast growth factor 2 
(FGF2), platelet-derived growth factor (PDGF), hepatocyte growth factor (HGF), 
vascular endothelial growth factor (VEGF), placental growth factor (PLGF), cluster 
differentiation (CD105) were of (n = 87), except for midkine (MK), (n = 35), 
pleiotrophin (PTN), (n = 30), and heparin binding epidermal growth factor (HB-
EGF), (n = 42), using the Spearman’s rank correlation test. The Rho represents 
Spearman’s rank correlation coefficient.  The p-value of < 0.05* and p-value of < 
0.01** and < 0.0001** is considered statistically significant.  
In addition, there was a significant positive correlation between staining intensity as 
shown in table 9 for HGF and FGF2 expression (Rho = 0.35, p = 0. 01**), PDGF 
versus FGF2 expression (Rho = 0. 24, p = 0. 04*), and PDGF versus HGF expression 
(Rho = 0.50, p = 0.001**), HGF and CD105 expression (Rho =0.02*, p =0.57) and 
VEGF and PDGF expression (Rho = 0.02*, p = 0.57).  Whereas, reminder of HBGFs 
expression showed a both weak positive correlation between staining intensity for 
 
 
Growth 
Factors 
 
 
                                                  Spearman’s rank correlation coefficient Rho and p-values. 
FGF2 HGF PDGF VEGF PLGF CD105 MK PTN HBEGF 
 
FGF2 
  
Rho=0.34 
 
Rho=0.28 
 
Rho=0.19 
 
Rho=-0.01 
 
Rho=-0.16 
 
Rho=-0.10 
 
 
Rho=0.27 
 
 
Rho=-0.31 
 
 
HGF 
 
P=0.01** 
  
Rho=0.50 
 
Rho=0.03* 
 
 
Rho=-0.06 
 
Rho=0.02* 
 
Rho=-0.29 
 
 
Rho=0.33 
 
 
Rho=-0.28 
 
 
PDGF 
 
P=0.04* 
 
P=0.0001** 
 
 
 
Rho=0.02* 
 
 
Rho=-0.07 
 
Rho=-0.07 
 
Rho=-0.04 
 
 
Rho=0.20 
 
 
Rho=-0.03 
 
 
VEGF 
 
P= 0.14 
 
P= 0.57 
 
P=0.57 
  
Rho=0.08 
 
Rho=0.15 
 
Rho=0.35 
 
 
Rho=0.21 
 
 
Rho=-0.45 
 
 
PLGF 
 
P= 0.46 
 
P=0.64 
 
P=0.30 
 
P= 0.75 
  
Rho=0.26 
 
Rho=-0.07 
 
 
Rho=0.45 
 
 
Rho=0.22 
 
 
CD105 
 
P=0.11 
 
P= 0.57 
 
 
P=0.32 
 
P= 0.90 
 
P= 0.98 
  
Rho=0.36 
 
 
Rho=0.17 
 
Rho=-0.14 
 
MK 
 
P=0.28 
 
P=0.06 
 
P=0.40 
 
P=0.97 
 
 
P=0.34 
 
P=0.98 
 
  
Rho=0.22 
 
Rho=0.29 
 
  PTN 
 
P=0.84  
 
P=0.90  
 
P=0.76 
 
P= 0.81 
 
P=0.97 
 
P= 0.75 
 
P=0.16 
  
Rho=-0.08 
 
HBEGF 
 
P= 0.11 
 
P=0.12 
 
P=0.46 
 
P=0.02 
 
P=0.83 
 
P=0.27 
 
P=0.82 
 
P=0.40 
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HGF and PTN expression (Rho = 0.33, p = 0.90), VEGF and PLGF expression (Rho 
= 0.08, p = 0.75), VEGF and CD105 expression (Rho = 0.15, p = 0.90), VEGF and 
MK expression (Rho = 0.35, p = 0.97), VEGF and PTN expression (Rho = 0.21, p = 
0.81), PLGF and VEGF expression (Rho = 0.08, p = 0.75), PLGF and CD105 
expression (Rho = 0.26, p = 0.98), PLGF and MK expression (Rho = 0.07, p = 0.34), 
PLGF and PTN expression (Rho = 0.45, p = 0.97), PLGF and HBEGF expression 
(Rho = 0.22, p = 0.83), PDGF and PTN expression (Rho = 0.20, p = 0.76), CD105 
and MK expression (Rho = 0.36, p = 0.98), CD105and PTN expression (Rho = 0.17, 
p = 0.75), MK and PTN expression (Rho = 0.22, p = 0.16) and MK and HBEGF 
expression (Rho = 0.29, p = 0.82) respectively.  
However, a weak negative correlation between staining intensity for FGF2 and VEGF 
expression (Rho = 0.19, p = 0. 14), FGF2 and PLGF expression (Rho = -0.01 p 
=0.46), FGF2 and CD105 expression (Rho = -0.16, p = 0.11), FGF2 and MK 
expression (Rho = -0.10, p = 0.28), FGF2 and PTN expression (Rho = -0.27, p =0.84), 
FGF2 and HBEGF expression (Rho = -0.31, p =0.11), HGF and PLGF expression 
(Rho = -0.06, p =0.64), HGF and MK expression (Rho = -0.29, p = 0. 06), HGF and 
HBEGF expression (Rho = -0.28, p = 0.12), VEGF and HBEGF expression (Rho = -
0.45, p = 0.02), PLGF and PDGF expression (Rho = -0.07, p = 0.30), PDGF and 
CD105 expression (Rho = -0.07, p = 0.32), PDGF and MK expression (Rho = -0.04, p 
= 0.40), PDGF and HBEGF expression (Rho = -0.03, p = 0.46), CD105 and HBEGF 
expression (Rho = -0.14, p = 0.27) and  PTN and HBEGF expression (Rho = -0.08, p 
= 0.40) respectively.  
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Growth 
Factors (a) 
Mann-Whitney U test 
          PE          PTL          TNL             TL 
Median 
 FGF2 
15 
P=0.23 
15 
P=0.09 
15 
P=0.22 
12 
P=0.004* 
 
HGF 
15 
P=0.27 
15 
P=0.01** 
10 
P=0.93 
10 
P=0.001** 
 
VEGF 
15 
P=0.36 
15 
P=0.18 
10 
P=0.09 
15 
P=0.03* 
       
PLGF 
15 
P=0.02* 
10 
P=0.41 
10 
P=0.28 
10 
P=0.21 
 
MK 
4 
P=0.03* 
10 
P=0.43 
8 
P=0.25 
8 
P=0.26 
 
PTN 
3 
P=0.04* 
15 
P=0.39 
15 
P=0.01** 
15 
P=0.09 
 
HB-EGF 
4 
P=0.33 
7 
P=0.03 
8 
P=0.01** 
8 
P=0.16 
 
 
Growth 
Factors (b) 
Mann-Whitney U test 
PE PTL TNL TL 
Median 
PDGF 
16 
       P=0.68 
16 
P=0.92 
20 
        P=0.26 
15 
       P=0.24 
CD105 10 
        P=0.07 
10 
       P=0.32 
10 
        P=0.42 
8 
       P=0.06 
Table 10 a and b. Represents the comparison of expression in staining score for Heparin 
binding growth factors present in placental tissues using the Mann-Whitney U test. 
Abbreviations: Fibroblast growth factor 2 (FGF2), platelet-derived growth factor (PDGF), 
hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), placental 
growth factor (PLGF) and cluster differentiation (CD105), midkine (MK), pleiotrophin 
(PTN), heparin binding epidermal growth factor (HB-EGF). PE- Pre-eclampsia, PTL-Pre-
term Labour, TNL-Term-non-Labour, and TL-term labour. Comparisons between each group 
versus all other groups combined. The median is given above and p-values are shown. The p-
value of < 0.05* and p-value of < 0.01** is considered statistically significant. 
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Table 10. a and b. represents the comparison of expression in staining score for 
(FGF2), pre-eclampsia, (m=15, p=0.23), pre-term labour, (m=15, p=0.09), term-non-
labour, (m=15, p=0.22), and term labour (m=15, p=0004*), HGF for pre-
eclampsia,(m=15, p=0.27), pre-termlabour,(m=15, p=0.01*),term-non-labour,(m=10, 
p=0.93),and term labour (m=10, p=0.001**), PDGF for pre-eclampsia, (m=16, 
p=0.68), pre-term labour,(m=16, p= 0.92),  term-non-labour, (m=20, p= 0.26), and 
term labour, (m=15, p=0.24), VEGF for pre-eclampsia,(m=15, p=0.02**), pre-term 
labour,(m=10, p= 0.41), term-non labour,(m=10, p=0.09), and term labour (m=15, p= 
0.03*), PLGF for pre-eclampsia, (m=15, p=0.02*), pre-term labour,(m=10, p= 0.41), 
term-non-labour, (m=10, p=0.28),  and term labour (m=10, p=0.21), and CD105 for 
pre-eclampsia,(m=10, p=0.07), pre-term labour,(m=10, p=0.32), term-non-labour, 
,(m=10, p= 0.42),  and term labour, (m=8, p=0.06), MK for pre-eclampsia,(m=4, p= 
0.03*), pre-term labour,(m=10, p=0.43),  term-non-labour, (m=8, p=0.25),  and term 
labour (m=8, p=0.26),  PTN for pre-eclampsia,(m=3, p=0.04), pre-term labour,(m=15, 
p=0.39),  term-non--labour, (m=15, p=0.01**), and term labour (m=15, p= 0.09), HB-
EGF for pre-eclampsia,(m=4, p= 0.33), pre-term labour,(m=7, p= 0.03), term-non-
labour, (m=8, p=0.01*), and term labour (m=8, p=0.16)  using the Mann-Whitney U 
test. The p-value of < 0.05* and p-value of < 0.01** is considered statistically 
significant. 
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Growth factors 
                               Mann-Whitney U test 
         PE          PTL        TNL           TL 
Median 
FGF2 
 
          3 
     P= 0.26 
 
          3 
     P= 0.24 
 
        3 
     P= 0.38 
 
          3 
     P= 0.02* 
 
 
HGF 
 
          3 
     P= 0.22 
 
         3 
     P= 0.01** 
 
         2 
     P= 0.46 
 
          2 
    P= 0.002** 
 
 
PDGF 
 
          4 
     P= 0.55 
 
          3.5 
     P= 0.56 
 
        4 
     P= 0.21 
 
          3 
        P= 0.20 
 
 
VEGF 
 
           3 
   P= 0.34 
 
         3 
     P= 0.19 
 
         3 
     P= 0.09 
 
          3 
       P= 0.04* 
 
 
PLGF 
 
         2 
      P= 0.02* 
 
         2 
     P= 0.40 
 
          2 
      P= 0.21 
 
          2 
      P= 0.14 
 
 
CD105 
 
         2 
      P= 0.07 
 
        2 
      P= 0.11 
 
          2 
      P= 0.29 
 
          2 
      P= 0.02* 
 
 
MK 
 
          2 
      P= 0.52 
 
 
         3 
     P= 0.44 
 
 
          2 
      P= 0.38 
 
 
         2.5 
      P= 0.42 
 
 
PTN 
        2.5 
 
      P= 0. 67 
 
         3 
 
      P= 0. 29 
 
         3 
 
      P= 0. 32 
 
        1.5 
 
      P= 0.07  
 
 
HB-EGF 
         3 
      P= 0. 30 
 
           2 
      P= 0. 04* 
 
          4 
      P= 0.03 
 
          3 
      P= 0. 42 
 
 
Table 11. Represents the comparison of expression in staining intensity for Heparin 
binding growth factors present in placental tissues using the Mann-Whitney U test. 
Abbreviations: Fibroblast growth factor 2 (FGF2), platelet-derived growth factor 
(PDGF), hepatocyte growth factor (HGF), vascular endothelial growth factor 
(VEGF), placental growth factor (PLGF) and cluster differentiation (CD105), midkine 
(MK), pleiotrophin (PTN), heparin binding epidermal growth factor (HB-EGF). PE- 
Pre-eclampsia, PTL-Pre-term Labour, TNL-Term-non-Labour, and TL-term labour. 
Comparisons between each group versus all other groups combined. The median is 
given above and p- values are shown. The p-value of < 0.05* and p-value of < 0.01** 
is considered statistically significant.  
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Table 11. represents the comparison of expression in staining intensity for FGF2, pre-
eclampsia, (m=3, p=0.26), pre-term labour, (m=3, p=0.24), term-non--labour, (m=3, 
p=0.38), and term labour (m=3, p=0.02*), HGF for pre-eclampsia, (m=3, p=0.22), 
pre-term labour, (m=3, p=0.01**), term-non-labour,  (m=2, p=0.46), and term labour 
(m=2, p=0.002**), PDGF for pre-eclampsia, (m=4, p=0.55), pre-term labour, (m=3.5, 
p=0.56),  term-non-labour, (m=4, p=0.21),  and term labour (m=3, p=0.20),VEGF for 
pre-eclampsia, (m=3, p=0.34), pre-term labour, (m=3, p=0.19), term-non-
labour,(m=3, p=0.09), and term labour (m=3, p=0.04*), PLGF for pre-
eclampsia,(m=2, p=0.02*), pre-term labour, (m=2, p=0.40), term-non-labour, (m=2, 
p=0.21),  and term labour (m=2, p=0.14),  and CD105 for pre-eclampsia, (m=2, 
p=0.07), pre-term labour,(m=2, p=0.11),  term-non-labour, (m=2, p=0.29),  and term 
labour, (m=2, p=0.02*), MK for pre-eclampsia, (m=2, p=0.52), pre-term labour, 
(m=3, p=0.44),  term-non-labour, (m=2, p=0.38),  and term labour (m=2.5, p=0.42),  
PTN for pre-eclampsia,(m=2.5, p=0.67), pre-term labour,(m=3,p=0.29),  term-non-
labour, (m=3, p=0.32), and term labour, (m=1.5, p=0.07), HB-EGF for pre-eclampsia, 
(m=3, p=0.30), pre-term labour, (m=2, p=0.04*), term-non-labour, (m=4, p=0.03), 
and term labour (m=3, p=0.42)  using the Mann-Whitney U test. The p-value of < 
0.05* and p-value of < 0.01** is considered statistically significant. 
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 Growth factors 
                      Mann-Whitney U test 
Labour versus Non-Labour Term versus Pre-term  
Median=M 
 
FGF2 
M=15    M=15 
P= 0.04* 
M=15    M=15        
P= 0.91 
HGF 
 
M=15    M=15 
P= 0.02* 
M=15    M=15 
P= 0.005* 
PDGF 
 
M= 20   M=15 
P= 0.25 
16 
P= 0.35 
VEGF 
 
M=15    M=15 
P= 0.19 
M=15    M=15 
P= 0.33 
PLGF 
 
M=10    M=10 
P= 0.03* 
M=10    M=10 
P= 0.05* 
CD105 
 
M=10    M=10 
P= 0.98 
M=10    M=10 
P= 0.01** 
 
 
MK 
 
M=12    M=7 
P= 0.20 
 
M=10    M=8 
P= 0. 50 
 
 
 
 
PTN 
 
M=4    M=13.5 
P= 0.04 *  
 
M=10    M=5 
P= 0.27 
 
 
HB-EGF 
 
M= 6   M=20 
P= 0.03 * 
 
M=7    M=20 
P= 0.02* 
 
 
 
Table 12. Represents the comparison of expression in staining score for Heparin 
binding growth factors present in placental tissues using the Mann-Whitney U test. 
Abbreviations: Fibroblast growth factor 2 (FGF2), platelet-derived growth factor 
(PDGF), hepatocyte growth factor (HGF), vascular endothelial growth factor 
(VEGF), placental growth factor (PLGF) and cluster differentiation (CD105), midkine 
(MK), pleiotrophin (PTN), heparin binding epidermal growth factor (HB-EGF). PE- 
Pre-eclampsia, PTL-Pre-term Labour, TNL-Term-non-Labour, and TL-term labour. 
Comparisons are labour (TL + PTL) versus non-labour (PE + TNL) and Term (TL + 
TNL) versus Pre-term (PE + PTL). The medians and p-values are shown. The p-value 
of < 0.05* and p-value of < 0.01** is considered statistically significant. 
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Table 12. represents comparison of labour (TL + PTL) versus non-labour (PE + TNL) 
and term versus pre-term (PE + PTL) in placental tissues and comparison of 
expression in staining score for FGF2, labour versus non-labour of (m=15, m=15, 
p=0,04*), and term versus pre-term of (m=15, m=15, p=0.91), HGF, labour versus 
non-labour of (m=15, m=15, p=0.02*), and term versus pre-term of (m=15, m=15, 
p=0.005*), PDGF, labour versus non-labour of (m=20, m=15, p=0.25),  and term 
versus pre-term of (m=16, p=0.35),  VEGF, labour versus non-labour of (m=20, 
m=15, p=0.19), and term versus pre-term of (m=15, m=15, p=0.33), PLGF, labour 
versus non-labour of (m=10, m=10, p=0.03*),  and term versus pre-term of (m=10, 
m=10, p=0.05*), CD105, labour versus non-labour of (m=10, m=10, p=0.98),  and 
term versus pre-term of (m=10, m=10, p=0.01**), MK, labour versus non-labour of 
(m=12, m=7, p=0.20),  and term versus pre-term of (m=10, m=8, p=0.05), PTN, 
labour versus non-labour of (m=4, m=13.5, p=0.04*),  and term versus pre-term of 
(m=10, m=5, p=0.27), HB-EGF, labour versus non-labour of (m=6, m=20, p=0.03*),  
and term versus pre-term of (m=7, m=20, p=0.02*) using the Mann-Whitney U test. 
The p-value of < 0.05* and p-value of < 0.01** is considered statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
  Farha Nazir Ahmad M00201045                                                            163 
 
 
Growth factors 
                      Mann-Whitney U test 
Labour versus Non-Labour    Term versus Pre-term  
Median=M 
 
FGF2 
 
M=3  M=3 
 
P= 0.11 
M=3  M=3 
 
P= 0.10 
HGF 
 
M=2  M=3 
 
P= 0.70 
M=2  M=3 
 
P= 0.003* 
PDGF 
 
M=3  M=4 
 
P= 0.18 
M=4  M=4 
 
P= 0.51 
VEGF 
 
M=3  M=3 
P= 0.21 
M=3  M=3 
P= 0.36 
PLGF 
 
M=2  M=2 
P= 0.02* 
M=2  M=2 
P= 0.56 
CD105 
 
M=2  M=2 
P= 0.80 
M=2  M=2 
P= 0.99 
 
MK 
 
 
M=3  M=2 
P= 0.33 
 
M=2  M=2 
P= 0.52 
 
 
 
 
PTN 
 
 
M=2  M=3 
P= 0.16 
 
 
 
 
M=3  M=3 
P= 0.26 
 
 
 
HB-EGF 
 
M=2  M=4 
P= 0.06 
 
M=4  M=2 
P= 0.022 
 
 
Table 13. Represents the comparison of expression in staining intensity for Heparin 
binding growth factors present in placental tissues using the Mann-Whitney U test. 
Abbreviations: Fibroblast growth factor 2 (FGF2), platelet-derived growth factor 
(PDGF), hepatocyte growth factor (HGF), vascular endothelial growth factor 
(VEGF), placental growth factor (PLGF) and cluster differentiation (CD105), midkine 
(MK), pleiotrophin (PTN), heparin binding epidermal growth factor (HB-EGF). PE- 
Pre-eclampsia, PTL-Pre-term Labour, TNL-Term-non-Labour, and TL-term labour. 
Comparisons are labour (TL + PTL) versus non-labour (PE + TNL) and Term (TL + 
TNL) versus Pre-term (PE + PTL). The median is given above and p-values are 
shown. The p-value of < 0.05* and p-value of < 0.01** is considered statistically 
significant.   
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Table 13. represents comparison of labour (TL + PTL) versus non-labour (PE + TNL) 
and term versus pre-term (PE + PTL) in placental tissues and comparison of 
expression in staining score for FGF2, labour versus non-labour of (m=3, m=3, 
p=0.11),  and term versus pre-term of (m=3, m=3, p=0.10), HGF, labour versus non-
labour of (m=2, m=3, p=0.70),  and term versus pre-term of (m=2, m=3, p=0.003*), 
PDGF, labour versus non-labour of (m=3, m=4, p=0.18),  and term versus pre-term of 
(m=4, m=4,p=0.51), VEGF, labour versus non-labour of (m=3, m=3, p=0.21),  and 
term versus pre-term of (m=3, m=3, p=0.36), PLGF, labour versus non-labour of 
(m=2, m=2, p=0.02*),  and term versus pre-term of (m=2, m=2, p=0.56), CD105, 
labour versus non-labour of (m=2, m=2, p=0.80),  and term versus pre-term of (m=2, 
m=2,p=0.99), MK, labour versus non-labour of (m=3, m=2, p=0.33),  and term versus 
pre-term of (m=2, m=2, p=0.52), PTN, labour versus non-labour of (m=2, m=3, 
p=0.16),  and term versus pre-term of (m=3, m=3, p=0.26), HB-EGF, labour versus 
non-labour of (m=2, m=4, p=0.06),  and term versus pre-term of (m=4, m=2, p=0.22) 
using the Mann-Whitney U test.The p-value of < 0.05* and p-value of < 0.01** is 
considered statistically significant. 
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                 Growth factors               Kruskal Wallis test 
FGF2  
 
T = 7.28 
P = 0.06 
HGF 
 
T = 14.26 
     P = 0.0001** 
PDGF 
 
T = 1.61 
P = 0.66 
VEGF 
 
T = 5.55 
P = 0.14 
PLGF 
 
T = 14.76 
   P = 0.0001* 
CD105 
 
T = 4.70 
P = 0.19 
MK 
 
T = 10.97 
P = 0.003* 
PTN 
 
T = 10.10 
P =0.004* 
HB-EGF 
 
T = 9.34 
P = 0.05* 
 
Table 14. Represents the comparison of expression in staining scoring results for each 
Heparin binding growth factors present in placental tissues. Abbreviations: Fibroblast 
growth factor 2 (FGF2), platelet-derived growth factor (PDGF), hepatocyte growth 
factor (HGF), vascular endothelial growth factor (VEGF), placental growth factor 
(PLGF) and cluster differentiation (CD105), midkine (MK), pleiotrophin (PTN), 
heparin binding epidermal growth factor (HB-EGF). Comparison here is between the 
four groups overall using the Kruskal Wallis analysis of variance. PE-Pre-eclampsia, 
PTL- Pre-term Labour, TNL-Term-non-Labour, and TL-term labour. The t values and 
p values are shown. The p-value of < 0.05* and p-value of < 0.01** is considered 
statistically significant. 
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Table 14. represents the comparison of expression in staining scoring and is between 
the four groups overall for FGF2 (t=7.28, p=0.06), HGF (t=14.26, p=0.0001**), 
PDGF (t=1.61, p=0.66), VEGF (t=5.55, p=0.14), PLGF (t=14.76, p=0.0001*), and 
CD105 (t=4.70, p=0.19), MK (t=10.97, p=0.003*), PTN (t=10.10, p=0.004*), HB-
EGF (t=9.34, p=0.05*) using the Kruskal Wallis analysis of variance test. The p-value 
of < 0.05* and p-value of < 0.01** is considered statistically significant. 
Table 15, represents the comparison of expression in staining scoring and is between 
the four groups overall for FGF2 (t=5.50, p=0.14), HGF (t=11.9, p=0.01*), PDGF 
(t=1.83, p=0.61), VEGF (t=4.36, p=0.22), PLGF (t=1.41, p=0.001**), and CD105 
(t=6.42, p=0.09), MK (t=2.18, p=0.70), PTN (t=2.91, p=0.57), HB-EGF (t=2.91, 
p=0.57) using the Kruskal Wallis analysis of variance test. The p-value of < 0.05* and 
p-value of < 0.01** is considered statistically significant. 
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                 Growth factors               Kruskal Wallis test 
FGF2  
 
T = 5.50 
P = 0.14 
HGF 
 
T = 11.9 
   P = 0.01**  
PDGF 
 
T = 1.83 
P = 0.61 
VEGF 
 
T = 4.36 
P = 0.22 
PLGF 
 
T = 1.41 
   P = 0.001** 
CD105 
 
T = 6.42 
P = 0.09 
MK 
 
T = 2.18 
P = 0. 70 
PTN 
 
T = 2.91 
P = 0.57 
HB-EGF 
 
T = 2.91 
P = 0.57 
 
Table 15. Comparison expression of staining intensity results for each Heparin 
binding growth factors present in placental tissues. Abbreviations: Fibroblast growth 
factor 2 (FGF2), platelet-derived growth factor (PDGF), hepatocyte growth factor 
(HGF), vascular endothelial growth factor (VEGF), placental growth factor (PLGF) 
and cluster differentiation (CD105), midkine (MK), pleiotrophin (PTN), heparin 
binding epidermal growth factor (HB-EGF). Comparison here is between the four 
groups overall using the Kruskal Wallis analysis of variance. PE-Pre-eclampsia, PTL-
Pre-term Labour, TNL-Term-non-Labour, and TL-term labour. The t values and p 
values are shown. The p-value of < 0.05* and p-value of < 0.01** is considered 
statistically significant.  
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3.2. Growth factor receptor localisation: for expression of VEGFR1, VEGFR2 and 
FGF2R2 receptor in the human placenta. 
 
 
I identified VEGFR1, VEGFR2, and FGF2R2 receptor expression in the human 
placenta. The VEGFR1, (soluble Fms-like tyrosine kinase1 is called sFlt), VEGFR2 
and FGF2 receptor study group comprised term placenta (after 36 weeks gestation) 
not in labour (n=22), preterm labour (before 36 weeks gestation, n=6), term following 
labour onset (n=21), and pre-eclampsia (after 20 weeks of gestation, n=12). 
Immunohistochemistry staining was performed and positive results obtained. The 
colour intensity and clarity of staining was observed in the photomicrographs as 
shown in Figure 32, 33, and 34. Characterization of FGF2R1, VEGFR1, and 
VEGFR2 receptors and its placental tissue distribution would facilitated the 
understanding of the role of FGF2, VEGF receptors present in the human placenta. 
The interactions of growth factors with specific, high affinity cognate receptors 
located in plasma membrane of target cells that triggers events inside the cells which 
eventually lead to DNA synthesis. The FGF2R-1, VEGF receptor-1 (VEGFR-1, FLt-
1), and VEGF receptor-2 (VEGFR-2, Flk-1/KDR) consists of protein-tyrosine 
kinases. These participate in vasculogenesis and angiogenesis during placental 
development.  As shown in Figure 32, 33 and 34, VEGFR-1 (sflt-1)/VEGFR-2 
receptors expression for the four groups PE-Pre-eclampsia, TL-term labour, TNL-
Term-non-Labour, and PTL-Pre-term Labour was distributed to the villous and extra 
villous trophoblast, villous mesenchyme, Hofbauer cells and maternal decidua cells. 
The receptor PLGF expression was abundant in villous trophoblast. FGFR-1 receptor 
expression was localised to the villous and extra villous trophoblast, villous 
mesenchyme.  
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Figure 32. Immunohistochemical moderate to strong positive staining in villous 
trophoblast (both syncytiotrophoblast and cytotrophoblast), weaker staining in the 
mesenchyme, and in the core foetal vessels for fibroblast growth factor 2 (FGF2) 
receptor expression distributed in placental tissues for the four groups PE-Pre-
eclampsia, (n = 12), and PTL-Pre-term Labour, (n = 6), TL-term labour, (n = 22), and 
TNL-Term-non- Labour, (n = 21), 3= moderate to strong with a magnification of 
x401. The arrows indicate the trophoblast and (*) the endothelial cells. 
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Figure 33. Immunohistochemical moderate to strong positive staining in villous 
trophoblast (both syncytiotrophoblast and cytotrophoblast), weaker staining in the 
mesenchyme, and in the core foetal vessels for vascular endothelial growth factor 
(VEGF) receptor I expression distributed in placental tissues for the four groups PE-
Pre-eclampsia, (n = 12), and PTL-Pre-term Labour, (n = 6), TL-term labour, (n = 22), 
and TNL-Term-non- Labour, (n = 21), 3=moderate to strong with a magnification of 
original x401. The arrows indicate the trophoblast and (*) the endothelial cells. 
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Figure 34. Immunohistochemical moderate to strong positive staining prominent in 
villous trophoblast (both syncytiotrophoblast and cytotrophoblast), weaker staining in 
the mesenchyme, and in the core foetal vessels for vascular endothelial growth factor 
(VEGF) receptor II expression in placental tissues for the four groups PE-Pre-
eclampsia, (n = 12), and PTL-Pre-term Labour, (n = 6), TL-term labour, (n = 22), and 
TNL-Term-non- Labour, (n = 21), 3 = moderate to strong with a Magnification of x 
401 The arrows indicate the trophoblast and (*) the endothelial cells. 
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Comparisons between four groups. 
The groups were compared by analysing differences between normal pregnancy and 
pre-eclampsia. The results of FGF2R1 (n =24), VEGFR1 (n=20) and VEGFR2 (n=16) 
were examined.  
 
Differences between groups with pre-eclampsia. 
The staining score for the expression TL, TNL and PTL for VEGFR1 and VEGFR2, 
FGF2R1 was significantly lower in pre-eclamptic compared to TL, TNL and PTL 
other placentas in this study (p< 0.05, Mann-Whitney U test) as shown in table 18. In 
contrast, the expression of VEGFR2 as shown in table 16. and Figure 34. was 
significantly higher in pre-eclampsia compared to other placenta groups studied (p 
<0.05) using the Mann-Whitney U test and Kruskal Wallis analysis of variance test. 
The VEGFR1 and VEGFR2, FGF2R1 investigated did not show a significant 
difference in staining in pre-eclampsia.  
 
Comparison Term versus pre-term. 
As shown in table 20. and Figure 34. the expression of staining score of VEGFR2 
were significantly lower in (preterm, m=12) compared to (term, m=15) placentas 
using the Mann-Whitney U test, p =0.06. In Figure 33. the expression of staining 
score of VEGFR1 showed no difference between (term, m=10) and (preterm, m=10) 
placentas giving the Mann-Whitney U test, p = 0.37. In table 20 the placental 
expression of FGF2R1 was similar in (pre-term, m=12) versus (term, m=12) 
placentas, as judged by obtaining a p = 0.38 compared to (labour, m=12) and (non-
labour, m=13.5) obtaining a p = 0.53 by the Mann-Whitney U test respectively. The 
expression of staining score was not significantly different in term compared to 
preterm according to gestational age in any of the following tested FGF2R1, VEGFR1 
and VEGFR2. 
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Comparison Labour versus non-labour 
The expression of staining score of FGF2R2 showed no significance difference in 
term labour (m=12) compared to other groups using the (Mann-Whitney U test, p = 
0.53) in table 20. The VEGFR1 expression of staining score showed no significance 
difference after labour onset using the Mann-Whitney U test p =0.16. The comparison 
of staining score expression was not associated with significant difference in 
VEGFR1 and VEGFR2 expression as the Mann-Whitney U test, (m=10, p =0.16) and 
(m=10, p=0.37). The comparison of staining intensity for labour and non-labour did 
not reveal a significant difference in VEGFR1 and VEGFR2 expression of (m=2, p = 
0.58) and (m=2, p=0.27) using the Mann-Whitney U test.  VEGFR1 and VEGFR2 
expression did not reveal a significant difference in pre-term labour compared to term 
(m=2, p=0.41 and m=4, p=0.18). The VEGFR1, VEGFR2 and FGF2R2 showed no 
significant difference in expression according to the presence or absence of labour. 
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Growth Factor 
Receptors 
 
Mann-Whitney U test P= value; Median= value 
 
PE 
 
PTL 
 
TNL 
 
TL 
 
FGF2 R-1 
 
 
M= 12 
P= 0.57 
 
 
M=12.5 
P=0.57 
 
 
M= 15 
P=0.40 
 
 
M=21 
P= 0.48 
 
 
VEGF R-1 
 
 
M= 10 
P=0.57 
 
 
M=10 
P=0.57 
 
 
M=10 
P=0.52 
 
 
M= 10 
P= 0.29 
 
 
VEGFR-2 
 
 
M=13.5 
P=0.33 
 
 
M=13.5 
P=0.33 
 
 
M=15 
P=0.21 
 
 
M=15 
P=0.36 
 
 
Table 16. Comparison for expression of staining score for fibroblast growth factor 2 
receptor (FGF2R-1), vascular endothelial growth factor (VEGFR-1, and VEGFR 2) 
receptors in placental tissues using the Mann-Whitney U test. PE-Pre-eclampsia, (n = 
12), PTL-Pre-term Labour, (n = 6), TNL-Term-non-Labour, (n = 21), and TL-term 
labour, (n = 22). Comparisons between each group versus all other groups combined. 
The medians and p values are shown.  
 
Table 16. represents the comparison for expression of staining score for FGF2 R-1, 
pre-eclampsia (m = 12, p = 0.57); pre-term Labour (m = 12.5, p = 0.57), term-non-
Labour (m = 15, p=0.40), and term labour (m= 21, p = 0.48). VEGFR-1, for pre-
eclampsia (m = 10, p = 0.57), pre-term Labour (m = 10, p = 0.57), term-non-Labour 
(m = 10, p = 0.52), and term labour (m = 10, p = 0.29). VEGFR-2, for pre-eclampsia 
(m = 13.5, p = 0.33), pre-term Labour (m = 13.5, p = 0.33), term-non-Labour (m = 15, 
p = 0.21), and term labour (m = 15, p = 0.36). 
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Growth Factor 
   Receptors 
                
           Mann-Whitney U test P= value; Median= value 
      
 
     PE 
     
 
    PTL 
      
 
    TNL 
      
 
     TL 
 
FGF2 R-1 
 
        
       M= 3       
       P= 0.48 
 
         
        M= 3  
        P=0.48 
 
        
        M= 3    
        P= 0.52 
 
        
       M= 3    
       P= 0.04* 
 
 
VEGF R-1 
 
         
        M= 2  
        P= 2.00 
 
         
        M= 2  
        P= 0.57 
 
        
      M= 2    
       P= 2.00 
 
       
      M= 2      
      P=2.00  
 
 
VEGFR-2 
 
         
        M= 4     
        P= 0.33 
 
        
       M=4 
       P= 0.33 
 
       
       M= 4   
       P=1.00  
       
     M=4 
      P= 0.78 
 
 
Table 17. Comparison for expression of staining intensity for fibroblast growth factor 
receptor 2 (FGF2R-2), vascular endothelial growth factor (VEGFR-1, and VEGFR 2)  
receptors  in placental tissues using the Mann-Whitney U test. PE-Pre-eclampsia, (n = 
12), PTL-Pre-term Labour, (n = 6), TNL-Term-non-Labour, (n = 21), and TL-term 
labour, (n = 22). Comparisons between each group versus all other groups combined. 
The medians and p values are shown.  
Table 17.  represents the comparison for expression of staining intensity for FGF2 R-
1, for pre-eclampsia (m = 3, p = 0.48); pre-term Labour (m = 3, p = 0.48), term-non-
Labour (m = 3, p = 0.52), and term labour (m = 3, p = 0.04*).VEGFR-1, for pre-
eclampsia (m = 2, p = 2.00 ), pre-term Labour (m = 2, p = 0.57 ), term-non-Labour (m 
= 2, p = 2.00), and term labour (m = 2, p = 2.00). VEGFR-2, for pre-eclampsia (m = 
4, p = 0.33), pre-term Labour (m = 4, p = 0.33), term-non-Labour (m = 4, p =1.00), 
and term labour (m = 4, p = 1.00) using the Mann-Whitney U test. 
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Growth factors 
      
                      Mann-Whitney U test 
Labour and non-labour 
P= value; median= value 
Term and Pre-term 
P= value; median= value 
 
FGF2 R-1 
 
     M=12      M=13.5 
              P= 0.53 
       M=12    M=12 
             P= 0.38 
 
VEGF R-1 
 
     M=10      M=10                       
             P=0.16  
 M=10    M=10                           
            P= 0.37 
 
VEGF R-2 
 
       M=15    M=15  
             P= 0.27 
       M=15    M=12 
            P=0.06 
 
Table 18. Comparison for expression of staining score for fibroblast growth factor 2 
receptor (FGF2R-1), vascular endothelial growth factor (VEGFR-1, and VEGFR 2) 
receptors present in placental tissues using the Mann-Whitney U test. PE-Pre-
eclampsia, (n = 12), PTL-Pre-term Labour, (n = 6), TNL-Term-non-Labour, (n = 21), 
and TL-term labour, (n = 22). Comparisons are labour (TL + PTL) versus non-labour 
(PE + TNL) and Term (TL + TNL) versus Pre-term (PE + PTL). The medians and p-
values are shown.  
Table18. represents the comparison for expression of staining score for FGF2 R-1, for 
labour (TL + PTL) versus non-labour (PE + TNL), (m = 12, m = 13.5, p = 0.53), term 
(TL + TNL) versus pre-term (PE + PTL), (m = 12, m = 12, p= 0.38).VEGFR-1, for 
labour (TL + PTL) versus non-labour (PE + TNL), (m = 10 , m = 10, p = 0.16), and  
term (TL + TNL) versus pre-term (PE + PTL), (m = 10, m = 10, p = 0.37).VEGFR-2, 
of labour (TL + PTL) versus non-labour (PE + TNL), (m = 15 , m =15 , p = 0.27), and 
term (TL + TNL) versus pre-term (PE + PTL), (m = 15 , m = 12 , p = 0.06) using the 
Mann-Whitney U test. 
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Growth Factor Receptor 
      
                      Mann-Whitney U test 
Labour and non-labour 
P= value; median= value 
Term and Pre-term 
P= value; median= value 
 
FGF2 R-1 
 
           M=3     M=3            
              P= 0.91 
         M=3   M=3                               
         P= 0.09 
 
VEGF R-1 
 
          M=2     M=2                                    
             P= 0.58 
M=2   M=2                               
            P= 0.41 
 
VEGF R-2 
 
          M=4   M=4                               
             P= 0.27 
M=4    M=4                               
            P=0.18 
 
Table 19. Comparison for expression of staining intensity for fibroblast growth factor 
2 receptor (FGF2R-1), vascular endothelial growth factor (VEGFR-1, and VEGFR 2)   
receptors present in placental tissues using the Mann-Whitney U test. PE-Pre-
eclampsia, (n = 12), PTL-Pre-term Labour, (n = 6), TNL-Term-non-Labour, (n = 21), 
and TL-term labour, (n = 22). Comparisons are labour (TL + PTL) versus non-labour 
(PE + TNL) and Term (TL + TNL) versus Pre-term (PE + PTL). The medians and p- 
values are shown.  
Table 19. represents the comparison for expression of staining intensity for FGF2R-1, 
for labour (TL + PTL) versus non-labour (PE + TNL), (m = 3, m = 3, p = 0.91), term 
(TL + TNL) versus pre-term (PE + PTL), (m = 3, m = 3, p = 0.09). VEGFR-1, for 
labour (TL + PTL) versus non-labour  (PE + TNL), (m = 2, m = 2, p = 0.58), term 
(TL + TNL) versus pre-term (PE + PTL), (m = 2, m = 2, p = 0.41). VEGFR-2, for 
labour (TL + PTL) versus non-labour (PE + TNL), (m = 4, m = 4, p = 0.27), term (TL 
+ TNL) versus pre-term (PE + PTL), (m = 4, m = 4, p = 0.18) using the Mann-
Whitney U test. 
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                  Growth factors receptor 
 
              Kruskal-Wallis test 
 
FGF2 R-1 
 
                      T =0.14  
                      P = 0.99 
 
VEGF R-1 
 
                      T = 1.07 
                      P = 0.78 
 
VEGF R-2 
 
                      T = 3.75 
                      P = 0.29 
 
Table 20. Comparison for expression of staining scoring results for fibroblast growth 
factor 2 receptor (FGF2R-1), vascular endothelial growth factor (VEGFR-1, and 
VEGFR 2) receptors present in placental tissues. Comparison here is between the four 
groups overall using the Kruskal Wallis analysis of variance. PE-Pre-eclampsia, (n = 
12), PTL-Pre-term Labour, (n = 6), TNL-Term-non-Labour, (n = 21), and TL-term 
labour, (n = 22). The t values and p values are shown.  
 
Table 20. represents the comparison for expression of staining scoring results for 
FGF2R-1, (t = 0.14, p= 0.99), VEGFR-1, for (t = 1.07, p= 0.78) and VEGFR-2, for 
(t= 3.75,  p= 0.29) using Kruskal Wallis analysis of variance test. 
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                  Growth factor receptors 
 
              Kruskal-Wallis test 
 
FGF2 R-1 
 
                      T = 0.94 
                      P = 0.82 
 
VEGF R-1 
 
                      T = 0.46 
                      P = 0.93 
 
VEGF R-2 
 
                      T = 3.42 
                      P = 0.33 
 
Table 21. Comparison for expression of staining intensity results for fibroblast growth 
factor 2 receptor (FGF2R-1), vascular endothelial growth factor (VEGFR-1, and 
VEGFR 2) receptors present in placental tissues. Comparison here is between the four 
groups overall using the Kruskal Wallis analysis of variance. PE-Pre-eclampsia, (n = 
12), PTL-Pre-term Labour, (n = 6), TNL-Term-non-Labour, (n = 21), and TL-term 
labour, (n = 22). The t values and p values are shown.  
Table 21. represents the comparison for expression of staining scoring results for 
FGF2R-1, of (t = 0.94, p = 82), VEGFR-1, of (t = 46, p = 93), and VEGFR-2, of (t = 
3.42, p = 0.33) using Kruskal Wallis analysis of variance test. 
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Correlation between growth factors receptors  
The Spearman rank correlation test was used to investigate relationship between the 
expression of the different VEGFR1, VEGFR2 and FGF2R2 because data was not 
normally distributed. FGF2R2 and VEGFR1 expression (Rho = 0.26, p = 0.13) and 
FGF2R2 and VEGFR2 (Rho = 0.14, p = 0.30) respectively showed a positive 
correlation between staining score as in table 23. There was a negative correlation 
between the staining score for VEGFR1 and VEGFR2 expression (Rho = 0.21, p = 
0.22).  
 
 
In addition there was a positive correlation between FGFR2 staining intensity and 
VEGFR2 (Rho = 0.08, p = 0.38) expression and for VEGFR1 and VEGFR2 
expression (Rho = 0.43, p = 0.07) respectively as shown in table 23. FGFR2 and 
VEGFR1 (Rho = -0.38, p = 0.05) expression showed a negative correlation between 
staining intensity. There was no significant correlation of the coefficient between 
staining intensity for VEGFR1, VEGFR2 and FGF2R2 expression. 
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Growth Factor 
Receptors 
 
 
    
Spearman’s rank correlation coefficient Rho and p-values 
        
 
  FGF2R-1                       VEGFR=1               VEGFR=2 
    FGF2R-1 
 
      
 Rho =0.26 
    
Rho = 0.14 
   VEGFR=1 
 
      
     P= 0.13 
 
   
 Rho = 0.21  
   VEGFR=2 
 
      
     P= 0.30 
    
       
    P= 0.22  
 
 
 
Table 22. Correlation between expression of staining score for fibroblast growth 
factor 2 receptor (FGF2R-1), vascular endothelial growth factor (VEGFR-1 and 
VEGFR-2) receptors in placental tissues. PE-Pre-eclampsia, (n = 12), PTL-Pre-term 
Labour, (n = 6), TNL-Term-non-Labour, (n = 21), and TL-term labour, (n = 22). 
Using the Spearman’s rank correlation test. The Rho represents Spearman’s rank 
correlation coefficient.   
 
Table 22. represents the correlation between for expression of staining score for FGF2 
R-1 and VEGFR-1, of (Rho = 0.26, p = 0.13), FGF2R-1 and VEGFR-2 of (Rho = 
0.14, p = 0.30), and VEGFR-1 and VEGFR-2, for (Rho = 0.21, p = 0.22) using the 
Spearman’s rank correlation test. 
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Growth factors 
Receptors 
 
 
 
Spearman’s rank correlation coefficient Rho and p-values 
          
 
         FGF2                       VEGFR=1               VEGFR=2 
    FGF2 R-1 
 
      
 Rho =-0.38 
    
Rho =  0.08 
   VEGFR=1 
 
      
     P=0.05   
 
   
 Rho = 0.43  
   VEGFR=2 
 
      
     P= 0.38  
    
       
    P= 0.07  
 
 
 
Table 23. Correlation between expressions of staining intensity for fibroblast growth 
factor 2 (FGF2), vascular endothelial growth factor (VEGFR-1 and VEGFR-2) 
receptors present in placental tissues. PE-Pre-eclampsia, (n = 12), PTL-Pre-term 
Labour, (n = 6), TNL-Term-non-Labour, (n = 21), and TL-term labour, (n = 22).  
Using the Spearman’s rank correlation test. The Rho represents Spearman’s rank 
correlation coefficient.   
Table 23. represents the correlation between for expression of staining intensity for 
FGF2R-1 and VEGFR-1, of (Rho = -0.38, p = 0.05), FGF2R-1 and VEGFR-2 of (Rho 
= 0.08, p = 0.38), and VEGFR-1 and VEGFR-2, of (Rho = 0.43, p = 0.07) using the 
Spearman’s rank correlation test. 
	
	
	
  Farha Nazir Ahmad M00201045                                                            183 
	
	
 
 
 
 
 
 
 
Chapter 4 
Invasion 
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4.1. Cell Invasion Assay: standard curve calibration. 
 
Cell invasion and migration are important events in placental development. An in 
vitro model, applying Matrigel is representative of in vivo invasion. This cell invasion 
assay study showed that invasive cells can penetrate a barrier consisting of basement 
membrane components in response to chemoattractant. Invasion and migration is 
fundamental for functions in cellular processes such as angiogenesis, embryonic 
development, immune response, metastasis and invasion of cancer cells. This second 
technique, I succeeded in performing the experiment for standard curve calibration in 
a 96-wells invasion assay. These results used different cell types such as the Human 
fibrosarcoma HT1080 invasive cells (positive control), and human villous trophoblast 
cell-line TCL-1 were reproduced in 4 further experiments. Cell invasion was detected 
and was quantified using Calcein-acetomethylester (AM). This Calcein-AM moiety 
generated free calcein. Internalized by the cells and intracellular esterases cleaved the 
acetomethylester. It’s the free calcein that fluoresces brightly. Its from this fluoresces 
that quantitate these number of cells that have migrated and invaded using standard 
curve. The fluorescence of each well was read on Fluorometer in a fluorescence plate 
reader with a 492nm excitation, and 520nm emission settings. The fluorescence 
measurement was performed at relative fluorescence units (RFU) of 1000 gain and 
2000 gain that were converted to number of cells as shown in Figure 35A and B. A 
standard curve was plotted and the derived equation used to convert fluorescence to 
cell number.  
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Invasion studies Protocol A 
 
Figure 35A. Represents the % of assumed invasion for the following cell line human 
trophoblast TCL-1 with the relative fluorescent unit (RFU) at 1000 gain. 
 
Figure 35B. Represents the % of assumed invasion for the following cell line human 
trophoblast TCL-1 with the relative fluorescent unit (RFU) at 2000 gain.  
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4.2. Invasion and Migration studies.  
 
The role of these heparin-binding growth factors on trophoblast invasion was 
determined using in vitro studies on immortalized cultured human villous trophoblast 
cell-line TCL-1. I performed the villous trophoblast invasion and migration assay 
with all the cells raised and developed cell culture for Human fibrosarcoma HT1080 
invasive cells (positive control) and NIH 3T3 mouse embryonic fibroblast non-
invasive cells (negative control). The cell invasion assay using BD Falcon    
FluoroBlok were the upper surface of the insert membrane is coated with a uniform 
layer of dried basement membrane matrix solution. The basement membrane layer 
serves as a barrier for invasive cells from non-invasive cells. Invasive cells are able to 
degrade the matrix protein in the layer, and pass through pores of the polycarbonate 
membrane. However, the migration assay principle is different because it has the 
uncoated membrane that serves as a barrier for migratory cells from non-migratory 
cells. Migratory cells are able to extend protrusions towards chemoattractants and 
pass through pores of the polycarbonate membrane. Finally, cells are removed from 
the top of the membrane and the invaded and migratory cells are stained and 
quantified. Detection of cell invasion is quantified using Calcein AM. Using this 
invasion assay the validated controls are shown in Figure 36, which represents the 
percentage of invasion of cells for HT1080 (83.2% ± 1.28, p <0.05), NIH 3T3 (27.8% 
± 2.64, p <0.05) and invasive cell-line TCL-1 (61.6% ± 1.25 p <0.05). Both the 
3T3/NIH and TCL-1 were significantly different from those for HT1080 (p<0.05 
versus HT1080 and 3T3.    
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Figure 36. Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 (+ve control) of (n = 3, 83.2% ± 1.28%, p<0.05), 
3T3/NIH (-ve control) (n = 3, 27.8% ± 2.64%, p<0.05), and human trophoblast TCL-
1 cell line at (n = 3, 61.6% ± 1.25%, p<0.05) 0nmol/l (*p <0.05 vs. HT1080 and 
3T3/NIH, Mann-Whitney U test). 
 
 
The invasion  assay in Figure 36. for the following cell lines HT 1080 (+ve control) of 
(n=3, 83.2% ±1.28%, p<0.05), 3T3/NIH (-ve control) (n=3, 27.8% ± 2.64%, p<0.05), 
and human trophoblast TCL-1 cell line at (n=3, 61.6% ± 1.25%, p<0.05) 0nmol/l (*p 
<0.05 vs. HT1080 and 3T3/NIH, Mann-Whitney U test). 
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Figure 37. Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 (+ve control) of (n = 3,	57.6% ± 10.8%, p<0.05) 1000 
gain, (n = 3,	59.7% ± 11.1%, p<0.05) 1500 gain, (n = 3,	65.5% ± 12.3%, p<0.05) 
2000 gain 3T3/NIH (-ve control) (n = 3,	21.9% ± 5.1%, p<0.05) 1000 gain, (n = 3,	
22.5% ±5.2%, p<0.05) 1500 gain, (n = 3,	25.2% ± 5.8%, p<0.05) 2000 gain and 
human trophoblast TCL-1 cell line in DMEM at (n = 3, 21.5% ± 5.0%, p<0.05) 1000 
gain, (n = 3, 22.0% ± 5.1% , p<0.05) 1500 gain, (n = 3, 24.6% ± 5.7% , p<0.05) 2000 
gain. The TCL-1 cell line in RPMI at  (n = 3, 22.9% ± 5.2%, p<0.05) 1000 gain, (n = 
3, 23.2% ± 5.3%, p<0.05) 1500 gain,   (n = 3, 25.9% ± 5.9%, p<0.05) 2000 gain (*p 
<0.05 vs. HT1080 and 3T3/NIH, Mann-Whitney U test) at 1000,1500 and 2000 gains. 
The invasion assay in Figure 37. represents the percentage of invasion presented as 
mean ± SEM for the following HT 1080 (+ve control) of (n = 3,	57.6% ± 10.8%, 
p<0.05) 1000 gain, (n = 3,	59.7% ± 11.1%, p<0.05) 1500 gain, (n = 3,	65.5% ± 
12.3%, p<0.05) 2000 gain 3T3/NIH (-ve control) (n=3,	21.9% ± 5.1%, p<0.05) 1000 
gain, (n = 3,	22.5% ± 5.2%, p<0.05) 1500 gain, (n = 3,	25.2% ± 5.8%, p<0.05) 2000 
gain and human trophoblast TCL-1 cell line  in DMEM at (n = 3, 21.5% ± 5.0%, 
p<0.05)1000 gain, (n = 3, 22.0% ± 5.1% , p<0.05) 1500 gain, (n = 3, 24.6% ± 5.7% , 
p<0.05) 2000 gain. The TCL-1 cell line in RPMI at  (n = 3, 22.9% ± 5.2%, p<0.05) 
1000 gain, (n = 3, 23.2% ± 5.3%, p<0.05)  1500 gain,  (n = 3, 25.9% ± 5.9%, p<0.05) 
2000 gain (*p <0.05 vs. HT1080 and 3T3/NIH, Mann-Whitney U test) at 1000,1500 
and 2000 gains. 
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Figure 38. Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 (+ve control) of (n = 3, 100% ± 20.1%, p<0.05), 
3T3/NIH (-ve control) (n = 3, 36.5% ± 7.5%, p<0.05), and human trophoblast TCL-1 
cell line with the presence of heparin binding-epidermal growth factor (HB-EGF) 
expression at (n = 3, 28.5% ± 2.3%, p<0.05) 0nmol/l, (n = 3, 28.7% ± 1.5%, p<0.05) 
1nmol/l, (n = 3, 30.2% ± 3.0%, p<0.05) 10nmol/l and (n = 3, 29.9% ± 2.4%, p<0.05) 
100nmol/l. (*p <0.05 vs. HT1080 and 3T3, Mann-Whitney U test). 
The invasion assay  in Figure 38. for the following cell lines HT 1080 (+ve control) of 
(n = 3, 100% ± 20.1%, p<0.05), 3T3/NIH (-ve control) (n = 3, 36.5% ± 7.5%, 
p<0.05), and human trophoblast TCL-1 cell line with the presence of heparin binding-
epidermal growth factor (HB-EGF) expression at (n = 3, 28.5% ± 2.3%, p<0.05) 
0nmol/l, (n = 3, 28.7% ± 1.5%, p<0.05) 1nmol/l, (n = 3, 30.2% ± 3.0%, p<0.05) 
10nmol/l and (n = 3, 29.9% ± 2.4%, p<0.05) 100nmol/l. (*p <0.05 vs. HT1080 and 
3T3, Mann-Whitney U test). RPMI media was preferred for TCL-1 cell line at 1500 
gain to represent the percentage of invasion. 
An in vitro model has been developed to investigate the effect of heparin and HBGFs 
on placental trophoblast invasion. I performed the villous trophoblast invasion assay 
and selected HB-EGF, VEGF, PLGF, FGF2, PDGF, HGF, MK and PTN for this 
study using BD FluoroBlok that has a uniform coated layer with Matrigel Matrix.  
The percentage of trophoblast invasion for TCL-1 in the presence of HB-EGF, VEGF, 
PLGF, FGF2, PDGF, HGF, MK and PTN at the concentrations 0,1, 10,100nmol/L 
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was investigated. MK and PTN role has never been examined in trophoblast invasion 
during placental development. Profiles are shown in the Figures 37A, 38B, 39C, 40D, 
41E, 42F, 43G and 44H giving the percentage of trophoblast invasion for TCL-1 in 
the presence of HB-EGF, VEGF, PLGF, FGF2, PDGF, HGF, MK and PTN at the 
concentrations 0,1,10, and 100nmol/L are shown. To compare 0 versus growth factor 
and 0 heparin the Mann-Whitney U test was used. This study suggests a role for some 
of the growth factors expressed in placenta on migration and invasion.  
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Figure 39A. Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 of (n = 3,	60.95% ± 15.70%; and 76.9% ± 6.26%, 
p<0.05), and TCL-1 with the presence of heparin-binding epidermal growth factor 
(HB-EGF) expression at (n = 3, 46.43% ± 4.40%, p<0.05) 0nmol/l, (n = 3, 
51.794.39%, p<0.05) 1nmol/l, (n = 3, 53.06% ± 2.58% p<0.05) 10nmol/l and (n = 3, 
54.28% ± 2.26%, p<0.05) 100nmol/l. In the presence of heparin at (n=3, 55.72% ± 
6.38%, p<0.05) 0ng/ml, (n = 3, 68.06% ± 4.45%, p<0.05) 1ng/ml, (n = 3, 76.51% ± 
6.80%, p<0.05) 10ng/ml, and (n = 3, 79.30% ± 6.84%, p<0.05) 100ng/ml. (* p <0.05 
vs. 0 growth factor, Mann-Whitney U test; † p <0.05 vs. 0 heparin). 
14.3.2.2. Figure 39A. presents the increase in trophoblast invasion in the presence of 
HT1080 (60.95% ± 15.70, m = 57.25, p <0.05), and HB-EGF was significantly higher 
than in cells with no heparin  (46.43% ± 4.40, m = 42.8, p <0.05), (51.79% ± 4.39, 
m= 55.0, p<0.05), (53.06% ± 2.58, m = 42.8, p<0.05), (54.28% ± 2.26, m = 52.5, 
p<0.05) at concentrations of 0,1, 10, 100nmol/L, respectively. The effect of 
trophoblast invasion in the presence of HB-EGF with no heparin produced a small 
increase but was significant with increasing concentrations. In the presence of heparin 
at concentrations of 0,1,10, and100ng/ml the values were again higher. The 
differences in HB-EGF stimulated invasion with heparin were significant for the 
concentrations 0, 1, 10, and 100nmol/L (55.723 % ± 6.38, m = 55.5, p<0.05), 
(68.06% ± 4.45, m = 65.7, p<0.05), (76.51% ± 6.80, m = 72.2, p<0.05), (79.30% ± 
6.84, m = 66.1, p<0.05), and HT1080 (76.9% ± 6.26, m = 82.6, p<0.05) respectively. 
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There was a small increase with increasing dose of HB-EGF, which was enhanced by 
heparin. The medians were increased in absence and presence of heparin. 
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Figure 40B. Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 of (n = 3,	10.46% ± 18.68;	 and 11.48% ± 19.56%, 
p<0.05), and TCL-1 with the presence of vascular endothelial growth factor (VEGF) 
expression at (n = 3, 13.38% ± 0.39%, p<0.05) 0nmol/l, (n = 3, 14.10% ± 0.99%, 
p<0.05) 1nmol/l, (n = 3, 14.56% ± 1.69%, p<0.05) 10nmol/l and (n = 3, 15.70% ± 
2.20%, p<0.05) 100nmol/l. In the presence of heparin at (n = 3, 14.60% ± 1.03%, 
p<0.05) 0ng/ml, (n = 3, 15.73% ± 1.55%, p<0.05) 1ng/ml, (n = 3, 16.73% ± 2.18%, 
p<0.05) 10ng/ml, and (n = 3, 16.85% ± 1.67%, p<0.05) 100ng/ml. (*p <0.05 vs. 0 
growth factor, Mann-Whitney U test; †p <0.05 vs. 0 heparin). 
14.3.2.3. In  Figure 40B. presents the effect of trophoblast invasion in the presence of 
HT1080 (10.46% ± 18.68, m = 10.53,p <0.05), and VEGF was significantly higher 
than in cells with no heparin  (13.38% ± 0.39, m = 11.32, p <0.05),  (14.10% ± 0.99, 
m = 12.74, p<0.05), (14.56% ± 1.69, m =12.95, p<0.05), (15.70% ± 2.20, m = 14.24, 
p<0.05) for concentrations 0, 1, 10, 100nmol/L, respectively. The increase in 
trophoblast invasion in the presence of VEGF at increasing concentrations was small. 
VEGF stimulated a trophoblast invasion in the presence of heparin at concentrations 
of 0,1,10, and 100ng/ml their values were again higher. The differences in VEGF 
stimulated invasion with heparin were significant (14.60% ± 1.03, m = 11.32, 
p<0.05), (15.73% ± 1.55, m = 11.88, p<0.05), (16.73% ± 2.18, m = 11.96, p<0.05), 
(16.85% ± 1.67, m = 12.03, p<0.05) for the concentrations 0, 1, 10, and 100nmol/L, 
HT1080 (11.48% ± 19.56, m = 10.28, p<0.05) respectively. VEGF response was 
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greater in presence of heparin. The medians were increased in absence and presence 
of heparin.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Farha Nazir Ahmad M00201045                                                            195 
	
Figure 41C. Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 of (n = 3, 24.7% ± 2.08%,	 and 29.17% ± 1.56%, 
p<0.05), and TCL-1 with the presence of fibroblast growth factor 2 (FGF2) 
expression at (n = 3, 9.69% ± 1.54%, p<0.05) 0nmol/l, (n = 3, 12.28% ± 1.65%, 
p<0.05) 1nmol/l, (n = 3, 12.41% ± 0.58%, p<0.05) 10nmol/l and (n = 3, 13.47% ± 
0.98%, p<0.05) 100nmol/l. In the presence of heparin at (n = 3, 15.87% ± 1.05%, 
p<0.05) 0ng/ml, (n = 3, 15.88% ± 0.91%, p<0.05) 1ng/ml, (n = 3, 18.22% ± 2.15%, 
p<0.05) 10ng/ml, and (n = 3, 20.24% ± 3.63%, p<0.05) 100ng/ml. (*p <0.05 vs. 0 
growth factor, Mann-Whitney U test; † p <0.05 vs. 0 heparin). 
14.3.2.3. Figure 41C. presents the effect in trophoblast invasion in the presence of for 
HT1080 (24.7% ± 2.08, m = 24.6, p <0.05), FGF2 was significantly higher than in 
cells with no heparin (9.69% ± 1.54, m = 7.84, p =0.05), (12.28% ± 1.65, m = 11.80, 
p<0.05), (12.41%  ± 0.58, m = 12.09,p<0.05), and (13.47% ± 0.98, m = 12.28, 
p<0.05) at concentrations of 0, 1, 10, 100nmol/L, was small respectively. FGF2 
stimulated trophoblast invasion in the presence of heparin at increasing concentrations 
of 0,1,10, and 100ng/ml produced values that were again higher. The differences in 
FGF2 stimulated invasion with heparin were significant (15.87% ± 1.05, m = 13.40, p 
<0.05), (15.88% ± 0.91, m = 17.98, p <0.05), (18.22% ± 2.15, m = 25.79, p <0.05), 
and (20.24  % ± 3.63, m = 27.71, p <0.05) for the concentrations 0, 1, 10, and 
100nmol/L, HT1080 of (29.17% ± 1.56, m = 29.17, p <0.05) respectively. Thus, the 
FGF2 response was enhanced following co-incubation in the presence of heparin. The 
medians were increased in absence and presence of heparin. 
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Figure 42D. Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 of (n = 3, 17. 84% ± 2.88%,	and 20.16% ± 9.87%, 
p<0.05), and TCL-1 with the presence of placental growth factor (PLGF) expression 
at (n = 3, 15.02% ± 2.70%, p<0.05) 0nmol/l, (n = 3, 20.18% ± 2.88%, p<0.05) 
1nmol/l, (n = 3, 23.88% ± 7.19%, p<0.05) 10nmol/l and (n = 3, 26.72% ± 10.18%, 
p<0.05) 100nmol/l. In the presence of heparin at (n = 3, 22.33% ± 4.03%, p<0.05) 
0ng/ml, (n = 3, 23.89% ± 6.51%, p<0.05) 1ng/ml, (n = 3, 26.64% ± 7.80%, p<0.05) 
10ng/ml, and (n = 3, 28.30% ± 8.82%, p<0.05) 100ng/ml (*p <0.05 vs. 0 growth 
factor, Mann-Whitney U test; † p <0.05 vs. 0 heparin). 
14.3.2.4. Figure 42D. presents the effect of trophoblast invasion in the presence of 
HT1080 (17. 84% ± 2.88,m=8.00,p <0.05), for PLGF was significantly higher than in 
cells with no heparin  (15.02  % ± 2.70, m = 21.36, p<0.05), (20.18% ± 2.88, m = 
35.52, p<0.05), (23.88 % ± 7.19, m = 51.10, p<0.05), and (26.72 % ± 10.18, m 
=54.71, p<0.05) at concentrations of 0, 1, 10, 100nmol/L, respectively. The increase 
in trophoblast invasion was stimulated in the presence of PLGF were small for 
increasing concentrations. PLGF stimulated trophoblast invasion in the presence of 
heparin at concentrations of 0,1,10, and 100ng/ml the values were again higher but 
showed small increases. The differences in PLGF stimulated invasion with heparin 
were significant (22.33 % ± 4.03, m = 13.08, p<0.05), (23.89 % ± 6.51, m = 37.85, 
p<0.05), (26.64 % ± 7.80, m = 44.16,p <0.05), and (28.30% ± 8.82%, m = 46.73, 
p<0.05), at increasing concentrations of 0, 1, 10, and 100nmol/L and HT1080 of 
(20.16% ± 9.87, m = 24.44, p<0.05) respectively. There was a small change with 
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increasing dose of PLGF, which showed very little effect by heparin. The medians 
were increased in absence and presence of heparin. 
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Figure 43E.Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 of (n = 3, 54.99% ± 3.65%,	 and 72.68% ± 5.22%, 
p<0.05), and TCL-1 with the presence of platelet-derived growth factor (PDGF) 
expression at (n = 3, 27.31% ± 4.50%, p<0.05) 0nmol/l, (n = 3, 28.18% ± 6.91%, 
p<0.05) 1nmol/l, (n = 3, 40.22% ± 18.74%, p<0.05) 10nmol/l and (n = 3, 83.51% ± 
3.80%, p<0.05) 100nmol/l. In the presence of heparin at (n = 3, 42.03% ± 6.79%, 
p<0.05) 0ng/ml, (n = 3, 43.87% ± 6.91%, p<0.05) 1ng/ml, (n = 3, 71.50% ± 18.74%, 
p<0.05) 10ng/ml, and (n = 3, 92.1% ± 8.85%, p<0.05) 100ng/ml (*p <0.05 vs. 0 
growth factor, Mann-Whitney U test; † p <0.05 vs. 0 heparin). 
 
14.3.2.5. Figure 43E. presents the effect of trophoblast invasion was stimulated in the 
presence of HT1080 (54.28% ±5.58, m=7.66, p <0.05), and PDGF, was presented in 
Figure 36E, was significantly higher than in cells with no heparin  (27.31% ± 4.50, m 
= 27.98, p<0.05), (28.18% ± 6.91, m = 28.93, p<0.05), (40.22% ± 18.74, m = 41.07, 
p<0.05), and (83.51% ± 3.80, m = 93.49, p<0.05) at concentrations of 0, 1, 10, 
100nmol/L, respectively. PDGF stimulated trophoblast invasion with a slight change 
in the presence of heparin for lower concentrations, but its values were pronounced 
and were significantly higher for the concentrations. In the presence of heparin at 
0,1,10, and 100ng/ml the values were higher. The differences in PDGF stimulated 
invasion with heparin were significant (42.03% ± 6.79, m = 36.62, p<0.05), (43.87% 
± 6.91, m = 37.31, p<0.05), (71.50% ± 18.74, m = 56.81, p<0.05), and (92.1% ± 8.85, 
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m=  88.80, p <0.05) at concentrations of 0, 1, 10, and 100nmol/L, HT1080 (72.68% ± 
5.22, m = 5.93, p <0.05), respectively. Thus, PDGF response was enhanced with 
following co-incubation in the presence of heparin only for higher doses. The medians 
were increased in absence and presence of heparin. 
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Figure 44F. Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 of (n = 3,	11.92% ± 0.58%,	12.01% ± 0.133% and, 
p<0.05), and TCL-1 with the presence of hepatocyte growth factor (HGF) expression 
at (n = 3, 11.94% ± 0.61%, p<0.05) 0nmol/l, (n = 3, 11.94% ± 0.055%, p<0.05) 
1nmol/l, (n = 3, 12.37% ± 0.10%, p<0.05) 10nmol/l and (n = 3, 12.43% ± 0.20%, 
p<0.05) 100nmol/l. In the presence of heparin at (n = 3, 12.28%±0.15%, p<0.05) 
0ng/ml, (n = 3, 12.37% ± 0.18%, p<0.05) 1ng/ml, (n = 3, 12.46% ± 0.02%, p<0.05) 
10ng/ml, and (n = 3, 12.52% ± 0.14%, p<0.05) 100ng/ml. (*p <0.05 vs. 0 growth 
factor, Mann-Whitney U test; † p <0.05 vs. 0 heparin). 
14.3.2.6. Figure 44F presents the effect of trophoblast invasion in the presence of 
HT1080 (11.92% ±0.58, m = 11.01, p <0.05), and HGF was significantly higher than 
in cells with no heparin  (11.94% ± 0.61, m = 11.91, p<0.05), (11.94% ± 0.055, m = 
11.93, p<0.05), (12.37% ± 0.10, m = 12.46, p<0.05), and  (12.43% ± 0.20, m = 12.53, 
p<0.05) at concentrations of 0, 1, 10, 100nmol/L, respectively. The trophoblast 
invasion was stimulated in the presence of HGF showed a significant dose dependent 
rise with increasing concentrations. In the presence of heparin at 0,1,10, and 100ng/ml 
there values were again higher. The differences in HGF stimulated invasion with 
heparin were significant (12.28% ± 0.15, m = 12.58, p<0.05), (12.37% ± 0.18, m = 
12.35, p<0.05), (12.46% ± 0.02, m = 12.46, p<0.05), (12.52% ± 0.14, m = 12.58, 
p<0.05) at concentrations of 0, 1, 10, and 100nmol/L, and HT1080 (12.01% ± 0.133, 
m = 12.45, p <0.05) respectively. Trophoblast invasion in the presence of HGF with 
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heparin presented small changes for increasing concentrations. The effect of heparin 
was only observed at higher concentrations. Thus, heparin modifies the HGF 
response. The medians were increased in the absence and presence of heparin. 
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Figure 45G. Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 of (n = 3, 42.38% ± 1.54%, and	46.27% ± 4.97%, 
p<0.05), and TCL-1 with the presence of Midkine (MK) expression at (n = 3, 44.16% 
± 5.80%, p<0.05) 0nmol/l, (n = 3, 45.11% ± 4.09%, p<0.05) 1nmol/l, (n = 3, 46.23% 
± 4.95%, p<0.05) 10nmol/l and (n = 3, 46.30% ± 5.57%, p<0.05) 100nmol/l. In the 
presence of heparin at (n = 3, 50.69%± 1.84%, p<0.05) 0ng/ml, (n = 3, 51.63% ± 
2.58%, p<0.05) 1ng/ml, (n = 3, 66.58% ± 5.72%, p<0.05) 10ng/ml, and (n = 3, 
68.82% ± 5.11%, p<0.05) 100ng/ml. (*p <0.05 vs. 0 growth factor, Mann-Whitney U 
test; † p <0.05 vs. 0 heparin). 
14.3.2.7. Figure 45G presents the effect of trophoblast invasion of HT1080 (42.38    
%±1.54,m=10.71,p <0.05), and were similar to the control for increasing 
concentrations of MK at 0,1,10, and 100nmol/L (44.16% ± 5.80, m = 40.17, p<0.05 ), 
(45.11% ± 4.09, m = 41.49, p<0.05 ), (46.23% ± 4.95, m = 42.82, p<0.05), and 
(46.30% ± 5.57, m = 46.05, p <0.05) with no heparin. MK stimulated trophoblast 
invasion in the presence of heparin and showed similar values for the lower 
concentrations, but were significant for the higher concentrations. The values were the 
same in the presence of heparin for 0 and 1mmol/L (50.69% ± 1.84, m = 53.40, p 
<0.05), (51.63% ±2.58, m = 53.42, p<0.05 ), HT1080 (46.27% ± 4.97, m = 11.83, 
p<0.05), but were significantly higher for the concentrations 10, and 100nmol/L 
(66.58% ± 5.72, m = 40.17, p<0.05), and (68.82% ± 5.11, m = 41.49, p<0.05). 
Therefore, MK effect was strikingly augmented as the largest dose response was 
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enhanced following co-incubation with higher doses of heparin. The medians were 
increased in absence and presence of heparin. 
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Figure 46H. Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 of (n = 3, 45.67%	 ± 2.88%, and	 45.96%	 ± 9.87%, 
p<0.05), and TCL-1 with the presence of Pleoitrophin (PTN) expression at (n = 3, 
75.65%	± 12.83%, p<0.05) 0nmol/l, (n = 3, 78.09% ± 3.03%, p<0.05) 1nmol/l, (n = 3, 
85.94% ± 8.02%, p<0.05) 10nmol/l and (n = 3, 99.84%	± 6.35%, p<0.05) 100nmol/l. 
In the presence of heparin at (n = 3, 81.38% ±13.39%, p<0.05) 0ng/ml, (n = 3, 83.25%	
± 6.73%, p<0.05) 1ng/ml, (n = 3, 87.94%	± 9.76%, p<0.05) 10ng/ml, and (n = 3, 
101.09%	± 20.78%, p<0.05) 100ng/ml. (*p <0.05 vs. 0 growth factor, Mann-Whitney 
U test; †p <0.05 vs. 0 heparin).  
14.3.2.8. Figure 46H presents the effect of trophoblast invasion in the presence of 
HT1080 (45.67% ± 2.88, m = 41.7, p<0.05), and PTN was significantly higher 
compared to cells with no heparin (75.65% ±12.83, m = 63.0, p<0.05), (78.09 % ± 
3.03, m = 69.5, p<0.05), (85.94% ± 8.02, m=77.5, p<0.05) and (99.84% ± 6.35, m = 
98.7, p<0.05) at concentrations of 0,1,10, and 100nmol/L respectively. The effect of 
trophoblast invasion was stimulated in the presence of HBGFs with no heparin 
HT1080 (45.96% ± 9.87, m = 49.2, p<0.05), demonstrated that increasing 
concentrations of PTN produced a small increase. In the presence of heparin at 
0ng/ml, (81.38% ± 13.39, m = 96.6, p<0.05) 1ng/ml, (83.25% ± 6.73, m = 77.5, 
p<0.05) 10ng/ml, (87.94% ± 9.76, m = 88.4, p<0.05 ) and 100ng/ml (101.09% ± 
20.78, m = 96.6, p <0.05) there was a further increase. PTN stimulated trophoblast 
invasion in the presence of heparin and showed a further significant increase for 
increasing concentrations. There was no significant difference between untreated and 
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heparin treated cells for each dose of PTN. The medians were increased in absence 
and presence of heparin. 
 
Thus, HBGFs yielding the greatest change and those that showed the greatest 
response to the presence of heparin were FGF2, PDGF, HGF, and MK. However, 
little is known about MK and PTN expression and their roles in the human placenta. 
The present results which are the first of the actions of MK and PTN show different 
effects of heparin. Namely large increases were observed at the higher dose for MK, 
but little effect was seen on the PTN response. HBGFs caused  villous trophoblast 
cells to invade, but only in the presence of heparin. This demonstrates that the in vitro 
trophoblast invasion model provides a useful method to determine the effects of 
heparin and these HBGFs on placental function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Farha Nazir Ahmad M00201045                                                            206 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
Expression 
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5.1. Quantify mRNA expression of HBGFs using real time polymerase chain reaction 
(RT-PCR). 
 
Since immunohistochemistry can only give semiquantitative information, this study 
was extended to quantify mRNA expression with HBGFs using RT-PCR. The 
progress of the reaction is monitored in “real-time”. I performed the stabilisation of 
RNA later reagent, in protocol 1 and extraction and purification in protocol 2 with 
homogenization of the total RNA production  from tissues-RNAeasy RNA mini 
purification, in human placentae samples (n=7) from placental normal development 
and  in pre-eclampsia in this first study. The quantification of RNA, concentration and 
purity (A260/280nm ratio) was determined in a spectrophotometer. The amount of 
total quatitative RNA was evaluated by measuring its integrity  and stability using 
Agilent 2100 bioanalyzer. Reverse-transcription with elimination of genomic DNA 
for quantitative RT-PCR  procedure in protocol 3 for cDNA synthesis. The RNA was 
converted to cDNA by quatification of mRNA expression with HBGFs using Real 
Time-Polymerase Chain Reaction (RT-PCR). Its amplification were monitered during 
two-step RT-PCR cycling  and relative expression of RNA per sample were quatified 
by Quantitect SYBER Green rPCR as in protocol 4. The PLGF, FGF2, MK, and PTN 
were selected because they showed significant alterations of placental expression in 
pre-eclampsia. I performed mRNA extraction from 7 placental tissue samples at a 
concentration of 100ng/ul that were used for the following primer assays: PLGF, 
FGF2, MK, PTN, and Succinate dehydrogenase complex subunit A (SDHA) an 
endogenous control, a housekeeping gene for standardization between tissue samples 
in Table 26 and 27. The results of specificity of PCR products were observed by RNA 
agarose gel electrophoresis and gel electrophoresis representation analysis on 
Multina.   
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Group 
 
Maternal age 
(Years) 
 
Gestational age at 
delivery (weeks) 
 
Birth weight (g) 
 
PE 
 
30 (16-39) 
 
34 (24-41) 
 
3025 (1960-3430) 
 
PTL 
 
28 (18-37) 
 
31(28-35) 
 
2865 (1860-2350) 
 
TL 
 
27 (16-38) 
 
39 (37-42) 
 
3415 (2250-5026) 
                 
TNL    
 
28 (17-38) 
 
39 (37-41) * 
 
3250 (2100-3936) 
 
Table 25. The clinical characteristics of pregnancies are represented for this cohort 
study of 87 women. The values are expressed as mean ± IQR (interquartile range). 
PE-Pre-eclampsia, PTL-Pre-term Labour, TNL-Term-non-Labour,* and TL-term 
labour.  
The clinical characteristics of pregnancies are represented for this cohort study of 87 
women represented in Table 25. There was no significance at maternal age and 
gestational delivery when occurred. However, the BMI and placental weight were not 
available for this study. 
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Labour: 
The birth weight in pre-eclampsia  women reflected the early delivery. For, maternal 
age 30 (interquartile range 16-39) years, gestational age at delivery of 34 
(interquartile range 24-41) weeks, the birth weight was of 3025 (interquartile range 
1960-3430)g.  
Pre-term Labour (PTL) women at birth weight delivered infants. For, maternal age 28 
(interquartile range 18-37) years, gestational age at delivery of 31  (interquartile range 
28-35) weeks, the birth weight was of 2865 (interquartile range 1860-2350)g. 
 
Non-Labour: 
Non-labour group (TL) women delivered infants at birth weight. For, maternal age 27 
(interquartile range 16-38) years, gestational age at delivery of 39  (interquartile range 
37-42) weeks, the birth weight was of 3415  (interquartile range 2250-5026)g. 
Term-non-labour (TNL) women at birth weight delivered infants but term-non-labour 
TNL women underwent  Caesarean section as gestational delivery occurred. For, 
maternal age 28 (interquartile range 17-38) years, gestational age at delivery of 39 
(interquartile range 37-41)* weeks, the birth weight was of 3250  (interquartile range 
2100-3936)g. 
The present results of this study cohort of 87 women showed that there was no 
significance at maternal age and gestational delivery when occurred. The labour 
group results showed that the birth weight in pre-eclampsia  women reflected the 
early delivery. The Pre-term Labour (PTL) women at birth weight delivered infants. 
The non-labour group results for (TL) women delivered infants at birth weight, but 
term-non-labour (TNL) women underwent Caesarean section as gestational delivery 
occurred. The TNL women delivered infants at birth weight. 
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Sample  
Number of 
7 different 
placental 
tissues 
 
 
                                     Concentration (ng/ul) 
 
 
 
Placental 
Growth 
factor 
 
 
Fibroblast 
Growth 
factor 2 
 
 
 
Pleiotrophin 
 
 
 
Midkine 
 
 
 
Succinate 
dehydrogenase 
complex 
subunit A  
  1.    PE    4.52 
 
   26.58 
 
     4.09 
 
     2.42 
 
    7.26 
 
     2. PE    5.55 
 
   27.05 
 
     2.97 
 
     6.01 
 
    5.13 
 
  3.Control*   12.38 
 
   29.73 
 
   10.38 
 
    3.03 
 
   20.71 
 
    4.  PE    6.91 
 
   30.23 
 
    8.52 
 
    2.37 
 
    0.42 
 
   5.Control    5.89 
 
   25.12 
 
    8.65 
 
    3.13 
 
    8.84 
 
  6. Control    5.84 
 
   24.76 
 
    6.46 
 
    1.62 
 
  10.24 
 
  7. Control    8.54 
 
   22.69 
 
   10.24 
 
    2.00 
 
  12.43 
 
 
 
Table 26. The 7 different placental tissue mRNA samples of control and pre-
eclampsia (PE) at a concentration of 100ng/ul for placental growth factor (PLGF), 
Fibroblast growth factor 2 (FGF2), Pleiotrophin (PTN), Midkine (MK), and Succinate 
dehydrogenase complex subunit A (SDHA) primer assays.* higher protein mRNA 
value for control 3. 
 
 
The 7 different placental mRNA samples of control and pre-eclampsia (PE) were 
determined by RT-PCR of heparin binding growth factor primer assays: for fibroblast 
growth factor 2 (FGF2), placental growth factor (PLGF), midkine (MK), pleiotrophin 
(PTN) and to endogenous house keeping gene Succinate dehydrogenase complex 
subunit A (SDHA) as represented in Table 26. Pre-eclampsia (PE-1, 2, and 4) at  a 
concentration of 100ng/ul for PLGF, of 4.52ng/ul, FGF2, of 26.58ng/ul, PTN, of 4.09 
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ng/ul, MK of 2.42ng/ul, and SDHA of 7.26ng/ul primer assays. PE-2 at a 
concentration of 100ng/ul for PLGF, of 5.55ng/ul, FGF2, of 27.05ng/ul, PTN, of 
2.97ng/ul, MK, of 6.01ng/ul, and SDHA of 5.13ng/ul primer assays. Control-3 at a 
concentration of 100ng/ul for PLGF, of 12.38ng/ul, FGF2, of 29.73ng/ul, PTN, of  
10.38ng/ul, MK  of 3.03ng/ul, and SDHA of  7.26ng/ul primer assays.* higher protein 
mRNA value for control 3. PE-4 at a concentration of 100ng/ul for PLGF, of 
6.91ng/ul, FGF2  of 30.23ng/ul, PTN of 8.52ng/ul, MK of  2.37ng/ul, and SDHA of 
0.42 ng/ul primer assays. Control-5 at a concentration of 100ng/ul for PLGF of 
5.89ng/ul, FGF2 of 25.12ng/ul, PTN of 8.65ng/ul, MK of   3.13ng/ul, and SDHA of   
8.84ng/ul primer assays. Control-6 at a concentration of 100ng/ul for PLGF of  
5.84ng/ul, FGF2 of  24.76ng/ul, PTN of  6.46ng/ul, MK of   1.62ng/ul, and SDHA of  
10.24ng/ul primer assays. Control-7 at a concentration of 100ng/ul for PLGF of  
8.54ng/ul, FGF2 of 22.69ng/ul, PTN of 10.24 ng/ul, MK of   2.00ng/ul and SDHA of   
12.43ng/ul primer assays. 
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Growth factors 
       
                        Control versus PE 
                   P= value; median= value 
      FGF2 Con m=2.12 PE m=5.27 
P=0.03* 
     PLGF Con m=0.63   PE m= 1.08  
P=0.11 
      MK Con m=0.160 PE m=1.17 
P=0.06 
      PTN Con m=0.73      PE m= 0.58 
P= 0.57 
      SDHA Con m= 11.34    PE m= 5.13 
P=0.03* 
 
Table 27. Comparison of 7 different placental tissue mRNA expression at a 
concentration of 100ng/ul for the following heparin binding growth factor primer 
assays using the Mann-Whitney U test. Abbreviations for growth factors: fibroblast 
growth factor 2 (FGF2), placental growth factor (PLGF), midkine (MK), pleiotrophin 
(PTN) and Succinate dehydrogenase complex subunit A (SDHA). Control (Term (TL 
+ TNL) not in labour) and pre-eclampsia (PE) were compared. The median is given 
above and p-values are shown. The p-values are indicated p < 0.05* and p< 0.01**. 
The comparison of 7 differnet placental mRNA levels were expressed as the ratio of 
heparin binding growth factor primer assays at a concentration of 100ng/ul: for 
fibroblast growth factor 2 (FGF2), placental growth factor (PLGF), midkine (MK), 
pleiotrophin (PTN) and to endogenous control, a housekeeping gene Succinate 
dehydrogenase complex subunit A (SDHA) required for normalization between 
placental tissue samples using the Mann Whitney U test. The comparison between 
control (Term (TL + TNL) not in labour) versus pre-eclampsia of placental tissue 
mRNA expression for PLGF of control, m = 0.63, PE m = 1.08, (p = 0.11), FGF2  of 
control m = 2, PE m = 5.27, (p=0.03*),  MK of control, m = 0.16, PE m = 1.17, (p= 
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0.06), PTN of control, m=0.73, PE m= 0.58, (p=0.57), and SDHA of control m= 
11.34, PE m=5.13, p=0.03*) primer assays.  Both FGF2 of contol m=2, PE m=5.27, 
(p= 0.03*),  and SDHA of control m=11.34, PE m=5.13, (p=0.03*) in the placenta 
was confirmed at the mRNA level by RT-PCR, showed  significant differences as 
shown in Table 26 and 27 using Mann-Whitney U test (*p<0.05).   
 
 
 
 
 
5.2.Specificity of PCR products by RNA agarose gel electrophoresis:  
The third technique of RNA quality was determined by RNA agarose gel 
electrophoresis. I performed on 7 different placental tissue mRNA samples at a 
concentration of 100ng/ul that were pipetted into the wells as in Figure 47 for 
Fibroblast growth factor 2 (FGF2) a, b, c, d and e for primer assay. Figure 47e was 
photographed using the portable UV–Trans illuminator for visible DNA ladder on 
agarose gel electrophoresis at the time the bands were gradually moving from upper 
to lower marker 2072 to100base pairs (bp) in size. These results used were 
reproduced for Fibroblast growth factor 2 (FGF2) and Midkine (MK) in 7 further 
experiments.  
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5.2.1.An agarose gel electrophoresis for 7 different placental tissue mRNA samples 
with a concentration of 100ng/ul for Fibroblast growth factor 2 (FGF2) primer assay. 
 
 
 
 
Figure 47. An agarose gel electrophoresis for 7 different placental tissue mRNA 
samples with a concentration of 100ng/ul for Fibroblast growth factor 2 (FGF2) 
primer assay a, b, c, d and e. This analysis required the DNA ladder and 2 internal 
standard markers (LM and UM). 
DNA samples are pipetted into the sample wells, seen as dark slots at the top of the 
picture. Application of an electric current at the top (anodal, negative) end causes the 
	
	
						a)		
		
	
	 	
	b)																																																																																							c)	
	
																																																																																		e)																											d)		
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negatively charged DNA to migrate (electrophorese) towards the bottom (cathodal, 
positive) end. Smaller DNA fragments move more quickly, and finish at the end of 
the gel. Although, each of the fragments of a single class of molecule is present in 
equimolar proportions, the smaller fragments have a less mass of DNA. The length of 
a DNA segment is accurately determined by running it on an agarose gel alongside a 
DNA ladder.  
                                 
                                                      
Figure 48. RT-PCR analysis for 7 different placental tissue mRNA samples from 
control and pre-eclampsia (100bp respectively) with their concentration (100ng/ul)  
for Fibroblast growth factor 2 (FGF2) primer assay. This analysis required the DNA 
ladder 100bp ladder (2072-100bp), lanes A1-7 by agarose gel electrophoresis, MW 
Lane: Molecular weight and 2 internal standard markers (LM and UM). 
 
I performed RT-PCR analysis on 7 different placental tissue mRNA samples at a 
concentration of 100ng/ul that were pipetted into the wells for Fibroblast growth 
factor 2 (FGF2)  primer assay as in Figure 48. The visible DNA ladder on agarose gel 
electrophoresis was photographed at the time the bands were gradually moving from 
upper to lower marker 2072 to100base pairs (bp) in size using the UV–Trans 
illuminator. The placental sample 456 bands in lanes A1 were bettered visualised with 
100bp. But the other placental samples 660, 728, 575, 502, 563, 079 bands in lanes 
A2-7 were all in the region of ≃1000bp to 800bp and travelled down to 100bp. 
                                                                                                 MW     A1   A2   A3   A4    A5    A6   A7 
                                                                           
  
 
      2072bp 
  
 
 
 
 
 
 
 
 
          
      100bp 
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                       ↑                                       ↑                                                ↑ 
                  A1 lane of ≃143bp       B1 lane of ≃ 85bp         C1 lane of ≃123bp 
Figure 49. A gel electrophoresis representation analysis on Multina of 7 different 
placental tissues RNA samples with their concentration (100ng/ul) for lanes (A1-7) 
Placental growth factor (PLGF), lanes (B1-7) Pleiotrophin (PTN), and lanes  (C1-7) 
Fibroblast growth factor 2 (FGF2) primer assays using the DNA sizing ladder on 
lanes (X1-2) and 2 internal standard markers (LM and UM). 
5.3. Figure 49. is a gel electrophoresis representation analysis that I performed on of 7 
different placental tissue RNA samples at a concentration of 100ng/ul for the 
following growth factor primer assays: PLGF, PTN, and FGF2 analysis using the 
DNA sizing ladder and 2 internal standard markers (LM and UM). The positions of 
DNA as distinct bands for lanes showed peaks for A1 of ≃143base pairs (bp), A2 lane 
of ≃145bp, A3 lane of ≃142bp, A4 lane of ≃146bp, A5 lane of ≃142bp, A6 lane of ≃146bp and A7 lane of ≃142bp. The lanes showed peaks for lane B1 lane of ≃ 85bp, 
B2 lane of ≃ 87bp, B3 lane of ≃87.5bp, B4 lane of ≃85.5bp, B5 of ≃84.5bp, B6 lane 
of ≃85.5bp and B7 lane of ≃ 87.5bp. The lanes showed peaks for lane C1 lane of  
 
                                  
                             660 728  575  502  563  079  456 660 728  575  502  563  079   456  660 728  575  502   563  079  456  
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≃123bp, C2 lane of ≃127bp, C3 lane of≃ 123bp, C4 lane of ≃127bp, C5 lane of ≃123bp, C6 lane of ≃127bp and C7 lane of ≃123bp. There were significant 
differences in mRNA expression for FGF2 and SDHA in placentae from pre-
eclampsia compared to the controls except for PLGF, MK, and PTN, using the Mann-
Whitney U test. 
 
                                                                       ↑                                                  
 
                                                                     A3≃105bp 
Figure 50. A gel electrophoresis representation analysis on Multina of 7 placental 
tissue mRNA samples at a concentration of 100ng/ul for lanes (A1-7) Midkine (MK) 
primer assay using the DNA sizing ladder on lanes (X1-2) and 2 internal standard 
markers (LM and UM).  
 
5.4. The Figure 50. is a gel electrophoresis representation analysis that I performed on 
7 placental tissue mRNA samples at a concentration of 100ng/ul represents the 
positions of DNA as a distinct bands for MK with A (3,5 of ≃105bp) and A 2 of ≃ 
97bp) and A4 of ≃102bp. The lane showed peaks for MK at a concentration of 
100ng/ul, but A1, A6 and A7 lanes showed no DNA base pairs.  
 
 
                                                       660  728  575  502  563  079  456  
                                       X1   X2    A1 A2  A 3   A4   A5  A6  A7  
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                                                                          ↑      
                                                                    A7 lane of ≃162bp 
Figure 51. A gel electrophoresis representation analysis on Multina of 7 placental 
tissue mRNA samples at a concentration of 100ng/ul for Succinate dehydrogenase 
complex subunit A (SDHA) primer assay (A1-7) analysis using the DNA sizing 
ladder on lanes (X1) and 2 internal standard markers (LM and UM). 
 
5.5. Figure 51 and table 25 and 26 is a gel electrophoresis representation analysis of 
the time course degradation that I performed on 7 different placental tissue mRNA 
samples at a concentration of 100ng/ul for endogenous control, a housekeeping gene 
SDHA primer assays analysis that remains stable under pathophysiological and 
experimental conditions by qRT-PCR was measured for normalization between tissue 
samples. The positions of DNA as a distinct band for A1 lane of ≃ 162base pairs (bp), 
A2 lane of ≃ 162bp, A3 lane of ≃165bp, A4 lane of ≃162bp, A5 lane of≃ 162bp, A6 
lane of ≃162bp and A7 lane of ≃162bp.  
            660   728    575    502    563    079   456  
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Figure 52. A gel electrophoresis representation analysis on Multina of 7 placental 
tissue mRNA samples with their sensitivity detection for dilutions at a concentration 
of 100ng/ul for Fibroblast growth factor 2 (FGF2 primer assay: analysis using the X1 
and X2 DNA ladder and 2 internal standard markers (LM and UM). 
 
5.6. In Figure 52 and Table 28 is a gel electrophoresis representation analysis that I 
performed on 7 different placental tissue mRNA samples. I demonstrated their 
sensitivity detection for dilutions at a concentration of 100ng/ul for FGF2 primer 
assay. This showed that the visible bands are obtained at highest lane A (1, 2, 3,). 
Lane A (4, 5, 6 and 7) represents decreasing dilutions using neat FGF2. However, A7 
showed no DNA bp.  
 
                                                                                                     575     575     575      575      575      575  
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Sample  
Number of 7 
different 
placental 
tissues 
 
 
 
 
 
                          Concentration (100ng/ul) 
 
 
 
 
 
Placental 
Growth 
factor 
 
 
 
Fibroblast 
Growth 
factor 2 
 
 
 
 
Pleiotrophin 
 
 
 
 
Midkine 
 
    1. PE    0.62 
 
   3.66 
 
     0.56 
 
     0.33 
 
    2. PE    1.08 
 
   5.27 
 
     0.58 
 
     1.17 
 
   3. Control     0.60 
 
   1.44 
 
    0.50 
 
     0.15 
 
   4. PE 
  
   16.45 
 
   71.98 
 
    20.28 
 
     5.64 
 
   5. Control    0.67 
 
   2.84 
 
     0.98 
 
     0.35 
 
   6. Control    0.57 
 
   2.42 
 
     0.63 
 
     0.16 
 
   7. Control    0.69 
 
   1.83 
 
    0.82 
 
     0.16 
 
 
Table 28. The 7 different placental tissue mRNA samples with their sensitivity 
dilutions at a concentration of 100ng/ul for Placental growth factor (PLGF), 
Fibroblast growth factor 2 (FGF2), Pleiotrophin (PTN), and Midkine (MK) primer 
assays.  
The 7 differnet placental mRNA samples of control and pre-eclampsia (PE) were 
determined by RT-PCR of heparin binding growth factor primer assays: for fibroblast 
growth factor 2 (FGF2), placental growth factor (PLGF), midkine (MK), pleiotrophin 
(PTN) and to endogenous housekeeping gene Succinate dehydrogenase complex 
subunit A (SDHA) as epresented in Table 28. Pre-eclampsia (PE-1, 2, and 4) with 
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their sensitivity dilutions at a concentration of 100ng/ul for PLGF of 0.62ng/ul, FGF2 
of 3.66ng/ul, PTN of 0.56ng/ul and MK of 0.33ng/ul, primer assays.  
 
 
PE-2 at a concentration of 100ng/ul for PLGF of 1.08ng/ul, FGF2 of 5.27ng/ul, PTN, 
of 0.58ng/ul and MK of 1.17ng/ul, primer assays. Control-3 at a concentration of 
100ng/ul for PLGF of 0.60ng/ul, FGF2, of 1.44ng/ul, PTN of 0.50ng/ul and MK, of   
0.15ng/ul, primer assays. PE-4 at a concentration of 100ng/ul for PLGF of 16.45ng/ul, 
FGF2 of 71.98ng/ul, PTN of 20.28ng/ul and MK of 5.64ng/ul, primer assays. Control-
5 at a concentration of 100ng/ul for PLGF of 0.67ng/ul, FGF2 of 2.84ng/ul, PTN of 
0.98ng/ul and MK of 0.35ng/ul, primer assays. Control-6 at a concentration of 
100ng/ul for PLGF of 0.57ng/ul, FGF2 of 2.42ng/ul, PTN of 0.63ng/ul, MK of   
0.16ng/ul, primer assays. Control-7 at a concentration of 100ng/ul for PLGF of 
0.69ng/ul, FGF2 of 1.83ng/ul, PTN of 0.82ng/ul, and MK of 0.16ng/ul primer assays. 
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Growth factors 
 
      
 Control versus PE 
P= value; median= value 
 
       FGF2 
Con m=2.13         PE m= 5.27 
P= 0.03* 
 
       PLGF 
Con m= 0.64        PE m= 1.08  
P=0.11 
 
       MK 
Con m= 0.16     PE m=1.17 
P= 0.06 
 
      PTN  
Con m= 0.73     PE m= 0.58 
P=0.57 
 
Table 29. Comparison of 7 placental tissue mRNA expression with their sensitivity at 
concentration  (100ng/ul) for the following Heparin-binding growth factors primer 
assays using the Mann Whitney U test. Abbreviations: fibroblast growth factor 2 
(FGF2), placental growth factor (PLGF), midkine (MK), and pleiotrophin (PTN). The 
control (Term (TL + TNL) not in labour) was compared versus pre-eclampsia (PE). 
The median is given above and p-values are shown. The p-values are indicated p < 
0.05* and p< 0.01. ** 
 
As shown in Table 29. the comparison of 7 differnet placental mRNA levels were 
expressed as the ratio of heparin-binding growth factor primer assays at a 
concentration of 100ng/ul: for fibroblast growth factor 2 (FGF2), placental growth 
factor (PLGF), midkine (MK), pleiotrophin (PTN) and to endogenous house keeping 
gene as a control Succinate dehydrogenase complex subunit A (SDHA) required for 
normalization between placental tissue samples using the Mann Whitney U test.  
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This comparison was between control (Term (TL + TNL) not in labour) versus pre-
eclampsia with their sensitivity at concentration 100ng/ul for PLGF of control m = 
0.64, PE m = 1.08, (p = 0.11), FGF2  of  control, m=2.13, PE m = 5.27, (p = 0.03*),  
MK  of control, m = 0.16, PE m=1.17, (p= 0.06), and PTN  of control, m=0.73, PE 
m= 0.58, (p = 0.57) primer assays.  FGF2 of  control, m = 2.13, PE m = 5.27, and (p= 
0.03*) in the placenta was confirmed at the mRNA level by RT-PCR, only showed  
significant difference using Mann Whitney U test.  
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Chapter 6 
Discussion 
 
 
 
 
 
 
 
 
 
 
 
The main findings of these studies that tested the novel hypothesis for this cohort 
study of 87 women is that the expression of heparin binding growth factor (HBGFs) 
in normal placental development was altered in the specific disorder of pre-eclampsia. 
This was the first study at Middlesex University London in United Kingdom of a 
cohort of 87 women of normal pregnancies including placenta from women with pre-
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eclampsia, pre-term labour, term labour and term non-labour. This first technique I 
performed on immunohistochemical localization showed the following growth factors 
VEGF, PLGF, FGF2, HGF, PDGF-BB, HB-EGF, CD105, PTN, and MK that were 
expressed in the human placentae. This present study has identified these growth 
factors that have been extensively studied as previously reported by (Duff et al, 2003; 
Tseng et al, 2006; Clark et al, 1998; Leach et al, 2002; Zhong et al, 2006; Gurski et 
al, 1990; Kilby et al, 1996; Milner et al, 1992; and Shulte et al, 1996). The purpose of 
observation that MK and PTN are present is a potential novel finding because little is 
known. The present study identified the localisation of receptors for VEGF, PLGF, 
and FGF2 in the human placenta.   
Many studies have investigated the potential of growth factors in early pregnancy as 
to act as predictors of pre-eclampsia. This study’s important discovery was devoted to 
demonstrating how several of heparin binding growth factors in normal pregnancy 
have altered the expression in association with the specific disorder known as pre-
eclampsia. The significance our immunohistiochemical findings for VEGF, PLGF, 
FGF2, HGF, PDGF-BB, HB-EGF, CD105, PTN, and MK expression, is that they 
have an important role in regulation of villous trophoblast development, promoting 
endothelial cell proliferation, vasculogenesis, and angiogenesis (Benirschke, 2006; 
Kay et al, 2010; Kingdom et al, 2000; Lyall and Belfort, 2007; Pijnenborg, 2010). 
However, the significance of our immunohistiochemical findings for HB-EGF, 
CD105, PTN, and MK is that they have an important role in regulation of villous 
development, vasculogenesis, and angiogenesis (Benirschke, 2006; Kay et al, 2010; 
Lyall and Belfort, 2007; and Pijnenborg, 2010).  
 
 
 
6.1. FGF2 expression, localisation of FGF2R-1 receptors in the human placenta and 
pre-eclampsia.  
I found that the FGF2 expression was confined to villous trophoblast and endothelial 
cells as shown in Figure 28a and negative control for pre-eclampsia as in Figure 28j.  
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                                                                                     Syncytial knots 
	
  
Figure 28a. 
Immunohistochemical positive staining in villous trophoblast (both 
syncytiotrophoblast and cytotrophoblast), in Figure 28a. for fibroblast growth factor 2 
(FGF2) expression, 3 = moderate to strong, Magnification of original (x101) 
distributed in placental tissues for Pre-eclampsia (PE), (n = 19). Magnification of 
original (x401). The arrow indicates the trophoblast and (*) the endothelial cells.  
                                                                       
 
 
 
 
                                                                                         Syncytial knots	
	
	
	
																								
																																		*	
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Figure 28j.  
Immunohistochemical representative negative control, 0 = none, without the antibody 
distributed in placental tissues in Figure 28j. for Pre-eclampsia (PE), (n = 19) in the 
absence of citrate buffer. Magnification  of original (x401). The arrows indicate the 
trophoblast and the endothelial cells. The arrow indicates the trophoblast and (*) the 
endothelial cells. 
The FGF2 expression was significantly lower at term labour compared to the other 
placenta groups studied. There was no significant difference in staining in pre-
eclampsia when compared to any of the other placenta groups studied. The fibroblast 
growth factor 2 (FGF2) is a potent angiogenic factor and promotes endothelial cell 
proliferation and vasculogenesis. Shams and Ahmed, (1994) demonstrated FGF2 gene 
expression in the syncytiotrophoblasts and foetal membranes at term human placenta 
by in situ hybridization. Hill et al’s, (1995) studies in human pregnancy revealed that 
maternal and cord serum levels of FGF2 correlated with foetal weight. The effect on 
foetal growth was also accompanied by alterations in the placenta growth suggesting 
that FGF2 may exert its effects by influencing placental development. Luo et al, 
(2011) investigated FGF2 release by endothelial cells of uterine spiral arteries. They 
showed decreasing MMP9 and increasing TIMP1 production in extravillous 
trophoblasts (EVT) in response to stress, resulting in reduced EVT invasion and 
shallow implantation of the placenta. Wang et al, (2009) showed that hypoxia 
promotes FGF2- and VEGF-stimulated cell proliferation in human placenta. 
	
							*	
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I identified FGF2R-1 receptor expression as shown in Figure 32 and found it to be 
localised to villous, extra villous trophoblasts, syntcytiotrophoblast, villous 
mesenchyme and Hofbauer cells.  
	
Figure 32. Immunohistochemical moderate to strong positive staining in villous trophoblast 
(both syncytiotrophoblast and cytotrophoblast), weaker staining in the mesenchyme, and in 
the core foetal vessels for fibroblast growth factor 2 (FGF2) receptor expression distributed in 
placental tissues for the four groups PE-Pre-eclampsia, (n = 12), and PTL-Pre-term Labour, (n 
= 6), TL-term labour, (n = 22), and TNL-Term-non-Labour, (n = 21), 3=moderate to strong 
with a magnification of x401. The arrow indicates the trophoblast and (*) the endothelial 
cells. 
 
Arany and Hill, (1998) observed this, but they found FGF2R-1 expression in placenta 
from diabetic women elevated compared to those of normal women. Anteby et al, 
(2005) found FGF2R1 was expressed only within the villous stroma and FGF2R1-4 
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expression was abundant in the Hofbauer cells. The mesenchyme trophoblast 
interactions are important for regulation of villous development (Anteby et al, 2005).  
There are 23 members of the FGF family (Haque et al, (2007). The human FGF gene 
produces FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9,FGF-
10,FGF-11, FGF-12, FGF-13, FGF-14, FGF-15, FGF-16, FGF-17, FGF-18, FGF-19, 
FGF-20,FGF-21,FGF-22, FGF-23 respectively by alternative exon splicing processes 
(Haque et al, 2007). Some FGFs exert their effects by interacting with 4 different 
(FGFR-1-4) receptors (Anteby et al, 2005; Folkman and Shing, 1992; Li et al, 1999; 
and Haque et al, 2007). 
It’s the interaction of VEGF and FGF2 with specific, high affinity cognate receptors 
located in plasma membrane of target cells that triggers events inside the cells 
promoting DNA synthesis (Anteby et al, 2005; Folkman and Shing, 1992; Li et al, 
1999; and Haque et al, 2007). The FGF2R-1, VEGF receptor-1 (VEGFR-1, FLt-1) 
and VEGF receptor-2 (VEGFR-2, Flk-1/KDR) consists of protein-tyrosine kinases. 
The significance of our immunocytochemical localization of FGF2R-1, VEGF R1 and 
2 placental expression is that these receptors have an important role in regulation of 
vasculogenesis, angiogenesis and villous trophoblasts development. Alterations of 
FGF2R-1, VEGF receptor-1 (VEGFR-1, FLt-1) and VEGF receptor-2 (VEGFR-
2,Flk-1/KDR) expression of which might be associated with the etiology of pre-
eclampsia (Anteby et al, 2005; Folkman and Shing, 1992; Li et al, 1999; and Haque 
et al, 2007). These receptor findings suggest a possible physiological mechanism 
involved in pre-eclampsia (Anteby et al, 2005; Folkman and Shing, 1992; Li et al, 
1999; and Haque et al, 2007).  
 
 
 
Previous evidence for hCG, VEGF and FGF2 during blastocyst implantation in vivo 
was reported. The cohort study of Paiva et al, (2011) provided a role for human 
chorionic gonadotrophin (hCG) in selectively modulating endometrial production of 
cytokines and growth factors such as VEGF and FGF2 that are important for human 
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endometrial receptivity during blastocyst implantation in vivo. They examined the 
effects of FGF2 from primary human endometrial epithelial cells hEEC line (ECC-1) 
associated with endometrial receptivity by adhesion assays. Their results showed that 
FGF2 stimulated phosphorylation of ERKI/2 in hEEC with no effect on ERKI/2 
abundance and stimulated hEEC adhesion to fibronectin and collagen IV. 
6.1.2.VEGF expression, localisation of VEGFR1 and VEGFR-2 receptors in the 
human placenta, and pre-eclampsia. 
I found that the expression of VEGF was localised to villous trophoblasts and 
endothelial cells as shown in Figure 28c.  
                                                                                   Syncytial knots	
	
Figure 28c.	
Immunohistochemical positive staining in villous trophoblast (both syncytiotrophoblast and 
cytotrophoblast), in Figure 28c. for vascular endothelial growth factor, placental growth factor (VEGF) 
expression, 3 = moderate to strong, Magnification of original (x401), distributed in placental tissues for 
Pre-eclampsia (PE), (n = 19). Magnification of  original (x101). The arrow indicates the trophoblast 
and (*) the endothelial cells. 
There was no significant difference in staining in pre-eclampsia, but expression 
showed a significant difference in term Labour when compared to any of the other 
placenta groups studied. There was no significant difference in VEGF expression in 
term compared to preterm and in the presence or absence of labour.  
	
	
	
	
	
	
	
	
											*		
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Previous studies by Demir et al, (2004) demonstrated that VEGF is strongly 
expressed in the villous cytotrophoblast cells and Hofbauer cells. VEGF is an 
endothelial-specific mitogen with a role in promoting angiogenesis and its receptors in 
the human placental villi are found in early pregnancy because placental 
vasculogenesis and angiogenesis are sequential events. Vuorela et al, (1997) in 
addition studied VEGF mRNA in the term human placenta by in situ hybridization in 
the chorionic mesenchyme and villous trophoblasts. They found that the 
immunostaining was co-localised with expression of VEGF protein in the vascular 
endothelium. Khaliq et al, (1996) demonstrated localisation of PLGF in human term 
placenta. Vuorela et al, (1997) showed the expression of PLGF mRNA in the term 
human placenta by in situ hybridization in the chorionic mesenchyme and villous 
trophoblasts. They found that the immunostaining was co-localized the expression of 
PLGF protein in the vascular endothelium. These studies by (Khaliq et al, 1996; and  
Vuorela et al, 1997) examined the VEGF mRNA levels.  
Demir et al, (2004) suggested that VEGF-A known as VEGF is most abundant form 
in the VEGF family The VEGF gene produces 5 different VEGF isoforms: VEGF121, 
VEGF145, VEGF165, VEGF189 and VEGF206 respectively by alternative exon 
splicing processes. VEGF-A function depends on their interactions with heparin-
binding growth factors to extracellular matrix and their receptors. However, the 
solubility of each isoform is different because of the presence or absence of heparin-
binding domains (Demir et al, 2004). 
VEGF is said to have a very important role in the pathogenesis of pre-eclampsia. 
Many studies have investigated the potential of growth factors in early pregnancy to 
act as predictors of pre-eclampsia (Anderson et al, 2012; and Lyall and Belfort, 
2007).  
There are many studies that have examined VEGF expression in pre-eclampsia with 
conflicting results. Some studies reported reduced levels of VEGF-A in maternal 
circulation (Cheng et al, 2001; Lyall et al, 1997; Reuvekamp et al, 1999; Sgambati et 
al, 2004; Sharkey et al, 1996; Simmons et al, 2000; and Vuorela et al, 1999). Other 
studies have shown increased levels of VEGF-A in maternal circulation, compared 
with normal pregnancies (Baker et al, 1995, Hefler et al, 2000; and Kupferminc et al, 
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1997). Rainheim et al, (2005) study found that VEGF expression was unaltered at the 
mRNA level.  
VEGF and their receptors are essential for embryonic vascular development because 
loss of a single VEGF allele results in embroyonic death. Shalaby et al, (1995) study 
demonstrated that lack of VEGFR-2 results in absence of endothelial cells with severe 
impairment for the development of cardiovascular system. Ahmed et al, (1995) and 
Clark et al, (1996) study confirmed VEGF and VEGFR-1 expression in the placenta 
throughout gestation. Lash et al, (1999) study suggested that the possible effect of 
VEGF on trophoblast invasion and motility were mediated by functional receptors. 
Ribatti et al, (2008) suggested several mechanisms that are involved in angiogenic 
function of PLGF. As, PLGF binds to VEGFR-1 in the endothelial cells which 
facilitates VEGF binding and activation of VEGFR-2. Li et al, (2005) study 
demonstrated that Hypoxia promotes VEGF and VEGFR-1(Flt-1), but not that of 
VEGFR-2 and down regulates PLGF expression and production.  
In the present study, I identified (VEGFR-1, sflt-1)/VEGFR-2 receptor expression as 
shown in Figure 33 and 34 was localized to villous and extra villous trophoblasts, 
villous mesenchyme, maternal decidua cells, and Hofbauer cells.  
Sharkey et al, (1993); Jackson et al, (1994); Clark et al, (1996); Khaliq et al, (1996); 
and Schiessl et al, (2009); and Andraweera et al, (2012) observations throughout 
gestation were consistent with this. They were found on blood vessels that are 
consistent with the observations of (Demir et al, 2004) where showed that VEGF 
expression was localised to villous cytrophoblast cells, Hofbauer cells in the human 
placental villi during early pregnancy. The VEGFR-1, (sFlt-1) receptors during 
placental development are found on vasculogenic and angiogenic precursors cells.  
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Figure 33.Immunohistochemical moderate to strong positive staining in villous trophoblast 
(both syncytiotrophoblast and cytotrophoblast), weaker staining in the mesenchyme, and in 
the core foetal vessels for vascular endothelial growth factor (VEGF) receptor I expression 
distributed in placental tissues for the four groups PE-Pre-eclampsia, (n = 12), 4=strong, of 
magnification of original x 101, and TL-term labour, (n = 22), 2=moderate, PTL-Pre-term 
Labour, (n = 6), and TNL-Term-non-Labour, (n = 21), 3=moderate to strong with a 
magnification of original x401. The arrow indicates the trophoblast and (*) the endothelial 
cells. 
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Figure 34. Immunohistochemical moderate to strong positive staining prominent in 
villous trophoblast (both syncytiotrophoblast and cytotrophoblast), weaker staining in 
the mesenchyme, and in the core foetal vessels for vascular endothelial growth factor 
(VEGF) receptor II expression in placental tissues for the four groups PE-Pre-
eclampsia, (n = 12), 4=strong, magnification of original x 101, TL-term labour (n = 
22), and TNL-Term-non-Labour (n = 21), and PTL-Pre-term Labour, (n = 6), 
3=moderate to strong with a Magnification of x 401 The arrow indicates the 
trophoblast and (*) the endothelial cells. 
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Lala et al, (2012) reported that the actions of decorin, a transforming growth factor 
(TGF)-B were mediated by its binding to multiple tyrosine kinase receptors, including 
VEGFR-2.  They examined the effect of decorin and their EVT cells were treated 
with VEGF121 for the migration assay. Their results demonstrated that EVT cell 
migration was enhanced in the presence of VEGF121 and suggested that decorin 
inhibits VEGFA stimulation of trophoblast migration and endovascular differentiation 
of EVT. Thus, angiogenesis may provide insights for pathogenesis of pre-eclampsia. 
Sundrani et al, (2013) employs tissue from pre-eclamptic women, and examining their 
genes expression of the promoter CpG methylation of VEGF and its receptors, 
VEGFR-1, /Flt-1 and VEGFR-2 in human term and preterm placentae. Their results 
indicated that alterations of DNA methylation patterns of VEGF and Flt-1 in pre-
eclampsia as compared to the normotensive group may be involved in 
pathophysiology of pre-eclampsia. G-protein receptors play an important role in 
control of cellular function. Two subunits are involved in modulation of hypertension 
and endothelial, protein subunit α-11 (GNA11) and subunit α-14 (GNA14). Using 
immunocytochemistry Zhao et al, (2014) found that these subunits were co-localised 
in primary trophoblasts, villous stromal cells and endothelial cells in placentas and 
that GNA 14 elevated expression was observed in severe pre-eclampsia placentae.  
G-protein linked receptors are distinct from the tyrosine kinases, but both families 
appear to activate, directly or indirectly to cellular processes. The significance of 
these findings is the confirmation that genes expression of these VEGFR-1, /Flt-1 and 
VEGFR-2 receptor have an important role in pathophysiology of   pre-eclampsia. 
6.1.3. PLGF expression and localisation of receptors in the human placenta and pre-
eclampsia. 
The PLGF receptor expression has been described as abundant in villous trophoblasts 
(Khaliq et al, 1996; Vuorela et al, 1997; and Andraweera et al, 2012) interestingly as 
present data show. Andraweera et al, (2012) demonstrated that the PLGFR-1 
expression for the FNL group was localised in the extravillous trophoblasts within the 
maternal decidua. Several other authors have made similar findings (Khaliq et al, 
1996; Vuorela et al, 1997; and Andraweera et al, 2012). The PLGFR-1 expression for 
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term is abundant and localised to villous trophoblast (Khaliq et al, 1996; and Vuorela 
et al, 1997).  
Maglione et al, (1991) study identified PLGF in a placental cDNA library. PLGF was 
structurally related to the different VEGF molecules. The PLGF gene produces 2 
different PLGF isoforms: PLGF-1 known as (PLGF131), and PLGF-2 known as 
(PLGF152) respectively by alternative exon splicing processes (Maglione et al, 1991) 
I found that the expression of PLGF was localised to villous trophoblasts and 
endothelial cells as shown in Figure 28b.  
                                               Syncytial knots  
	
	
Figure 28b.	
Immunohistochemical positive staining in villous trophoblast (both 
syncytiotrophoblast and cytotrophoblast), in Figure 28b. for placental growth factor 
(PLGF) expression, 2 = moderate distributed in placental tissues for pre-eclampsia 
(PE), (n = 19). Magnification  of original (x401). The arrows indicate the trophoblast 
and (*) the endothelial cells.  
The expression of PLGF score was significantly lower after labour onset. PLGF levels 
were significantly higher in pre-term compared to term placentas. Rainheim et al, 
(2005) showed that there is no evidence of abnormal VEGF expression (VEGF 
mRNA levels) at delivery in the decidua’s basalis or the placenta in pregnancies 
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complicated by pre-eclampsia compared with the controls. Sgambati et al, (2004) 
showed that the levels of VEGF mRNA were higher in the gestational hypertension 
cases and lower in the cases of pre-eclampsia. PLGF showed a significant increase in 
pre-eclampsia compared to other group studied. Maynard et al, (2003) study of in vivo 
animal model of the rat and mouse established that overexpression of VEGFR-1, 
sFLt-1 using recombinant adenoviral vector developed hypertension, proteinuria, and 
glomerular endotheliosis except for soluble VEGF receptor-2 (sFlk-1), because these 
conditions were similar to pre-eclampsia. Maynard et al, (2003), suggested that 
development of pre-eclampsia resulted from the imbalance of VEGF and PLGF. This 
effect was prevented in pregnant rats by exogenous administration of VEGF and 
PLGF. Maynard et al, (2003), hypothesized that excess circulating soluble fms-like 
tyrosine kinase 1 (sFlt-1) was associated with decreased free VEGF and PLGF in the 
serum and are secreted by the placenta in pre-eclampsia women. This may contribute 
to endothelial dysfunction, hypertension, and proteinuria due to an imbalance between 
the circulating VEGF and PLGF (Maynard et al, (2003). Several studies on 
expression of anti-angiogenic growth factors, soluble fms-like tyrosine kinase 1 (sFlt-
1), transforming growth factor β (TGF-β) and endoglin are upregulated in pregnancies 
affected with pre-eclampsia. However, pro-angiogenic growth factors such as VEGF, 
and PLGF are downregulated in these pregnancies inadequate cytotrophoblast 
invasion, endothelial dysfunction and impaired placental angiogenesis in pre-
eclampsia women (Young et al, 2010; Maynard et al, 2003; and Ahmad and Ahmed, 
2004). 
Numerous studies have documented that beginning in the early second trimester and 
as early as 10 to 11 weeks of gestation, PLGF concentrations in women who go on to 
develop pre-eclampsia are lower than those of normotensive controls (Bersinger et al, 
2004; Krauss et al, 2004; Levine et al, 2004; Livingston et al, 2000; Taylor et al, 
2003; Thadhani et al, 2004; Tidwell et al, 2001; Torry et al, 2003; Polliotti et al, 
2003; and Su et al, 2001). Athanassiades and Lala, (1998) showed that PLGF promote 
EVT cell proliferation and suggest that PLGF and VEGF receptor-1 (VEGFR-1, Flt-
1) interactions may be regulated by heparan sulphate proteoglycans (HSPGs) in situ. 
In pre-eclampsia, PLGF concentrations begin to decrease before the appearance of 
hypertension and proteinuria, during the 5 weeks before the onset of disease. More 
than 5 weeks preceding occurrence of the maternal syndrome, the difference in PLGF 
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levels between normotensive controls and those who later developed pre-eclampsia 
was less marked (Levine, 2004). Various studies have investigated PLGF in the first 
or second trimester as a possible predictor of pre-eclampsia (Levine, 2004; Thadhani 
et al, 2004; Taylor et al, 2003; Tidwell et al, 2001; Tjoa et al, 2001; Polliotti et al, 
2003; and Su et al, 2001).  
6.1.4. CD105 expression	in the human placenta and pre-eclampsia. 
 I found that the CD105 expression was confined to villous trophoblast, and 
endothelial cells as shown in Figure 28f. 
                                                                        Syncytial knots	
	
Figure 28f.  
Immunohistochemical positive staining in villous trophoblast (both 
syncytiotrophoblast and cytotrophoblast), in Figure 28f. for cluster differentiation 
(CD105) expression, 2 = moderate, distributed in placental tissues for Pre-eclampsia 
(PE), (n = 19). Magnification of original  (x401 and x402). The arrows indicate the 
trophoblast and (*) the endothelial cells. 
CD105 expression in staining intensity was significantly higher in term Labour 
compared to any of the other placenta groups studied. Gougos et al, (1992) showed 
that the syncytiotrophoblasts of the term placenta contained high levels of CD105. 
There was no significant difference in staining score in pre-eclampsia when compared 
to any of the other placenta groups studied. Many of the studies have looked 
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statistically at CD105, an endoglin, as a potential predictor of pre-eclampsia. Our 
findings are consistent with those of Duff et al, (2003) because the staining 
expressions for CD105 were positive. Duff et al, (2003) examined staining intensity 
results for syncytiotrophoblast of term placenta and found 3 out of 4 antibodies used 
for CD105 produced positive results. CD105 can be categorised as a marker of 
endothelial cells activation and proliferation, marker of hypoxic stress, undefined 
endothelial cell antigens and proteins that are expressed in newly formed or 
remodelled basement membrane. CD105 may be involved in TGF-β signal 
transduction. It is soluble endoglin known as another anti-angiogenic factor. Studies 
by Venkatesha et al, (2006) suggest that the soluble endoglin derived from 
syncytiotrophoblast, whose circulating levels are increased in pre-eclampsia. Yinon et 
al’s, (2008) study shows that CD105 is upregulated by hypoxia.  
6.1.5.  HGF expression in the human placenta and pre-eclampsia. 
I found that the expression of HGF was confined to villous trophoblast and 
endothelial cells as shown in Figure 28e.  
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Figure 28e.  
Immunohistochemical positive staining in villous trophoblast (both syncytiotrophoblast and 
cytotrophoblast), in Figure 28e. for hepatocyte growth factor (HGF) expression, distributed in placental 
tissues for Pre-eclampsia (PE), (n = 19). Magnification of original  (x401 and x402). The arrows 
indicate the trophoblast and (*) the endothelial cells. 
	
						*		
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HGF expression was significantly higher in pre-term Labour compared to term 
Labour placentae. The median of HGF was significantly higher for pre-term Labour 
than term Labour. There was no significant difference in staining in pre-eclampsia 
when compared to any of the other placenta groups studied. Hepatocyte growth factor 
is a potent mitogen. It has been shown to stimulate dissociation and mobility of the 
epithelial cells.  In the placenta, HGF promotes trophoblast migration and invasion 
but does not affect cellular proliferation. The study by Wolf et al, (1991), suggested a 
role for HGF during pregnancy. They demonstrated high levels of HGF mRNA 
expression and HGF protein was extracted from the human placentae. Kilby et al, 
(1996) showed mRNA for HGF and its receptor c-met in the human term placenta 
using in situ hybridisation. The study of Liu et al, (2012) demonstrated in the 
placental trophoblast cells up regulation by both small interfering RNA (siRNA) gene 
targeting and protein levels because of mRNA expression of HLX1 in response to 
HGF.  
Kauma et al, (1996) examined HGF in the placenta and determined the expression of 
a tyrosine kinase receptor Met for the ligand HGF. The immunocytochemistry of 
HGF was localised to the villous core but not to the trophoblast. Met was localised to 
cytotrophoblast. Somerset et al’s, (2000) study suggested that HGF-activator (HGF-
A) is a circulating serine protease known to be responsible for activation of HGF and 
is produced via proteolytic cleavage of its zymogen by thrombin. An important 
regulator of trophoblast growth is the active HGF. The study demonstrated the anti-
HGF-A/zymogen antibody immunostaining in placental villi and membranes 
throughout gestation.  
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6.1.6. PDGF-BB expression in the human placenta and pre-eclampsia. 
I found that the PDGF-BB expression was confined to villous trophoblast and 
endothelial cells as shown in Figure 28d.  
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Figure 28d. 
Immunohistochemical positive staining in villous trophoblast (both 
syncytiotrophoblast and cytotrophoblast), in Figure 28d. platelet-derived growth 
factor (PDGF-BB) expression, 4 = strong distributed in placental tissues for Pre-
eclampsia (PE), (n = 19). Magnification of original  (x101). The arrows indicate the 
trophoblast and (*) the endothelial cells. 
PDGF-BB expression showed no significant difference in pre-eclampsia when 
compared to any of the other placenta groups studied. The lack of altered expression 
in pre-eclampsia suggests that other HBGFs may be more critical for this condition. 
The platelet-derived growth factor (PDGF) functions are proliferation, survival, 
movement, deposition of extracellular matrix (ECM) and tissue remodelling. 
Holmgren et al, (1992) demonstrated the expression of PDGF alpha and beta-
receptors in different subpopulations of the human placental cytotrophoblast while 
PDGF-BB was confined to the cytotrophoblast primary cultures. Rolny et al, (2002) 
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showed that heparin did not potentiate the effect on PDGF-BB stimulation of its ß-
receptor.  Gurski et al, (1990) and Lash et al, (2003) showed that in the human 
placental PDGFR α/ ß-receptors are both expressed within the syncytiotrophoblast 
and villous cytotrophoblast.  
6.1.7. HB-EGF expression in the human placenta and pre-eclampsia. 
I found that the expression of HB-EGF was localised to villous trophoblast as shown 
in Figure 28g.  
                                                                               Syncytial knots	
	
Figure 28g. 
Immunohistochemical moderate to strong positive staining in villous trophoblast 
(both syncytiotrophoblast and cytotrophoblast), for heparin-binding epidermal growth 
factor (HB-EGF) expression in Figure 28g. 4 = strong, distributed in placental tissues 
for Pre-eclampsia (PE), (n = 21). Magnification of original (x401). The arrow indicate 
the trophoblast and (*) the endothelial cells. 
 
										*	
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The HB-EGF expressions were significantly higher in preterm compared to term 
placentae. A significant difference was observed in term Labour and term non-Labour 
of HB-EGF expression. There was no significant difference in pre-eclampsia, when 
compared to any of the other placenta groups studied. Heparin-binding epidermal-
growth-factor (HB-EGF) has strong cytoprotective activity and is an important 
signalling protein that regulates trophoblast invasion during early placentation. In 
addition to the cytoprotective effect there is evidence that HB-EGF regulates 
trophoblast invasion during early placentation. For example in pre-eclampsia, 
deficient HB-EGF signalling during placental development could impair trophoblast 
survival, differentiation, and invasion, leading to poor placental perfusion and 
hypertension. Leach et al, (2002) showed that the HB-EGF expression was found in 
pre-eclamptic pregnancies. Thus, heparin and some associated HBGFs appear to have 
cytoprotective effects in the placenta. HB-EGF is induced by low oxygen tension and 
is expressed in both villous and extravillous trophoblasts at high levels in the first 
trimester and throughout gestation (Yoo et al, 1997). Furthermore, HB-EGF 
expression is downregulated following hypoxia/reperfusion in an in vitro model of 
oxidative stress (Leach et al, 2008).  
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6.1.8 MK expression in the human placenta and pre-eclampsia. 
I found that MK was localised to villous trophoblast as shown in Figure 28h.  
                                       Syncytial knots	
	
Figure 28h.	
	
Immunohistochemical positive staining in villous trophoblast (both 
syncytiotrophoblast and cytotrophoblast), as in Figure 28h. for midkine (MK) 
expression distributed in placental tissues for Pre-eclampsia (PE), (n = 19). 
Magnification of original  (x401). The arrows indicate the trophoblast and (*) the 
endothelial cells. 
MK functions are involved in neural survival, carcinogenesis, and tissue repair. Qi-
Wen Fan et al, (2001) showed that MK was present in the chorion, the foetal 
component of the placenta, whereas pleiotrophin was found in the decidua basalis, the 
maternal component of the placenta. The distinct expression of midkine and 
pleiotrophin suggests their differential role in early development in mouse. Midkine 
(MK) and pleiotrophin (PTN) are implicated in neuronal survival, differentiation and 
tissue repair, (Muramatsu, 2010). MK expression was significantly lower in pre-
eclampsia other group studied. 
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6.1.9. PTN expression in the human placenta and pre-eclampsia. 
I found that PTN was localised to villous trophoblast as shown in Figure 28i.  
                               Syncytial knots	
	
Figure 28i. 
Immunohistochemical positive staining in villous trophoblast (both 
syncytiotrophoblast and cytotrophoblast), as in Figure 28i. for pleiotrophin (PTN) 
expression, 4 = strong, distributed in placental tissues for Pre-eclampsia (PE), (n = 
19). Magnification of original (x401). The arrows indicate the trophoblast and (*) the 
endothelial cells. 
The PTN expression was significantly higher in pre-term labour compared to term 
placentae. PTN is a heparin-binding protein with mitogenic and transforming effects 
on the fibroblasts and growth factor activity on the epithelial and endothelial cells. 
PTN is involved in cell growth, migration and differentiation effects mediated 
through multiple receptors. Expression of PTN in the trophoblast is found in the 
human (Schulte et al, 1996: and Ball et al, 2009). Schulte et al, (1996) showed that 
PTN was detected in normal human trophoblasts cell cultures as early as 9 weeks 
after gestation and in term placenta. Ball et al, (2009) found PTN in foetal 
macrophages and microvasculture in the villous mesenchymal core. They showed that 
the villus staining of the cytotrophoblasts suggests that PTN expression commences at 
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a pre-fusion stage of differentiation. Ball et al, (2009) found that different patterns of 
overlapping expression of PTN and its receptors occur in different trophoblast 
subtypes. The receptor anaplastic lymphoma kinase (ALK) had a similar staining 
pattern to PTN in the trophoblasts, suggesting an autrocrine action. PTN staining of 
extravillous cytotrophoblasts and syncytial microvillous membrane was consistent 
with increasing levels of PTN measured by ELISA in the maternal bloodstream for 
pregnancy (Ball et al, 2009). PTN expression was significantly lower in pre-
eclampsia other group studied.  There have been reported studies on changes on PTN 
in the human placenta in patients presenting with pre-eclampsia. The lack of altered 
expression in pre-eclampsia suggests that other HBGFs may be more critical for this 
condition. 
 
6.2. Heparin-binding growth factors and in vitro villous trophoblast invasion and 
migration. 
The third technique in this study employed BD Fluoroblok was focused on VEGF, 
PLGF, FGF2, HB-EGF, PDGF, HGF, MK and PTN induced interestingly villous 
trophoblast invasion and migration studies using the immortalized human villous 
trophoblast invasive cell-line TCL-1. This thesis essentially uses the technique 
described by Partridge and Flaherty, (2009) who showed that calcein AM detects 
invaded cells in their model of Fluroblok tumour invasion assay. They used human 
fibrosarcoma HT-1080 invasive cells as a positive control, and NIH 3T3 mouse 
embryonic fibroblast, a non-invasive choriocarcinoma cells as a negative control. I  
found that 3T3/NIH and TCL-1 were significantly different using the Mann-Whitney 
U test from HT1080 cell lines of invasion and migration studies. There are no 
previously reported studies using a similar approach to that employed in this first 
present study using the immortalized human villous trophoblast invasive cell-line 
TCL-1. This first study suggests an important novel role for some of the heparin 
binding growth factors expressed in placenta on migration and invasion through 
extracellular matrix in vitro. This in vitro model, using Matrigel are representative of 
in vivo invasion. Invasion and migration are important events in placental 
development and cellular processes such as angiogenesis, embryonic development, 
immune response, metastasis, and invasion of cancer cells. Published findings suggest 
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that VEGF, PLGF, HB-EGF, FGF2, PDGF, and HGF regulate placental function 
(Anteby et al, 2004; Dessai et al, 1995; and Hills et al, 2006). The studies of others 
using Matrigel invasion and migration assays found that HBGFs regulation of the 
process of trophoblast invasion were not clarified.  
The effect of villous trophoblast invasion in the presence of HBGFs with no heparin 
showed increasing concentrations of HB-EGF and PTN stimulated a significant small 
increase in trophoblast invasion. The increase in trophoblast invasion was stimulated 
in the presence of VEGF, PLGF, and FGF2 at increasing concentrations was 
significantly small. The increase in trophoblast invasion in the presence of PDGF was 
significantly higher, than in cells with no heparin. The trophoblast invasion in the 
presence of HGF stimulated a significant dose dependent rise for increasing 
concentrations. The trophoblast invasion was stimulated and its values were similar to 
the control for increasing concentrations of MK.  
 
6.2.1. In vitro villous trophoblast invasion and HBGFs following co-incubation in the 
presence of heparin. 
This study has identified heparin-binding growth factors (HBGFs) that are important 
in vivo regulating trophoblast invasion and are potentially amenable to alteration by 
heparin. Evidence that the effect of villous trophoblast invasion was stimulated by 
HBGFs following co-incubation in the presence of heparin. The effect of villous 
trophoblast invasion was stimulated by HBGFs following co-incubation in the 
presence of heparin. As shown in  Figure 39C. for FGF2, Figure 41E. for PDGF-BB, 
Figure 42F. for HGF and Figure 43G. for MK produced the greatest stimulation of 
increase in villous trophoblast invasion with co-incubation of heparin enhanced each 
of these responses except for PTN. A major strength in this present study is evident 
from the interesting results from in vitro villous trophoblast invasion model 
demonstrating that heparin has a potential therapeutic use. 
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Figure 41C. Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 of (n = 3, 24.7% ± 2.08%,	 and 29.17% ± 1.56%, 
p<0.05), and TCL-1 with the presence of fibroblast growth factor 2 (FGF2) 
expression at (n = 3, 9.69% ± 1.54%, p<0.05) 0nmol/l, (n = 3, 12.28% ± 1.65%, 
p<0.05) 1nmol/l, (n = 3, 12.41% ± 0.58%, p<0.05) 10nmol/l and (n = 3, 13.47% ± 
0.98%, p<0.05) 100nmol/l. In the presence of heparin at (n = 3, 15.87% ± 1.05%, 
p<0.05) 0ng/ml, (n = 3, 15.88% ± 0.91%, p<0.05) 1ng/ml, (n = 3, 18.22% ± 2.15%, 
p<0.05) 10ng/ml, and (n = 3, 20.24% ± 3.63%, p<0.05) 100ng/ml. (*p <0.05 vs. 0 
growth factor, Mann-Whitney U test; † p <0.05 vs. 0 heparin). 
 
FGF2 stimulated trophoblast invasion in the presence of heparin, at increasing 
concentrations produced values that were again significantly higher. Therefore, FGF2 
response was enhanced following co-incubation in presence of heparin as in Figure 
41C. 
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Figure 43E.Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 of (n = 3, 54.99% ± 3.65%	 and 72.68% ± 5.22%, 
p<0.05), and TCL-1 with the presence of platelet-derived growth factor (PDGF) 
expression at (n = 3, 27.31% ± 4.50%, p<0.05) 0nmol/l, (n = 3, 28.18% ± 6.91%, 
p<0.05) 1nmol/l, (n = 3, 40.22% ± 18.74%, p<0.05) 10nmol/l and (n = 3, 83.51% ± 
3.80%, p<0.05) 100nmol/l. In the presence of heparin at (n = 3, 42.03% ± 6.79%, 
p<0.05) 0ng/ml, (n = 3, 43.87% ± 6.91%, p<0.05) 1ng/ml, (n = 3, 71.50% ± 18.74%, 
p<0.05) 10ng/ml, and (n = 3, 92.1% ± 8.85%, p<0.05) 100ng/ml. (*p <0.05 vs. 0 
growth factor, Mann-Whitney U test; † p <0.05 vs. 0 heparin). 
 
PDGF stimulated trophoblast invasion in with a slight change in the presence of 
heparin for lower concentrations, but its values were pronounced for significantly 
higher concentrations. Thus, the PDGF response was enhanced with only higher doses 
of heparin as in Figure 43E. 
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Figure 44F. Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 of (n = 3,	11.92% ± 0.58%,	12.01% ± 0.133% and, 
p<0.05), and TCL-1 with the presence of hepatocyte growth factor (HGF) expression 
at (n = 3, 11.94% ± 0.61%, p<0.05) 0nmol/l, (n = 3, 11.94% ± 0.055%, p<0.05) 
1nmol/l, (n = 3, 12.37% ± 0.10%, p<0.05) 10nmol/l and (n = 3, 12.43% ± 0.20%, 
p<0.05) 100nmol/l. In the presence of heparin at (n = 3, 12.28%±0.15%, p<0.05) 
0ng/ml, (n = 3, 12.37% ± 0.18%, p<0.05) 1ng/ml, (n = 3,12.46 % ± 0.02%, p<0.05) 
10ng/ml, and (n = 3, 12.52% ± 0.14%, p<0.05) 100ng/ml. (*p <0.05 vs. 0 growth 
factor,  Mann-Whitney U test; † p <0.05 vs. 0 heparin). 
 
 
HGF stimulated trophoblast invasion in the presence of heparin produced a significant 
dose dependent rise for increasing concentrations. The effect of heparin was only 
observed at higher concentrations. Thus, heparin modifies the HGF response as in 
Figure 44F. 
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Figure 45G. Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 of (n = 3, 42.38% ±1.54%, and	 46.27% ± 4.97%, 
p<0.05), and TCL-1 with the presence of Midkine (MK) expression at (n = 3, 44.16% 
± 5.80%, p<0.05) 0nmol/l, (n = 3, 45.11% ± 4.09%, p<0.05) 1nmol/l, (n = 3, 46.23% 
± 4.95%, p<0.05) 10nmol/l and (n = 3, 46.30% ± 5.57%, p<0.05) 100nmol/l. In the 
presence of heparin at (n = 3, 50.69% ± 1.84%, p<0.05) 0ng/ml, (n = 3, 51.63% ± 
2.58%, p<0.05) 1ng/ml, (n = 3, 66.58% ± 5.72%, p<0.05) 10ng/ml, and (n = 3, 
68.82% ± 5.11%, p<0.05) 100ng/ml. (*p <0.05 vs. 0 growth factor, Mann-Whitney U 
test; † p <0.05 vs. 0 heparin). 
 
MK stimulated trophoblast invasion in the presence of heparin showed similar values 
for the lower concentrations, but were significant for the higher concentrations. 
Therefore, MK effect was striking as the greatest dose response was enhanced with 
only of higher doses of heparin as in Figure 45G. However, little is known about MK 
and PTN expression and their roles in the human placenta. 
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Figure 39A. Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 of (n = 3,	60.95% ± 15.70%, and 76.9% ± 6.26%, 
p<0.05), and TCL-1 with the presence of heparin-binding-epidermal growth factor 
(HB-EGF) expression at (n = 3, 46.43% ± 4.40%, p<0.05) 0nmol/l, (n = 3, 
51.794.39%, p<0.05) 1nmol/l, (n = 3, 53.06% ± 2.58% p<0.05) 10nmol/l and (n = 3, 
54.28% ± 2.26%, p<0.05) 100nmol/l. In the presence of heparin at (n = 3, 55.72% ± 
6.38%, p<0.05) 0ng/ml, (n = 3, 68.06% ± 4.45%, p<0.05) 1ng/ml, (n = 3, 76.51% ± 
6.80%, p<0.05) 10ng/ml, and (n = 3, 79.30% ± 6.84%, p<0.05) 100ng/ml. (* p <0.05 
vs. 0 growth factor, Mann-Whitney U test; † p <0.05 vs. 0 heparin). 
 
 
HB-EGF as in Figure 39A. and VEGF as in Figure 40B. stimulated trophoblast 
invasion in the presence of heparin produced significantly higher values. There was 
small increase with increasing dose of HB-EGF which was significantly enhanced 
into heparin as VEGF. 
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Figure 40B. Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 of (n = 3,	10.46% ± 18.68;	 and 11.48% ± 19.56%, 
p<0.05), and TCL-1 with the presence of vascular endothelial growth factor (VEGF) 
expression at (n = 3, 13.38% ± 0.39%, p<0.05) 0nmol/l, (n = 3, 14.10% ± 0.99%, 
p<0.05) 1nmol/l, (n = 3, 14.56% ± 1.69%, p<0.05) 10nmol/l and (n = 3, 15.70% ± 
2.20%, p<0.05) 100nmol/l. In the presence of heparin at (n = 3, 14.60% ± 1.03%, 
p<0.05) 0ng/ml, (n = 3, 15.73% ± 1.55%, p<0.05) 1ng/ml, (n = 3, 16.73% ± 2.18%, 
p<0.05) 10ng/ml, and (n = 3, 16.85% ± 1.67%, p<0.05) 100ng/ml. (*p <0.05 vs. 0 
growth factor, Mann-Whitney U test; †p <0.05 vs. 0 heparin). 
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Figure 42D. Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 of (n = 3, 17. 84% ± 2.88%;	 and 20.16% ±9.87%, 
p<0.05), and TCL-1 with the presence of placental growth factor (PLGF) expression 
at (n = 3, 15.02% ± 2.70%, p<0.05) 0nmol/l, (n = 3, 20.18% ± 2.88%, p<0.05) 
1nmol/l, (n = 3, 23.88% ± 7.19%, p<0.05) 10nmol/l and (n=3, 26.72% ± 10.18%, 
p<0.05) 100nmol/l. In the presence of heparin at (n = 3, 22.33% ± 4.03%, p<0.05) 
0ng/ml, (n = 3, 23.89% ± 6.51%, p<0.05) 1ng/ml, (n = 3, 26.64% ± 7.80%, p<0.05) 
10ng/ml, and  (n = 3, 28.30% ± 8.82%, p<0.05) 100ng/ml. (*p <0.05 vs. 0 growth 
factor, Mann-Whitney U test; † p <0.05 vs. 0 heparin). 
 
PLGF stimulated trophoblast invasion in Figure 42D. in the presence of heparin only 
showed significant small increases because its response was little affected by heparin.  
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Figure 46H. Represents the percentage of invasion presented as mean ± SEM for the 
following cell lines HT 1080 of (n = 3, 45.67%	 ± 2.88%, and	 45.96%	 ± 9.87%, 
p<0.05), and TCL-1 with the presence of Pleoitrophin (PTN) expression at (n = 3, 
75.65%	± 12.83%, p<0.05) 0nmol/l, (n = 3, 78.09% ± 3.03%, p<0.05) 1nmol/l, (n = 3, 
85.94% ±8.02%, p<0.05) 10nmol/l and (n = 3, 99.84%	± 6.35%, p<0.05) 100nmol/l. In 
the presence of heparin at (n = 3, 81.38% ±13.39%,  p<0.05) 0ng/ml, (n = 3, 83.25%	± 
6.73%, p<0.05) 1ng/ml,  (n = 3, 87.94%	± 9.76%, p<0.05) 10ng/ml, and (n = 3, 
101.09%	± 20.78%, p<0.05) 100ng/ml.  (*p <0.05 vs. 0 growth factor, Mann-Whitney 
U test; †p <0.05 vs. 0 heparin).  
PTN stimulated trophoblast invasion in Figure 46H. in the presence of heparin 
showed a further significant increase for increasing concentrations.  
Although, the mechanisms responsible for heparin effects in the pathophysiology of 
pre-eclampsia have yet to be fully elucidated. Many of these HBGFs bind to heparin, 
a glycosaminoglycan (GAG) affecting activity. The interesting present data indicates 
a role and a possible physiological mechanism for the effect of heparin in promoting 
placental development. This suggests that dysregulation of HBGFs, and possibly 
changes in heparin may contribute to pre-eclampsia. Thus, our finding suggests a role 
for heparin or other glycosaminoglycans in mediating effect in placental tissue and a 
potential therapeutic use of heparin in treatment of pre-eclampsia. I identified growth 
factors produced the greatest change and those that showed the greatest response with 
heparin were FGF2, PDGF, HGF, and MK. Trophoblast invasion was augmented with 
increasing doses of HBGF. For example, the MK effect was strikingly augmented 
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then for VEGF, PLGF, FGF2, HB-EGF, PDGF, and HGF as the greatest response 
was enhanced with following co-incubation in the presence of higher doses for 
heparin except for PTN. However, little is known about MK and PTN expression and 
their roles in the human placenta. The present results are the first of the actions of MK 
and PTN and show different effects of heparin. Whether, MK and PTN plays a role in 
villous trophoblast invasion during placental development has never been examined. 
Namely large increases were seen at the higher dose for MK, but little effect was seen 
in response to PTN.  
 HBGFs caused trophoblast cells to invade, but only in the presence of heparin. A 
major strength in this present study is evident from the results demonstrating that 
through extracellular matrix in vitro villous trophoblast invasion model using human 
fibrosarcoma HT1080 as a positive control, mouse fibroblast NIH/3T3 as a negative 
control, and immortalised human primary villous trophoblastic cell lines provides a 
useful method to determine the effects of heparin and these HBGFs on trophoblast 
placental function. This technique is unique as it closely mimics the normal processes 
of placental development of early pregnancy. This demonstrated that heparin has a 
potential therapeutic use in treatment of pre-eclampsia.  
 
6.2.2. Previous findings of Transwell invasion or migration of Matrigel assays.  
Several authors previously have employed different methods and used  transwell 
invasion (in presence of Matrigel), or migration in absence of Matrigel assays. 
Hemberger et al, (2004), demonstrated that the mouse differentiation of trophoblast 
cells in vitro into trophoblast giant cells recapitulates the invasive capacity of normal 
trophoblast cells in vivo. Kliman and Feinberg, (1990), and Librach et al, (1991) 
studied the general invasive phenotype of human trophoblast cells in vitro. The study 
of Lewis et al, (1996) demonstrated the presence of colony-stimulating factor-1 (CSF-
1) autocrine loop found in immortalised Human trophoblast cell line TCL-1. Several 
authors assessed various factors affecting and regulating trophoblast invasion 
(Librach et al, 1994; Mandl et al, 2002; O’Brien et al, 2003; Sato et al, 2002; Xu et 
al, 2002; Janatpour et al, 2000; and Lala, 2000). The study of Athanassiades and Lala, 
(1998), suggested that PLGF -Flt-1 interactions may be regulated by the HSPGs in 
situ because PLGF promotes EVT cell proliferation. Exogenous PLGF-1 had any 
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effect on EVT cell proliferation migration and invasion assay. Previous studies 
suggested that the effects are modified by heparin for VEGF, PLGF, and HB-EGF 
(Lash et al, 2003; and Hills et al, 2006). However, Lash et al, (1999), study found that 
VEGF, and PLGF did not mediate heparin induced the in vitro invasion model of 
trophoblast cells into extracellular matrix. Their results suggested that addition of 
VEGF resulted in a significant decrease in number of trophoblasts and this effect was 
not influenced by heparin. Trew et al, (2000) re-investigated cytotrophoblast invasion 
using the Matrigel invasion assay for VEGF from first trimester placentae. Their 
results suggest that immunoflurorescent cytokeratin-positive staining on Matrigel 
coated transwell was not for cell invasion. Harris et al, (2008), demonstrated that 
trophoblast heparanase is not required for invasion in vitro transwell assay. Their 
results showed that its expression was evident on the cell surface and the nucleus of 
trophoblast and decidual cells. Dubinsky et al, (2010) reported that the expression of 
VEGF in trophoblast cells are involved in the control of invasion and migration. Liu 
et al, (2012) discovered that HLX1, a homeobox gene is essential for downstream 
signalling because it’s an important component of HGF response that leads to growth 
and invasiveness of trophoblasts. 
It’s the primary human trophoblast cells in cell culture that are valuable in research of 
placental physiology (Benirschke, 2006; Kingdom et al, 2000; and Knobil and Neil, 
1994). As, isolation of human trophoblast cells is essential to investigate the early 
placental human trophoblast cell lineages because of their self-renewing properties. 
These differentiate into all trophoblast cell types of the mature placenta (Benirschke, 
2006; Kay et al, 2010; and Kingdom et al, 2000). The trophoblast invasion is of 
physiological importance as this begins early in pregnancy and continues until the 
20th week of gestation. Abnormal placental function, trophoblast differentiation, and 
defects in trophoblast invasion and spiral artery remodelling are associated with the 
placental pathology of pregnancy complications in obstetrical disorder as pre-
eclampsia (Benirschke, 2006; Kay et al, 2010; Kingdom et al, 2000; Lyall and 
Belfort, 2007; Pijnenborg, 2010; and Williams, 2010). Trophoblast proliferation, 
migration and invasion are controlled by both soluble autocrine and paracrine factors, 
signalling pathways and regulatory transcription factors (Benirschke, 2006; Kay et al, 
2010; Kingdom et al, 2000; Lyall and Belfort, 2007; and Williams, 2010). Autocrine 
factors are expressed in the trophoblast such as IGF-II, hCG, HB-EGF and 
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interleukins. Paracrine factors are EGF, interleukin-11 (IL-11), activins and 
chemokines that are expressed in different decidua cell types, uterine natural killer 
(uNK) cells and macrophages that produce growth factors, cytokines, interleukins, 
chemokines, prostaglandins and angiogenic growth factors (Benirschke, 2006; Kay et 
al, 2010; Kingdom et al, 2000; Lyall and Belfort, 2007; and Williams, 2010). In vitro 
invasion models using human trophoblast cells will provide to be beneficial because 
of new insights into the characteristics of human trophoblast cells (Benirschke, 2006; 
Kay et al, 2010; Kingdom et al, 2000; Lyall and Belfort, 2007; and Pijnenborg, 2010). 
Particularly, in vitro invasion assays which mimic the in vivo environment of the 
placental human trophoblast (Benirschke, 2006; Kay et al, 2010; and Pijnenborg, 
2010). A comparison of in vitro effects of angiogenic and anti-angiogenic growth 
factors activities to results observed with in vivo assays can be assessed. This may 
prove valuable in the future for placental human trophoblast research and lead to a 
new approach for treating pre-eclampsia, eclampsia and IUGF women with 
trophoblast cells transfer (Benirschke, 2006; Kay et al, 2010; Kingdom et al, 2000; 
Lyall and Belfort, 2007; and Pijnenborg, 2010).   
Heparin is important because its reported cytoprotective effect which promotes 
trophoblast survival and proliferation. This present results from in vitro studies show 
heparin can influence migration and invasion. The heparin-binding growth factors 
(HBGFs) are important in regulating trophoblast invasion in vitro. These observations 
may indicate that heparin-binding growth factors (HBGFs) are important in vivo 
regulating trophoblast invasion. There is evidence to suggest that the cytoprotective 
effects of heparin are mediated through binding to HB-EGF and enhancement of HB-
EGF activity (Bose et al, 2005; and Hills et al, 2006). Hills et al, (2006) showed that 
the effect of HB-EGF in vitro and in vivo is modified by heparin eliciting epidermal 
growth factor receptor (EGFR) signalling transduction pathways in primary villous 
trophoblast. This is directly relevant to pathological pregnancies. They demonstrated 
that heparin protects human villous trophoblast against apoptosis and its effect was 
maximal at a concentration of 100ng/ml. Hills et al, (2012) showed that co-incubation 
with IGF-II and heparin at 100ng/ml decreased trophoblast apoptosis within the 
placenta. The Tunnel staining was employed to determine trophoblast apaoptosis 
(Hills et al, (2012). Hills et al, (2012) study investigated cell line model of villous 
cytotrophoblast cells from first trimester (n=12) and term placental tissues (n=21) 
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using negative immmunoselection with an antibody for HLA class 1 antigens. The 
present data indicate a role and a possible mechanism for the effect of heparin in 
promoting placental development which could suggest that dysregulation of HBGFs, 
and possibly heparin may contribute to pre-eclampsia.  
 
 
 
The second technique in this study was the first devoted to extraction and purification 
of the total RNA production in normal placenta and in pre-eclampsia. Then, 
quatification  of mRNA expression with HBGFs using  qRT-PCR. Extraction of 
mRNA was from 7 placental tissue samples and it was used for the following primer 
assays: PLGF, FGF2, MK, PTN, and succinate dehydrogenase complex subunit A 
(SDHA) as a endogenous housekeeping gene. Identification of PCR products of 7 
different placental tissue mRNA samples for FGF2 and MK by RNA agarose gel 
electrophoresis as in Figure 47 and 48 resulted fragments sizes as expected. A gel 
electrophoresis analysis as in Figure  49A. Figure 50A. and  Figure 51B. of the time 
course degradation of 7 different placental tissue mRNA samples resulted as expected 
fragments sizes in the placenta tissue for PLGF, FGF2, MK, PTN and SDHA.  
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Figure 49A. Represents the positions of DNA as a distinct bands for growth factor 
primer assays: placental growth factor (PLGF), pleiotrophin (PTN), and fibroblast 
growth factor (FGF2) analysis at a concentration of 100ng/ul for lanes showed peaks 
for A1 of 143base pairs (bp), A2 lane of 145bp, A3 lane of 142bp, A4 lane of 146bp, 
A5 lane of 142bp, A6 lane of 146bp and A7 lane of 142bp. The lanes showed peaks 
for lane B1 lane of 85bp, B2 lane of 87bp, B3 lane of 87.5bp, B4 lane of 85.5bp, B5 
of 84.5bp, B6 lane of 85.5bp and B7 lane of 87.5bp. The lanes showed peaks for lane 
C1 lane of 123bp, C2 lane of 127bp, C3 lane of 123bp, C4 lane of 127bp, C5 lane of 
123bp, C6 lane of 127bp and C7 lane of 123bp. In Figure 51B. Succinate 
dehydrogenase complex A (SDHA) at a concentration of 100ng/ul showed peaks for 
lanes (A1-7) with A1 lane of 62base pairs (bp), A2 lane of 162bp, A3 lane of 165bp, 
A4 lane of 162bp, A5 lane of 162bp, A6 lane of 162bp and A7 lane of 162bp using 
the DNA sizing ladder and 2 internal standard markers (LM and UM).  
The comparison between control (Term (TL + TNL) not in labour) versus pre-
eclampsia of placental tissue mRNA expression for FGF2 and SDHA showed  
significant differences except for PLGF, and MK, and PTN  primer assays, using the 
Mann-Whitney U test.  
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Figure 50A. Represents the positions of DNA as a distinct bands for growth factor 
primer assays: MK at a concentration of 100ng/ul, For lanes (A1-7) showed peaks 
with A (3,5 of 105bp) and A (2 of 97bp) and A(4 of 102bp), but A1, A6 and A7 lanes 
showed no DNA base pairs. In Figure 51B. Succinate dehydrogenase complex A 
(SDHA) at a concentration of 100ng/ul showed peaks for lanes (A1-7) with A1 lane 
of 62base pairs (bp), A2 lane of 162bp, A3 lane of 165bp, A4 lane of 162bp, A5 lane 
of 162bp, A6 lane of 162bp and A7 lane of 162bp using the DNA sizing ladder and 2 
internal standard markers (LM and UM).  
 
There are no previously reported qRT-PCR studies for MK and PTN using a similar 
approach to that employed in this current study is a novel finding. 
6.2.3. Previous studies on mRNA expression in the placenta.  
Poston’s (2002) and Radaelli et al, 2003 studies on the placenta established that 
regulation of specific placental genes in the tissue may be related to the gestational 
disorder, such as pre-eclampsia. Identifying gene expression alterations may advance 
the knowledge of pathophysiology of disorders of the placenta. In addition, 
monitoring changes of gene expression may identify new biomarkers that might 
predict pre-eclampsia earlier in pregnancy. It is by measuring the RNA expression in 
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the placenta that determines certain genes that are specifically transcribed in the 
placenta tissue and how their regulation can lead to abnormal gestational effects. The 
study of Bustin, (2002) on quantification of mRNA using RT-PCR suggested that 
comparison of RNA samples by controlling the amount of total RNA is time 
consuming. This required accurate quantification of RNA samples that was 
complicated by many physiologically variations.  
6.2.4. Other studies on Housekeeping genes in the human placenta. 
 As few reports are available on stability of housekeeping genes in the human 
placenta. Studies of Meller et al, (2005) and Cleal et al, (2009) found that GAPDH 
varied within placenta and unreliable reference gene. However, Murthi et al, (2008) 
employed GAPDH and found it stable and suitable for normalisation. It is an 
important concern in relative gene analysis to have a reliable normalisation factor, and 
this should be a reference gene that shows a comparative expression i.e. with high 
stability and low variability irrespective of experimental conditions. Molecular studies 
of pre-eclampsia placentae may elucidate etiologically important genomic alterations. 
RNA measurement by RT-PCR in comparative gene expression studies requires 
endogenous housekeeping genes to normalise between sample variations.  
Tricarico et al, (2002) suggested that housekeeping genes are measured to better 
normalize between samples. Sample variation was avoided by reporting the amount of 
particular gene expression relative quantitation to that of a housekeeping gene 
demonstrated accurate normalisation of RT-PCR data reported that for comparison of 
genes in placental tissue samples, geometric averaging of housekeeping gene should 
be employed. 
Yuen et al, (2002) study on RNA measured by RT-PCR and microarray analysis 
showed subtle changes in relative quantities for large number of genes and consume 
smaller amounts of each sample. This sensitivity variation between samples must be 
quantified, accounted for  and minimized. Thus, endogenous control genes are 
evaluated for stability between many types of placenta samples, including samples 
from complicated pregnancies.  
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Meller et al, (2006) study compared 7 different housekeeping genes β-2 
microglobulin  ( B2M), Hydroxymethyl-bilane synthase (HMBS), Hypoxanthine 
phosphoribosyl-transferase I (HPRT), TATA box binding protein (TBA), and 
Tyrosine 3-monoxygenase/tryptophan 5-monooxgenase activation protein, zeta 
polypeptide (YWHAZ) including the commonly used Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and Succinate dehydrogenase complex subunit A (SDHA) 
expression in the placenta. Their tissue samples were taken from uncomplicated and 
complicated pregnancies. They examined both maternal and foetal sides of the 
placenta, but our study examined neither the villous nor the decidual sides of the 
placenta. They looked at the mRNA isolated from 20 placentae and relative overall 
levels of expression of 7 genes using RT-PCR. They found that GAPDH analysis 
resulted a large variability and that TBA, SDHA and YWHAZ produced greater 
expression stability. 
Rosenberg et al, (2011) longitudinal study on 42 pregnant women showed that 
heparin did not effect circulating levels of VEGF, and PLGF using ELISA. They 
showed a distinct band of 100-112kDa by Western blot analysis both in vivo and in 
vitro as heparin induced shedding of the extracellular domain of soluble fms-like 
tyrosine kinase 1 (sFlt-1). Kauma et al, (1996) confirmed Met (a tyrosine kinase 
receptor for the ligand HGF) in placental villi and trophoblast cells to be 140kDa 
band and placental villous tissues demonstrated approximately 100-110kDa band by 
Western Blot analysis. Obama et al, (1995) identified that MK and PTN mRNA 
expression was present in the mouse extraembryonic membranes but only MK was 
found in the placenta at gestation. Their Western Blot analysis showed MK presence 
in amniotic fluid and cerebrospinal fluid.  
Different methods of quantitative RT-PCR were employed by several authors for their 
studies on placentae from pre-eclampsia women. Lala and Athanassiades (1998) 
examined first trimester EVT cells propagation in vitro mRNA expression of VEGF, 
and for Flt-1 using RT-PCR. Their results demonstrated presence for both protein and 
mRNA of VEGF, Flt-1 and expressed SV40 tag-immortalised EVT cells. 
Interestingly, study of 30 women with gestational diabetes mellitus (GDM) and their 
30 macrosomia (foetal overgrowth) babies by Grissa et al, (2010)  demonstrated 
several concentrations of growth factors IGF-1, EGF, FGF2 and PDGF-B and their 
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receptors in women with GDM and their macrosomia babies. There results 
demonstrated that serum concentrations of IGF-1, IGF-BP3, EGF, FGF2 and PDGF-B 
were determined by ELISA were higher in GDM women and their macrosomia babies 
compared to their controls. The expression of mRNA for these growth factors and 
their receptors were quantified by qRT-PCR. The mRNA expression was upregulated 
for FGF2 and PDGF-B but was unaltered for IGF-1 and EGF in the placenta of GDM 
women. The mRNA expression of 3 growth factor receptors IGF-1R, EGFR, and 
PDGFR-β were upregulated in the placenta of GDM women. Therefore, growth 
factors might be implicated in GDM and possibly pathology of macrosomia via the 
materno-foeto-placental axis in regulation of foetal growth. 
Andraweera et al, (2012a) quantified a reduction in mRNA expression when 
compared to control  (uncomplicated term pregnancies) of both VEGF, and PLGF and 
Flt-1 using RT-PCR in pregnancies complicated by pre-eclampsia, gestational 
hypertension disorders, small for gestational age SGA and preterm births. Maebavashi 
et al, (2012) quantified mRNA expression by using RT-PCR. Their results showed a 
decrease of mRNA expression for PLGF, and Ftl-1 increased in pre-eclampsia 
placentae. The effect of pre-eclampsia sera was analysed using choriocarcinoma cells 
(JEG3) from pre-eclampsia patients (Maebavashi et al, (2012).  
 Arany and Hill, (2012) quantified and localised the sites and expression for FGF2 
and its receptor FGFR-1 in placentae from normal term pregnancies and from 
pregnancies complicated by type 1 diabetes. Both in situ hybridization and 
immunocytochemistry demonstrated the presence FGF2 mRNA in low abundance in 
foetal villous tissue, and syncytiotrophoblast in normal term placenta. The Northern 
blot hybridization showed an significant increase of mRNA for both FGF2 and 
FGFR-1 in placentae and intense staining existed in syncytiotrophoblast from diabetic 
women when compared to the normal women. Grissa et al, (2010), investigated 
FGF2, PDGF-B and their receptors using RT-PCR. Their results demonstrated that 
the placental mRNA expression of growth factors might be implicated gestational 
diabetes mellitus and in pathology of macrosomia. The serum concentrations of FGF2 
and PDGF-B were higher in GMD women and their macrosomic babies as compared 
to the controls. 
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Chauhan et al, (2013) examined concentrations of glycosaminoglycans and the 
proteoglycan syndecan-1 within villous trophoblast. They investigated changes 
associated with pre-eclampsia on seventy-five placental samples from third trimester 
singleton pregnancies. There results showed a decrease in sulphated 
glycosaminoglycans and syndecan-1 in pre-eclampsia women that were independent 
of labour, gestational age and birth weight centile. 
Recently, a study of Escudero et al, (2014) in which mRNA expression was 
determined and which employed placentas showed that from both early on set 
(EOPE) and late onset pre-eclampsia (LOPE) were associated with differential 
activation of VEGFR-2 and hence demonstrated increased placental angiogenesis.  
During normal pregnancy increases in sFtl-1 occur; but in pre-eclampsia the sFlt -1 
concentrations significantly increase and exceed normal levels. Kumasawa et al, 
(2011) developed a mouse model for pre-eclampsia reproduces findings similar to 
those in LOPE. They demonstrated that the lipid lowering drug pravastatin induces 
PLGF and ameliorates pre-eclamptic changes in sFlt-1 in their model. Taguchi et al, 
(2008) study showed that pravastatin could be used in treatment of pre-eclampsia 
does not cross the human placenta because it is hydrophilic.  
I have established the three techniques in this study by employing firstly 
immunocytochemistry, secondly invasion and migration assays and thirdly qRT-PCR 
for pre-eclampsia. I confirmed FGF2 expression significantly in 3 techniques. 
Although, PLGF, MK, and PTN expressions were significant for both 
immunocytochemistry, invasion and migration studies, they were not by qRT-PCR. 
This was probably due to placental tissue mRNA transcription or protein level. This 
present study of 3 years time did not permit a further study to clarify these results. 
Therefore, our findings suggests a role for heparin has potential therapeutic use in 
mediating effect in placental tissue and can be applied for prediction, prevention and 
achieve an earlier diagnosis to better treatment of pre-eclampsia in the future. 
 
 
 
  Farha Nazir Ahmad M00201045                                                            266 
6.2.5. Findings on prediction, prevention, diagnosis and treatment of pre-eclampsia. 
Pre-eclampsia is a complex multifactorial pregnancy disorder characterised by 
hypertension, and proteinuria after 20 weeks of gestation, followed later by oedema. 
Previous studies suggested that pre-eclampsia is an important threat to public health 
and is the leading cause of maternal and foetal morbidity and mortality in pregnancy 
in both developed and developing countries (Duley, 2006; Tattersall et al, 2008; 
Meads et al, 2008; and Munir, 2013). The histopathologic correlation is the shallow 
invasion and aberrant remodelling of maternal spiral arteries, which leads to decreased 
uteroplacental perfusion. Reduced perfusion in the pre-eclamptic placenta, inducing 
trophoblast cell death apoptosis, has been linked to proinflammatory cytokine 
processes, hypoxia, and oxidative stress. Pre-eclampsia is associated with numerous 
changes including: deleterious effects on the extravillous trophoblast; failure of the 
extravillous trophoblast to adequately transform the uterine spiral arteries; reduced 
flow of maternal blood into the intervillous space; hypoxia or intervals of hypoxia 
followed by reoxygenation of the placenta; hypoxic damage of the villous trophoblast; 
and release of syncytiotrophoblast membrane fragments (STBM) into the maternal 
blood stream. The maternal inflammatory response to the STBM results in the 
development of the clinical symptoms of pre-eclampsia (Huppertz, 2008).  
 
Clinical research may contribute to developing new insights into placentology and 
novel therapeutic technologies for placental disorders as pre-eclampsia (Benirschke, 
2006; Kay et al, 2010; Kingdom et al, 2000; Lyall and Belfort, 2007; Pijnenborg, 
2010; Williams, 2010). New methodologies such as genomics, proteomics and 
metabolomics are widely available for research (Kay et al, 2010; Kingdom et al, 
2000; Lyall and Belfort, 2007; and Pijnenborg, 2010). There are many maternal 
clinical characteristics such as ethnicity, age, parity, multiple pregnancy and a history 
of pre-eclampsia in earlier pregnancies in first-world countries that are identified as 
risk factors for developing pre-eclampsia (Anderson et al, 2012; and Lyall and 
Belfort, 2007). Angiogenic growth factors promote vasculogenesis and angiogenesis 
in the placenta and the most potent include the VEGF, FGF2, and PLGF family. 
There are many other growth factors for example HB-EGF, PDGF, HGF, PTN, MK, 
CD105, and Endoglin (Eng) (TGF)- β1 and (TGF)-β3 (Pijnenborg et al, 2010). Many 
  Farha Nazir Ahmad M00201045                                                            267 
of these angiogenic and (sFlt-1) a trophoblast derived anti-angiogenic factors are 
promising biochemical markers for example free foetal haemoglobulin (HbF), alpha-
1-microglobulin (A1M), pregnancy-associated protein A (PAPP-A), placental protein 
13(PP13) Eng, metabolomics, angiogenesis factors and PLGF (Anderson et al, 2012; 
and Lyall and Belfort, 2007). Alterations in circulating levels are evident with 
increased levels of sFlt-1 and reduced levels of VEGF and PLGF and thus prevents 
their availability to stimulate angiogenesis this occur weeks before the clinical onset 
of pre-eclampsia (Ahmed and Ramma, 2014; Luttun and Carmeliet, 2003; Maynard et 
al, 2003). The largest study to evaluate PLGF and other factors in suspected pre-
eclampsia women were by Chappell et al, (2013). They studied the diagnostic 
accuracy of low plasma PLGF concentrations (<5th centile for gestation, Alere Triage 
Assay) in suspected pre-eclampsia women between 20 and 30 weeks of gestation, 
(including up to 41 weeks gestation as a secondary analysis) in determining delivery 
for pre-eclampsia within 14 weeks of testing. A total of 625 women were tested. 
There outcome was delivery for confirmed 346 pre-eclampsia. However, 287 women 
had enrolled before 35 weeks of gestation, and their PLGF showed high sensitivity 
and negative predictive value for suspected pre-eclampsia within 14 days. This 
technique confirmed to be better than many currently used tests for management of 
pre-eclampsia women.  
As, the pathophysiological mechanisms are not fully understood for aetiology of pre-
eclampsia (Benirschke, 2006; Kay et al, 2010; Kingdom et al, 2000; Lyall and 
Belfort, 2007; Pijnenborg, 2010; and Williams, 2010). There is an emphasis on the 
recently characterised circulating anti-angiogenic proteins (Mutter and Karumanchi, 
2008). In pre-eclampsia, as in the vast majority of pregnancies complicated by 
preterm labour, a vascular component has an important role in the course of the 
disease (Hediger et al, 1995). Placental histology has revealed similar findings in 
some cases of preterm labour (Pijnenborg et al, 1991; and Salafia et al, 1995). The 
expression Hypoxia inducible factor-1 α (HIF-1α) protein and mRNA in human foetal 
membranes and placenta was investigated in study by (Singh et al, 2006). VEGF 
expression activates HIF-1α in the placenta. Singh et al, (2006) showed that VEGF 
protein levels were decreased in foetal membranes after preterm labour and term 
labour.  
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As, the pathophysiological mechanisms are not fully understood for aetiology of pre-
eclampsia (Benirschke, 2006; Kay et al, 2010; Kingdom et al, 2000; Lyall and 
Belfort, 2007; Pijnenborg, 2010; Williams, 2010). Recently, VEGF, PLGF and (sFlt-
1) a trophoblast derived anti-angiogenic markers are of interest particularly, relating 
to the potential role of biomarkers for predication and diagnosis of pre-eclampsia 
(Benirschke, 2006; Kay et al, 2010; Kingdom et al, 2000; Lyall and Belfort, 2007; 
Pijnenborg, 2010; and Williams, 2010). Anderson et al, (2012), suggested that an 
ideal biochemical marker should show the following characteristics for both 
prediction and diagnosis of pre-eclampsia for routine use in clinical practice. Several 
important points that are considered for clinical investigations are as follows. These 
biochemical markers must have central role in the pathogenesis and would be 
specific. They should be detected and appear early or before the clinical 
manifestations. It is important that they are safe, easy and cost-effective approach to 
measure in maternal blood or urine. They should prove a high sensitivity and 
specificity. The severity of the condition should be correlated with the progression of 
disease. They should in normal pregnancies be expressed at very low levels. Lyall and 
Belfort, (2007); and Hadker et al, (2010) suggests that screening pregnant women 
with an effective diagnostic marker for pre-eclampsia could reduce suffering and 
major health care costs. Therefore, a significant impact on maternal and foetal health 
worldwide could occur if an intervention could prevent pre-eclampsia. Pre-eclampsia 
is a dominant in the third world, and diagnosed in women present with eclamptic 
seizures. There is clinical need for improving screening or diagnostic tests for pre-
eclampsia. This would advance obstetric care by reducing maternal and foetal 
morbidity and mortality in third world countries. The effective treatment of pre-
eclampsia is simple, early delivery of baby and the placenta, there is no known cure. 
It is after delivery that symptoms resolve within 48–72 h. Potential novel 
pharmacological treatment strategies may restore the normal angiogenic balance in 
the maternal circulation (Wang et al, 2015; Lyall and Belfort, 2007). Heparin can be 
applied for prediction, prevention and achieve an earlier diagnosis to better treatment 
of pre-eclampsia in the future. Thus, improving the development of interventions and 
to increase normal pregnancy outcome reducing maternal and foetal morbidity and 
mortality. 
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6.2.6.Limitations in this study 
There were several limitations in three major techniques immunocytochemistry, 
invasion and migration assays and RT-PCR studied for pre-eclampsia. 
Immunocytochemistry of FGF2 expression for covering the placental specimen slides 
specimen (n=109) in different dilutions (1 in 100, 1 in 200, and 1 in 400), control 
(n=43), and a negative control IgG (n=11) in the absence of citrate buffer showed no 
staining with overnight incubation at 2-8°C. In this study, a total of (n=4) slides 
comprised first trimester prior to labour were too small number for analysis. 
Therefore, no scoring was performed. Thus, a larger cohort of placenta tissue samples 
should been used for further investigations on the placental pathologies including pre-
eclampsia.  
For the invasion and migration studies, the experiment for standard curve calibration 
was performed. These results were reproduced in 4 further experiments at relative 
fluorescence units (RFU) measurement of 1000 and 2000 were converted to number 
of cells. Its from the free calcein that fluoresces, and quantitate these number of cells 
that have migrated and invaded using standard curve. This invasion assay used 
different cell types such as the Human fibrosarcoma HT1080 invasive cells (positive 
control), and human villous trophoblast cell-line TCL-1 in the absence of BD 
FluoroBlok that has a uniform coated layer with Matrigel Matrix. The identification 
of PCR products by RNA agarose gel electrophoresis, of 7 different placental tissue 
mRNA samples with their concentration (100ng/ul) were optimised for some of 
growth factor primer assays. These results were reproduced in 7 further experiments.  
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6.9.7. In summary, these studies support the novel hypothesis tested for cohort study 
of 87 women is that the expression of heparin binding growth factors (HBGFs) in 
normal placental development was altered in the specific disorder of pre-eclampsia.  
• Heparin-binding growth factors are involved in placental development and 
many of these bind glycosaminoglycans (GAGs) and this binding affects 
activity. 
• It suggests that heparin-binding growth factors (HBGFs) are important in 
regulating trophoblast invasion.  
• It suggests that dysregulation of HBGFs and possibly changes in heparin may 
contribute to pre-eclampsia. 
• This indicates a role for heparin in mediating the effects of HBGFs.  
• This indicates a possible mechanism for the effect of heparin in promoting 
placental development.  
 
6.9.8. In conclusion, our main finding for this current study is that alterations in 
growth factor are involved in the pathophysiology of pre-eclampsia. Future research 
may elucidate further roles of HBGFs in placental development and pre-eclampsia. It 
suggests that heparin has a new potential therapeutic use in the treatment of pre-
eclampsia. 
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6.9.9. Recommendations for future studies: 
These results from experiments employing techniques as immunocytochemistry, qRT-
PCR and invasion and migration assays provide evidence for future research that 
would provide new insights and better understanding of pathophysiology in pre-
eclampsia for human and the mouse placental development. New developments in 
diagnosis with a focus on angiogenic growth factors as VEGF, PLGF and (sFlt-1) a 
trophoblast derived anti-angiogenic factors are promising biochemical markers and 
contribute to early diagnosis, management and treatments of obstetrical disorder 
complications of pregnancy for predication of disease onset in pre-eclampsia with 
recent management strategies for patients. Thus, reducing maternal and foetal 
morbidity (Benirschke et al, 2006; Lyall and Belfort, 2007; Kay et al, 2010; 
Pijnenborg et al, 2010; and Williams, 2010). As, placental abnormalities of pre-
eclamptic women lead to reduce blood supply and deficient placental trophoblast 
invasion during implantation contribute to inadequate spiral artery remodelling 
(Benirschke et al, 2006; Lyall and Belfort, 2007; Kay et al, 2010; Pijnenborg et al, 
2010; and Williams, 2010). Its through the activation of increased placental oxidative 
stress, and formation of reactive oxygen species (ROS) production, promoting 
alterations in syncytiotrophoblast apoptosis in maternal circulation via syncytial knots 
that are associated with increased release of syncytiotrophoblast microparticles 
(STBM) and initiation of inflammatory cytokine production in placental tissues that 
cause endothelial dysfunction in pre-eclampsia (Benirschke et al, 2006; Lyall and 
Belfort, 2007; Reddy et al, 2008; and Kay et al, 2010).  
The aim of the study would be to test the hypothesis for the role of STBMs in the 
pathophysiology of pre-eclampsia which has not been determined. Further studies, of 
placental ischaemia, hypoxia, and oxidative stress due to reduced perfusion in vitro or 
in vivo during labour of normal pregnancies, Gestational Diabetes Mellitus, and pre-
eclamptic women would be clarified (Benirschke et al, 2006; Lyall and Belfort, 2007; 
and Kay et al, 2010). The new therapeutic use of heparin in mediating effects of 
HBGFs such as on villous trophoblast, STBMs, cell survival, proliferation, invasion, 
migration, and differentiation of placental villi to these different O2 tensions could be 
determined. 
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